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SUMMARY 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with 
more than half of the cases attributed to persistent viral infection by the hepatitis B or C 
virus. To date, the exact molecular pathogenesis of HCC remains ambiguous. In this 
study, proteomic based approaches were used to identify protein targets with the aim to 
unravel the molecular pathogenesis of HCC. Three quantitative approaches, viz, 2-D 
DIGE, cICAT and iTRAQ coupled with 2-D liquid chromatography were used to analyze 
tumour lysates from moderately- and poorly-differentiated HBV-related HCC. To our 
knowledge, this is the first study using 3 proteomic techniques to analyse HCC tissues 
belonging to two different stages of differentiation. 
In this study, a total of 163 and 181 proteins were found to be dysregulated in 
moderately- and poorly-differentiated HCC tissues respectively, among which only 12 
proteins were common between all three techniques. Disparity among identified proteins 
was expected as it is known that each method has its inherent bias and limitation. A 
subset of these proteins was also verified using western blots to independently confirm 
the presence of the proteins identified by 2-D DIGE, cICAT and / or iTRAQ. These 
proteins were further grouped according to their function as annotated by Gene Ontology 
for the ease of analysis. The majority of affected proteins were those involved in 
metabolism. Most significantly, we are able to observe increasing abrogation of these 
metabolic pathways from moderately- to poorly-differentiated HCC. In addition, proteins 
related to iron homeostasis and defense mechanisms were also shown to be severely 
impaired. These indicate that the tumourigenic liver had lost its ability to perform its 
basic metabolic and detoxification functions. 
 xi
Among the proteins identified, further analysis was conducted on a novel protein 
family, far upstream binding proteins (FUBPs) that were identified by 2-D DIGE. The 
over-expression of FUBPs in both stages of HCC are of particular interest due to their 
transcriptional activity on the oncogene, c-myc. Interestingly, a large number of 
dysregulated proteins identified were also c-myc associated proteins. In addition, c-myc 
was also observed to be elevated in the tissues used in this study. It has generally been 
accepted that c-myc plays an important role in HCC progression, especially in a viral 
associated carcinogenesis. The exact activators and functions of c-myc, however remain 
poorly understood. It is possible that FUBPs over-expression is responsible for elevated 
c-myc levels. Preliminary experiment using FUBP siRNA transfection on Hep3B, a HBV 
antigen positive liver cell line showed a decrease in cell viability. This effect was 
however not observed in HepG2, a HCC cell line without HBV in the genome. We 
therefore propose that the FUBP family of proteins may be one of the possible upstream 
players that are involved in HBV-related HCC tumourigenesis.  
 
 xii
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1. LITERATRUE REVIEW 
1.1  Hepatocellular Carcinoma (HCC) 
1.1.1  Epidemiology 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Globally 
HCC ranks fifth amongst the most common cancers but it is the third leading cause of cancer 
death with an estimated one million death annually (Bosch et al., 2004; Cha and DeMatteo, 
2005). It has a high fatality ratio with most patients who develop liver cancer dying within a 
year (Yuen et al., 2009).  
HCC has a wide geographical variability with the highest incidence in developing 
nations, such as Asia and sub-Saharan Africa, accounting for 80% of new cases (Parkin, 2006; 
Wong and Ng, 2008). In Southeast Asia, HCC is the second most fatal cancer since the 1970s 
with a male predominance of 2 to 4 times more than for females (El-Serag and Rudolph, 2007). 
Over the last 2 decades, there has also been a noticeable increase of HCC in developed 
countries such as Europe and the United States (El-Serag and Mason, 1999; Zucman-Rossi and 
Laurent Puig, 2007).  
In Singapore, HCC is the fourth most frequently occurring cancer in men with an 
overall incidence of 18.9 per 100 000 person-year (Singapore Cancer Society). The incidence is 
highest among the Chinese population compared to the other ethnic groups (Yuen et al., 2009). 
 
1.1.2 Aetiological factors  
The risk factors of HCC have been well established. These include persistent hepatitis B 
or C virus (HBV or HCV) infection, cirrhosis and aflatoxin B1 which accounts for almost 80% 
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of all HCC cases (Bosch et al., 2005; Thorgeirsson et al., 2006). Other aetiological factors 
include severe alcohol abuse leading to cirrhosis (Stickel et al., 2002; Morgan et al., 2004), 
smoking, as well as abnormal levels of oestrogen and androgen (Seow et al., 2001). In addition, 
metabolic abnormalities such as hereditary haemochromatosis (Kowdley, 2004), α-1-antitrypsin 
defiency, hereditary tyrosinaemia and Wilson’s disease can also lead to HCC.  
In recent years, diabetes and obesity have also been identified as probable risk factors 
for HCC (Polesel et al., 2009). HCC, due to obesity, most likely progresses through 
steatohepatitis disease to cirrhosis and eventually carcinogenesis (Calle et al., 2003). It should 
also be noted that the risk of HCC increases in the event of multiple risk factors.  
 
1.1.2.1 Hepatitis B virus   
Hepatitis B virus (HBV) is a 3.2kb partially double stranded DNA virus which can 
cause an acute and chronic inflammatory response from the liver. The estimated number of 
HBV chronic carrier world-wide is 400 million, of which 75% reside in Asia (Lai et al., 2003). 
This incident level correlates strongly with the incidence of HCC. HBV is the first human virus 
proven to cause cancer (Parkin, 2001; Beasley, 2009). In Singapore alone, a third of HCC 
patients are HBV positive (Yuen et al., 1999). Further evidence has shown that patients who are 
seropositive with chronic HBV infection are about 70-fold more likely to develop HCC (Rabe 
et al., 2001). Numerous human HCC studies have also shown integrated HBV DNA sequences 
and expression of viral proteins from these sites (Matsubara and Tokino, 1990; Su et al., 1998).  
HBV infection consists of a replicative phase which results in prolonged cycles of liver 
cell damage followed by regeneration of the hepatocytes and inflammatory processes. This 
 3
leads the development of chronic hepatitis, liver fibrosis and cirrhosis that may eventually 
develop to HCC (Li et al., 2004; Kao et al., 2005). HBV-related HCC has also been observed in 
non-cirrhotic liver background. In addition the viral genome has also been identified in the 
early stages of tumourigenesis, suggesting that its integration precedes HCC development 
(Brechot, 2004). This implies the possibility that the HBV viral genome may have some 
intrinsic hepatocarcinogenic properties. The genomic alterations that occur as a result of viral 
integration may therefore be an additional mechanism that causes HCC (Matsubara and Tokino, 
1990).  
The viral integration is a dynamic process and rearranges as hepatocytes proliferate. 
This integration can cause cis- or trans-activiation and has been observed to affect a variety of 
genes involved in proliferation, cell viability and cell signalling (Rabe et al., 2001). Possible 
transactivators of the virus include truncated preS2/S, hepatitis B spliced protein and HBV-X 
protein (Caselmann, 1995; Brechot, 2004; Tang et al., 2006). At least one of these sequences 
has been identified in more than 80% of HBV-related HCC (Schluter et al., 1994).   
The most studied candidate, HBV-X protein transactivating function was first 
hypothesized by Miller and Robinson (1986). In vivo studies have shown that HBV-X is able to 
transactivate a large number of promoters related to inflammation and cell proliferation through 
protein-protein binding. This thus improves the cellular environment for further viral replication 
(Tang et al., 2006). HBV-X is also able to increase sensitivity to possible carcinogens or 
directly affect cellular oncogene levels such as c-myc (Yang et al., 2008) or inactivate tumour 
suppressors such as p53 (Ueda et al., 1995). It can also modulate protein degradation via 
proteosome regulation (Brechot, 2004) and stabilization of hypoxia inducible factor (HIF) 
(Moon et al., 2004). Elevated levels of HIF have been observed during hypoxia conditions 
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induced by tumourigenesis. Although its direct interactions are not clear, concerted effects of 
HBV-X and other players such as c-myc and HIF can potentially encourage survival and 
invasion of tumour cells. HBV is the best investigated aetiological agent with overwhelming 
evidence in numerous animal models and human samples. However, the exact mechanism of its 
malignant transformation has yet to be fully understood.  
 
1.1.2.2 Hepatitis C virus  
 Hepatitis C virus (HCV), a 9.6 kb single stranded RNA virus, with an estimate of 170 
million chronically infected individuals worldwide. HCV has increasingly been the major cause 
of HCC (McGlynn and London, 2005), predominantly in the developed nations such as Europe, 
United States and Japan (Bosch et al., 1999). Due to its great sequence heterogeneity, HCV is 
classified according to its various subtype, with 1b having the greatest risk of chronic infections 
resulting in severe liver damage (Purcell, 1997; Colombo, 1999).  
HCV also induces liver inflammation followed by a continuous cycle of hepatocyte 
death and regeneration. Analogous to HBV infection, this provides a context of genetic 
mutations and aberrations. Though HCV, made up of RNA, is unable to integrate to its host 
genomes, it is hypothesized that immune responses against the virus could substantially 
promote tumourigenesis.  Studies have also suggested that the HCV RNA and core proteins are 
able to impair dendritic cell functions that are important for T-cell activation (Pachiadakis et al., 
2005) and evade immune-mediated cell death by interactions with interferon-α and tumour 
necrosis factor-α (Melen et al., 2004; Gale and Foy, 2005).  
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HCV core proteins, for example, have been shown to interact with MAPK signalling 
pathways such as ERK, MEK and Raf, to modulate cell proliferation. Another protein, NS5A of 
the HCV, is also able to sequester p53 thereby affecting p53-regulated pathways. Studies using 
mouse models also show that HCV core proteins are able to induce hepatic steatosis as well as 
reactive oxygen species (ROS) and oxidative stress which may be responsible for HCC 
development (Moriya et al., 1998; 2001). All these results provide evidence that viral proteins 
are capable of directly inducing tumourigenesis. 
 
1.1.2.3 Aflatoxins 
Aflatoxins are naturally occurring mycotoxins that are produced by many species of 
Aspergillus fungus. Aflatoxin contamination in food remains a serious problem and may 
account for more than half of the HCC in Africa, China and South-East Asia (Bosch et al., 
2005). High levels of exposure to aflatoxins can result in acute hepatic necrosis, and cirrhosis 
and possibly liver carcinoma. Aflatoxin B1 (AFB1), produced by Aspergillus flavus and 
Aspergillus parasiticus, is the most commonly occurring and potent of the aflatoxins (Mc Lean 
and Dutton, 1995).  
AFB1 is metabolised predominantly in the liver to an AFB1-8,9-exo-epoxide which in 
turn forms a promutagenic AFB1-N7-guanine DNA adduct. This results in a guanine to 
thymine transversion mutation (Bressac et al., 1991). Fifty percent of human HCC with high 
levels of AFB1 exposure has been shown to harbour a specific point mutation in guanine to 
thymine of codon 249 (AGG to AGT) in the tumour suppressor, p53 (Moradpour and Blum, 
2005; Wild and Montesano, 2009). This loss of p53 function may affect apoptosis and 
eventually promote carcinogenesis.  
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1.1.2.4 Inherited disorders  
Hepatocellular carcinoma may also arise from several inborn errors of metabolism. For 
example hereditary haemochromatosis results in high iron levels in the liver that leads to 
increased oxidative stress and probable DNA damage. Approximately 40-60% of patients with 
hemochromatosis will develop HCC (Niederau et al., 1985). Other autosomal recessive diseases 
such as α-1 antitrypsin defiency and tyrosinaemia can lead to inflammations and excessive liver 
necrosis and regeneration. In both cases, about 40% of patients will develop HCC (Eriksson 
1985; Cha and DeMatteo, 2005).  
It has also been proposed that HCC can be familial, due to occurrences of HCC in 
children. It has also been shown that HBV infected males with a family background of HCC 
have 84% chance of getting HCC in comparison to just 9% of individuals without a HCC 
family history. Similarly, females have 46% chance of HCC compared to 1% in those with no 
HCC family history (Shen et al., 1991). However, due to confounding environmental factors, 
the possibility of genetic factors that may contribute to HCC has yet to be defined.  
 
1.1.3  Morphological changes in Hepatocarcinoma 
 Hepatocarcinogenesis, like other cancers are multistage and multifactorial and involves 
various genetic alterations that ultimately lead to malignant transformation of normal cells. 
However unlike other cancers, notably colorectal cancer, no significant progress has been made 
in elucidating the various molecular players, sequence of events and their interactions in HCC. 
This is not surprising considering the heterogeneity of numerous aetiological factors that are 
implicated in HCC.  
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 Despite the complexities presented, the pathogenesis of HCC is believed to develop 
through a series of possible common events which leads to morphological changes. This 
consists of a preneoplastic phase that may take about 10 – 30 years to develop, dysplasia and 
eventually neoplasia (Thorgeirsson and Grisham, 2002). These proposed chronological 
sequence of events that culminated in the development of HCC are separable and can be studied 
by well-established histocytological criteria (Fig. 1.1).  





1.1.3.1 Preneoplasia and Dysplasia 
Hepatocarcinogenesis is believed to have a long preneoplastic phase. This often begins 
with chronic hepatitis as a result of various insults that leads to liver inflammation. The liver is 
hence exposed not just to the aetiological agents, but pronounced levels of inflammatory 
cytokines, matrix degrading enzymes and mitogenic growth factors (Brechot, 2004). These 
sustained chronic inflammation and cytokine induced hepatocyte death results in remodelling of 
liver matrix and rapid liver regeneration.  
Formation of excess fibrous connective tissue during its reparative process leads to liver 
fibrosis. Cirrhotic liver is another common phenomenon which is characterized by replacement 
of liver tissue by abnormal regenerative nodules surrounded by collagen and scarring. It may 
occur independently or as a result of fibrosis. It is an irreversible process which leads to 
progressive loss of liver functions. More than 80% of HCC is formed on a cirrhotic background 
(Simonetti et al., 1991). Only a small portion of HCC develops from normal looking liver and 
others display fibrosis or steatosis or liver cell dysplasia.  
Rapid cell proliferation without the proper genetic checks and control mechanisms may 
also lead to a series of lesions such as dysplastic foci or dysplastic nodules. Dysplastic foci 
consist of abnormal monoclonal hepatocytes that differ from adjacent cells. Microscopic 
examination of the liver is able to differentiate these cells via cytoplasmic staining, nuclear size 
or degree of nuclear atypia (Hytiroglou, 2004). Dysplastic foci can be characterized by either 
small cell change (SCC) or large cell change (LCC) (Watanabe et al., 1983). SCC bears similar 
cytological similarities to HCC with small cell size and a high nucleus to cytoplasm ratio has 
been suggested to be precancerous.  
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Dysplastic nodules, is another characteristic lesions that can be observed in 20-30% of 
liver biopsies in HCC-virus associated cirrhosis. These nodules, categorized as low or high 
grade dysplasia, have been established by clinicopatholical studies as precancerous lesions 
(Takayama et al., 1990). Both grades of dysplasia can be characterized by abnormal cytological 
lesions, such as clear cell changes and nuclear crowding. High grade dysplastic nodule 
manifests nuclear hyperchromasia, mild nuclear contour irregularities with 1.3 – 2 times greater 
in cell density as compared to surrounding hepatic tissues (Theise et al., 2002). Structural 
changes also include thickening of the trabeculae with up to 3 cells, areas of increased fibrosis 
and “nodule-in-nodule lesions” which indicates abnormal liver architecture (Hytiroglou, 2004). 
The subnodules may demonstrate definite features of HCC such as fatty change or iron 
resistance or higher vascular supply.   
 
1.1.3.2 Neoplasia 
Pronounced hepatic lesions, dysplastic nodules and continued genomic alterations may 
result in changes in the molecular pathways that drive the hepatocytes to evolve into a 
malignant phenotype, leading to the eventual hepatocarcinoma. Microscopic examination of 
tumours describes critical increase in cell density or nuclear crowding of at least 2 times 
compared to the surrounding hepatocytes (Kojiro, 1998). The nucleus may demonstrate further 
contour irregularities, prominent nuclei or mitotic figures. Tumour cells often arrange in 
irregular trabeculae forming thicker plates of cells, with clear cell change, fatty accumulation or 
Mallory bodies and are accompanied by increased vascularisation (Hytiroglou, 2004).  
This neoplastic progression of HCC continues to occur in a multi-step histological 
process that can be broadly classified into well differentiated (where the tumour cells are often 
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with indistinct margins from the surrounding hepatocytes), followed by moderately 
differentiated and poorly differentiated. The latter being the most severe stage with high 
vascular networks and metastatic potential. Although the exact differences in the molecular 
events is not clear, these stages of HCC can be differentiated by pathological examinations.  
 
1.1.4 Staging of HCC  
 It is well established that staging systems provide a common language that provides 
guided patient assessment as well as facilitates the exchange of information in cancer research 
and clinical trials. A perfect staging system will be advantageous in the prognosis, therapeutic 
interventions and the overall treatment of the disease.  
The vast heterogeneity in risk factors, development and progression HCC has presented 
a unique challenge in creating a prefect staging system. The most commonly used staging 
systems for HCC is the Okuda system (see Table 1.1) (Okuda et al., 1985; Gannon and Curley, 
2008) and the pathological tumour node metastasis (TMN) staging that was adopted by the 









Table 1.1 : The Okuda staging system for HCC (adapted from Gannon and Curley, 2008) 
Parameters Value Points 
Tumour size* >50% 1 
 <50% 0 
Ascites Present 1 
 Absent 0 
Serum Albumin (g/dL) >3 0 
 <3 1 
Serum Bilirubin (g/dL) <3 0 
 >3 1 
Stage 
1 0 points 
2 1 – 2 points 
3 3 – 4 points 
 
* Tumour size is measured in comparison to the largest cross-sectional area of the liver.
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Table 1.2 : The UICC TNM staging system (adapted from Gannon and Curley, 2008) 
Classification                                                     Morphology 
Primary tumours 
TX: Primary tumour cannot be assessed. 
T0: No evidence of primary tumour. 
T1: Solitary tumour without vascular invasion. 
T2: Solitary tumour 2 cm or less in greatest dimension with vascular invasion, OR 
multiple tumors limited to one lobe, none greater than 2 cm and without 
vascular invasion, OR a solitary tumor more than 2 cm in greatest dimension 
without vascular invasion. 
T3: Solitary tumor more than 2 cm in greatest dimension with vascular invasion, 
OR multiple tumors limited to one lobe, none more than 2 cm with vascular 
invasion, OR multiple tumors limited to one lobe, any more than 2 cm in 
greatest dimension, with or without vascular invasion. 
T4: Multiple tumors in more than one lobe or tumor(s) involve(s) a major branch 
of the portal or hepatic vein. 
Regional Lymph Node  
NX  Regional lymph nodes cannot be assessed. 
N0  No regional lymph node metastasis present. 
N1  Regional lymph node metastasis present.  
Distant Metastasis 
MX Presence of distant metastasis cannot be assessed 
M0 No distant metastasis present 
M1 Distant metastasis present. 
Stage Grouping 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III A T1 N1 M0 
Stage III B T2 N1 M0 
Stage III C T3 N0 M0 
Stage III D T3 N1 M0 
Stage IV A T4 any N M0 




 Both staging systems have their own weaknesses. The Okuda system, for instance, lack 
sensitivity, while TNM staging on the other hand, relies solely on tumour morphology and does 
not account for other aspects such as cirrhosis of the liver. Both also lack prognostic value for 
patients that are diagnosed at an earlier asymptomatic stage (Yan and Yan, 2003). Thus in 
recent years, numerous other staging systems have been introduced by various countries such as 
CLIP (Cancer of the Liver Italian Programme) (CLIP investigators, 1998), BCLC (Barcelona 
Clinic Liver Cancer staging) (Llovet et al., 1999) and China Classification System (Yan and 
Yan, 2003).  
 To-date, there has been no consensus as to which staging system should be applied to 
HCC. This is mainly due to insufficient knowledge in the development and factors involved in 
predicting its prognosis. These limitations and the lack of proper staging methodology, 
continues to hamper efforts to not only study HCC but the inability to properly assign the best 
therapeutic approach to the patients.  
  
1.1.5 Diagnosis and treatment 
Due to the asymptomatic features during the course of neoplastic development and the 
lack of reliable biomarkers, it is not surprising that HCC patients are often diagnosed at very 
late stages. The disease thus has very poor prognosis with more than 50% of the patients dying 
within 1 year and less than 6% have a 5 year survival rate (Hoofnagle, 2004).  
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1.1.5.1 Screening tests 
Successful screening and diagnosis of HCC is complicated by the lack of reliable 
biomarkers. Alpha-fetoprotein (AFP) is the best possible marker today for HCC with sensitivity 
and specificity that varies in the range of 40 to 60% and 76 to 96% respectively (Spangenberg 
et al., 2006). In recent years, a fucosylated AFP (AFP-L3) has been found to be a specific 
indicator of poorly-differentiated and unfavourable diagnosis (Tateishi et al., 2006). Most 
importantly, AFP levels seem to have a better predictive value in detecting HCC patients 
without viral hepatitis (94% in non-viral HCC versus 70% in viral-induced HCC) (Spangenberg 
et al., 2006).  
Another commonly used biomarker is an abnormal prothrombin, des-gamma-carboxy 
prothrombin (DCP) (Liebman, 1989; Aoyagi et al., 1996). It is found to be elevated in 62% of 
HCC patients and 84% of patients with HCC recurrence (Ikoma et al., 2002). DCP is associated 
with the risk of portal vein invasion in one of the main end-stage observations (Hamamura et 
al., 2000). Hence it is more commonly used as a diagnostic marker rather than for surveillance. 
Though a combination of AFP and DCP would markedly improve its sensitivity, its usefulness 
for early detection of HCC is controversial. Other promising biomarkers reported include 
Golgi-protein 73 (Kladney et al., 2000; Marrero et al., 2005), glypican-3 (Nakatsura et al., 
2003; Capurro et al., 2003), hepatocyte-growth factor (Yamagamim et al., 2002), insulin 
growth factor 1 (Mazziotti et al., 2002), vascular endothelial growth factor (Poon et al., 2004; 
Schoenleber et al., 2009) and transforming growth factor β-1 (Song et al., 2002; Yao et al., 
2007). However due to the lack of studies and confounding factors, more work will be needed 
to confirm their effectiveness.  
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In addition to tumour markers, other screening strategies used in HCC screening depend 
on imaging studies. These include ultrasonography, which is reportedly very operator-
dependant. It is also biased for detection of large tumour masses, which typically indicates late 
stages of cancer. Combined use of AFP and ultrasonograpy has been proposed to potentially 
increase detection rates although this may also increase cost and false-positive rates (Zhang et 
al., 2004). Furthermore, confirmatory diagnosis often requires computed tomography (CT) or 
magnetic resonance imaging (MRI) which may also be costly.  
 
1.1.5.2 Treatment  
To date, the only curative treatments for HCC are surgical resection or liver 
transplantation (Poon et al., 2000). However, even for the patients who undergo resection, the 
recurrence rate can be as high as 50% at 2 years, especially in cirrhotic patients (Belghiti et al., 
1991; Figueras et al., 1999). The main cause of recurrence is the development of new tumours 
in the remnant liver which are often in a preneoplastic state (Imamura et al., 2003). Hence for 
such cases, a liver transplantation is often a better option. The scarcity of donor liver continues 
to be a universal problem and many succumb to death while waiting due to tumour 
advancement.  
In some cases when HCC lesions are unresectable, there is a need for non-surgical 
treatment. Radiofrequency ablation (RFA), for example, utilises a needle with an electrode is 
placed percutaneously into targeted tumour using ultrasound guidance and tumour tissues are 
heated to cause necrosis (Gough-Palmer and Gedroyc, 2008). Other treatments include 




 Since chronic HBV and HCV are amongst the predominant cause of HCC, infection 
control is a priority in primary prevention of HCC. The first nationwide HBV vaccination at 
birth programme was launched in Taiwan in 1984 (Beasley, 2009). Twenty years after its 
launch, the number of chronic HBV infections dropped from 10 – 17% before the vaccination 
programme to 0.7 – 1.7% after its launch. This corresponded to a lowered childhood HCC 
incidence rate (Chang, 1998; Chang, 2009). The study also reported cases of vaccine failure, 
due to vaccine escape mutants, genetic hyporesponsiveness and poor compliance.  
Nevertheless, universal vaccination has since been implemented by the World Health 
Organisation (WHO), especially for high risk population groups such as healthcare workers, 
neonates of HBV carrier mothers and patients with immuncompromised states (Zanetti et al., 
2008). HBV vaccination success in preventing HCC will however be better evaluated in several 
years to come. On the other hand, development of an effective vaccination against HCV has 
been severely hampered by the high genetic variability of the virus. HCV spread can however 
be better managed through awareness of blood-borne infection and better screening in blood 
banks (Lavanchy, 2009).  
Secondary prevention includes interferon therapy and anti-HBV drugs (oral nucleotides 
analogs) to prevent deterioration of liver damage by suppressing hepatitis. Although interferon 
effects are still debatable, anti-HBV nucleotides analogs suppresses viral duplication and viral 
DNA integration into the host genome (Patterson and Angus, 2009). Secondary prevention is 




1.1.6 Common molecular themes in HCC 
Biological research on HCC to-date had focused on deciphering the various aetiologies 
of HCC and the common pathological pathways that preceded tumourigenesis. Inflammatory 
processes and oxidative stress are in particular a common occurring event in viral-induced 
hepatocarcinogenesis. This often is a consequence of the continuous cycle of liver necrosis and 
regeneration (Farazi and DePinho, 2006).  
This continued uncontrolled growth also led to numerous genetic and epigenetic 
alterations (Thorgeirsson and Grisham, 2002) resulting in numerous chromosomal aberrations 
such as loss of heterozygosity and aberrant DNA methylation patterns (Saito et al., 2001; Lin et 
al., 2001). p53 mutations and inactivation is another event observed in the molecular 
pathogenesis of viral- and AFB1-induced HCC (Feitelson et al., 2002; Zhang et al., 2006; 
Farazi and DePinho, 2006). Other molecular targets of specific pathways such as cyclin 
dependent kinase, oncogenes (cyclin D1, c-myc and c-met) (Fietelson et. al., 2002) and several 
signalling molecules (MAPK) have also been described in HCC. Ability to identify of these 
common molecular targets holds great importance in understanding the molecular processes 
involved in HCC and the promise of creating better drugs or preventive measures. 
 
1.1.6.1 Challenges in understanding HCC  
Despite the continued success of identifying numerous affected genes in 
tumourigenesis, no “true specific” genetic changes have been identified in HCC (Tannapfe and 
Wittekind, 2002). The heterogeneity of genetic aberrations as documented by numerous 
independent HCC studies suggested that distinct molecular players but related genetic pathways 
are likely to be affected during hepatocarcinogenesis (Thorgeirsson and Grisham, 2002). Thus, 
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proposing that neoplastic morphological / pathological changes that are observable in HCC are 
contributed by a variety of possible combinations of molecular alterations.  
The on-going aim to elucidate the development and progression of HCC is currently 
dedicated to identify and characterize new molecular players along with their interactions using 
large scale profiling and comparative technologies. Hypothesis free approaches using “omics” 
based studies are non-biased and have the ability to compare and identify novel molecular 
players. Most importantly, “omics” approaches will provide the opportunity to simultaneously 
highlight groups of aberrant molecules in a sample set. These analyses may shed some light on 
the specific regulatory pathways that are involved in the pathogenesis of HCC. In addition, the 
dysregulated proteins that are identified may assist in identifiying potential biomarkers and to 
elucidate therapeutic targets.  
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1.2 “Omics” based biology in Hepatocarcinogenesis 
The traditional scientific study to solving problems often relies on a “one-gene at a 
time” approach. “Omics” based biology, on the other hand refers to the study of entities in 
aggregate (Weinstein, 1998; Evans, 2000). With the success of genomics in Human Genome 
Project in the late 1990s, coupled with major advancement in high-throughput techniques and 
computational tools, new “omics” disciplines are being developed. These include 
transcriptomics, proteomics, metabolomics, pharmacogenomics and numerous other large scale 
techniques (Weinstein, 2002).  
The promises of “omics” have since led to an explosive number of applications in 
evolutionary analysis, metabolic diseases, drug studies as well as cancer research. The emphasis 
have thus shifted from a linear method of investigating known genes, proteins or mechanism 
towards a hypothesis-free, discovery driven approach with the hope of identifying novel players 
and their interactions. Although, discovery-driven research is different from the traditional 
hypothesis-driven research, it has slowly been accepted to be complementary and synergistic 
(Hieter and Boguski, 1997).  
Current efforts in HCC are also geared towards revealing global expression profiles of 
proteins with the aim to understand the mechanisms involved in hepatocarcinogenesis. The 
following sections describe the “omics” based studies that have been employed for 
identification of molecular alterations and the discovery of various prognostic or diagnostic 
biomarkers. 
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1.2.1  Functional genomics in HCC  
Genomics is one of the major “omics” research directions to date. Genomics, coined by 
Thomas Roderick (1986), described the “scientific discipline of mapping, sequencing and 
analyzing genomes”. The current emphasis is on functional genomics which refers to “genome-
wide or system-wide approaches to assess gene functions using information provided by 
structural genomics” (Hieter and Boguski, 1997). In addition to cytogenetics and interphase 
fluorescence in situ hybridization (FISH), systematic genomic analysis using array-based 
comparative genomic hybridization (aCGH) and genome-wide allelotyping have been routinely 
used to search for genetic aberrations in various diseases including HCC.  
 
1.2.1.1 Chromosomal instabilities  
Genomic alterations such as aberrant patterns of chromosomal instability, CpG 
methylation and DNA arrangements due to HBV integration are often observed in HCC. In an 
attempt to systematically identify these chromosomal rearrangements, aCGH was used on a 
total of 158 HBV-associated HCC cases. In this study, Poon et al., (2006) revealed a tumour 
progression model that associated gains in the chromosomal arm 1q21-23 and 8q22-24 as an 
early event. Additional chromosomal gains in the 3q22-24 arm were described as late genomic 
events that were associated with poor prognosis and tumour recurrence. These results were also 
consistent with previous findings which showed 21% and 17% gains of 1q and 8q in 
preneoplastic lesions of HCC (Zondervan et al., 2000; Marchio et al., 2001).  
Several other frequently reported chromosomal loci aberrations are summarized in 
Table 1.3. These regions have also been reported to contain essential genes that are potentially 
important players in carcinogenesis. Among the chromosomal regions listed in Table 1.3, loss 
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of heterozygosity (LOH) in 17p, 13q, 9p and 6q can be related to reported loss of function in 
p53, retinoblastoma (Rb), p16 and IGF2R respectively. Over-expression of proto-oncogene, c-
myc often observed in HCC may also be attributed to the chromosomal gain in 8q arm.  
 
Table 1.3 : Common chromosomal alterations in HCC 
Chromosomal 
loss  
1p, 4q, 5q, 8p, 9q,13q, 16p, 
16q, 17p 
Nagai et al., 1997 
Kusano  et al., 1999 
Nishida et al., 2003 
Herath  et al., 2006 
Poon et al., 2006 
Hertz et al., 2008 
Saelee et al., 2008 
Chromosomal 
gain 
1q, 3q, 6p, 8q, 17q, 20q 
 
1.2.1.2 Epigenetic alterations 
In addition to chromosomal alterations, malignant transformations due to epigenetic 
alterations such as DNA methylation and histone modifications have also been reported in HCC 
(Herath et al., 2006). Chromatin immunopercipitation assays (ChIP-on-chip) coupled with 
polymerase chain reactions (PCR) or microarray for quick detections is one of the most widely 
used techniques.  
One such study by Kondo et al., (2007) evaluated multiple DNA methylation sites 
quantitatively in 23 paired HCC tissue sample. They identified increase hypermethylation in 
p16INK4a promoter sites with reduced levels of p16 INK4a expression as tumour progresses. Other 
frequent promoter methylation in HCC had also been described in p15 INK4b (Wong et al., 
2000), E-cadherin (Kanai et al., 1997) and 14-3-3 sigma (Kondo et al., 2000).  
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1.2.2 Transcriptomics: gene expression profiling in HCC 
 HCC progression can also be determined by changes in expression levels of cancer-
related genes. With the use of genome wide mRNA expression studies, we are able to obtain a 
comprehensive view of the alteration of gene expression patterns in a disease state. Genomic 
analysis can be conducted with the use of oligonucleotide chips, serial analysis of gene 
expression (SAGE) and complementary DNA (cDNA) microarrays.  
The first cDNA microarray analysis for HCC was reported by Lau et al., (2000) using 
10 pairs of HCC and non-tumourous tissues. Since then, more than 300 microarray studies 
coupled with statistical analysis and bioinformatics had since been applied on HCC studies to 
identify dysregulated genes based on clinicopathological features such as cancer staging, 
progression (Anders et al., 2003; Shao et al., 2005), viral infection (Okabe et al., 2001; Iizuka 
et al., 2002), prediction of metastasis (Chen et al., 2002) and tumour recurrence (Iizuka et al., 
2003).  
 Deregulation of the Wnt/β-catenin pathway, cyclins, cyclin-dependent kinases and 
metabolic proteins, as described earlier in hypothesis driven studies, were also observed in 
microarray analysis (Xu et al., 2001; Thorgeirsson et al., 2006). This thus has increased the 
level of confidence in large scale profiling techniques. Aside from merely identifying molecular 
aberrations, such genome wide studies also enables one to draw insights based on all regulated 
genes as a whole. Iizuka et al., (2005) for example, described that many of the regulated genes 
identified in their HBV-associated HCC analysis were all downstream of c-myc. Although, 
over-expression of c-myc identified was not statistically significant in the study due to large 
heterogeneity in the samples, the data obtained strongly suggested the oncogene as a central 
molecule in HCC progression particularly in genotype-C HBV. 
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DNA microarray has also been used to identify new biomarkers to improve HCC 
detection. Using 218 HCC tissue specimens from patients with either low or high serum AFP, 
Jia et al., (2007) proposed 5 new candidate genes. These include known serum proteins, GPC3, 
midkine (MDK) and SERPINI1 as well as 2 additional genes, PEG10 and QP-C with diagnostic 
potential on patients with normal AFP levels or small HCC. Some of these genes have also 
been observed via other molecular techniques to be up-regulated in tumour tissues (Midorikawa 
et al., 2003; Hippo et al., 2004).  
Collectively, these microarray analyses identified diverse up- and down-regulated genes 
which suggest that a variety of cellular processes are affected in HCC progression. These 
differences could be the result of multiple aetiologies involved in HCC and its mutifactorial 
tumour development (Iizuka et al., 2008). Choi et al., (2004) also cautioned that although 
results from each microarray analysis maybe promising, a single-set analysis may lead to false 
findings. The use of data integrations in meta-analysis was suggested to help identify molecular 
alterations and pathways in uncovering the processes involved in HCC.  
 
1.2.3 MicroRNAs involvement in HCC 
Identification of small non-coding RNAs such as small nucleolar RNA (snRNA), small 
interfering RNAs (siRNA) and microRNAs (miRNA), capable of regulating gene expression 
has since led to the study of RNomics (Filipowicz, 2000; Huttenhofer et al., 2001). miRNA, 
endogenous non-coding RNAs of 20 ± 2 nucleotides, had taken centre-stage due to its ability to 
alter gene expression through mRNA degradation and translational inhibition (Zhang, 2008). 
Consequently, dysregulation of miRNA have been identified in several diseases including 
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cancer (Visone and Croce, 2009). Its expression signatures in tumours can be studied efficiently 
with commercially available microarray with miRNA probes. 
One of the earliest work comparing HCC tumours and non-tumour tissues using miRNA 
by Murakami et al., (2006) identified 8 dysregulated miRNA. Most significantly, using support 
vector machines (SVM) these miRNAs had a prediction accuracy of 97.8 % of HCC versus 
non-tumours classification. Similar analysis had since been used to identify important 
signatures of miRNA clusters in determining metastatic potential (Budhu et al., 2008), HBV 
and HCV specific alterations (Ura et al., 2009) and prognosis of HCC (Li et al., 2008). Other 
studies using miRNA as a new strategy to understand HCC were summarized by Gramantieri et 
al., (2008).  
 
1.2.4 Proteomics  
Proteomics is another key area of research in the post-genomic era which has been 
utilized extensively in numerous cancer studies (Godovac-Zimmermann and Brown, 2001).  
High throughput analysis of the total proteome has been suggested to provide a better 
representation of biological processes as proteins are dynamic and constantly changing in 
response to both external and internal stimuli (Anderson and Anderson, 1998). Proteome 
analysis hence provides data which is not readily apparent from DNA aberrations or expression 
levels of mRNA transcripts. These are of critical importance for the description of the state of a 
biological system such as quantity of protein expression, the subcellular location, the state of 
modification, association with ligands as well as the rate of change with time.  
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The proteome of any cell consists of normally thousands to tens thousands of complex 
mixture of proteins present in different organelles (Haynes and Yates, 2000). Proteins also have 
diverse physicochemical properties such as molecular weight, isoelectric point and 
hydrophobicity which make it impossible to analyse the global expression levels with just a 
single technique. In addition to total protein profiling, studies have also developed sub-cellular 
proteome analysis to focus on protein regulation levels in organelles and post-translational 
modifications. Such prefractionation strategies however involve additional pre-processing steps 
which may cause variations in sample preparations and costs. These extra steps will also require 
higher amounts of proteins which may be limiting for clinical samples.  
Most significantly, proteome analysis can be effectively applied to cell lines, tissues and 
biological fluids such as serum, cerebrospinal fluid and urine. The availability of a wide range 
of samples enables a more encompassing study of a particular organism or disease. The use of 
biological fluids also makes proteomics a more apt technique in biomarker discovery. As 
technology improved, different proteomic platforms have emerged to improve global profiling 
as well as comparative studies. The widely used proteomic platforms are summarized in Figure 
1.2.  Most of these platforms are coupled to mass spectrometry (MS) such as matrix assisted 
laser desorption / ionization (MALDI) or electrospray ionization (ESI) and bioinformatics 




Figure 1.2 : Summary of the various sample, analysis and platforms available in a proteomic 
study. 2-DE; 2-dimensional electrophoresis, 2-D DIGE; 2-dimensional Difference Gel 
electrophoresis, LC; liquid chromatography, MudPIT; Multidimensional Protein Identification 
Technology, SILAC; Stable-isotope labelling by amino acids in cell culture, cICAT; cleavable 
Isotope Coded Affinity Tag; iTRAQ; isobaric tags for relative and absolute quantitation; 
SELDI; surface enhance laser desorption and ionization, SERPA; serological proteome 
analysis, SEREX; serologic analysis of recombinant cDNA expression, MS; mass spectrometry.  
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1.2.4.1 Proteome analysis of HCC cell lines  
Early proteomic studies on hepatocarcinogenesis were dedicated on large scale profiling 
using 2-dimensional gel electrophoresis (2-DE) on various HCC cell lines such as Chang, 
WRL-68 (Wirth et al., 1995) and HCC-M (Seow et al., 2000). 2-DE can also be used in 
comparative analysis to investigate differences between hepatoma (BEL-7404) and normal liver 
cell line (L2) (Yu et al., 2000). These studies also initiated uploading of 2-D gel images and 
data-mining software as a useful resource for other HCC groups (Hochstrasser et al., 1992; 
Liang et al., 2002; Cho et al., 2002). 
HCC cell lines were also used as in vitro models to understand the mechanisms of viral 
induced tumourigenesis. Studies investigating HCV interacting proteins (Choi et al., 2004; 
Kang et al., 2005) and HCV induced liver cell lines (Mannova et al., 2006) identified 
dysregulation in a myriad of factors such as HSP 27, HSP 90, cytokeratins and vesicle 
formation in lipid rafts suggesting direct roles of HCV in inducing tumourigenesis. Similar 
study, using Chang liver cells transfected with HBV-X gene selected 16 regulated protein spots 
but failed to identify them (Tan and Chen, 2005). Without protein identification, no probable 
mechanistic role of HBV-X can be established. 
HCC cell lines with different metastatic capacities were also evaluated using 2-DE by 
comparing cell clones, MHC97-H and MHC97-L (Ding et al., 2004; Cui et al., 2004). It was 
proposed that cytokeratin 19 (Ding et al., 2004) and S100A4 (Cui et al., 2007) might be capable 
in strengthening motility and invasive mechanisms. The same cell lines were also used in a 
recent study using stable-isotope labelling by amino acids in cell culture (SILAC) to identify 
differentially regulated proteins (Chen et al., 2008). A total of 152 proteins were identified, 
several were common to proteins identified in earlier studies. Solute carrier family 12 member 
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2 (SLC 12A2) significantly showed higher levels in MHC97-H and was able to distinguish 
patients’ sera that had high metastasis. Another protein disulfide-isomerase A4 (PDIA4) was 
also able to identify patients’ sera with metastasized lesions. This study described confidently 
that the results from in vitro models can potentially be translated to clinical settings.  
 
1.2.4.2 Proteomic approaches using animal models 
 Animal models have also been used extensively to study the physiological and 
molecular mechanisms of HCC. Various genetic alterations (HBV or HCV induction, HBV-X 
gene, p53 knockouts, c-myc transfections, β-catenin) and chemical induction using 
thioacetamide (TAA), N-nitrosomorpholine (NNM) and ciprofibrate are just some examples 
that have been used to induce cirrhosis and HCC in rodents (reviewed by Newell et al., 2008). 
These models have been instrumental in understanding the various pathway involved in 
initiation and progression of HCC. 
 Some of these studies have also utilized proteomics as a global wide approach in 
identifying the potential molecular players upon drug treatment. Using 2-DE gels, Low et al., 
(2004) proposed the involvement of 4 major metabolic clusters (energy, iron and heme, 
carbonyl compound and gluthathione related proteins) as primary players in the development of 
TAA induced cirrhosis in rat livers. Similar approach was also conducted to study the effects of 
another drug, NNM, and to identify early players in the carcinogenesis process (Fella et al., 
2005). This study also described changes in metabolism and anti-oxidative activities. In another 
study, 2-DE analysis was conducted on an anti-cancer drug, cell differentiated agent II (CDA-
II), to analyse its effects in a metastatic HCC nude mice model (LCI-D20) (Shen et al., 2006; 
Fan et al., 2009). The study successfully showed a 41.8% inhibition of tumour growth and 
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identified 27 differentially expressed proteins (HSP 27, HSP 60, alpha-enolase, cytokeratin 8, 
etc). The study also showed that CDA-II drug reduced the levels of cancer related genes (c-
myc, N-ras, MMP-9).  
 Another well established animal model for HBV-associated HCC, is the woodchuck 
(Marmota monax) which has been shown to develop hepatocellular adenomas upon infection of 
another hepadnaviridae, woodchuck hepatitis virus (WHV) (Tennant et al., 2004). Similar to 
HBV, WHV can also cause chronic hepatitis and HCC. The woodchuck infected by WHV had 
hence been a useful model to understand HBV progression and evaluation of antiviral drugs.  
Among the numerous studies using the woodchuck model, a glycoprotein serum profile 
of WHV infected woodchucks was conducted using 2-DE (Block et al., 2005). This study 
showed higher levels of α-1,6-linked fucosylation in the serum of HCC woodchucks compared 
to those non-HCC. HCC associated proteins such as AFP and α-1-antitrypsin were identified to 
be hyperfucosylated. Additionally, Golgi Protein 73 (GP73) was identified to be elevated and 
hyperfucosylated in woodchucks with HCC. Elevated levels of GP73 were verified in human 
sera infected by HBV with or without tumourigenesis but it was specifically hyperfucosylated 
in viral induced HCC (Mehta and Block, 2008).  
Though further validations of GP73 on a larger human sample size are necessary, this 
study provides evidence of the significance of animal models. Identification of differentially 
expressed proteins in these animal studies enables understanding of the effects of drug 
treatments or genetic alterations as well as novel tumour markers. As it is usually difficult to 
obtain tissues of early stages of tumour in human samples, animal models can help bridge this 
gap and facilitate the understanding of HCC progression.  
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1.2.4.2 Proteome analysis of HCC tissues  
The identification of dysregulated proteins were also extended to comparing proteome 
profiles of human HCC tumour versus non-tumour tissues as well as cirrhotic livers (Kim et al., 
2002; Lim et al., 2002; Park et al., 2002). As summarised in Table 1.4, the most extensively 
used method in HCC analyses had been 2-DE. It was a popular choice because of its ability to 
provide a global view of protein expression and its high resolving power to identify protein 
isoforms and post-translational modifications. The use of fluorescence CyDye labelled samples 
in 2-dimensional Difference Gel electrophoresis (2-D DIGE) (Liang et al., 2005; Lee et al., 
2005) had further improved the conventional 2-DE by minimizing technical limitations such as 
inter-gel non-reproducibility. This had also greatly enhanced the statistical confidence in 
detecting and quantifying true biological changes. 
With the use of gel based comparative analysis, different protein levels in HBV induced 
HCC (Li et al., 2005; Liang et al., 2005; Song et al., 2006; Sun et al., 2007; Zhang et al., 2007) 
and HCV associated HCC (Takashima et al., 2003; Yokoyama et al., 2004; Blanc et al., 2005) 
were evaluated. Comparisons between these 2 viral induced HCC were also described by Kim 
et al., (2003). There were also other works which focused on identifying differences between 
tumour and non-tumour tissues by disregarding the different aetiological factors (Kim et al., 
2002; Zeindl-Eberhart et al., 2004; Lee et al., 2005). In general, these studies revealed frequent 
alterations in enzymes involved in glycolysis, fatty acid metabolism and S-adenosylmethionine 
(AdoMet) cycle. Down-regulation in antioxidation proteins such as catalase and glutathione 
synthetase along with over-expression of heat shock proteins were also common phenomenon.  
High levels of HSP 27, first identified in metastatic tumour tissues by 2-DE, were 
confirmed by western blots and immunohistochemistry (IHC) (Song et al., 2006). This over-
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expression was however not observed in RT-PCR thus illustrating the poor correlation 
efficiency between mRNA and proteins. Phosphorylation levels of HSP 27 were also shown to 
decrease as tumour progresses (Yasuda et al., 2005), suggesting that phosphorylated HSP 27 
has protective mechanisms against tumourigenesis. Luk et al., (2006) further implicated over-
expression of 2 HSP members (HSP 70 and GRP 78) along with HSP27 in determining poor 
prognosis of HBV-associated HCC. Up-regulation of other proteins such as proliferating cell 
nuclear antigen (PCNA) and isoforms of stathmin were also proposed as tumour markers in 
HBV-associated HCC (Li et al., 2005).  
In addition to comparing tumour versus non-tumour tissues, Yokoo et al., (2007), 
elegantly conducted the first proteomic study analysing HCC intrahepatic recurrence. The 
group conducted a comparative proteomics study using 2-D DIGE on tissue samples from 
patients with or without HCC recurrence over a 2 year period after corrective surgery. Twenty-
three differentially expressed proteins involved in signal transduction, glucose metabolism, 
cytoskeletal and chaperone proteins were selected. These were proposed to identify patients 
with a high risk of recurrence that will require further therapeutic strategies. 
A major drawback in 2-DE based studies is the inability to detect low abundant proteins. 
In view of this, Codarin et al., (2009) analysed only nuclear enriched proteins from the tumour 
and its corresponding non-tumour samples. This was the first study to analyse subfractionated 
HCC liver samples. The group identified 52 proteins including HSPs and metabolic proteins 
that have been well described in earlier studies and 7 proteins not previously studied in HCC. 
Though the proteins identified also included non-nuclear proteins possibly due to 
contaminations during enrichments, the identification of these proteins will shed light on their 
functional roles in tumourigenesis.  
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Although the majority of the work conducted thus far were dominated by 2-DE, the 
limitations of gel based method had became gradually apparent. Its inability to identify low 
copy number proteins, hydrophobic proteins and proteins with extreme size and isoelectric 
point has often been raised. Therefore, in recent years alternative proteomic platforms have 
been progressively introduced in numerous cancer researches. To date, there have only been 5 
HCC proteomic studies using protein microarray, SELDI-TOF MS and non-isotope labels 
coupled with liquid chromatography (Table 1.4).  
Protein microarrays made up of 83 different antibodies were used to analyse 30 HCC 
and the non-tumour tissues. This technique enabled high-throughput analysis of a specific list of 
proteins of interest. Thus Tannapfel et al., (2003) were able to successfully identified 32 
significantly regulated proteins. These proteins were confirmed with western blots and 2 of 
which (cyclin D1 and suppressor of cytokine signalling 1) were further investigated using tissue 
microarray on 210 HCC samples. By using parallel methods, these studies were able to 
convincingly prove the dysregulation of the proteins identified.  
Using another array based technique, SELDI, Melle et al., (2004) were able to 
successfully identify 2 distinct peptide sequences but were however, unable to identify the 
proteins. SELDI coupled with 2-DE was later used by the same group (Melle et al., 2007) and 
they identified 53 proteins, 3 of these (ferritin light subunit, adenylate kinase 3 and bliverdin 
reductase B) were further confirmed by IHC. Since SELDI technique required small amount of 
samples for analysis, it was proposed to be an ideal method for HCC studies. 
In addition, stable isotope labelling techniques using, isotope-coded affinity tags (ICAT) 
and isobaric tags for relative and absolute quantitation (iTRAQ) have also been used in recent 
HCC analysis. These methods allow the multiplexing of different samples that have been pre-
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labelled with the respective isotopes before undergoing liquid chromatography and mass 
spectrometry (MS). The difference in expression levels can be determined by the relative peak 
intensities from the MS spectrum. Li et al., (2004) used cICAT to compare the expression 
profile of one pair of HCC tumour and non-tumour tissue. Although the work identified 149 
regulated proteins, the use of only 1 pair of tissues rendered it statistically insignificant and 
would require further anlaysis.  
Similarly, in a recent iTRAQ study, only one pair of HCC tumour and non-tumour 
tissues were used and identified 141 regulated proteins (Chaerkady et al., 2008). This study 
however used 174 tissue microarrays (TMAs) to validate a subset of proteins. These include 
enzymes in the urea cycle, which were described for the first time as being down-regulated in 
HCC tumours. The significance of urea cycle aberration is however not clear from their studies. 
Despite the use of only one pair of HCC tissue and the lack of in depth analysis, the use of 
liquid chromatography separation coupled to cICAT or iTRAQ labels greatly enhanced the 
number of proteins being identified. This may enable us to better understand the molecular 
prognosis of HCC.  
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1.2.4.3 Proteome analysis of serological markers for HCC  
 Identification of biomarkers using biological fluids has been especially attractive due to 
the non-invasive nature of sample collection. Serum proteomics were traditionally conducted on 
2-DE comparing disease patients’ sera against normal sera. Steel et al., (2003) identified 
decrease of carboxy terminal fragment of complement C3 and an isoform of apolipoprotein 
A1in HBV-associated HCC patients. However lowered levels were also observed in HBV 
carriers without HCC which suggest that the changes were not cancer specific. 
 A common problem in serum 2-DE profiles (Steel et al., 2003) is the inherent high 
abundant serum proteins such as albumin and immunoglobulin that often masks other proteins 
in the region. This also limits the dynamic range of proteins that can be identified. This can be 
overcome by immunodepletion of abundant proteins (Kawakami et al., 2005; Feng et al., 2005). 
Alternative strategies using surface enhance laser desorption and ionization-time of flight mass 
spectrometry (SELDI-TOF MS) have also been used extensively (Schwegler et al., 2005; 
Paradis et al., 2005; He et al., 2008). This technique was however only able to identify 
differential peaks without protein identification. Other drawbacks also included limited 
dynamic range and reproducibility (Anderson and Anderson, 2002).  
 There is also increasing evidence that there is a human immune system response to 
tumours, hence indicating the presence of tumour derived auto-antibodies. Taking advantage of 
this, several studies aimed at elucidating auto-antibodies in serum were reported. This was 
accomplished by serologic analysis of recombinant cDNA expression libraries (SEREX) (Wang 
et al., 2002), screening serum auto-antibodies against protein antigens on microarrays and 2-DE 
western blots (serological proteome analysis; SERPA).  
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 Using SEREX and SERPA, Takashima et al., (2006) successfully identified 4 proteins 
which elicited immunoreactivity against HCC sera. The pathological significance of heat shock 
70 kDa protein 1 (HSP70), glyceraldehyde 3-phosphate dehydrogenase, peroxiredoxin and 
manganese superoxide dismutase (Mn-SOD) remained to be elucidated. A similar study 
identified 28 immunoreactive proteins, 17 of which also showed response using sera from 
cirrhosis or chronic hepatitis patients (Looi et al., 2008). The eleven HCC specific proteins 
include HSP70, peroxiredoxin as identified earlier and several others such as aconitate 
dehydrogenase and fumarate hydratase. Whilst the potential of these tumour associated auto-
antibodies is great, studies have cautioned of the lack of cancer specific auto-antibody. There is 
thus, a need to validate these makers against other malignancies (Wright et al., 2007).  
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1.3 Current perspective in HCC studies  
The pioneer HCC proteomic studies reported earlier highlighted the enormous potential 
of proteomics in understanding HCC. A large number of studies described aberrations in 
metabolic pathways, dysregulations of antioxidation proteins, heat-shock protein members and 
various transport proteins. These common alterations have also been summarized in several 
recent reviews (Sun et al., 2007; Santamaria et al., 2007; Sun et al., 2009).  
The increasing number of differentially regulated proteins obtained thus far has no 
doubt extended the current knowledge of HCC molecular pathogenesis. There is however 
increasing concerns in the heterogeneity of protein repertoires identified by the different 
proteomic analyses (Santamaria et al., 2007). This disparity in protein data observed may be 
attributed by the concept that tumours are often heterogeneous and are capable of progressing 
through diverse molecular pathways. Additionally, these variations are also likely contributed 
by the use of non-standardized tissues samples (as observed in Table 1.4). This included 
analyses using different stages of HCC tissues and various aetiologies such as HBV- , HCV- or 
alcohol-induced HCC. Other confounding factors include the use of different controls or 
reference samples. Therefore, these variations in the choice of biological samples used, hinders 
our ability to constructively integrate the molecular data obtained from the different HCC 
studies. This thus hampers the ability to fully understand the disease and create hurdles in 
identification of biomarkers. 
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1.3.1 Advantages and limitations of proteomic platforms 
 Another possible contributing factor that results in the variation of proteins identified 
could be due to the techniques utilized. As described earlier, most of the studies to date had 
employed gel based (2-DE and 2-D DIGE) separation coupled with mass spectrometry analyses 
(Table 1.4). This technique aimed to identify differentially regulated proteins by visualization 
of thousands of proteins on a 2-D gel. It is commonly used because of its ability to identify 
protein isoforms and post-translational modifications. In addition to merely eye-balling the 
differences, softwares are currently available to aid in improving the accuracy in selecting 
regulated protein spots. Despite these improvements, and the utility of CyDye in 2-D DIGE, 
this technique still has its inherent limitations. Identification of HCC dysregulated proteins are 
hence constrained by protein resolution in the 2-D gel. For example, low abundant proteins as 
well as proteins with extreme molecular weight, isoelectric point, or hydrophobicity are often 
missed in HCC analysis utilizing 2-D DIGE.  
 As an alternative to gel based separation, liquid chromatography techniques directly 
coupled to mass spectrometers had also been used in HCC proteome profiling. These 
techniques are capable of identifying complex samples via separation of peptides in one or 
more consecutive chromatographic steps such as strong cation exchange followed by reverse-
phase column to increase resolution (e.g. MudPIT). Liquid chromatographic techniques 
overcome the major limitation that 2-DE faced, by separating peptides instead of proteins. The 
other advantages of LC-MS include automation and high processing speed.  
 This approach can also be used for comparative proteomics with the use of stable 
isotope labelling. Peptide mixtures can be pre-labelled with cleavable Isotope Coded Affinity 
Tags (cICAT) (Li et al., 2004) and isobaric tags for relative and absolute quantitation (iTRAQ) 
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(Chaerkady et al., 2008). Differential protein expression between HCC tumours and non-
tumours can then be determined by the relative abundance of the various peptides as determined 
by the mass spectrometers. Despite the successes in using this technique, it does have its 
limitations. For example, it requires strong computational capabilities to manage the large data 
generated and accurately and significantly identify differentially regulated proteins. Most 
significantly, is the loss information for post-translational modifications and / or protein 
isoforms that are not able to be discern by peptide sequences that are identified by mass 
spectrometry.  
Therefore in recent years it is apparent that due to the inherent bias and limitations of 
each methodology, each approach results in limited targets with lack of depth and coverage. It 
is thus accepted that no single technique in protein separation is complete when attempting to 
profile proteome changes.  
 
1.3.1.1 Proposed multiple proteomic approaches  
In an effort to overcome the limitations and to harvest the advantages of the different 
platforms discussed, new strategies to combine these approaches had been gaining popularity. 
Several comparative studies had since employed two different techniques to increase the ability 
of identifying dysregulated proteins effectively. These included HCC analysis using SELDI-
TOF and 2-DE (Melle et al., 2007), brain ischemia using 2-DE and ICAT approaches (Khwaja 
et al., 2007; Haqqani et al., 2007) and endometrial cancer tissues using ICAT and iTRAQ 
(DeSouza et al., 2005).  
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The possibility of using 3 different proteomic approaches was also explored by Wu et 
al., (2006). They used a 6-protein mix standard and optimization on colorectal cancer cell line 
(HCT-116) and observed that there was limited overlap of proteins identified by the different 
methods. These preliminary studies suggest that these techniques are complementary and the 




2. AIMS OF THE STUDY 
Carcinogenesis of the liver represents a complex and multi-factorial disease. It entails a 
myriad of aetiologies and molecular mechanisms that may not be justifiably elucidated by 
single-candidate studies. Despite numerous functional genomics researches thus far, the 
challenges of understanding HCC are continuously fuelled by the inconsistencies in targets 
identified by the different groups. This is most commonly due to maverick choices of samples 
and differing identification methods. Henceforth, even with the most computationally-advanced 
analytical platforms, we are unable to comprehend the changes that occur during the 
development and progression of the disease.  
In this project, we utilize 3 quantitative proteomic strategies to comprehensively identify 
the differentially expressed proteins involved in hepatocarcinogenesis. This effort aims to 
reconcile the library of data by restricting technology-specific limitations and technical 
discrepancies. Additionally the panel of tissue samples, carefully selected to reflect local 
demographics, were matched for gender, presence of liver cirrhosis and HBsAG positivity. The 
end point of this project concomitantly seeks to identify new targets that may narrow gaps of 
missing links involved in the progression of HBV-associated hepatocarcinogenesis.  
The main aims of this project can be summarized as following:  
1. Identify differentially expressed proteins in tumour tissues against their adjacent 
non-tumour tissues using three quantitative proteomic analyses. These techniques 
are (i) 2-D DIGE using CyDye labels followed by gel-based separation as well as 
stable isotope labels (ii) cICAT and (iii) iTRAQ followed by 2-dimensional liquid 
chromatography (2-D LC).  
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2. Ascertain the proteins that are involved in the progression of HCC by profiling two 
stages of the cancer, moderately- and poorly-differentiated tissues, separately. 
3. Verify the selected proteins identified from this study using western blots. This will 
confirm the observations made by the proteomics approaches.  
4. Characterize a novel protein family, far upstream binding proteins (FUBPs), 
identified as over-expressed in both stages of HCC analysed in this study. In order to 
understand FUBPs role in cancer progression in vitro transfections were also 
conducted on two different HCC cell lines, Hep3B and HepG2. 
 
This is the first single effort to apply three quantitative techniques to achieve a 
comprehensive snapshot of proteomic changes in HCC tumourigenesis. The proteins identified 
serve as a basis of future investigative work to extend better understanding in the molecular 
pathogenesis of HCC. Studies as such opens up novel avenues towards understanding the 
biology of liver cancer, and in turn advance areas in disease preventive, treatment and 




3. MATERIALS AND METHODS 
3.1  Materials  
3.1.1 Hepatocellular Carcinoma Tissues 
The liver tissues used in this study were obtained from twelve patients diagnosed with 
either moderately differentiated HCC or poorly differentiated HCC. All patients were male and 
suffered from cirrhosis with chronic HBV infection. There was also no metastasis at the point 
of surgery. Tissues collected were grouped according to histology report; 5 had moderately 
differentiated HCC; and 7 had poorly differentiated HCC. The clinical data of the patients are 
presented in Table 3.1. Paired tissues were obtained from each patient, one from the adjacent 
non-tumour (normal) region and the other from the tumour region of the resected liver. The 
tissues were immediately snap-frozen in liquid nitrogen and stored at -151oC before use. Usage 
of these samples was approved by the Ethics committee. 
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Table 3.1 : Clinical characteristics of patient samples used in this study. 
Patient 
No. TNM Tumour size (cm) Serum ALB (g/L) 
Age at 
operation Ehinicity  
Moderately differentiated HCC      
131 T3N0M0 8.00 42 32 Chinese  
196 T3N0M0 2.50 44 40 Chinese  
199 T3NXMX 7.80 31 63 Chinese  
200 T4N0M0 4.50 39 42 Chinese  
203 T3NXMX 4.50 39 69 Chinese  
Poorly differentiated HCC      
120 T3NXMX 6.00 25 66 Indian  
126 T3N0M0 5.00 37 53 Chinese  
155 T4NXMX 9.00 38 63 Chinese  
157 T3N0M0 8.00 17 66 Chinese  
187 T3N0M0 13.10 38 61 Chinese  
207 T3N0MX 6.00 40 61 Javanese  
215 T4NXMX 3.80 42 83 Chinese  
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3.1.2 Cell lines  
Liver cell lines, HepG2 and Hep3B were provided by Dr Theresa Tan (Department of 
Biochemistry, NUS) and Bioprocessing Technology Institute respectively. All cells were 
maintained at 37oC in a 5% CO2 humidified atmosphere.  
 
3.1.2.1 Cell culture media and reagents 
Cell Culture Reagents Source 
Dulbecco’s Modified Eagles’ Medium 
(DMEM)  
Sigma Aldrich (St. Louis, MO, USA) 
Fetal Bovine Serum (FBS) Gibco, Invitrogen Corporation (Carlsbad, 
CA, USA). 
Sodium Bicarbonate Sigma Aldrich 
Trypsin (+ EDTA) GIBCO BRL (Gaithersburg, MD, USA) 
10X PBS NUMI  
 
3.1.3 Instruments and Equipments 
3.1.3.1 Isoelectric Focusing (IEF) 
Pre-cast non-linear (NL) 7 cm or 18 cm Immobilized pH Gradient (IPG) strips, pH 3-10 (GE 
Healthcare Bio-Sciences, Sunnyvale, CA, USA) 
Ettan IPGphor / IPGphor II IEF unit (GE Healthcare Bio-Sciences) 
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3.1.3.2 SDS-PAGE  
PROTEAN-II XL electrophoresis cell (Bio-Rad Laboratories, Hercules, CA, USA) 
Mini PROTEAN-III electrophoresis module (Bio-Rad Laboratories) 
 
3.1.3.3 Liquid Chromatography  
 UltimateTM dual-gradient LC system equipped with a ProbotTM MALDI (Dionex-LC Packings, 
Sunnyvale, CA, USA) 
Strong cation-exchange (SCX) column (FUS-15-CP, Poros 10S) (Dionex-LC Packings) 
C18 PepMapTM, 0.3 × 1-mm trap column (3 –µm, 100 Å) ( Dionex-LC Packings) 
Monolithic PS-DVB,  0.2 × 50-mm reverse-phase column ( Dionex-LC Packings). 
 
3.1.3.4 Mass Spectrometry  
Applied Biosystems 4700 and Applied Biosystems 4800, Proteomics Analyzer [Matrix-assisted 
laser desorption/ ionization time-of-flight/time-of-flight mass spectrometer (MALDI-
TOF/TOF-MS)] (Applied Biosystems Inc., Framingham, MA, USA) 
 
3.1.3.5 Transblotter 




Beckman TL-100 Ultracentrifuge (Beckman Coulter Inc., Fullerton, CA, USA) 
Eppendorf Centrifuge 5810R (Hamburg, Germany) 
 
3.1.3.7 Spectrophotometer 
Infinite M200 Tecan (Männedorf, Switzerland) 
 
3.1.3.8 Scanners 
UMAX ImageScanner (UMAX Technologies Inc.) (Fremont, CA, USA) 
Molecular Dynamics TYPHOON 9410 variable mode Imager (GE Healthcare Bio-Sciences) 
 
3.1.4 General Chemicals and Reagents  
  Chemicals & Reagents Source 
2D Cleanup Kit GE Healthcare Bio-Sciences 
α-cyano-4-hydroxycinnamic acid (CHCA) Sigma Aldrich (St. Louis, MO, USA) 
Acetic acid Merck (Darmstadt, Germany) 
Acetonitrile EM Science (Gibbstown, NJ, USA) 
Ammonium bicarbonate Sigma Aldrich 
Ammonium Persulfate (APS) Bio-Rad Laboratories  





Cleavable Isotope Coded Affinity Tags (cICAT) labels 
and reagents  
Applied Biosystems Inc. 
Coomassie® Plus Protein Assay Reagent Kit Pierce (Rockford, IL, USA) 
Cover Fluid GE Healthcare Bio-Sciences 
Cy3 N-hydroxysuccinamide ester DIGE dyes (Cy3) 
Cy5 N-hydroxysuccinamide ester DIGE dyes (Cy5) 
Cy2 N-hydroxysuccinamide ester DIGE dyes (Cy2) 
GE Healthcare Bio-Sciences 
 
 
Dimethyl sulphoxide (DMSO) Sigma Aldrich 
Dithiothreitol (DTT) Bio-Rad Laboratories 
DNase I Roche Diagnostic (Mannheim, 
Germany) 
EDTA disodium dihydrate Bio-Rad Laboratories 
Formaldehyde Merck 
Glycerol BDH laboratory Supplies (Poole, 
England) 
Glycine Merck 
Glycine, ultrapure, MB Grade USB 
HALT™ protease inhibitor cocktail (100X) Pierce 
Iodoacetamide (IAA) Sigma Aldrich 
IPG buffer GE Healthcare Bio-Sciences 
isobaric Tags for Relative and Absolute Quantification 
(iTRAQ) labels and reagents Kit 
Applied Biosystems Inc. 
LipofectamineTM RNAiMAX  Invitrogen 
Methanol Merck 
RNase A Roche Diagnostic 
Seaplaque® GTG® Agarose, Low melting temperature 
agarose 
BMA ( Rockland, ME, USA) 
Silver Nitrate Merck 
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Non-Targetting Pool Control, D-001810-10-05 
Dharmacon RNAi Technologies 




Skimmed Milk Anlene 
Sodium carbonate Merck 
Sodium dodecylsulfate (SDS) Bio-Rad 
Sodium thiosulfate Merck 
Thiourea Fluka Chemie (Buchs, Switzerland) 
Tris(hydroxymethyl)-aminomethane (Tris) J.T. Baker (Phillipsburg, NJ, USA) 
Tris(hydroxymethyl)-aminomethane (Tris) ultrapure, 
MB Grade 
USB 
 Trifluoroacetic acid (TFA) Sigma Aldrich 
Trypsin (sequencing grade)  Promega Corporation (Madison, WI, 
USA) 
Trypsin (+ CaCl2) Applied Biosystems Inc. 
Urea Bio-Rad Laboratories 
Urea, ultrapure, MB Grade USB 
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3.1.5 Western Blot reagents 
3.1.5.1 Antibodies 
Antibodies Source 
Mouse anti-Fumarate Hydratase  
(H00002271-M01) 
Abnova (Taipei City, Taiwan) 




Rabbit anti-Alpha enolase (sc15343) Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA, USA). 
Rabbit anti-Superoxide dismutase (Cu-Zn)  
(ab20926) 
Abcam PLC (Cambridge, UK) 
Rabbit anti-Catalase (AB1212) Millipore (Billerica, MA, USA) 
Mouse anti-DJ1 (sc70964) Santa Cruz Biotechnology Inc. 
Rabbit anti-Regucalcin (SML-RO1001-EX) 
 
CosmoBio Ltd. (Tokyo, Japan 
Mouse anti-ES1 (H00008209-M01) Abnova 
Mouse anti-GRP75 (SPS825) Stressgen (Victoria, BC Canada, USA) 
Rabbit anti-Ezrin (ab40839) Abcam 
Mouse anti-Nucleophosmin (ab10530) Abcam 
Rabbit anti-Periostin (ab14041) 
 
Abcam 
Rabbit anti-Lupus LA (sc33593) 
 
Santa Cruz 
Mouse anti- Nucleotide diphosphate kinase A 
/ NDKA  (ab27719) 
Abcam 




Mouse anti-FUSE Binding Protein 3 (FUBP3) 
(ab53438) 
Abcam 
Rabbit anti- c-myc (sc764) Santa Cruz 
Rabbit anti-actin (A2066) Sigma 
Rabbit anti-glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (sc25778) 
Santa Cruz Biotechnology Inc. 
Goat anti-rabbit IgG, HRP conjugated Pierce  
Sheep anti-mouse IgG, HRP conjugated GE Healthcare Bio-Sciences 
 
3.1.5.2 Detection System 
Enhance Chemiluminescence (ECL) Western blotting detection system (GE Healthcare Bio-
Sciences). 
Advanced- ECL (AECL) Western blotting detection system (GE Healthcare Bio-Sciences).  
Super Signal West Dura substrate (Pierce)  
Kodak Biomax MR Film (Eastman Kodak Company, Rochester NY, USA)  
Konica Minolta Processing Machine SRX-101A (Germany) 
 
3.1.6 Softwares and Databases 
3.1.6.1 Image Analysis 
ImageQuant software (GE Healthcare Bio-Sciences) 
DeCyder image analysis software (Ver. 6.5):  Differential In-gel Analysis (DIA) and Biological 
Variation Analysis (BVA) software (GE Healthcare Bio-Sciences) 
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3.1.6.2 MS Data Analysis 
GPS ExplorerTM software Version 3.6 (Applied Biosystems Inc.) 
MASCOT search engine (version 2.1; Matrix Science)  
International Protein Index (IPI) human database Version 3.31 (European Bioinformatics 







3.2 Sample preparation 
3.2.1   Tissue sample preparation  
Human liver tissues were ground into a fine powder in liquid nitrogen and subsequently 
solubilized in a cocktail of 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 10 mM Tris 
supplemented with 1x HALT protease inhibitor cocktail, 50 µg/ml DNase I and 50 µg/ml 
RNase A. The lysates were then centrifuged at 50 000 g (Beckman TL-100 Ultracentrifuge) for 
2hr at 15oC to remove any insoluble cell debris. The supernatant was stored at -80oC. All 
protein estimations were carried out using the Coomassie Plus Protein Assay Reagent kit with 
minor modifications. Bovine serum albumin provided in the kit was used as the standard. 
 
3.2.2 Cell line sample preparation  
3.2.2.1 Cell culture  
HepG2 and Hep3B cells were cultured in Dulbecco’s Modified Eagles’ Medium 
(DMEM) in 10% MEM non-essential amino acid, 10% sodium pyruvate and 10% FBS. Media 
were changed every 3-4 days and cells were split by trypsinization with 0.5% (w/v) trypsin and 
0.2% (w/v) ethylenediaminetetraacetic acid disodium salt (EDTA) when they reached 
confluence.  
 
3.2.2.2 Cell lysate preparation  
At the appropriate time point and confluence, cells were rinsed with 1X PBS and 
trypsinized. After 5 min, media containing FBS were added to terminate the action of trypsin. 
The resulting suspension was centrifuged at 100g for 10 min at 4 oC. After discarding the 
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supernatant, the cells were resuspended in ice-cold 1X PBS. The cells were washed thrice 
before centrifuging at 8000g for 5 min at 4 oC and the supernatant was removed. The final cell 
pellet was incubated for 30 min in a cocktail of 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 10 
mM Tris supplemented with 1x HALT protease inhibitor cocktail, 50 µg/ml DNase I and 50 
µg/ml RNase A. This solution was centrifuged at 20 817 g (Eppendorf Centrifuge 5810R), 15oC 
for 1 hr to remove any insoluble cell debris. The supernatant was stored at -80oC and protein 
concentration was determined using Coomassie Plus Protein Assay Reagent kit with some 
modifications. 
 
3.3  2-dimensional gel electrophoresis (2-DE) 
3.3.1 Isoelectric Focusing on IPG (Immobilized pH gradient) Strips 
Pre-cast 7 cm or 18 cm, pH 3-10 nonlinear immobilized pH gradient (IPG) strips were 
rehydrated passively for 16 hr with 150 µl or 350 µl of rehydration buffer respectively. The 
rehydration buffer consisted of 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 20 mM dithiothreitol 
(DTT), 0.2% (w/v) IPG buffer and trace amounts of bromophenol blue. The IPG strips were 
overlaid with a low viscosity Immobiline DryStrip Cover Fluid to minimize evaporation and 
urea crystallization.  
Rehydrated IPG strips were transferred onto a flatbed Ettan IPGphor Electrophoretic 
Unit for isoelectric focusing. The samples were then loaded using the cup loading method on 
Ettan IPGphor Strip Holders. First dimensional IEF was performed at a maximum current 
setting of 50 µA per strip at 20 oC. The protocol for 7 cm IPG strip was as follows : (i) 100 V, 
50 Vhr; (ii) 200 V, 100 Vhr; (iii) 500 V, 250 Vhr; (iv) 1000 V, 500 Vhr; (v) 1000 V-8000 V, 
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4500 Vhr; (vi) 8000 V, 12000 Vhr achieving a total of 17400 Vhr for 4.5 hr. Isoelectric 
focusing for the 18 cm strip was performed with the following parameters: (i) 200 V, 500 Vhr; 
(ii) 500 V, 750 Vhr: (iii) 1000 V, 500 Vhr; (iv) 1000-8000 V, 2250 Vhr; and (v) 8000V, 40 000 
Vhr; achieving a total of 44 000 Vhr for 10 hr. 
 
3.3.2 Second Dimension Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis 
(SDS – PAGE)  
A two-step equilibration procedure using SDS-containing buffer was performed on the 
focused IPG strip prior to the second dimensional separation in SDS-PAGE. In the reducing 
step the strip was saturated with solution containing 6M urea, 30% (v/v) glycerol, 50mM Tris-
HCl (pH 6.8), 1% (w/v) DTT, 2% (w/v) SDS and trace amounts of bromophenol blue dye for 
15 min with constant mixing on a shaker. This was followed by an alkylating reaction using a 
similar buffer with DTT being replaced by 2.5% (w/v) iodoacetamide (IAA) buffered at pH 8.8 
for 15 min.  
IPG strips were then loaded onto 1.0-mm thick, 10 % polyacrylamide gels and sealed in 
place with 0.75% (w/v) agarose dissolved in Tris/Glycine/SDS electrophoresis buffer with trace 
amount of bromophenol blue. SDS-PAGE was performed at a constant current of 15 mA/gel for 
the small gels and 15 mA/gel for 20 min followed by 30 mA/gel for the large format gels. 
MINI-PROTEAN III was used for the small gels and PROTEAN II xi cell electrophoresis unit 
was used at 10oC for the large gels. Tris/Glycine/SDS electrophoresis buffer used was 25 mM 
Tris, 192 mM glycine and 0.1% (w/v) SDS. SDS-PAGE was carried out until the tracking dye 
had migrated to within 3 mm from the end of the gel. Broad range or dual-colour molecular 
weight standards applied on sample application strips were electrophoresed concurrently. 
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3.3.3 Vorum Silver Staining  
After SDS-PAGE, the gels were removed from the glass plates for silver staining. The 
gels were fixed in 50% methanol, 12% acetic acid and 0.05% formalin for at least 2 hr. They 
were washed in 35% ethanol thrice for 20 min. The gels were then sensitized in 0.02% sodium 
thiosulphate for 2 min. After each gel was rinsed thrice with water for 5 min, they were 
incubated in 0.2% silver nitrate and 0.076% formalin for 20 min. The silver nitrate solution was 
then discarded and each gel was washed twice for 1 min with water.  
The gels were then developed in 6% sodium carbonate, 0.004% sodium thiosulphate and 
0.05% formalin. The developer was removed upon attaining the desired intensity and 1.46% 
sodium EDTA was added for 20 min to stop the reaction. Finally, each gel was washed thrice 
with water for 5 min. Every step was carried out under constant shaking. The images of silver 
stained gels were captured using the Image Master Lab Scan v3.01 software. 
 
3.3.4  Difference Gel Electrophoresis  
3.3.4.1 Labeling with CyDye Flours 
Liver tissue lysates were labelled with Cy2, Cy3 and Cy5 following the protocols in the 
Ettan DIGE User Manual (GE Healthcare Biosciences) with minor modifications. Briefly, 40 
µg of protein from either the non-tumour or tumour lysates were labelled with of 320 pmol of 
Cy3 or Cy5. For each pair of tissue, triplicate gels were run. A dye-swap was performed on one 
out of the three gels. The pooled standard which contained all the samples was labelled with 
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320 pmol of Cy2 to serve as an internal standard for image matching and cross-gel statistical 
analysis.  
The amount of dye added ensured that only 3% of the available proteins and only a 
single lysine residue per protein molecule was labelled (minimal labelling) so that the 
molecular weight and solubility of labelled proteins were not affected. These were incubated on 
ice in the dark for 30 min before 1 µl of 10 mM free lysine was added to quench the reaction.  
An equal volume of sample buffer consisting of 7 M urea, 2 M thiourea, 4% CHAPS 
and 10 mM Tris was added to each labelled sample and allowed to stand on ice for 10 min. 
These labelled samples were then pooled accordingly for 2-D DIGE analysis. IEF and SDS-
PAGE was conducted as stated above. The DIGE experimental design for moderately and 
poorly differentiated HCC liver tissues are shown in Table 3.2 and 3.3 respectively.  
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Table 3.2 : DIGE experimental design for moderately-differentiated HCC liver tissues. A total of five 
paired samples were used. For each sample pair triplicate gels were run, and which are represented by A, 
B and C.  
Gel  No. Cy 2 Standard Cy 3 Cy 5 
01 
Pooled sample from all 5 
patients – 131 , 196 , 199 
, 200 , 203 
Non-Tumorous 131A Tumorous 131A 
02 Non-Tumorous 131B Tumorous 131B 
03 Tumorous 131C Non-Tumorous 131C 
04 Non-Tumorous 196A Tumorous 196A 
05 Non-Tumorous 196B Tumorous 196B 
06 Tumorous 196C Non-Tumorous 196C 
07 Non-Tumorous 199A Tumorous 199A 
08 Non-Tumorous 199B Tumorous 199B 
09 Tumorous 199C Non-Tumorous 199C 
10 Non-Tumorous 200A Tumorous 200A 
11 Non-Tumorous 200B Tumorous 200B 
12 Tumorous 200C Non-Tumorous 200C 
13 Non-Tumorous 203A Tumorous 203A 
14 Non-Tumorous 203B Tumorous 203B 
15 Tumorous 203C Non-Tumorous 203C 
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Table 3.3 : DIGE experimental design for poorly-differentiated HCC liver tissues. A total of seven 
paired samples were used. For each sample pair triplicate gels were run, and which are represented by A, 
B and C. 
Gel  No. Cy 2 Standard Cy 3 Cy 5 
01 
Pooled sample from all 7 
patients – 120 , 126 , 155 
, 157 , 187 , 207 , 215 
Non-Tumorous 120A Tumorous 120A 
02 Non-Tumorous 120B Tumorous 120B 
03 Tumorous 120C Non-Tumorous 120C 
04 Non-Tumorous 126A Tumorous 126A 
05 Non-Tumorous 126B Tumorous 126B 
06 Tumorous 126C Non-Tumorous 126C 
07 Non-Tumorous 155A Tumorous 155A 
08 Non-Tumorous 155B Tumorous 155B 
09 Tumorous 155C Non-Tumorous 155C 
10 Non-Tumorous 157A Tumorous 157A 
11 Non-Tumorous 157B Tumorous 157B 
12 Tumorous 157C Non-Tumorous 157C 
13 Non-Tumorous 187A Tumorous 187A 
14 Non-Tumorous 187B Tumorous 187B 
15 Tumorous 187C Non-Tumorous 187C 
16 Non-Tumorous 207A Tumorous 207A 
17 Non-Tumorous 207B Tumorous 207B 
18 Tumorous 207C Non-Tumorous 207C 
19 Non-Tumorous 215A Tumorous 215A 
20 Non-Tumorous 215B Tumorous 215B 
21 Tumorous 215C Non-Tumorous 215C 
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3.3.4.2 Protein visualization  
Each of the fluorescent tagged samples in a gel was visualized independently by the 
Typhoon Variable Mode Imager 9410 using optimal excitation/emission wavelength for each 
DIGE fluor: Cy2 (488/520 nm), Cy3 (532/580 nm), and Cy5 (633/670 nm). The images were 
previewed and checked by ImageQuant v5.0. By overlapping Cy3 and Cy5 images, the spots 
that were up- or down- regulated could be visualized. Protein spots stained mainly by Cy5 had 
red hues, while those stained by Cy3 appeared greenish in colour. An equal representation of 
both dyes in the protein spots appeared yellow. Following fluorescence scanning, the CyDye 
labeled gels were post stained with silver stain to detect protein spots for excision. Silver 
staining was carried out as stated in Section 3.3.3.  
 
3.3.4.3 Decyder image analysis 
Computerized evaluations of the highly complex DIGE gels patterns were performed 
using a specially designed DeCyder image analysis software (Ver. 6.5): Differential In-gel 
Analysis (DIA) and Biological Variation Analysis (BVA). The DIA software was used to co-
detect the Cy2, Cy3 and Cy5 images for each gel. It also helped to detect protein spots for the 
calculation of the normalized protein abundance difference between samples relative to the 
internal standard. BVA was used to match multiple images from different gels and provide 
statistical data on differential protein expression levels for comparative cross-gel statistical 
analysis.  
A threshold limit of 1.5-fold difference was selected as the statistically significant 
quantitative change and student’s t-test at 95% statistical confidence (significance level, p < 
0.05) was set. Spots were also manually confirmed to be significantly regulated when viewed 
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using the 3-D simulation of the protein spot intensity. In addition, the spots must be present in 
at least 3 out of 5 gels for the moderately differentiated and 4 out of 7 for the poorly 
differentiated HCC tissues.  
 
3.3.5 In-gel tryptic digestion 
Spots that satisfied the above criteria were selected for excision and in-gel tryptic 
digestion. Briefly, differentially expressed proteins were manually excised using a self made 
plunger from the silver stained DIGE labeled gels and transferred to a 96-well polymer 
microtitre plate. Each gel spot was incubated in 150µl of washing buffer (2.5mM ammonium 
bicarbonate, 50% (v/v) ACN) at 4°C for at least 24 h. A fresh aliquot of washing solution was 
replaced and each spot was incubated for 15 min at 37°C, followed by drying in a centrifugal 
concentrator. The spots were then subjected to reduction with 20 µl of 10 mM DTT in 100 mM 
ammonium bicarbonate and incubated at 56 °C for 1 h with constant shaking. Each spot was 
then alkylated with 20 µl of 55 mM IAA in 100 mM ammonium bicarbonate and incubated in 
the dark at ambient temperature for 45 min. After washing each spot with 100 µl of 100 mM 
ammonium bicarbonate for 10 min, the gel spots were dehydrated with 100 µl of ACN for 10 
min. The washing and dehydration steps were repeated before the spots were dried in a 
centrifugal concentrator. 
Enzymatic digestion was performed with the addition of 10 µl of 0.01 µg/µl sequencing 
grade modified trypsin in 25 mM ammonium bicarbonate to each gel spot. To reduce the 
number of trypsin peaks in mass spectrometry analysis, the plugs are first left in the 4°C fridge 
for 30 min to maximize trypsin uptake. Following this the excess trypsin was removed and 10 
µl of 25mM ammonium bicarbonate was added to hydrate each gel spot and incubated at 37 °C 
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for 16 hr. Upon removing the tryptic digested peptides from each gel spot, 10 µl of 0.1% (w/v) 
trifluoroacetic acid (TFA) in 50% (w/v) aqueous acetonitrile (ACN) was added to each spot to 
enhance peptide extraction and sonicated for 20 min. 
 
3.3.6 Mass Spectrometry Analysis and Database Search  
Peptide digest from each gel spot were mixed with 1.2 µl CHCA matrix solution (5 
mg/mL α-cyano-4-hydroxy-cinnamic acid in 0.1% (v/v) TFA, 50% (v/v) ACN) and spotted 
onto a MALDI target plate. Peptide mass spectra were obtained using the ABI 4800 Proteomics 
Analyzer MALDI-TOF/TOF Mass Spectrometer. For MS analysis, typically 1000 shots were 
accumulated for each sample. MS data were automatically obtained with the five most intense 
ions selected for MS/MS. The peptides were subsequently subjected to MS/MS analyses using 
air with a collision energy of 2kV and a collision gas pressure ~1 x10 -6 Torr. Stop conditions 
were implemented so that 2000 to 3000 shots were accumulated depending on the quality of the 
spectra.  
MASCOT search engine (version 2.1; Matrix Science) was used to search all of the 
tandem mass spectra. GPS ExplorerTM software Version 3.6 was used to create and search files 
with MASCOT search engine for peptide and protein identification. International Protein Index 
(IPI) human database Version 3.31 was used for the search which was restricted to tryptic 
peptides. The search parameters allowed for N-terminal acetylation, cysteine C-terminal 
carbamidomethylation and methionine oxidation. Peptide mass tolerance and fragment mass 
tolerance were set to 150 ppm and ± 0.4 Da respectively.  
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3.4 Quantitative Proteomics using stable-isotope labeling technologies 
Protein lysates from either the non-tumour or tumour were first precipitated using the 2-
D Clean-Up kit. The protein pellets were subsequently resuspended in either 
(i) denaturing buffer (50mM Tris and 1.0% (w/v) SDS, pH 8.5) for cleavable Isotope 
Coded Affinity Tag (cICAT) labeling or 
(ii)  dissolution buffer (500mM triethylammonium bicarbonate and 0.1% (w/v) SDS) for 
isobaric Tag for Relative and Absolute Quantification (iTRAQ) labeling.  
 
3.4.1 cleavable Isotope Coded Affinity Tag (cICAT) labeling 
cICAT labeling and processing of the samples were carried out according to 
manufacturer’s protocol using the reagents provided (Applied Biosystems Incorporation). 
Briefly, a total of 100 µg of proteins from the non-tumour and tumour lysates were reduced 
with 1.25 mM Triscarboxyethylphosphine (TCEP). Non-tumour and tumour lysates were 
subsequently labeled with cICAT light and heavy reagents respectively for 2 hr at 37oC in the 
dark. They were subsequently combined and trypsinized at 37oC for 16 hr. Upon completion of 
in-situ digestion, the digested peptide mixture was passed through a strong-cation exchange 
cartridge before being enriched with an avidin affinity cartridge. Next, the cICAT-labeled 
peptides were dried by lyophilization and re-dissolved in cleaving reagents and incubated at 
37oC for 2 hr. After the removal of biotin, peptides were lyophilized again before reconstituted 
for 2-Dimensional liquid chromatography (2-D LC). 
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3.4.2 isobaric Tag for Relative and Absolute Quantification (iTRAQ) labeling.  
iTRAQ labeling and processing of the samples were carried out as described by the 
protocol with minor modifications and using the reagents provided from Applied Biosystems. 
100µg of protein from each sample was reduced with 5mM of TCEP at 60OC for 1 hr, followed 
with alkylation step for 10 min using 10mM of methyl methanethiosulfonate (MMTS) in room 
temperature. Each sample was subsequently diluted to achieve a final concentration of 0.05% 
(w/v) SDS prior to trypsinization at 37OC for 16 hr. Each tryptic digest was then labeled for 1 hr 
with one of the four isobaric amine-reactive tags. The labeling was carried out at random 
ensuring that 2 pairs of patient tissues were labeled as follows: Tag114 – non-tumour; Tag115 – 
tumour; Tag116 – non-tumour; and Tag117 – tumour samples.  
These four iTRAQ-labeled samples were then combined and passed through a strong 
cation exchange cartridge as recommended by Applied Biosystems. The eluate obtained was 
further desalted using a Sep-Pak cartridge (Millipore), lypholised and reconstituted in 
appropriate buffers for 2-D LC. 
 
3.4.3 Two-Dimensional Liquid Chromatography separation of labeled peptides. 
Each of the lypholised cICAT and iTRAQ-labeled peptide mixtures were then dissolved 
in 2% (v/v) acetonitrile (ACN) containing 0.05% (v/v) TFA and further separated using an 
UltimateTM dual-gradient LC system (Dionex-LC Packings) with a ProbotTM MALDI spotting 
device. A two-dimensional LC separation was performed as follows: for the first dimensional 
separation, the labeled peptide mixture was injected into a 0.3 × 150-mm strong cation-
exchange (SCX) column (FUS-15-CP, Poros 10S; Dionex-LC Packings). The mobile phase A 
used was 5mM KH2PO4 buffer, pH 3, 5% ACN and mobile phase B was 5mM KH2PO4 buffer, 
 68
pH 3, 5% ACN + 500 mM KCl respectively. The flow rate was 6µl/min. A total of 9 fractions 
were obtained using step gradients of mobile phase B: unbound, 0-5, 5-10, 10-15, 15-20, 20-30, 
30-40, 40-50, 50-100% of B. The eluting fractions were captured alternatively onto two 0.3 × 1-
mm trap column (3-µm C18 PepMapTM, 100 Å; Dionex-LC Packings), washed with 0.05% 
TFA and followed by gradient elution in a 0.2 × 50-mm reverse-phase column (Monolithic PS-
DVB; Dionex-LC Packings). In the second-dimensional separation, mobile phase A was 2% 
ACN with 0.05% TFA and mobile phase B was 80% ACN with 0.04% TFA. The gradient 
elution step was 0-60% B in 15 min at a flow rate of 2.7µl/min. The LC fractions were mixed 
directly with MALDI matrix solution (7mg/ml CHCA and 130µg/ml ammonium citrate in 75% 
ACN) at a flow rate of 5.4µl/min via a 25-nl mixing tee (Upchurch Scientific) before they were 
spotted onto a 192-well MALDI target plate (Applied Biosystems) using a Probot Micro 
Precision Fraction collector (Dionex-LC Packings), at a speed of 5 sec per well. An internal 
standard consist of 50 fmol of ACTH (18-39) peptide (m/z = 2465.199) was also spiked into 
each well. 
 
3.4.4 Mass spectrometry analysis and Database search 
The samples on the MALDI target plates were analyzed using a 4700 Proteomics 
Analyzer mass spectrometer (Applied Biosystems Incorporation) with MALDI source and 
TOF/TOF™ optics. MS/MS analyses were performed using nitrogen at collision energy of 1 
kV and a collision gas pressure of ~1 × 10-6 Torr.    
The GPS ExplorerTM software Ver. 3.6 (Applied Biosystems Incorporation) was used to 
create and search files with the MASCOT search engine (version 2.1; Matrix Science) for 
peptide and protein identifications in both the cICAT and iTRAQ-labeled samples. The 
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International Protein Index (IPI) human database (Version 3.31) was used for the search and 
this was restricted to tryptic peptides.  
 
3.4.4.1 cICAT-labeled samples  
For MS analysis, an average of 1000 shots was accumulated for each sample well. In 
MS/MS fragmentation only cICAT pairs with normalized ratio (normalized against median 
ratio of all the cICAT pairs detected) greater than 40% were selected. These also include 
singletons. The resolution used for parent ion selection was 200. Variable modifications such as 
heavy and light cICAT-labeled cysteine, N-terminal acetylation and pyroglutamation (E & Q), 
and methionine oxidation were selected. One missed cleavage was allowed, with precursor 
error tolerance set to 150 ppm and MS/MS fragment error tolerance to 0.4 Da. 
cICAT quantification was performed using GPS ExplorerTM software (Ver. 3.6) and 
normalized against median ratio obtained from all the cICAT peptide pairs detected in one 
sample. The ratios were calculated by comparison of the cluster area of the heavy-ICAT labeled 
peptide with that of the light-ICAT labeled peptide.  
 
3.4.4.2 iTRAQ-labeled samples  
For each MS spectrum, 1000 shots were accumulated. In MS/MS fragmentation, 6 000 
shots were combined for each precursor ion with signal to noise (S/N) ratio greater or equal to 
100. For precursors with S/N ratio between 50 and 100, 10 000 shots were acquired. The 
resolution used to select the parent ion was 200. For both MS and MS/MS, peaks were 
deisotoped and no smoothing was applied before peak detection. In MS/MS, only the peaks 
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from 60 Da to 20 Da below each precursor mass with S/N ≥ 10 were selected. Peak density was 
also limited to 30 peaks per 200 Da and the maximum number of peaks was set at 125. Fixed 
modification such as cysteine methanethiolation, N-terminal iTRAQ labeling, and iTRAQ 
labeled-lysine were selected while methionine oxidation was considered as variable 
modification. One missed cleavage was allowed and precursor error tolerance was set to 150 
ppm while MS/MS fragment error tolerance was set to 0.4 Da.  
iTRAQ quantification was performed using the GPS ExplorerTM software (Ver. 3.6) and 
normalized among samples. iTRAQ ratios were calculated based on the areas of the iTRAQ 
reporter fragment peaks (114, 115, 116 and 117), and included only peptides identified with 
C.I. % above cutoff thresholds as described in 3.4.4.4. The average iTRAQ ratio and standard 
deviation (S.D.) were determined using the GPS ExplorerTM software. 
 
3.4.4.3 Determination of cut-off threshold for fold change 
To determine cut-off threshold for cICAT and iTRAQ fold changes, 2 equal amounts of 
bovine serum albumin (BSA) or 6-protein mix were labeled with the cICAT or iTRAQ reagents 
respectively (Tan et al., 2008). The significant cut-off threshold proposed was based on the 
standard deviation (S.D.) of all the ratios of the respective labeled peptides. The respective 
ratios determined were as follows: cICAT labeled peptides 1.36 based on 1 + 3 S.D and iTRAQ 
labeled peptides 1.3 based on 1 + 2 S.D. 
A more stringent ratio of 1.4 was used in this study for up-regulated proteins and 
reciprocally 0.71 was the cut-off threshold for down-regulated proteins. These values were 
selected to ensure the similar stringency as the proteins selected for 2-D DIGE. In addition, 
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regulated proteins will only be selected if it is consistently regulated in 3 out of 5 patients or 4 
out of 7 patients in moderately- and poorly-differentiated HCC.  
 
3.4.4.4 Estimation of false positive rate to determine cut-off score.  
A randomized database generated using IPI human database Version 3.31, via a Pearl 
script downloaded from http://www.matrixscience.com/help/decoy_help.html, was also used to 
search for both the cICAT and iTRAQ labeled samples. The false positive rate was calculated 
by comparing the peptide hits obtained from these 2 databases at different ion score C.I. % in 
the peptide level. The minimum ion score C.I. % was determined to ensure that no more than 
5% false positive rate was achieved. Based on this cut-off threshold, all the proteins identified 
from the random database search were matched to a single-peptide. Proteins identified that were 
matched to at least 2 peptides were thus statistically confident. For single-peptide matched 
proteins, only those with ion score C.I. % greater than the highest C.I. % obtained from the 
random database search were selected as significant.  
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3.5 Bioinformatics annotation tools  
 Proteins annotations obtained from the IPI database (http://www.ebi.ac.uk/IPI/) were 
converted to Swiss-Prot accession numbers as derived from the IPI database. Theoretical Mr 
and pI values were derived from Swiss-Prot database (http://au.expasy.org/tools/pi_tool.html). 
An in-house program, Click-Me, was used to estimate the experimental Mr and pI of the protein 
spots identified from 2-D DIGE. 
The GRAVY scores were determined using the ProtParam tool (http://au.expasy.org/cgi-
bin/protparam). Data obtained were tabulated and summarized using a PHP script developed in-
house. The proteins’ sub-cellular localization and biological functions were obtained from Gene 
Ontology consortium (http://www.geneontolgy.org/) and further verified by Swiss-Prot 
database annotations. Protein pathways and interactions were determined by the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/).  
Venn diagrams were drawn proportionally using 3Venn applet 
(http://www.cs.kent.ac.uk/people/staff/pjr/EulerVennCircles/EulerVennApplet.html) (Chow 
and Rodgers, 2005). Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Mountain View, 
CA, USA, www.ingenuity.com) was used to further analyse the proteins identified. Direct 
relationships between proteins are displayed graphically as nodes (individual proteins) and 
edges (biological relationship between nodes).  
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3.6 FUBP siRNA transfection  
Both cell lines, HepG2 and Hep3B, were seeded in 24-well plates one day prior to 
transfection. Each well consists of 1.25 x 104 cells in 500µl of DMEM media with 10% (v/v) 
FBS. Cells at 60% density were then transfected with non-targetting control siRNA or FUBP1, 
FUBP2, FUBP3 or mixture of all 3 FUBP siRNA (ON-TARGETplusTM, Dharmacon RNAi 
Technologies, Thermo Scientific, IL, USA).  
The transfection mixture was prepared by first mixing 50 µl of DMEM containing 
varying concentration of siRNA with 50 µl of DMEM containing 0.5 µl of LipofectamineTM 
RNAiMAX (Invitrogen) reagent followed by an addition of 400 µl of DMEM with 10% (v/v) 
FBS. This mixture was incubated at room temperature for 30 min. The seeding media from each 
well was then replaced with the respective media with siRNA. The transfected cells were 
returned to the CO2 incubator.  At appropriate time points, the cells were either treated with 3-
(4,5-dimethylthiazolyl-2,5-diphenyl-tetrazolium bromide (MTT) reagent for cell proliferation 
assays or lysed as mentioned earlier for western blot analysis. 
 
3.6.1 Cell proliferation assay 
At the 72 hr time point, 250 µl of MTT at 5mg/ml were added to each well and 
incubated at 37oC for 2 hrs. In this assay, MTT was used as a colorimetric substrate for 
measuring cell viability. Non-viable cells, with altered cellular redox activity were unable to 
reduce the dye. The media was aspirated and formazan precipitates were dissolved in 500 µl of 
DMSO. Wells containing all mixtures except cells were used as blanks. The absorbance in each 
well was measured at 550 nm using a spectrophotometer. All experiments were conducted in 4 
sets of wells and was repeated using 3 separate batches of cells. 
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3.7  Immunoblotting 
Equal aliquots of whole cell lysate from the HCC tissues were either resolved on 1-DE 
or 2-DE gels using 7cm, pH 3-10, nonlinear IEF strips. IEF and SDS-PAGE were carried out as 
described earlier. Upon completion of electrophoresis, the gels were equilibrated in Towbin 
transfer buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS, 20 % methanol). Proteins were then 
electro-blotted onto PVDF membranes. After transfer, blots were blocked with 2% (w/v) BSA 
dissolved in TBS-T (20 mM Tris-HCl, 150 mM NaCl, 0.1 % (v/v) Tween 20, pH 7.5) 
overnight.  
 Table 3.4 summarised all the various antibody concentrations and respective blocking 
solutions used. In general, all primary antibodies were diluted (as recommended) in 1% (w/v) 
blocking solution in TBS-T and incubated for 2 hrs. Three 15 min washes with TBS-T were 
performed which were followed by 1 hr of secondary antibody incubation with 1% (w/v) 
blocking solution in TBS-T. The blots were again rinsed with TBS-T to remove any non-
specific binding. Subsequent visualization was performed using Enhance Chemiluminescence 
(ECL), Advance Enhance Chemiluminescence (AECL) or Super Signal West Dura substrate. 
The image was exposed to Kodak Biomax MR Film and developed by the KONICA 











Primary antibody (Ratio) Secondary antibody (Ratio) Developing reagent (Time) 
Fumarate Hydratase (1: 1000) Sheep anti-mouse (1 : 5000) ECL (8 min) 
Triosephosphate isomerase (1:1000) Sheep anti-mouse (1 : 5000) ECL Advance (2 min) 
Alpha-enolase (1:1000) Goat anti-rabbit (1 : 5000) Dura (3 min) 
Superoxide dismutase (Cu-Zn) 
(1:1000) Goat anti-rabbit (1 : 5000) ECL (3 min) 
Catalase (1: 10 000) Goat anti-rabbit (1 : 5000) ECL Advance (3 sec) 
DJ-1 (1:1000) Sheep anti-mouse (1 : 5000) Dura (3 min) 
Regucalcin (1: 1000) Goat anti-rabbit (1 : 5000) Dura (10 sec) 
ES1 (1:1000) Sheep anti-mouse (1 : 5000) ECL (8 min) 
Stress-70 / GRP75 (1:1000) Sheep anti-mouse (1 : 5000) ECL Advance (10 sec) 
Ezrin (1 : 1000) Goat anti-rabbit (1 : 5000) ECL Advance (1 min) 
Nucleophosmin (1 : 1000) Sheep anti-mouse (1 : 5000) Dura (30 sec) 
Lupus LA (1 : 1000) Goat anti-rabbit (1 : 5000) Dura (30 sec) 
Nucleotide diphosphate kinase A 
NDKA (1 : 1000) Sheep anti-mouse (1 : 5000) Dura (3 min) 
FUSE Binding Protein 1/2  
(FUBP1/2) 1 : 1000 Sheep anti-mouse (1 : 5000) Dura (8 min) 
FUSE Binding Protein 3 (FUBP3) 
(1 : 1000) 
Sheep anti-mouse (1 : 5000)                 
 
Dura (1 min) 
c-myc (1 : 1000) Goat anti-rabbit (1 : 5000) ECL Advance (1 min) 
Actin (1 : 1000) Goat anti-rabbit (1 : 5000) ECL Advance                     (15 min) 
GAPDH (1 : 1000) Goat anti-rabbit (1 : 5000) Dura (5 min) 
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 4. RESULTS 
4.1  Differential proteome analysis of HCC tissues  
4.1.1 Difference gel electrophoresis (2-D DIGE)  
In 2-D DIGE, three spectrally distinct CyDye probes (Cy2, Cy3 and Cy5) were used to 
pre-label the proteins before separation by 2-DE gel for analysis. Their non-overlapping 
excitation/emission spectra enabled multiplexing of different samples on the same gel. Three 
different fluorescent images can thus be derived from a single gel. By overlaying Cy3 and Cy5 
images, which represent the control and treated fractions respectively, differentially expressed 
protein spots could be detected visually in a differential display image.  
Proteins that were up-regulated in HCC tumour tissues would show progressively higher 
red hues while those that are down-regulated would be greenish in colour. Unaffected proteins 
would be represented by yellow spots. A representative 2-D DIGE image of proteins from 
























4.1.2 Decyder Analysis and MALDI TOF/TOF MS 
DeCyder-DIA and DeCyder-BVA software were subsequently used to perform 
automated intra-gel co-detection of labeled samples, background removal and inter-gel 
matching for differential expression analysis. The protein abundance (a measure of the 
spot intensity) of each experimental sample is directly normalized to the internal standard 
(Cy2 label of control and treated sample). An average of 2500 spots was detected in each 
2-D DIGE gel.  
A total of 148 protein spots that exhibited more than 1.5-fold difference in 
intensity and with a statistical confidence of p<0.05 were excised for mass spectrometry. 
In addition these protein spots were also manually checked to ensure each were present 
with similar regulation in at least 3 out of 5 or 4 out of 7 of the paired samples in 
moderately differentiated and poorly differentiated HCC respectively.  
With these criteria, a total of 54 and 26 proteins (excluding isoforms) were 
successfully identified by mass spectrometry for the moderately- and poorly-
differentiated HCC tissues respectively. These protein spots are highlighted on the 
representative silver stained gel images using the master numbers generated by the 
DeCyder software (Figs. 4.2 A and B). A significant number of the proteins identified 
were isoforms arising from post-translational modifications. The complete lists of these 




 Figure 4.2 : Differentially expressed protein spots in the 2D gels are marked with master 
numbers in (A) moderately
tumour tissues. *Protein 
proteins are in red. 
-differentiated tumour tissues and (B) poorly






4.1.2 Stable-isotope labeling techniques  
4.1.2.1 cICAT coupled to 2-D LC and MALDI TOF/TOF MS  
Affinity-purified cICAT labeled peptides were separated by two-dimensional 
chromatography and analysed by mass spectrometry. With the aid of GPS ExplorerTM 
software and manual checks, an average of 100 statistically significant proteins with 
confidence interval greater than 95% was typically identified from each sample set.  
cICAT ratio of each protein were determined by comparison of the cluster area of 
the heavy-ICAT labelled peptide (tumour) with that of the light-ICAT labelled peptide 
(non-tumour) from each mass spectrometry runs. Figure 4.3A depicts an enlarge image of 
the MS spectrum image of a peptide from 60kDa heat shock protein (HSP60) labelled 
with the light  and heavy cICAT reagents. The ratio can thus be obtained by comparing 
the relative abundance of the 2 peaks. MS/MS spectrum from the precursor ion at m/z 
1864.035 (Fig. 4.3B) illustrates the identification of the sequence of the peptide.  
In this study, the criterion for protein identification includes an average cICAT 
ratio of each protein by more than 1.4 or less than 0.71. In addition, these proteins must 
be consistently regulated in at least 3 out of 5 and 4 out of 7 in each moderately- and 
poorly-differentiated HCC tissues respectively. A total of 57 and 24 proteins from 
moderately and poorly differentiated proteins respectively were identified as significantly 
regulated (Appendix II).   
 
 Figure 4.3: Representative mass spectra of 60kDa heat shock protein (HSP60)
digestion. (A) MS spectrum with tryptic peptides of 
= 1864.035 selected for MS/MS (B) MS/MS spectrum of the pept
ions are denoted along with immonium ions (V, valine; L, leucine
above and below the sequence, respectively.  
 analyzed by MALDI-TOF/TOF MS upon tryptic 
HSP60 labelled by the cICAT heavy and light reagents; arrow indicates ion at 
ide AAVEEHIVLGGGCALLR (m/z = 1864.035




), where y- and b-
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4.1.2.2 iTRAQ coupled to 2-D LC and MALDI TOF/TOF MS  
iTRAQ labeled peptides were also fractionated by two-dimensional 
chromatography and analysed by mass spectrometry. With the aid of GPS ExplorerTM 
software, using statistical stringencies as described earlier, an average of 500 proteins 
with quantitative information were typically identified from each sample set.  
iTRAQ ratios were calculated based on the cluster areas of the iTRAQ reporter 
fragment peaks (114, 115, 116 and 117) obtained from MS/MS fragmentation. Figure 
4.4A depicts an enlarged image of the MS spectrum containing the precursor ion 
NAGVEGSLIVEK (m/z 1503.8) from the protein HSP60. The MS/MS spectrum of this 
peptide is shown in Figure 4.4B. The relative abundance of this peptide can be calculated 
using the reported ion peaks at m/z 114, 115, 116 and 117 (Fig. 4.4C).  
Proteins from each sample sets that were over-expressed by 1.4 or down-regulated 
by 0.71 folds were accepted. These proteins must also be consistently regulated in at least 
3 out of 5 and 4 out of 7 in each moderately- and poorly-differentiated HCC tissues 
respectively. In moderately differentiated HCC samples a total of 90 proteins were 
significantly regulated, whilst in the poorly differentiated HCC samples, a total of 151 
differentially expressed proteins were selected (Appendix III). 
 
 Figure 4.4: Representative iTRAQ mass spectra of 
tryptic digestion. (A) MS spectrum with tryptic peptides of 
MS/MS spectrum of the peptide NAGVEGSLIVEK (
valine; L, leucine); y- and b-fragmentations are also indicated with tilted
Reporter ion region of MS/MS m/z 1503.8.  
60kDa heat shock protein (HSP60) analyzed by MALDI
HSP60; arrow indicates ion at m/z = 1503.8 
m/z = 1503.8), where y- and b-ions are denoted along with immonium ions (
 dotted lines above and below the sequence, respectively. 
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-TOF/TOF MS upon 




4.2 Identification of differentially expressed proteins  
The differentially expressed proteins identified from all 3 techniques were 
grouped according to their biological functions as annotated in the Gene Ontology 
database. Table 4.1 and 4.2 contains the list of proteins identified from moderately and 
poorly differentiated HCC respectively. Down arrows in each column in 2-D DIGE, 
cICAT and iTRAQ indicated the under-expression of the protein identified while the up 
arrows showed over-expression. The value of protein regulation can be obtained from the 
individual dataset available in Appendix I, II and III.  
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Table 4.1 : Significantly regulated proteins in moderately-differentiated HCC as identified by 2-D DIGE, cICAT and iTRAQ are summarized 
according to their respective biological functions. Expression levels are summarized by arrows; down and up arrows indicate down-regulation 
or up-regulation respectively.  





















P05062 Fructose-bisphosphate aldolase B (liver) Glycolysis
P60174  Triosephosphate isomerase Glycolysis 
P18669 Phosphoglycerate mutase 1 Glycolysis
Q96C23 Aldose 1-epimerase Carbohydrate metabolism 
P36871 Phosphoglucomutase-1 Carbohydrate metabolism 
Q9UJM8 Hydroxyacid oxidase 1 Carbohydrate metabolism (Glyoxylate metabolism)
Q00796 Sorbitol dehydrogenase Carbohydrate metabolism
P09467 Fructose-1,6-bisphosphatase 1 Gluconeogenesis
Q16822 Phosphoenolpyruvate carboxykinase Rate-limiting step in the metabolic pathway that produces 




Q16851 UTP-glucose-1-phosphate uridylyltransferase Glucosyl donor in metabolic pathways
P07954
Isoform mitochondrial of Fumarate hydratase, or 
Isoform cytoplasmic of Fumarate hydratase, 
mitochondrial percursor
Tricarboxylic acid cycle
P30038 Aldehyde dehydrogenase 4 family (ALDH4A1) Involved in connecting TCA and Urea cycle
Q53FB6 Mitochondrial aldehyde dehydrogenase 2 variant (ALDH2) Urea and glycolysis 
P21695 Glycerol-3-phosphate dehydrogenase [NAD+], 
cytoplasmic
Glycerol lipid metabolism
P30084 Enoyl-CoA hydratase, mitochondrial precursor  Fatty acid elongation / Beta-oxidation 
P33121 Long-chain-fatty-acid CoA ligase 1 Activation of Beta-oxidaton
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic (ACAT1) Beta-oxidation 
P24752 Acetyl-CoA acetyltransferase, mitochondrial precursor (ACAT2) Beta-oxidation 
P16219 Short-chain specific Acyl CoA dehydrogenase, 
mitochondrial precursor Beta-oxidation 
P45954 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial Beta-oxidation 
P42765 3-ketoacyl-CoA thiolase, mitochondrial Beta-oxidation 
P80404  4-aminobutyrate aminotransferase, mitochondrial 
precursor
Amino acid metabolism
P49448 Glutamate dehydrogenase 2, mitochondrial precursor Glutamate metabolism (connecting TCA and Urea cycle)
P11586  C-1-tetrahydrofolate synthase Amino acid biosynthesis
P00439 Phenylalanine-4-hydroxylase Amino acid biosynthetic process
O43175 Phosphoglycerate dehydrogenase Amino acid metabolism (Glycine/threonine/serine metabolism)
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Q96GK7 Fumarylacetoacetate hydrolase domain containing 2A Tyrosine Catabolism
P50440 Isoform Cytoplasmic of Glycine amidinotransferase Urea Cycle (Amino acid metabolism)
Q03154 Aminoacylase-1 Urea Cycle (Amino acid metabolism)
P31327 Isoform 1 of Carbamoyl-phosphate synthase Urea Cycle (Amino acid metabolism)
P00966  Argininosuccinate synthase Urea cycle
P04424 Arginosuccinate Lyase Urea cycle
P05089 Arginase-1 Urea cycle
Q7Z4W1    L-xylulose reductase Participates in the uronate cycle of glucose metabolism. 
P24298 Alanine aminotransferase 1 Glutamate metabolism / Liver gluconeogenesis
Q00266 S-adenosylmethionine synthetase Methionine / Selenoamino acid metabolism
Q93088  Betaine-homocysteine S-methyltransferase 1 Methionine / Homocysteine metabolism
P25325 3-mercaptopyruvate sulfurtransferase Cysteine metabolism
Q96N76 Urocanase family protein Histidine catabolic process
Q02252 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondria
Valine and pyrimidine metabolism 
/ fatty acyl-CoA.
O94760 NG, NG-dimethylarginine dimethylaminohydrolase 1 Arginine catabolic process
P61457 Pterin-4-alpha-carbinolamine dehydratase Tetrahydrobiopterin biosynthesis
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Q59HD5 3-mercaptopyruvate sulfurtransferase variant (Fragment)
Involved in cyanide degradation and in thiosulfate 
biosynthesis
P31937 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor
Pentose phosphate shunt
P54819 Isoform 1 of Adenylate kinase isoenzyme 2, 
mitochondrial Nucleic acid metabolic process
P14550 Alcohol dehydrogenase Catalyzes the NADPH-dependent reduction
P07327 Alcohol dehydrogenase 1A Cellular alcohol metabolic processes
P00325 Alcohol dehydrogenase 1B Cellular alcohol metabolic processes
P08319 Alcohol dehydrogenase 4 Cellular alcohol metabolic processes
P00352 Retinal dehydrogenase 1 (ALDH1A1) Retinol metabolism
P21549 Serine-pyruvate aminotransferase Amino acid metabolism (forms pyruvate)
P00915 Carbonic anhydrase 1 Carbon compund metabolic process
P00918 Carbonic anhydrase 2 Reversible hydration of carbon dioxide
P07099 Epoxide hydrolase 1, microsomal Biotransformation enzyme that catalyzes the hydrolysis of 
arene and aliphatic epoxides to less reactive
P16083 Ribosyldihydronicotinamide dehydrogenase / 
NAD(P)H dehydrogenase Quinone reductase
O60218 Aldo-keto reductase family 1 member B10 Aldehyde metabolic process
P15531 Nucleoside diphosphate kinase A
 / Nucleoside diphosphate kinase B





P21964 Isoform Soluble of Catechol O-methyltransferase Shortens the biological half-lives of certain neuroactive drugs
P16152 Carbonyl reductase [NADPH] 1 Catalyzes reduction carbonyl compounds including antitumor 
anthracycline antibiotics
P50225 Sulfotransferase 1A1 Steroid metabolic process
O00748 Carboxylesterase 2 Isoform 1 Involved in the detoxification of xenobiotics and in the 
activation of ester and amide prodrug
P05181 Cytochrome P450 2E1 Inactivates a number of drugs and xenobiotics 
P16662 UDP-glucuronosyltransferase 2B7 precursor Amino acid metabolism (elimination of toxic xenobotics)
O75795 UDP-glucuronosyltransferase 2B17 precursor Amino acid metabolism (elimination of toxic xenobotics)
P04040 Catalase Hydorgen peroxide catabolic process
P00441 Superoxide dismutase [Cu-Zn] Removal of superoxide radicals
P30043 Flavin reductase Converts biliverdin to bilirubin (protects from oxidative damage & iron metabolism)
Q93099 Homogentisate 1,2-dioxygenase Oxidation / reduction
Q99497 Protein DJ-1 Sensor for oxidative stress / Positive regulator of androgen 
receptor-dependent transcription
Q16762 Thiosulfate sulfurtransferase Iron-sulfur complexes
P78417 Glutathione transferase omega-1 Redox Homeostasis
P08263 Glutathione S-transferase A1 Redox Homeostasis
P09210 Glutathione S-transferase A2 Redox Homeostasis
Detoxification
Defense related protein - Antioxidants 
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P07203 Glutathione peroxidase 1 Response to oxidative stress 
Q06278 Aldehyde oxidase 1(AOX1) FAD and NADH binding
Q9NVS9 Pyridoxine-5'-phosphate oxidase Involved in pyridoxamine-phosphate oxidase activity
P30041 Peroxiredoxin-6 Involved in redox regulation of the cell
P30039 Phenazine biosynthesis-like domain-containing 
protein (MAWD binding protein)
P30048 Thioredoxin-dependent peroxide reductase, 
mitochondrial percursor Involved in redox regulation of the cell
P07237 Protein disulfide-isomerase precursor Redox Homeostasis / Catalyzes rearrangement of disulfide bonds
Q15084 Isoform 1 of Protein disulfide-isomerase A6 precursor Catalyzes the rearrangement of -S-S- bonds in proteins
P01009 Alpha-1-antitrypsin precursor Acute-phase response. Inhibitor of serine proteases.
P61604 10 kDa heat shock protein, mitochondrial (HSP10) Probable involvement with caspase activation
P04792 Heat shock protein beta-1 (HSP27) Stress resistant and actin organization
Q38L19  60kDa Heat shock protein (HSP60) Interacts with HBV X gene
P08107 Heat shock 70kDa protein 1A (HSP70) Molecular chaperone
P17066 Heat shock 70 kDa protein 6 (HSP70B) Molecular chaperone
P11142  Isoform 1 of Heat shock cognate 71 kDa protein (HSP73) Molecular chaperone
Defense related proteins - Inflammation response
Defense related protein - Heat Shock Proteins (HSPs)
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Q12931 Heat shock protein 75 kDa, mitochondrial (TRAP1) Molecular chaperone
P08238  Heat shock protein HSP 90-beta (HSP90B) Molecular chaperone
P38646 Stress-70 protein, mitochondrial precursor (GRP75) Implicated in cell proliferation and anti-apoptosis
P02787 Serotransferrin precursor Iron binding transport protein / Heme degradation
P02794 Ferritin heavy chain Stores iron in a soluble, non-toxic, readily available form. 
Important for iron homeostasis. 
Q86WI9 Ferritin light chain Stores iron in a soluble, non-toxic, readily available form. 
Important for iron homeostasis
P00738 Haptoglobin precursor Haptoglobin combines with free plasma hemoglobin and 
protecting the kidneys from damage
P68871 Hemoglobin subunit beta  Involved in oxygen transport
P02790 Hemopexin precursor Binds heme and transport to liver for breakdown
Q13228 Selenium binding protein 1 Selenium binding / protein transport
Q15493 Regucalcin (Senescence marker-30) Calcium binding (regulates in liver and kidney)
P27797 Calreticulin Calcium binding chaperone promoting folding, quality control 
in the ER via the calreticulin/calnexin cycle
P02768 Serum albumin precursor
P28838  Cytosol aminopeptidase Presumably involved in the processing and regular turnover of 
intracellular proteins
Protein Binding - Iron related 
Protein Binding
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P00167 Isoform 1 of Cytochrome B5 Membrane bound hemoprotein which function as an electron 
carrier for several membrane bound oxygenases.
P11712 Cytochrome P450 2C9 NADPH-dependent electron transport pathway
P22307 Sterol carrier protein 2 isoform 2 Mediates in vitro the transfer of phospholipids, cholesterol and 
gangliosides between membranes
P14854  Cytochrome c oxidase subunit VIb isoform 1
P07108 Isoform 2 of Acyl-CoA-binding protein Fatty acid binding
P30040 Endoplasmic reticulum protein ERp29 percursor Processing of secretory proteins within ER
Q06323 Proteasome activator complex 1 Implicated in immunoproteasome assembly and its down-
regulation leads to possible loss of antigen processing
Q9UL46.3 Proteasome activator complex subunit 2 (PA28) Needed for presentation of viral MHC class I epitopes, down-
regulation in tumour cells results in impaired representation
P19652 Alpha-1-acid glycoprotein 2 precursor Modulate activity of immune system during acute-phase 
reaction.
Q6IAT8 Beta-2 microglobulin Related to immune response, beta-chain of major 
histocompatibility complex class I molecules.
P14317 Hematopoietic lineage cell-specific protein Substrate of the antigen receptor-coupled tyrosine kinase / 
Transcription factor activity
P06748 Isoform 1 of Nucleophosmin
Involved in diverse cellular processes such as protein 
chaperoning, cell proliferation and regulation of tumor 
suppressors TP53/p53 and ARF. 
P10909 Clusterin isoform 1 Associated with apoptosis - function not clear
P63104 14-3-3 protein zeta/delta Adaptor protein / Anti-apoptosis
P02649 Apolipoprotein E precursor Binding of lipoprotein particles
P62937 Peptidyl-prolyl cis-trans isomerase A Accelerate the folding of proteins / Involved in initiation of 
viral induction
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P07355 Annexin A2  Calcium-regulated membrane-binding protein 
P17931 Galectin-3 Required for terminal differentiation of columnar epithelial cells 
during early embryogenesis
Q9Y3C8 Ubiquitin fold modifier 1-conjugating enzyme 1 E2-like enzyme which forms an intermediate with UFM1
Q1JUQ4 FK506 binding protein12 Involved in protein folding
P02749 Beta-2-glycoprotein 1 precursor Binds to various kinds of negatively charged substances
P52758  Ribonuclease UK114 Inhibition of the translation by cleaving mRNA / Upregulated during cellular differentiation
Q96AE4  Far upstream element-binding protein 1 Regulates MYC expression by binding to a single-stranded far-
upstream element (FUSE) 
P05455  Lupus La protein Plays a role in the transcription of RNA polymerase III
P62992 Ubiquitin and ribosomal protein S27a precursor Involves in translation
P09651 Isoform A1-A of Heterogeneous nuclear 
ribonucleoprotein A1 Involved in the packaging of pre-mRNA into hnRNP particles
P22626  Heterogeneous nuclear ribonucleoproteins A2/B1 Involved with pre-mRNA processing
P26038 Moesin Connections of cytoskeletal structure to plasma membrane
P06753 Isoform 2 of Tropomyosin alpha-3 chain Binds to actin filament
P67936 Isoform 1 of Tropomyosin alpha-4 chain Binds to actin filament




Cytoskeletal modelling / Cell Motility
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Q01995 Transgelin (SMP22) Actin cross-linking
P37802 Transgelin (TAGLN2 / SMP22 homolog) Actin binding protein, early markers of differentiated smooth 
muscle. Exact function is not clear
P02545 Isoform C of Lamin-A/C Components of nuclear lamina 
P13668 Stathmin 1/oncoprotein 18  Involved in the regulation of the microtubule (MT) filament 
system by destabilizing microtubules
P40121.1 Gelsolin-like capping protein / Macrophage capping protein 
Calcium-sensitive protein which reversibly blocks the fast 
growing ends of actin filaments but does not sever preformed 
actin filaments.
P15311 Ezrin Probably involved in connections of major cytoskeletal 
structures such as actin filament bundle formation.
P04004 Vitronectin precursor Cell adhesion and spreading factor in serum and tissues
Q15063 Isoform 2 of Periostin precursor Induces cell attachment and spreading. Plays a role in cell 
adhesion
P07858 Cathepsin B precursor Thiol protease (intracellular degradation) / implicated in tumor 
invasion and metastasis.
Q01082 Isoform Short of Spectrin beta chain Interacts with camodulin in a calcium dependant manner / 
movement of cytoskeleton at the membrane
P08670 Vimentin Class-III intermediate filaments found in various non-epithelial 
cells, especially mesenchymal cells
P07437 Tubulin beta chain Major constituent of microtubules
P68371 Tubulin beta-2C chain Major constituent of microtubules
P30086 Phosphatidylethanolamine-binding protein 1 Serine protease inhibitor which inhibits thrombin
P05783 Keratin, type I cytoskeletal 18 Involved in the uptake of thrombin-antithrombin complexes by 
hepatic cells / cell proliferation inducing gene
P02675 Fibrinogen beta chain precursor
Fibrinogen has a double function: yielding monomers that 
polymerize into fibrin and acting as a cofactor in platelet 
aggregation
P02751 Isoform 1 of Fibronectin precursor Fibronectins are involved in cell adhesion, cell motility, 




P02671 Isoform 2 of Fibrinogen alpha chain precursor Platelet aggregation
P08758 Annexin A5 Anticoagulant protein that acts as an indirect inhibitor of the 
thromboplastin-specific complex
Q9H0W9  Ester hydrolase 
O94903 Proline synthetase co-transcribed bacterial homolog 
protein
Q96LK9 3-OXO-5-Beta-Steroid 4-Dehydrogenase
Q6UW68 Transmembrane protein 205 Multi-pass membrane protein
P30042 Isoform Long of ES1 protein homolog, mitochondrial 
precursor
P35237  Serine (or cysteine) proteinase inhibitor (SERPINB6)
A6NBZ8 Putative uncharacterized Albumin
P04264 Keratin, type II cytoskeletal 1 Structural protein
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P50053  Ketohexokinase Glycolysis
P05062 Fructose-bisphosphate aldolase B (Liver) Glycolysis
Q00796 Sorbitol dehydrogenase Glucose metabolic process
P06737 Glycogen Phosphorylase (liver form) Involved in glycogen metabolic processes
P09467 Fructose-1,6-bisphosphatase 1 Gluconeogenesis
P11498 Pyruvate carboxylase, mitochondrial precursor Gluconeogenesis
Q16822 Phosphoenolpyruvate carboxykinase Rate-limiting step in the metabolic pathway that produces 
glucose from lactate 
Q16851 UTP-glucose-1-phosphate uridylyltransferase Glucosyl donor in metabolic pathways
P07954
Isoform mitochondrial of Fumarate hydratase, or Isoform 
cytoplasmic of Fumarate hydratase, mitochondrial 
percursor
Tricarboxylic acid cycle
P31040 Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondria
Tricarboxylic acid cycle 
electrons transfer from succinate to ubiquinone.
Q96I99 Succinyl-CoA ligase Tricarboxylic acid cycle
Metabolic proteins
 
Table 4.2 : Significantly regulated proteins in poorly-differentiated HCC as identified by 2-D DIGE, cICAT and iTRAQ are summarized 
according to their respective biological functions. Expression levels are summarized by arrows; down and up arrows indicate down-
regulation or up-regulation respectively. 
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P21399 Cytoplasmic aconitate hydratase(Iron-responsive element-binding protein 1) Tricarboxylic acid cycle
P48735 Isocitrate dehydrogenase [NADP], mitochondrial precursor Tricarboxylic acid cycle 
Q53FB6 Mitochondrial aldehyde dehydrogenase 2 Urea and glycolysis 
P30038 Aldehyde dehydrogenase 4 family, member A1 Involved in connecting TCA and Urea cycle
P00367 Glutamate dehydrogenase 1 Glutamate metabolism (connecting TCA and Urea cycle)
P54868 Hydroxymethylglutaryl-CoA synthase, mitochondrial 
precursor
Cholesterol biosynthesis
Q06520 Bile salt sulfotransferase Lipid metabolism (Catalyzes bile acids in the liver and adrenal glands)
Q14032  Bile acid CoA:amino acid N-acyltransferase Bile acid metabolism 
in hepatocytes catalyzes the 2nd step 
P07148 Fatty acid binding protein Binds free fatty acid and free coenzyme A/billirubin Organ 
morphogenesis
P30084 Enoyl-CoA hydratase, mitochondrial percursor Fatty acid elongation / Beta-oxidation 
P33121 Long-chain-fatty-acid--CoA ligase 1 Activation of Beta-oxidaton
P23786 Carnitine O-palmitoyltransferase 2, mitochondrial precursor Beta-oxidation / Carnitine shuttle
Q08426  Enoyl-CoA hydratase (Peroxisomal bifunctional enzyme) Beta-oxidation 
Q5R1W7  3-ketoacyl-CoA thiolase (Trifunctional enzyme beta 
subunit) Beta-oxidation 
P45954 Short/branched chain specific acyl-CoA dehydrogenase, 
mitochondrial
Beta-oxidation 
P11310 Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial Beta-oxidation 
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P16219 Short chain specific acyl-CoA dehydrogenase, 
mitochondrial precursor Beta-oxidation 
Q16836 Isoform 2 of Hydroxyacyl-coenzyme A dehydrogenase Beta-oxidation 
P24752 Acetyl-CoA acetyltransferase, mitochondrial precursor Beta-oxidation 
P42765 3-ketoacyl-CoA thiolase, mitochondrial Beta-oxidation 
P09110 3-ketoacyl-CoA thiolase, peroxisomal precursor Beta-oxidation 
Q16698 2,4-dienoyl-CoA reductase, mitochondrial precursor Auxiliary enzyme of beta-oxidation (unsaturated fatty acids)
Q02252 Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondria precursor
Binds fatty acyl-CoA / Amino acid metabolism 
(Plays a role in valine and pyrimidine metabolism) 
Q6IB77 Isoform 1 of Glycine N-acyltransferase Acyl-CoA metabolic process
P11182 Lipoamide acyltransferase component of branched-chain 
alpha-keto acid
Fatty acid degradation (Acyl-CoA biosynthesis)
Q3LXA3 Dihydroxyacetone kinase Glycerol metabolic process
P00505 Aspartate aminotransferase, mitochondrial precursor (GOT2)
Amino acid metabolism 
(aspartate)
P36269 Isoform 2 of Gamma-glutamyltransferase 5 precursor Amino acid metabolism (Glutathione biosynthesis)
P32754 4-hydroxyphenylpyruvate dioxygenase (HPD) Amino acid metabolism (Phenylalanine catabolism)
P34896 Isoform 2 of Serine hydroxymethyltransferase, cytosolic Amino acid metabolism (Serine catabolism)
P21549 Serine-pyruvate aminotransferase Amino acid metabolism (forms pyruvate)
P24298 Alanine aminotransferase 1 Glutamate metabolism / Liver gluconeogenesis
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P11586   C-1-tetrahydrofolate synthase, cytoplasmic Amino acid biosynthesis
P80404 4-aminobutyrate aminotransferase, mitochondrial precursor Amino acid metabolism
Q93088 Betaine--homocysteine S-methyltransferase 1 Methionine / Homocysteine metabolism
Q00266 S-adenosylmethionine synthetase isoform type-1 Methionine / Selenoamino acid metabolism
P50440 Isoform Cytoplasmic of Glycine amidinotransferase Urea Cycle (Amino acid metabolism)
P00480 Ornithine carbamoyltransferase, mitochondrial precursor Urea Cycle (Amino acid metabolism)




Q03154 Aminoacylase-1 Urea cycle
P00966 Argininosuccinate synthase Urea cycle
P05089 Arginase-1 Urea cycle
P30837 Aldehyde dehydrogenase X, mitochondrial precursor Major role in the detoxification of alcohol-derived acetaldehyde
P05091 Aldehyde dehydrogenase, mitochondrial precursor Carbohydrate / Cellular alcohol metabolic processes
P22033 Methylmalonyl-CoA mutase, mitochondrial precursor Degradation of amino acids, odd-chain fatty acids and cholesterol 
via propionyl-CoA to TCA
Q02338 D-beta-hydroxybutyrate dehydrogenase, mitochondrial 
precursor
Converts hydroxybutyrate to acetoacetate
P07099 Epoxide hydrolase 1 Biotransformation enzyme that catalyzes the hydrolysis of 
arene and aliphatic epoxides to less reactive
P38117 Isoform 2 of Electron transfer flavoprotein subunit beta
Electron transport chain, specific electron acceptor for 
dehydrogenases, (five acyl-CoA dehydrogenases, glutaryl-CoA 
and sarcosine dehydrogenase).
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P61457 Pterin-4-alpha-carbinolamine dehydratase Tetrahydrobiopterin biosynthesis
P31937 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor
Pentose phosphate shunt
O75891.2 Formyltetrahydrofolate dehydrogenase isoform a variant Carbon compound metabolic process
Q15181 Inorganic pyrophosphatase Phosphate metabolic process
Q14117 Dihydropyrimidinase Catalyzes the second step of the reductive pyrimidine 
degradation.
P07327  Alcohol dehydrogenase 1A Cellular alcohol metabolic processes
P00325 Alcohol dehydrogenase 1B Cellular alcohol metabolic processes
P00326 Alcohol dehydrogenase 1C Cellular alcohol metabolic processes
P08319 Alcohol dehydrogenase 4 Cellular alcohol metabolic processes
P14550 Alcohol dehydrogenase Cellular alcohol metabolic processes
P00352 Retinal dehydrogenase 1 (ALDH1A1) Retinol metabolism
Q7Z4W1 L-xylulose reductase Participates in the uronate cycle of glucose metabolism. 
P04075 Fructose-bisphosphate aldolase A (Muscle) Glycolysis
P06733 Alpha-enolase Glycolysis
Q53EM5 Transketolase variant (Fragment) Pentose phosphate pathway
O60218 Aldo-keto reductase family 1 member B10 Aldehyde metabolic process
P15531 Nucleoside diphosphate kinase A 
/ Nucleoside diphosphate kinase B
Major role in the synthesis of nucleoside triphosphates other 
than ATP
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P21964 Isoform Soluble of Catechol O-methyltransferase Shortens the biological half-lives of certain neuroactive drugs
P05181 Cytochrome P450 2E1 Inactivates a number of drugs and xenobiotics 
P50225 Sulfotransferase 1A1 Catalyzes the sulfate conjugation of catecholamines, phenolic 
drugs and neurotransmitters
P16152 Carbonyl reductase [NADPH] 1 Catalyzes reduction carbonyl compounds including antitumor 
anthracycline antibiotics
O00748 Carboxylesterase 2 isoform 1 Involved in the detoxification of xenobiotics and in the 
activation of ester and amide prodrug
O95154 Aflatoxin B1 aldehyde reductase member 3 Protection of liver against the toxic and carcinogenic effects of 
AFB1, a potent hepatocarcinogen.
P40261 Nicotinamide N-methyltransferase Important for biotransformation of many drugs and xenobiotic 
compounds.
Q86WA6 Isoform 1 of Valacyclovir hydrolase precursor Serine hydrolase that catalyzes the hydrolytic activation of amino 
acid ester prodrugs of nucleoside analogs 
P16662 UDP-glucuronosyltransferase 2B7 precursor Major importance in the conjugation and subsequent 
elimination of potentially toxic xenobiotics
P22309 UDP-glucuronosyltransferase 1-1 precursor Major importance in the conjugation and elimination of 
potentially toxic xenobiotics
P04040 Catalase Hydorgen peroxide catabolic process
P00441 Superoxide dismutase [Cu-Zn] Removal of superoxide radicals
P04179 Superoxide dismutase isoform B [Mn] Removal of superoxide radicals
P30043 Flavin reductase Converts biliverdin to bilirubin (protects from oxidative damage & iron metabolism)
Metabolic proteins - Detoxification
Defense related proteins - Antioxidants
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Q93099 Homogentisate 1,2-dioxygenase Oxidation / reduction
P09210 Glutathione S-transferase A2 Redox Homeostasis
Q16762 Thiosulfate sulfurtransferase Iron-sulfur complexes
Q99497 Protein DJ-1 Sensor for oxidative stress / Positive regulator of androgen 
receptor-dependent transcription
Q06278  Aldehyde oxidase (AOX1) Oxidation / reduction
Q9NVS9 Pyridoxine-5'-phosphate oxidase Involved in pyridoxamine-phosphate oxidase activity
P30041 Peroxiredoxin-6 Involved in redox regulation of the cell
P30039 Phenazine biosynthesis-like domain-containing protein  (MAWD binding protein)
P10632 Cytochrome P450 2C8 In liver microsomes, this enzyme is involved in an NADPH-
dependent electron transport pathway / Oxidaton Reduction
P01009 Alpha-1-antitrypsin precursor Acute-phase response. Inhibitor of serine proteases.
P02763 Alpha-1-acid glycoprotein 1 precursor Appears to function in modulating the activity of the immune 
system during the acute-phase reaction.
P05164 Myeloperoxidase precursor It is responsible for microbicidal activity against a wide range of 
organisms. 
P59666 Neutrophil defensin 3 precursor Defensin 2 and defensin 3 have antibiotic, fungicide and antiviral 
activities. 
P33241 Lymphocyte-specific protein 1 Mediating neutrophil activation / Actin binding protein
P61626 Lysozyme C precursor
Lysozymes have primarily a bacteriolytic function; associated 
with the monocyte-macrophage system and enhance the activity 
of immunoagents.
P05109 S100A8 Protein S100-A8 Expressed by macrophages in chronic inflammations
Defense related proteins - Inflammation response
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P06702 S100A9 Protein S100-A9 Expressed by macrophages in acutely inflammated tissues and in 
chronic inflammations / Probable inhibitor of protein kinases
P25815 S100P Protein S100-P ?
P11021 HSPA5 / Glucose regulated protein 78 (GRP78) Probably plays a role in facilitating the assembly of multimeric 
protein complexes inside the ER
P38646 Stress-70 protein, mitochondrial precursor (GRP75) Implicated in cell proliferation and anti-apoptosis
P08238  Heat shock protein HSP 90-beta (HSP90B) Molecular chaperone
Q58FF6  Heat shock protein 90Bd Putative molecular chaperone
P02787 Serotransferrin precursor Iron binding transport protein / Heme degradation
Q86WI9 Ferritin light chain Stores iron in a soluble, non-toxic, readily available form. 
Important for iron homeostasis
P00738 Haptoglobin precursor Haptoglobin combines with free plasma hemoglobin and 
protecting the kidneys from damage by hemoglobin
P68871 Hemoglobin subunit beta  Involved in oxygen transport
Q16743 Cytochrome P-450 II C (Fragment) Heme / Iron binding 
P02790 Hemopexin precursor Binds heme and transport to liver for breakdown
P02788 Lactotransferrin Iron binding and transport/ iron homeostasis
P02768 Serum albumin precursor 
Defense related proteins - Heat Shock Proteins (HSPs)
Protein Binding - Iron related 
Protein Binding
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P28838 Cytosol aminopeptidase Presumably involved in the processing and regular turnover of 
intracellular proteins.
P00167 Isoform 1 of Cytochrome b5 Membrane bound hemoprotein which function as an electron 
carrier for several membrane bound oxygenases.
P11712 Cytochrome P450 2C9 NADPH-dependent electron transport pathway
P22307 Sterol carrier protein 2 isoform 2 Mediates in vitro the transfer of all common phospholipids, 
cholesterol and gangliosides between membranes
P80297 Metallothionein-1X Binds to various heavy metals
Q96KP4.2   Cytosolic non-specific dipeptidase Involves in proteolysis / Zinc ion binding
P61026 RAB10 Ras-related protein Rab-10 Involved in protein transport and vesicular trafficking
Q00610 Isoform 2 of Clathrin heavy chain 1 Intracellular protein transport
P02774 Vitamin D-binding protein precursor (GC globulin)
Multifunctional protein found in plasma, cerebrospinal fluid, urine 
and cell surfaces. Carries Vit.D sterols in plasma; may prevent 
actin polymerization
P27348 14-3-3 protein theta (YWHAQ) Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathway. 
P63104 14-3-3 protein zeta/delta (YWHAZ) Adapter protein
P02649 Apolipoprotein E precursor Binding of lipoprotein particles
P62937 Peptidyl-prolyl cis-trans isomerase A Accelerates protein folding
P04080 Cystatin-B Intracellular liver thiol proteinase inhibitor; binds tightly to 
reversible inhibitor of cathepsins L, H and B.
O14828 Isoform 2 of Secretory carrier-associated membrane protein 
3
 Functions in post-Golgi recycling pathways. Acts as a recycling 
carrier to the cell surface.
P02749 Beta-2-glycoprotein 1 precursor Binds to various kinds of negatively charged substances
P30740 Leukocyte elastase inhibitor (SERPINB1) Regulates the activity of the neutrophil proteases elastase, cathepsin G, proteinase-3, chymase, chymotrypsin, and kallikrein-
3.
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O15260 Surfeit 4 Endoplasmic reticulum membrane; multi-pass membrane protein
P52758 Ribonuclease UK114 Endoribonuclease responsible for the inhibition of the translation by cleaving mRNA
Q96AE4  Far upstream element-binding protein 1 (FUBP1) Regulates MYC expression by binding to a single-stranded far-
upstream element (FUSE) 
Q92945 KH-type splicing regulatory protein (FUBP2) Regulates MYC expression by binding to a single-stranded far-
upstream element (FUSE) 
P62828 RAN 26 kDa protein
Required for the import of protein into the nucleus and also for 
RNA export / Involved in chromatin condensation and control of 
cell cycle
P68105 Elongation factor 1-alpha (EF-Tu) This protein promotes the GTP-dependent binding of aminoacyl-
tRNA to the A-site of ribosomes during protein biosynthesis
P19338 Isoform 1 of Nucleolin Major nucleolar protein, induces chromatin decondensation by binding to histone H1
P55209 Nucleosome assembly protein 1 like 1 (NAP1L1) May be involved in modulating chromatin formation and 
contribute to regulation of cell proliferation.
P05455 Lupus La protein Plays a role in the transcription of RNA polymerase III
Q08211 ATP-dependent RNA helicase A Transcriptional activator (Unwinds double-stranded DNA and 
RNA in a 3' to 5' direction).
Q9Y5S9 Isoform 2 of RNA-binding protein 8A Part of a post-splicing multiprotein complex involved in both 
mRNA nuclear export and mRNA surveillance.
Q13185 Chromobox protein homolog 3 Seems to be involved in transcriptional silencing in 
heterochromatin-like complexes.
P23246 Isoform Long of Splicing factor, proline- 
and glutamine-rich mRNA processing ; DNA binding and repair protein
P78527 Isoform 2 of DNA-dependent protein
 kinase catalytic subunit
DNA recombination / Double stranded break repair
Q59F68 CD68 antigen variant Nucleic acid binding
P09651 Isoform A1-A of Heterogeneous nuclear 
ribonucleoprotein A1 Involved in the packaging of pre-mRNA into hnRNP particles
Nucleic Acid Binding Proteins
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P51991 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3
Plays a role in cytoplasmic trafficking of RNA and pre-mRNA 
splicing.
P31943 Heterogeneous nuclear ribonucleoprotein H1 Involves in processing events that pre-mRNAs undergo before 
becoming functional, translatable mRNAs in the cytoplasm.
P52272 Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein M Plays a role in  pre-mRNA splicing.
O60506 Isoform 2 of Heterogeneous nuclear ribonucleoprotein Q Binds to mRNA and has high affinity for scaffold-attached region 
DNA.
Q00839 Heterogeneous nuclear ribonucleoprotein U isoform a Plays a role in  pre-mRNA splicing and processing
P05787 Keratin, type II cytoskeletal 8 Involved in cytoskeletal organization /  Known to interact with HCV core protein
Q5XKE5 Keratin, type II cytoskeletal 79 (K6L) Expressed in skeletal muscle, skin and scalp.
P02452 Collagen alpha-1(I) chain precursor Collagen fibril organization / Blood vessel development
P12109 Collagen alpha-1(VI) chain precursor Cell adhesion protein
P47756 F-actin-capping protein subunit beta (CAPZB) Binds in a Ca2+-independent manner to the fast growing ends of actin filaments thereby blocking the exchange of subunits at 
these ends.
P29966 Myristoylated alanine-rich C-kinase substrate (MARCKS) Most prominent cellular substrate for protein kinase C, binds 
calmodulin, actin, and synapsin / A filamentous (F) actin cross-
linking protein.
P13796 Plastin-2  Actin-binding protein found in intestinal microvilli
Q01518  Adenylyl cyclase-associated protein Directly regulates filament dynamics / Actin binding
P07437 Tubulin beta chain Major constituent of microtubules
Q6P9V9 Tubulin alpha-1B chain Major constituent of microtubules
Q13885 Tubulin beta-2A chain Major constituent of microtubules
Cytoskeletal modelling / Cell Motility
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P68371 Tubulin beta-2C chain Major constituent of microtubules
Q13509 Tubulin beta-3 chain Major constituent of microtubules
P30086 Phosphatidylethanolamine-binding protein 1 Serine protease inhibitor which inhibits thrombin
P05783 Keratin, type I cytoskeletal 18 Involved in the uptake of thrombin-antithrombin complexes by 
hepatic cells / cell proliferation inducing gene
P02675 Fibrinogen beta chain precursor
Fibrinogen has a double function: yielding monomers that 
polymerize into fibrin and acting as a cofactor in platelet 
aggregation
P08758 Annexin A5
Anticoagulant protein that acts as an indirect inhibitor of the 
thromboplastin-specific complex, which is involved in the blood 
coagulation cascade.
P02679 Isoform Gamma-A of Fibrinogen gamma chain precursor
Fibrinogen has a double function: yielding monomers that 
polymerize into fibrin and acting as a cofactor in platelet 
aggregation
Q9H0W9 Ester hydrolase 
Q8WY24 SNC66 protein Ig-like? (down in CRC)
Q6PI81 IGHM IGHM protein
Q6NWZ1 CKAP4 protein (Fragment)







4.2.1  Summary of proteins identified  
The total number of regulated proteins that were identified in moderately and poorly 
differentiated HCC tissues are summarized in Table 4.3. The use of the same samples in all 
techniques enabled direct comparisons between the methods with respect to their sensitivity in 
identifying the differentially expressed proteins. It is observed that iTRAQ is the most sensitive 
method identifying a total of 241 proteins. While cICAT, appears to be as sensitive as 2-D 
DIGE detected a total of 81 and 80 differentially expressed proteins respectively (Table 4.3). It 
should be noted that a third of the proteins identified by 2-D DIGE were protein isoforms 
arising from post-translational modification.  
 
Table 4.3 : Total number of proteins identified from each technique. 
 
 







No. of spots selected 119 79 40 
No. of proteins 
identified  
(excl. isoforms) 
80 54 26 
cICAT No. of proteins identified 81 57 24 
iTRAQ No. of proteins identified 241 90 151 
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4.2.2  Common proteins identified in different techniques 
A Venn diagram is used to illustrate the type of proteins identified in both 2-D gel based 
and stable isotope labelling based techniques. Note that proteins that were identified as multiple 
spots in 2-D DIGE; possibly due to post translational modificationd or isoforms are represented 
as a single identification. In moderately-differentiated HCC, 30 out of 201 proteins were 
common in at least 2 techniques and only 8 proteins are common in all 3 techniques. Similarly 
in poorly-differentiated HCC only a small subset of proteins were identified in more than 1 
technique (13 out of 201 proteins were common in at least 2 techniques with only 4 proteins 
identified in all techniques). This therefore results in a total of 344 proteins identified as 
differentially expressed in this study. 
All overlapping proteins except two were regulated in the same direction (either over-
expressed or down-regulated). These were heat shock protein β1 (HSPβ1) and heterogeneous 
nuclear ribonucleoproteins A2/B1 (HNRNP A2/B1), which were identified as down-regulated 
in 2-D DIGE but up-regulated in iTRAQ. The difference observed in the regulation level of 
these proteins can be attributed to the possible presence of different isoforms of the protein such 





Figure 4.5 : Venn diagram of proteins identified from 2-D DIGE, cICAT and iTRAQ approaches in (A) moderately differentiated HCC and 
(B) poorly differentiated HCC. * denotes the presence of additional 2 proteins identified in 2-D DIGE and iTRAQ techniques but are 
differentially regulated 
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4.3 Protein physiochemical and biological properties  
Disparity in proteins identified was expected as it is known that each method has its 
inherent biasness and limitations. In order to better portray these differences, we classified all 
the proteins identified by each technique according to several physiochemical properties. These 
include molecular weights, isoelectric points, total number of cysteines and protein 
hydrophobicity. Proteins were also grouped according to the cellular localization and biological 
function as described by Gene Ontology (GO) consortium. For ease of analysis, proteins 
identified in moderately- and poorly-differentiated HCC were classified together.    
 
4.3.1 Molecular weight and Isoelectric point  
 Theoretical molecular weight and isoelectric point (pI) were obtained from SwissProt 
database. The molecular weight and pI of the regulated proteins are represented in the scatter 
plot (Fig. 4.6). All the proteins identified by 2-D DIGE are in the molecular mass range of 12 
kDa to 82 kDa. In cICAT technique, the majority of the proteins identified were also smaller 
than 100 kDa with the exception of one protein, fibronectin precursor (Accession No.: P02751, 
MW of 221 kDa). Proteins identified via iTRAQ labels have a wider coverage with an estimate 
of 10% of the proteins having molecular masses being greater than 100 kDa. The largest protein 
identified is DNA-dependent protein kinase (Accession No.: P78527) with a theoretical 
molecular mass of 508 kDa. 
The proteins identified by 2-D DIGE and cICAT are clustered at the pI range of 5 – 9. 
The majority of the 2-D DIGE proteins are located in the pI 6 – 7 region which is most 
expanded in a non-linear IPG strip. In addition, basic proteins were under-represented by 2-D 
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DIGE in comparison to cICAT and iTRAQ methods. Lastly, the proteins identified by the 
iTRAQ technique have a slightly wider pI range of 4.5 – 10. This is advantageous as it enables 





Figure 4.6 : Scatter plot of molecular weight (kDa) and isoelectric point (pI) of all the proteins identified by (A) 2-D DIGE; yellow, (B) 
cICAT; green and (C) iTRAQ ; red.  
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4.3.2 Hydrophobicity plot  
 The extent of hydrophobicity is obtained from the general average hydropathicity 
(GRAVY) score obtained from ProtParam Tool. GRAVY score is calculated as the mean of the 
sum of the hydropathic indices of amino acids. According to Kyte and Doolittle (1982), integral 
membrane proteins typically have higher GRAVY scores than globular proteins. This score 
however is not able to reliably predict the structure without the help of hydropathy plots.  
The GRAVY scores of all the proteins identified are represented in histograms in Fig. 
4.7. Bars in darker grey hue indicate possible hydrophobic proteins. Interestingly, the GRAVY 
score of proteins identified by 2-D DIGE are in the range of -0.9 to 0.2 (with 11% having 
positive scores) and a similar coverage from -1.0 to 0.3 were observed in the cICAT and 
iTRAQ methods (with only an average of 10% of the proteins had positive scores). Proteins 
identified with positive GRAVY scores include membrane proteins such as a peripheral 
membrane protein, L-xylulose reductase (Accession No: Q7Z4W1) and a multi-pass membrane 
protein, Transmembrane protein 205 (Accession No.: Q6UW68) identified via cICAT and 
iTRAQ respectively. However, in general all the 3 methods seemed to show under 
representation of hydrophobic proteins. 
 Figure 4.7 : Plots of the GRAVY values of all the proteins 
cICAT (C) iTRAQ. Bars in darker grey hue indicate proteins with positive GRAVY scores. The 
numbers in brackets indicate the total number of proteins identified by each technique. 
identified via (A) 2
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-D DIGE, (B) 
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4.3.3 Localization and biological functions  
The cellular localization and biological functions of these dysregulated proteins as 
obtained from Gene Ontology (http://www.geneontology.org/) were shown in Figs. 4.8. 
Interestingly, there are no differences between the cellular localization and functions of proteins 
identified by the 3 methods. In all approaches, an average of 50% of the proteins identified in 
all the different techniques is localized in the cytoplasm. The majority of them were identified 







Figure 4.8 : Distribution of the identified proteins according to (A) cellular localization and (B) biological functions based on GO consortium. 
(A) moderately-differentiated HCC tissues and (B) poorly-differentiated HCC tissues 
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4.3  Biological functions of regulated proteins 
  Regardless of the technique used for separation and identification, the differentially 
expressed proteins were subsequently analyzed based on differentiation status : viz, moderately 
and poorly differentiated HCC. A total of 85 common proteins were found to be regulated in 
both HCC stages (Fig. 4.9). These proteins are listed in italics in Table 4.1 and 4.2. The 3 major 
groups of proteins that are affected include those that are involved in metabolic and catalytic 
activities and binding (Fig 4.10). A significant portion (>30%) proteins being affected are those 
involved in energy metabolism.  
 
 
 Figure 4.9 : Distribution of the moderately and poorly differentiated proteins. (Proteins that 
were identified in more than one technique or with multi-isoforms are counted as a single / 
unique protein) 
 
 Figure 4.10 : Distribution of the





























Selected proteins of interests from Table 4.1 and 4.2 are represented as stacked bar 
charts according to their biological functions as annotated by KEGG and Gene Ontology (Fig. 
4.11). These consist of mainly enzymes involved in amino acid metabolism (e.g. arginase), 
glucose catabolism (e.g. fumarate hydratase) and fatty acid β-oxidation (e.g. enoyl-CoA 
hydratase). Down-regulation of these proteins had also been reported earlier by various gene 
and protein profiling studies of HCC. 
These groups of proteins were selected based on their importance with respect to proper 
maintenance of liver function and tumourigenesis. Proteins that are over-expressed include 
inflammation response, heat shock proteins, cell motility and nuclear proteins. The functions of 






 Figure 4.11 : Distribution of selected moderately and poorly differentiated proteins according to KEGG and Gene Ontology biological 
functions. (Grey bars represent total number of proteins that are down-regulated; Black bars represent total number of proteins that are up-
regulated proteins.) 
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4.4  Verification of protein regulation  
4.4.1 Western blotting  
A group of proteins were further selected for western blot verification using 
commercially available antibodies. All 12 pairs of samples used in this study, were separated 
via 1- or 2-dimensional SDS-PAGE and probed for the respective antibodies. The concentration 
of the antibodies used and duration of exposure was listed in Table 3.4. This verification was 
carried out to confirm the identification and, most importantly, the regulation level of the 
proteins as identified from the each technique. 
As illustrated in Fig. 4.12 and 4.13, a selected group of proteins identified from the 
different techniques (5 proteins from 2-D DIGE; 1 protein from cICAT; 5 proteins from 
iTRAQ; 3 proteins were identified by multiple techniques) were selected for verification. A 
protein was determined as regulated by comparing its expression level between tumour and its 
paired non-tumour. The extent of regulation between a pair of tumour and its non-tumour 
sample was also observed to vary across the different pairs of tissues. All the proteins verified 
using western blots confirmed the regulation level as that observed in the proteomic screening.   
Actin and GAPDH (Fig. 4.12 C) were also immunoblot as controls to ensure equal 
loading of proteins. These common housekeeping proteins were also observed to be regulated 
and vary extensively across the patient samples. The limitations of using housekeeping proteins 
as normalizations of protein samples in western blotting had also been discussed by Ferguson et 
al., (2005). Hence, in this study silver colloidal stains of the PVDF membranes were used 







Figure 4.12 : Verification of selected proteins using 1D western blot; (A) down-regulated proteins, (B) up-regulated proteins and (C) 
housekeeping proteins. (N: non-tumour, T: tumour) 
 
 Figure 4.13 : Western blot images of nucleotide diphosphate kinase A (NDKA)













4.4.2 Over expression of FUSE binding protein (FUBP) 
Over-expression of protein spots from two members in the far upstream binding protein 
(FUBP) family1 [FUBP1 and FUBP2 (KHSRP)2] were identified from 2-D DIGE / MS-MS 
analysis. Three over-expressed protein spots were identified as FUBP1 in moderately-
differentiated HCC tissues. These protein spots (# 977, # 985 and # 992) have experimental pIs 
of 6.7, 6.9 and 7.2 and molecular mass of 83 kDa (Fig. 4.15 A). In poorly differentiated HCC 
samples, two of the FUBP1 protein spots (# 882 and # 895) with a experimental pIs of 6.9 and 
7.2 were observed to be significantly over expressed. In addition, 2 over-expressed protein 
spots corresponding to FUBP2 (# 681 and # 694) with experimental pIs 6.6 and 6.9 and with a 
molecular mass of 94 kDa were also observed in patients with poorly differentiated tumours 
(Fig. 4.15 B).  Table 4.4 summarizes the average ratio and frequency of occurrences of these 
FUBP protein spots in the tissue samples as obtained by DeCyder analysis.  
 
 
                                                 
1 Far upstream binding protein (FUBP) is also reported in literature as FUSE binding protein, FBP and FABP.  
2 FUBP2 is also known as KH-splicing regulatory protein (KHSRP). 
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Figure 4.15 : Representative image of ImageQuant and DeCyder analysis of (A) moderately-
differentiated HCC – 3 protein spots of FUBP1 977, 985 and 992 with average ratios of 3.65, 
1.60 and 1.99 respectively, (B) poorly-differentiated HCC – FUBP1 882 and 895 with average 
ratio of 1.68 and 1.90; FUBP2 681 and 694 with average ratios of 1.86 and 2.34. (N: non-
tumour, T: tumour ; Image view and 3-D view obtained from DeCyder) 
 
4.4.2.1 Mass spectra of FUSE binding protein (FUBP) 
The mass spectra of the tryptic digests of FUBP1 and FUBP2 are shown in Figs. 4.16 A 
and 4.16 C. It can clearly distinguish the 2 FUBP isoforms. This was further confirmed and 
supported by the MS/MS analysis of one of the peptides from each of the isoforms selected for 





Figure 4.16 : Representative mass spectra of FUBP1 and FUBP2 analyzed by MALDI-
TOF/TOF MS upon tryptic digestion. (A) MS spectrum with tryptic peptides of FUBP1; arrow 
indicates ion at m/z = 1336.70 selected for MS/MS (B) MS/MS spectrum of the peptide 
IGGNEGIDVPIPR (m/z = 1336.69), where y- and b-ions are denoted along with immonium 
ions (G, glycine; P, proline; V, valine;  I, isoleucine;  R, arginine); y- and b-fragmentations are 
also indicated with tilted dotted lines above and below the sequence, respectively. (C) MS 
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spectrum with tryptic peptides of FUBP2; arrow indicates ion at m/z 1184.72 selected for 
MS/MS and (D) MS/MS spectrum of the peptide IINDLLQSLR (m/z = 1184.72), where y- and 
b-ions are denoted along with immonium ions (I, isoleucine; L, leucine; Q, glutamine; R, 
arginine); y- and b-fragmentations are also indicated with tilted dotted lines above and below 










                                                 










Ratio T-test Freq+ 
Moderately differentiated HCC 
977 Q96AE4 
Far upstream element-
binding protein 1 
FUBP1 
67.6 / 7.2 83.3 / 6.7 3.65 3.90E-08 5 / 5 
985 Q96AE4 
Far upstream element-
binding protein 1 
FUBP1 
67.6 / 7.2 83.3 / 6.9 1.60 0.0018 3 / 5 
992 Q96AE4 
Far upstream element-
binding protein 1 
FUBP1 
67.6 / 7.2 83.3 / 7.2 1.99 8.30E-05 4 / 5 
Poorly differentiated HCC 
882 Q96AE4 
Far upstream element-
binding protein 1 
FUBP1 
67.6 / 7.2 84.6 / 6.9 1.68 0.035 4 / 7 
895 Q96AE4 
Far upstream element-
binding protein 1 
FUBP1 
67.6 / 7.2 83.3 / 7.2 1.90 6.00E-04 5 / 7 
681 Q92945 
Far upstream element-
binding protein 2 
FUBP2, KHSRP 
73.1 / 6.8 94.4 / 6.6 1.86 0.024 5 / 7 
694 Q92945 
Far upstream element-
binding protein 2 
FUBP2, KHSRP 
73.1 / 6.8 94.0 / 6.9 2.34 0.0052 5 / 7 
 4.4.2.2 Over expression of FUSE binding protein (FUBP)
To confirm the 2-D DIGE results, FUBP1 and FUBP2 were validated in 6 individual 
tissue samples using western blots. As shown in Fig. 
differentiated HCC tumour tissues showed over
6 tumour tissue lysates.  
Figure 4.17 : Western blot image
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 4.4.2.3 c-myc validation by western blot 
FUBP1 and FUBP2 are known to be involved in the transcriptional control of the proto
oncogene, c-myc. Thus a western blot analysis was conducted to check the protein expression 
level of c-myc in our HCC tissues (Fig
tumour tissues especially the poorly
significance of this result will be discussed later.
Figure 4.18 :  1-D Western blot images of 
and poorly-differentiated HCC tissue lysates. Equal loading of proteins were confirmed in a 
colloidal stained membrane (data not shown). 
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4.5 In vitro study on FUBP  
 As observed in the tissue lysates, over-expression of FUBP 1 and 2 is involved in HCC. 
In order to investigate if changes in FUBP levels might directly influence tumourigenesis, 
knock-downs of each of FUBP isoforms using siRNA from Dharmacon RNAi Technologies, on 
liver cell lines as a model was carried out. 
 
4.5.1 Optimization of concentration of siRNA  
 HepG2 liver cell lines grown in 24 well plates were used for optimization. Three 
different concentrations of siRNA (25 nM, 50 nM and 100 nM) against FUBP 1, 2, 3 and 
siRNA cocktail of all 3 FUBP isoforms at 33 nM each (FUBPmix) were also introduced. 
siRNA against GAPDH at similar concentrations were used as a positive control to ensure the 
technique employed is successful. HepG2 control cells without any treatment, transfectant only 
and non-targeting (NTC) siRNA with are used as negative controls. Cells were treated at 70% 
confluence for 48 hours before they were lysed in urea/thiourea buffer.   
 10µg of proteins from each treatment was separated in 1-D western blot and probed 
against FUBP 1, 2, 3 and GAPDH. Figure 4.19 showed that the knockdown was successful in 
all the concentrations used. Subsequently, 50 nM of siRNA were used for all the following 
experiments on HepG2 and Hep3B cell lines.  
 Figure 4.19 :  1-D Western blot images of FUBP 1 / 2 / 3 and GAPDH on HepG2 whole cell 
lysates following addition of 3 different concentration of siRNA, NTC : non
GAPDH, FUBP 1 / 2 / 3.  
 
  In view that each FUBP has multiple isoforms a 2
HepG2 cell lysates after siRNA treatment. A total of 10µg of proteins from each treatment were 
probed against FUBP 1, 2, 3. As illustrated by Figure 4.20
expressed at lower levels, indicating 
any isoforms. This also showed that the multi protein spots of FUBP 1 / 2 / 3 observed were 
likely due to post-translational modification
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 Figure 4.20 :  1-D Western blot images of FUBP 1 / 2 / 3 and GAPDH on HepG2 whole cell 
lysates following addition of 3 different concentration of siRNA, NTC : non





 4.5.2 Effects of FUBP knockdown 
 50nM of siRNA against FUBP 1 / 2 / 3 
10µg of proteins were separated on 1
Figure 4.21, despite effective knockdowns of the respective FUBPs, the levels of 
vary significantly in both cell lines. FUBPmix which contains all 3 FUBP siRNA showed a 
slight decrease in c-myc level in Hep3B. 
Figure 4.21 :  1-D Western blot images of 
siRNA treatment. GAPDH levels are used as 
 
on c-myc levels  
were treated for 72 hrs in HepG2 and Hep3B. 
-D SDS PAGE and probed for c-myc levels. As shown in 
 
(A) HepG2 and (B) Hep3B upon FUBP 1 / 2 / 3 
loading controls. 
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c-myc did not 
 
 4.5.3 Effects of FUBP knockdown in cell
 In addition to c-myc 
and Hep3B cells using MTT reagent (Fig. 4.22
were not affected upon siRNA treatment. Hep3B cells on the other hand showed significant 
decrease in viable cells in each of the siRNA treatment. All experiments were conducted in 4 
sets of wells. All 3 separate batches of cells used showed similar changes in viabil
Figure 4.22 :  Cell viability were measured using absorbance value at 550nM upon treatment of 
FUBP siRNA. All absorbance value
(NTC). X-axis indicates the concentration of siRNA used. 
black bars represent Hep3B cells (p <0.05).
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western blots, cell viability assay were conducted on both HepG2 
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s were normalized to the respective non-
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This study is the first report using multiple quantitative proteomic approaches to identify 
differentially expressed proteins with the aim to understand the molecular pathogenesis of 
HBV-associated HCC. With the use of three complementary approaches (2-D DIGE, cICAT 
and iTRAQ), we successfully identified a total of 344 dysregulated proteins excluding isoforms 
from HCC tumour versus non-tumour tissues (Table 4.3).  
The use of multiple but complementary techniques on the same set of tissues has been 
proposed to enable a more comprehensive identification of regulated proteins (Choe et al., 
2005; Wu et al., 2006). As observed in this study, the significance of this approach is evident 
by the total number of dysregulated protein targets identified in comparison to previous HCC 
proteomic studies (Table 1.4).  In addition, it was also observed that each of the 3 techniques 
identified different sets of proteins (as illustrated in Fig. 4.5). This thus further emphasized that 
the use of only one proteomic technique in global profiling studies may provide insufficient 
information. Most significantly, the use of complementary techniques in this study had 
substantially improved the coverage of differentially regulated proteins in 
hepatocarcinogenesis. This should enable us to better understand the molecular events that are 
involved in HBV-associated HCC.  
 
5.1 Protein expression of moderately- and poorly-differentiated HCC 
 Out of the total of 344 proteins identified, 163 and 181 proteins were expressed in 
moderately- and poorly-differentiated HCC respectively. Eighty-five of these proteins were 
observed to be common in both stages of HCC (Fig. 4.9). Most of these commonly affected 
proteins are involved in metabolism, catalytic activity and binding properties (Fig. 4.10). 
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 It was initially anticipated that critical molecular players of HCC would reveal stepwise 
increasing or decreasing regulation levels between the 2 stages of HCC tissues. While all 85 
proteins indicated common direction of regulation between moderately- and poorly-
differentiated stages, only a handful of these proteins revealed such a progressive change in 
their regulation levels. It is therefore probable that to delineate the significant molecular events 
in tumour progression, emphases should not be on individual players but on the combinatory 
effects of proteins from a common pathway.  
 
5.1.1 Alterations of proteins from common pathways 
Proteins identified were further analysed according to their known pathways and 
interactions as annotated by Ingenuity Pathway Analysis (IPA). As illustrated in Figure 4.11, 
we observed a significant increase in regulated proteins of a specific pathway as tumour 
progress from moderately- to poorly-differentiated HCC. The number of dysregulated proteins 
in metabolic activities for example increased from moderately- to poorly-differentiated HCC. 
This increasing aberration of proteins will result in perturbation of important molecular and 
cellular events.  
We anticipate that these pathways or groups of proteins will aid in understanding the 
progression of hepatocarcinogenesis. The functional roles of major clusters of differentially 
expressed proteins identified in this study are described in the following sections : metabolic 
proteins, oxidative stress related proteins and c-myc associated proteins.  Emphases were also 
made on protein clusters that showed a progressive loss or gain of function across the 2 stages 
of HCC.  
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5.2 Dysregulation of Metabolic Proteins  
Metabolic pathways represent one of the major groups of proteins that showed 
increasing dysregulation from moderately- to poorly-differentiated HCC (Table 4.1 and 4.2, Fig 
4.12). This includes glucose, amino acids and lipid metabolism (Fig. 4.10 and Fig. 4.11). 
Dysregulations of these metabolic pathways had also been observed in other tumour phenotypes 
(Warburg, 1956; Dang and Semenza, 1999). Differential expressions of these enzymes are also 
likely a reflection of the gross effect of the loss of liver function across the various stages of 
HCC (Liang et al., 2005). Although metabolic defects may not be fundamental in causing 
cancer, they may confer a common advantage that ensures the survivability of tumour cells 
(Dang and Semenza, 1999). 
 
5.2.1 Glucose metabolism and oxidative phosphorylation 
One of the most frequent and well studied metabolic alterations is glucose metabolism. 
It is commonly accepted that most tumours invest heavily in glycolysis as their main source of 
energy (Altenberg and Greulich, 2004) even in aerobic conditions, exhibiting a phenomenon 
described as Warburg effect (Warburg, 1956). Most tumour cells including HCC has been 
shown to alter their glycolytic and mitochondrial machinery resulting in a preference to produce 
lactic acid to obtain immediate energy rather than catabolising glucose via tri-carboxylic acid 
(TCA) cycle (Kim and Dang, 2006). Maintaining a high glycolytic rate also implies a “longer 
tumour survival time” when these rapidly proliferating cells are exposed to a hypoxia micro-
environment (Pedersen, 2007).  
In addition, these enzymes can also be activated during hypoxia by transcription factors 
such as hypoxia inducible factors-1α (HIF-1α) (Maxwell, 2005; Esteban and Maxwell, 2005). 
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Alterations in glycolysis can also be attributed to various tumour suppressors (such as loss of 
p53 affects TIGAR pathway, Bensaad et al., 2006; Corcoran et al., 2006) as well as oncogenes 
(c-myc, Dang and Semenza, 1999). Although the “cause and effect” of glycolysis and cancer is 
controversial (Zu and Guppy, 2004, Pan and Mak, 2007), elevated levels of glycolysis in cancer 
cells ensures survivability and enhances proliferation.  
 
5.2.1.1 Alterations in glycolytic pathway 
In this study, we also observed over-expression of glycolytic enzymes such as muscle 
type aldolase A and alpha-enolase in poorly-differentiated HCC. Transketolase, an enzyme 
involved in pentose phosphate pathway, was also identified as up-regulated only in poorly 
differentiated HCC. However, several other glycolytic enzymes such as ketohexokinase (KHX), 
aldolase B, triosephosphate isomerase (TPI) (Fig. 4.12A) and phosphoglycerate mutase (PGM) 
were shown to be down-regulated (Table 4.1 and 4.2). Figure 5.1 highlights the different 




Figure 5.1 : Diagrammatic representation of glycolysis and the various dysregulated enzymes. Enzymes that were identified in moderately- 
and poorly-differentiated HCC are boxed in blue and red respectively. In addition, enzymes that were over-expressed are in red and those that 
are down-regulated are in black. (KHK, ketohexokinase; FBP, fructose-1,6 bisphosphatase; ALDO A / B, aldoalase A / B; TKT, transketolase; 
PGM, phosphoglucomutase; ENO, alpha-enolase.)
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Under-expression of these enzymes in HCC tumour tissues had also been reported in 
other proteomic studies (Yokoyama et al., 2004; Liang et al., 2005; Blanc et al., 2005). 
Contrary to Warburg effect, low levels of glycolytic enzymes in tumour tissues would hamper 
glucose utilization and hence energy production. With the exception for PGM, these 
discrepancies can be best explained by analyzing energy flux for glycolysis (Fig. 5.1).  
Glycolysis is composed of firstly, energy investment followed by energy acquiring 
steps. Aldolase A / B, KHX and TPI are involved in the first half of glycolysis. It is thus 
tempting to suggest that the down regulation of these enzymes allows the tumour to utilize 
other less energy investing route to produce ATP. This might have been achieved as observed 
via up regulation of transketolase (identified in our poorly differentiated HCC samples) through 
the pentose phosphate pathway. This also ensures nucleotide biosysnthesis which is necessary 
in proliferating cells. Thus low expression of enzymes in the energy investment steps (such as 
KHX and TPI) coupled with the up-regulation of energy acquiring step (e.g. enolase) could be 
beneficial for the tumour. These observations suggest that HCC might have successfully 
identified alternative pathways that can feed into the energy acquiring steps of glycolysis. This 
might add a ‘twist’ to the Warburg effect. 
 
5.2.1.2 Over-expression of aldolase A but not liver specific aldolase B  
Most vertebrates have 3 different aldolase isozymes (Izzo et al., 1987). Aldolase A is 
identified predominantly in foetal liver as well as adult muscle. While aldolase B is found 
exclusively in the adult liver and aldolase C in the brain (Mamczur and Dzugaj, 2008). Aldolase 
is involved in cleaving of fructose-1,6-bisphosphate into two carbon-3 molecules in the energy 
investing step of glycolysis. In this study we observed differential regulation levels of 2 
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isozymes of aldolase. Down-regulation of liver specific aldolase B was observed in both stages 
of HCC and over-expression of aldolase A was shown in only poorly-differentiated HCC.  
The under expression of aldolase B had also been reported in several HCC studies 
(Kinoshita and Miyata, 2002, Yokoyama et al., 2004, Lee et al., 2005; Liang et al., 2005) and 
were correlated with poor prognosis and early HCC recurrence (Peng et al., 2008). Elevated 
levels of aldolase A was first observed more than 20 years ago and was proposed as a serum 
marker for HCC (Asaka et al., 1983). Castaldo et al., (2000) also reported up-regulation of 
mRNA transcript levels of specifically aldolase A in HCC tissues compared to cirrhotic liver. In 
addition, HIF-1α is also able to induce expression levels of aldolase A suggesting its role for 
tumour survival in hypoxia environment (Dang and Semenza, 1999).   
The interplay of aldolase isoforms suggests that tumours in the late stage have de-
differentiated from normal hepatocytes. Thus, it is capable to enhance glycolysis by utilizing 
embryonic form of aldolase. Further investigation of the different levels of aldolase isozymes 
may be useful in understanding HCC initiation and progression. 
 
5.2.1.3 Elevated levels of alpha-enolase   
Another glycolytic enzyme, alpha-enolase was also identified to be up-regulated in 
poorly differentiated HCC only (Table 4.2, Fig. 4.12A). Alpha-enolase is responsible for 
formation of phosphoenolpyruvate in the second half of glycolysis. Over-expression of alpha-
enolase was described in vascular endothelial cells as protective response in hypoxia 
environment (Aaronson et al., 1995) and it is a target of HIF-1α (Semenza et al., 1996). High 
expression levels of alpha-enolase have been reported in various cancers such as colon cancer 
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cell lines (Katayama et al., 2006), breast cancer (Somiari et al., 2003) and cervical cancer (Lee 
et al., 2004).  
In HCC, elevated levels of alpha-enolase were associated with increasing tumour size 
and venous invasion in late stage HCV-associated tumour tissues (Takashima et al., 2005). 
However, down-regulation of alpha-enolase was reported in early HBV-associated HCC using 
Grade I and II human tissues (comparable to well and moderately-differentiated HCC) (Kim et 
al., 2003). This correlates with identification of higher levels of alpha-enolase in only poorly 
differentiated HCC tissues analysed in this study (Fig. 4.12A). This suggests a prognostic value 
of alpha-enolase in identification of late stage HCC tumours. Additional studies will be 
necessary to confirm these differences in expression levels. 
 
5.2.1.4 Tri-carboxylic acid (TCA) cycle 
 The TCA cycle is the main source of reducing molecules (NADH
 
and FADH2) that 
sustains the mitochondrial respiratory chain activity for producing ATP. It consists of a series 
of 8 progressive oxidative decarboxylations of acetyl-coA. It takes place in the mitochondrial 
matrix and it is an essential cycle connecting various molecular pathways. 
In this study, a progressive loss of TCA cycle was observed from moderately- to poorly-
differentiated HCC. In the earlier stage, only 1 enzyme, fumarate hydratase was identified as 
down-regulated. While in poorly differentiated HCC, a total of 5 TCA cycle enzymes (aconitate 
hydratase, isocitrate dehydrogenase, fumarate hydratase, scuccinyl Co-A ligase and succinate 
dehydrogenase) were shown to be down-regulated (Table 4.1, 4.2 and Fig 5.2). Though low 
expression levels of fumarate hydratase (Liang et al., 2005) and succinyl CoA-ligase (Blanc et 
al., 2005) had been reported earlier, this is the first report that identified dysregulation of 5 out 
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of 8 TCA enzymes . Regulation levels of fumarate hydratase levels in both stages of HCC were 
also verified using western blots (Fig 4.12A). Disruption of TCA cycle had been suggested as 
one of the mechanisms employed by tumours to ensure rapid energy production via glycolysis 
(Pedersen, 2007). 
Recent discoveries had also implicated direct involvement of succinate dehydrogenase 
and fumarate hydratase in tumour formation. Mutations or low expression levels of these 2 
enzymes had been implicated in paraganglioma, uterine leiomyosarcoma and renal cancer 
(Baysal et al., 2000; Launonen et al., 2001; Tomlinson et al., 2002). It was shown that the 
accumulation of succinate and fumarate due to defects in succinate dehydrogenase and fumarate 
hydrates lead to inhibitin of HIF prolyl hydolases (PHD) (Isaacs et al., 2005; Briere et al., 2005, 
2006; Sudarshan et al., 2009). In the absence of PHD, HIF-1α is translocated into the nucleus 
and results in the subsequent activation of target genes (King et al., 2006). Therefore, 
dysfunctional TCA cycle may induce glycolysis (as suggested by Warburg effect) and also 






Figure 5.2 : Schematic representation of tri-carboxylic acid (TCA) cycle and dysregulation of 
enzymes observed in both stages of HCC. Proteins identified in moderately- and poorly-
differentiated are in blue and red boxes respectively. All the enzymes identified were down-
regulated. (ACO1, aconitate dehydrogenase; IDH1, isocitrate dehydrogenase; SUCLG, 
succinyl-CoA ligase; SDHA, succinate drhydrogenase; FH, fumarate hydratase). 
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5.2.2  Lipid metabolism 
Under normal physiological conditions, liver is necessary for lipid homeostasis. In this 
study, we observed that during HCC progression β-oxidation levels are affected. Four 
mitochondrial enzymes of β-oxidation (fatty acid coA ligase, acetyl-coA acetyltransferase, acyl-
coA dehydrogenase and ketoacyl-coA thiolase) recurring steps were down-regulated in 
moderately and poorly differentiated HCC. In addition, enzymes responsible of activating β-
oxidation (fatty acid-CoA ligase and carnithine palmitoyltransferase) and other peroxisomal 
localized isozymes were also identified as down regulated in only poorly differentiated HCC. 
This again describes the successive loss of metabolic integrity from moderately- to poorly- 
differentiated HCC. Dysregulation of lipid metabolism will lead to accumulation of free fatty 
acid that may eventually lead to hepatic steatosis and hepatocellular injury (Browning and 
Horton, 2004). 
Impairment of β-oxidative and fatty acid metabolic enzymes has also been observed in 
other profiling studies (Sun et al., 2007). High levels of free fatty acid increased the 
susceptibility of lipid peroxidation damage that may occur in the presence of reactive oxygen 
species (Browning and Horton, 2004). This may lead to oxidative stress, liver inflammation and 
fibrosis. Interestingly, down-regulation of fatty acid enzymes are more prominent in HCV-
related than in HBV-related HCC. In addition, steatosis has also been associated with chronic 
HCV infection and changes in lipid level can affect HCV replication (Powell et al., 2005). 
Aberration in the enzyme levels have been credited to both host and direct HCV viral factors.  
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5.2.3  Down-regulation of methylation cycle proteins 
 In agreement with previous HCC omics analyses (Shen et al., 1998; Avila et al., 2000; 
Liang et al., 2005), we also observed down-regulation of enzymes in the methylation cycle (S-
adenosylmethionine synthetase and betaine-homo cysteine S-methyltransferase). Oxidative 
stress, high levels of nitric oxide and hypoxia has been associated with inactivation of S-
adenosylmethionine synthetase (Corrales et al., 2002). Synthesis of S-adenosylmethionine 
(AdoMet) is essential in all cells but methylation occurs mainly in the liver (Avila et al., 2002).  
 
 
Figure 5.3 : Schematic illustration of the methylation cycle. Proteins identified in moderately- 
and poorly-differentiated are in blue and red boxes respectively. All the enzymes identified 
were down-regulated. (MAT, methionine adonesyltransferase; BHMT, betaine homocysteine 
N-methyltransferase; Adomet, adenosylmethionine).  
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This cycle is hence crucial as this determined the proper methylation of DNA, RNA and 
other macromolecules (Tsukada et al., 1985). DNA methylation is also an important epigenetic 
factor (Laird and Jaenisch, 1996). Hypomethylation of liver DNA, was described to increase 
expression of oncogenes (c-jun, c-myc, ras) and generation of liver tumours in rats (Christman 
et al., 1993; Simile et al., 1994). 
 Low AdoMet levels were shown to impair mitochondrial function (Santamaria et al., 
2003) and generate oxidative stress in the liver (Corrales et al., 2002; Martinez-Chantar et al., 
2002). Mice without adenosylmethionine synthetase showed spontaneous steatosis and HCC 
(Martinez-Chantar et al., 2002). In another study, AdoMet administration is able to reduce liver 
damage and improve alcohol dependant cirrhosis (Vendemiale et al., 1989). This thus provides 
additional evidence that the imbalance in methionine metabolism is an important player in 
tumourigenesis. 
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5.3  Oxidative stress in HCC 
 Oxidative stress is one of the earliest cellular responses during chronic viral infections 
and rapid cell growth. This cluster of proteins includes pathways that augmented production of 
oxidative stress, inactivation of scavenging mechanism and over-expression of anti-
inflammatory proteins.  
   
5.3.1 Perturbation in iron homeostasis results in oxidative stress 
The liver is the major site for iron storage. It regulates iron traffic around the body and 
synthesizes major proteins involved in iron metabolism (Anderson and Frazer, 2005). The liver 
maintains iron homeostasis in the body mainly by uptake of circulating iron via serotransferin, 
hemoglobin, heme and ferritin. Our data collected suggests that the integrity of basic iron 
regulatory system is greatly compromised.  
Elevated hemopexin is observed in both moderately- and poorly-differentiated HCC. 
This implies an increase in the uptake of heme into the liver, which will be degraded to 
biliverdin and free iron. Free iron is normally bound to iron-binding proteins such as tissue 
ferritin and serotransferin for storage or degradation. In these tumour tissues however, these 
proteins were both down regulated. This now indicate high level of unbound iron in the liver.  
It has been suggested that untreated iron overload may lead to liver fibrosis, cirrhosis 
and cancer (Kowdley, 2004; Asare et al., 2006). This can be mediated by either direct and/or 
indirect mechanisms. Direct mechanism would include possible DNA damage, inactivation of 
tumour suppressor and cell proliferation (Dong-yun et al., 2003). Indirect effects would 
comprise of free iron forming reactive oxidative species (ROS) such as the hydroxyl radicals 
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(OH.), superoxide and singlet oxygen (Cadenzas, 1989). This can lead to oxidative damage to 
DNA, proteins and lipids (Cheeseman, 1993) which have been implicated in inflammatory 
diseases and cancer including HCC (Wiseman and Halliwell, 1996; Jungst et al., 2004). It is 
proposed that oxidative damage due to excess hepatic iron may result in chronic inflammatory 
hepatic disease. This will result in more ROS and oxidative damage (Hagen et al., 1994; Jungst 
et al., 2004).   
 
5.3.2 Inactivation of scavenging mechanisms 
Under normal conditions, the presence of ROS and free radicals in the body usually 
leads to an increase in antioxidant proteins to protect the cells. This scavenging mechanism is 
however, abolished in many cancer cells including HCC (Sun et al., 2005). Similarly in the 
HCC tissues that we had analysed, we observed diminished levels of a repertoire of antioxidant 
proteins. Proteins such as superoxide dismutase, catalase, peroxiredoxin 6, thioredoxin-
dependent peroxide reductase and glutathione peroxidase were all also shown to be down 
regulated in both moderately and poorly differentiated HCC. The regulation of superoxide 
dismutase and catalase were also verified by western blots (Fig. 4.12A). This under expression 
could result in prolonged oxidative insult.  
Diminished antioxidant defense mechanism, in concert with iron overloading, would 
lead to excessive oxidative stress in the hepatocytes. At present, there is little doubt that 
oxidative stress is important in the pathophysiological component of tumourigenesis. There is 
also evidence that ROS could also directly promote cell proliferation and the invasive ability of 
hepatoma cells (Miura et. al., 2003). ROS and free radicals have the ability to react with a wide 
range of cellular constituents such as amino acids, membrane lipids to initiate a chain of free 
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radical reactions known as lipid peroxidation and insult on pyrimidine residues of DNA. All 
these could possibly lead to mitochondrial and DNA damage that will contribute to initiating 
and promoting tumorigenesis. 
 
5.3.3 Elevated heat shock protein and inflammatory response 
 In concert with liver inflammation, hypoxia and high levels of free radicals, a cluster 
defense related proteins were identified to be up-regulated. This consists of a family of heat 
shock proteins (HSPs), glucose regulated proteins (GRPs) and inflammatory response proteins. 
With the exception of HSPs, we observed a progressive increase in the number of dysregulated 
proteins involved in inflammatory response across the two stages of HCC (Fig. 4.12). The over-
expression of inflammatory responses enables the tumour cells to protect from high levels of 
oxidative stress. These inflammatory response proteins also display tumourigenic properties. 
The following sections describe the current literature on these chaperone proteins and their 
possible prognostic value.  
 
5.3.3.1 Dysregulations of heat shock proteins 
 Heat shock proteins (HSPs) are protein chaperones responsible for facilitating protein 
folding and translocation (Bukau and Horwich, 1998). Some members have also been shown to 
promote cancer cell growth and survival (Rohde et al., 2005). In this study, over-expression of 
a myriad of heat shock proteins such as HSP 70 isoforms and HSP 90 isoforms were identified 
in both stages of HCC.  
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The HSP 70 protein family for example, had been well characterized and had shown to 
play a crucial role in caspase de-activation leading to its anti-apoptotic effect (Beree et al., 
2000). Elevated levels of HSPs had also been reported earlier in HCC studies (Kim et al., 2002; 
Takashima et al., 2003; Kim et al., 2003; Kim et al., 2006; Luk et al., 2006). 
 Interestingly, HSP27 was identified in moderately differentiated HCC as down 
regulated using 2-D DIGE approach but up-regulated in our iTRAQ results. This difference in 
regulation level may be due to a specific isoform identified in 2-D DIGE. In the literature, 
variable levels of HSP 27 had also been reported. Kim et al., (2002) analysed 11  HCC tissues 
and reported down-regulation of HSP27. Another group (Kim et al., 2003) identified over-
expression and down-regulation of HSP27 in HBV- and HCV-associated HCC respectively. A 
recent study on HBV-associated HCC however identified over-expression of HSP27 (Luk et al., 
2006). This discrepancies observed by these studies may have been due to different aetiology of 
HCC or simply a different protein isoforms.  
 
5.3.3.2 Up-regulation of glucose regulated proteins (GRPs)  
 In addition to HSPs, a family of glucose regulated proteins (GRPs) had also been of 
great interest in carcinogenesis. GRPs are endoplasmic reticulum (ER) chaperones that can be 
induced under glucose starvation and other ER perturbations (Lee, 2001). Elevated levels of 
GRP75 were identified in both moderately- and poorly- differentiated HCC and GRP78 was 
found in poorly differentiated HCC tissues used in this study. High levels of GRPs had been 
associated in several HCC studies (Kim et al., 2003; Takashima et al., 2003).  
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GRP75 was recently shown to indicate high metastatic potential and early recurrence in 
HCC (Yi et al., 2008). Preliminary test indicated that GRP75 showed far superior sensitivity in 
predicting early recurrence compared to AFP (90.90 % (GRP75) versus 33.33% (AFP)) and had 
comparable specificity value at 71.4 % (GRP75) versus 80.0% (AFP). Yi et al., (2008) also 
suggested the use of GRP75 in combinatory with AFP to improve diagnostic performance for 
identification of early HCC recurrence. Additionally, GRP75 autoantibodies had also been 
identified in HCC patients’ serum (Uemura et al., 2003) further suggesting its application for 
surveillance after curative surgery to prevent tumour recurrence.    
Levels of GRP78 had also been evaluated by several HCC studies (Lim et al., 2002; 
Luk et al., 2006). Shuda et al., (2003) showed exclusive over-expression of GRP78 transcript 
levels in poorly differentiated HCC and highlighted a potential involvement of ER stress 
pathway in HCC progression. GRP78 was also shown to be strongly correlated with HCC 
progression (Lim et al., 2005).  
Although the mechanistic value of GRPs are not clear, it was shown that reduced levels 
of GRP75 in immortalized cells can cause senescence like growth arrest (Wadhwa et al., 2003; 
Deocaris et al., 2007). Using an animal model on fibrosarcoma, Jamora et al., (1996) had also 
demonstrated that inhibition of GRP78 can lead to tumour regression. It is therefore hopeful 
that in addition to prognostic value for HCC progression or recurrence, these proteins are also 
potential candidates for cancer therapy.  
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5.3.3.3 Over expression of S100 proteins in only poorly differentiated HCC 
  In addition to elevation of protein chaperones, we also identified a family of S100 
proteins- S100A8, S100A9 and S100P that were up-regulated in only poorly-differentiated 
HCC tissues. S100 proteins are calcium-binding protein with diverse roles in a spectrum of 
tissues (Salama et al., 2008). These S100 proteins were identified by the iTRAQ approach only. 
Its low relative molecular mass (10- 12 kDa) probably makes it difficult to be detected by 2-D 
DIGE method.  
Over-expression of S100A4 (another member of this protein family) had been proposed 
as a marker for tumour invasion and metastasis using a HCC cell line model (Ding et al., 2004; 
Cui et al., 2006). In another study, higher levels of S100A6 were indentified in colon-derived 
liver metastases compared to HCC (Melle et al., 2008). To our knowledge, this is the first HCC 
study to identify elevated levels of these three additional members of S100 proteins. 
S100A8 has been shown to have chemo-attraction for leukocytes and S100A9 are 
involved in the regulation of cytoskeleton components (Salama et al., 2008). Both proteins have 
been shown to be up-regulated in gastric cancer (Yong and Moon, 2007), prostate cancer 
(Hermani et al., 2006), colorectal cancer (Stulik et al., 1999) and breast cancer (Arai et al., 
2008). These two protein isoforms can form a heterodimer complex and have been 
hypothesized to act as chemo-attractants to prepare the tumour cells to pre-metastatic state 
(Hermani et al., 2006).  Most importantly, both proteins had also been implicated in poor 
prognosis and metastatic potential in invasive ductal carcinoma of the breast (Arai et al., 2008).  
S100P another member of the S100 family of proteins was first purified from placenta 
(Becker et al., 1992). Its over-expression had also been positively correlated with tumour 
malignancy in pancreatic cancer (Logsdon et al., 2003, Arumugam et al., 2005), decrease 
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patient survival in lung cancer (Beer et al., 2002) and resistance to chemotherapy in colon 
cancer (Bertram et al., 1998).  S100P levels were also associated with cellular immortalization 
of human breast epithelial cells (Guerreiro et al., 2000). Expression levels of S100P have not 
been highlighted or directly examined in any HCC studies.  
In our tissue samples, over-expression of S100A8, S100A9 and S100P were only 
identified in poorly differentiated HCC. Although S100 proteins lack tissue specificity, their 




5.4 Dysregulation of c-myc associated proteins   
Another prominent cluster of proteins identified were c-myc associated proteins. c-myc, 
proto-oncogene, is a transcriptional factor known to be crucial in various biological processes 
and is often over-expressed during tumourigenesis. It is capable of acting as either an activator 
or repressor. c-myc was shown, via gene expression studies and in vivo mapping of binding, 
sites to govern up to 10 – 15% of genes (Chung and Levens, 2005).  
c-myc appears to be tightly regulated in resting cells and even in tumours, with RNA 
and protein levels of an order of 1 transcript and 500 proteins per fibroblast (Lockhart and 
Winzeler, 2000; Warrington et al., 2000). Moreover, this oncogene has very short half lives in 
the range of 20 – 30 min (Eisenman, 2001). Therefore, slight dysregulation of c-myc levels can 
lead to a myriad of undesirable chain of events. This includes uncontrolled cell-proliferation, 
DNA damage, mitochondrial biogenesis, ROS production and even apoptosis (Vafa et al., 
2002; Morrish and Hockenbery, 2003; Dang et al., 2005). 
 
5.4.1 Central role of c-myc in HBV-associated HCC 
In this study, c-myc was observed as a central node to 33 proteins identified in this 
study (as illustrated by Ingenuity Pathways Analysis, Fig. 5.4). These interactions are based 
primarily on a curated database collected from publications maintained by Ingenuity Systems. 
Though c-myc was not identified in this proteomic screening, its over-expression in the HCC 
samples used in this study was confirmed using western blotting (Fig. 4.19).  
A similar study using microarray analysis on HBV-associated HCC tissues (Iizuka et 
al., 2006) also reported 17 of the top most regulated genes were directly associated with c-myc. 
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Alike the observations in our study, transcription level of c-myc was also not identified in the 
genome-wide microarray analysis but direct analysis using RT-PCR showed an over-expression 
of 1.4 fold times between tumour and non-tumour samples. It is thus possible that the large 
heterogeneity of human HCC tissues as well as low abundance and short half live of c-myc 
renders it difficult to be captured using a large scale screening approach.  
It is however generally accepted that c-myc plays an active role in HCC (Thorgeirsson 
and Grisham, 2002; Feitelson et al., 2004). High levels of c-myc in HCC tissues has been 
identified by various groups using southern blot (Peng et al., 1993),  differential polymerase 
chain reaction (PCR) analysis (Abou-Elella et al., 1996) and immunohistochemistry (Niu et al., 
2002). Frequent amplification of the chromosome arm 8q24 (where c-myc gene locus is found) 
in HCC tissues may also contribute to higher expression level of c-myc in liver cancer (Kusano 
et al., 1999; Zimonjic et al., 1999; Schlaeger et al., 2008). Nevertheless, there were also several 
studies that contradict c-myc’s association in hepatocarcinogenesis (Yuen et al., 2001; Ikeguchi 
and Hirooka, 2004; Liu et al., 2004).  
Most significantly, data obtained from animal models showed that c-myc’s over-
expression can induce HCC (Murakami et al., 1993; Terradillos et al., 1997) and its inhibition 
resulted in loss of HCC neoplastic properties (Simile et al., 2004). An elegant study by Shachaf 
et al., (2004) showed that over-expression of a tet-inducible c-myc in transgenic mice not only 
induced liver cancer but subsequent inactivation of c-myc’s transgene expression was able to 
cause sustained tumour regression. These liver tumours were shown to be able to re-
differentiate back to normal hepatic lineages with lowered cancer markers such as alpha-feto 
protein (AFP) levels and induced tumour dormancy.  
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Although c-myc expression levels and functions in HCC is an unresolved issue, higher 
levels of c-myc had been consistently observed in HBV associated in liver tissues. Peng et al., 
(1993) observed a significant correlation between elevated c-myc levels in patients with poor 
prognosis and HBV infections. Similar observations were made by Wu et al., 2001 in 
microarray analysis using 7 human HBV-infected and normal liver tissues. Cell line models 
transfected with HBV-X gene was shown to induce elevated c-myc expression levels (Wu et 
al., 2001; Yang et al., 2008). A HBV-X transgenic mouse model also showed stronger c-myc 
expression in dysplastic nodules of the hepatocytes and in tumour cells than in the adjoining 
liver cells (Lakhtakia et al., 2003). The knowledge gained thus far from the literature supports 






Figure 5.4 : Schematic diagram illustrating the different proteins identified that interacts with c-myc as annotated by Ingenuity Pathway 
Analysis (IPA). Arrows are used to describe increasing expression and inhibitory interactions are described using T-shape connectors. Protein-
protein bindings are represented by solid grey lines. In addition up-regulated proteins that are identified in this study are in red and those 
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down-regulated are in green. (FUBP1; far upstream binding protein 1, KHSRP; far upstream binding protein 2 (FUBP2), HNRNPA1; 
heterogeneous nuclear ribonuclearprotein A1, HNRNPU; heterogeneous nuclear ribonuclearprotein U, HNRNPH1; heterogeneous nuclear 
ribonuclearprotein H1, NME1; non-metastatic cells 1 (NDKA), PRKDC; prortein kinase, DNA activated catalytic polypeptide, NAP1L1; 
nuclesome assembly protein 1- like 1, NCL; nucleolin, NPM; nucleophosmin, TUBB2A; tubulin beta 2A, CTSB; cathepsin B, ASS1; 
arginosuccinate synthetase 1, ANXA2; annexin A2, HADHB; hydroxyacyl-coenzyme A dehydrogenase beta, PRDX3; peroxiredoxin 3, DBI; 
diazepam binding inhibitor, TAGLN2; transgelin 2, SHNT1; serine hydroxymethyltransferase 1, FTH1; ferritin heavy polypeptide 1, EIF4A1; 
eukaryotic translation initiation factor 4A isoform 1, FN1; fibronectin 1, UGT; UDP-glucoronosytransferase, SOD2; superoxide dismutase 2, 
CPT2; carnithine palmotyltransferase 2, HSPD1; heat shock protein 60, ALDH1B1; aldehyde dehhydrogenase 1 B1, CAPZB; capping protein 
beta, ENO1; enolases 1, YWHAQ; tyrosine 3-monoooxygenase, STMN1; stathmin 1, HSPB1; heat shock protein 27, VIM; vimentin, LMNA; 
lamin A) 
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5.4.2 Differentially expressed proteins governed by c-myc 
 Akin to the numerous literature evidences, the observation made in this study also 
supports the importance of c-myc as a central transcriptional control in HBV-associated HCC. 
The 33 proteins identified displayed protein-protein interaction with c-myc as well as down-
stream activators that are controlled by c-myc (Figure 5.4). Most of the proteins identified 
(except for 6 proteins) showed expected regulation levels as predicted from an over-expression 
of c-myc. These proteins include metabolic proteins such as aldehyde dehydrgenase, UDP 
glucoronyltranferase, carnithine palmitoyl transferase and oxidative stress related proteins such 
as ferritin heavy chain and superoxide dismutase. In addition to metabolic proteins, we also 
identified several nuclear localized proteins that are regulated by c-myc. Their interaction with 
the oncogene and significance in HCC is elaborated below. 
 
5.4.2.1 Dysregulation of hnRNP protein family  
Heterogeneous nuclear ribonucleoproteins (hnRNP) family consists of 19 different 
members that have important roles in DNA repair, telomere biogenesis and regulation of gene 
expression including c-myc via transcription and translation machineries (Carpenter et al., 
2006). In this study we identified over-expression of 2 hnRNP members (hnRNP A1 and 
hnRNP A2/B1) and 6 hnRNP members (hnRNP A1, hnRNP A3, hnRNP H, hnRNP M, hnRNP 
Q, hnRNP U) in moderately and poorly differentiated HCC respectively. The increase number 
of dysregulated hnRNP proteins in poorly-differentiated HCC tissues suggests its role in late 
stage tumourigenesis.  
Several hnRNP members such as hnRNP A2/B1 (Codarin et al., 2008), hnRNP C 
(Blanc et al., 2005; Sun et al., 2006), hcc-1 (similar sequences to hnRNP, Choong et al., 2001), 
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hnRNP H (Honore et al., 2004) and hnRNP K (Li et al., 2005; Ng et al., 2005) have also been 
identified as up-regulated in other HCC genomic and proteomic analyses. In addition, 
autoantibody against hnRNP A2 had also been identified in HCC patient’s sera (Li et al., 2008).  
Though only a few selected members have been extensively studied, hnRNPs appear to 
be promiscuous and illustrated high expression levels in majority of cancers (Zech et al., 2006; 
Matta et al., 2009; Barboro et al., 2009).  It is unclear how hnRNPs execute its action and each 
protein members are likely to have its own mechanism (reviewed by Carpenter et al., 2006). 
Gene sequences of hnRNP A1, A2, E, H and K for example were shown to contain E box 
elements, hence may be regulated by c-myc (Dang 1999, Carpenter et al., 2006). In addition, 
several other in vitro studies highlighted various members of hnRNP could promote mRNA 
stabilization of c-myc (Brewer, 1991) and increase its translation activity (Kim et al., 2003). 
 
5.4.2.2 Over-expression of nucleotide diphosphate kinase  
Nucleotide diphosphate kinase (NDKA/nm 23), a controversial metastatic protein was 
shown to be over-expressed in both moderately and poorly differentiated HCC. Its differential 
regulation was also confirmed via 2-D western blot (Fig 4.13). Transcription levels of NDKA 
was shown to be regulated by c-myc in several reports (Godfried et al., 2002, Menssen and 
Hermeking, 2002) 
Over-expression of NDKA has been shown to correlate with tumourigenicity as shown 
in neuroblastoma (Hailat et al., 1991) and pancreatic cancer (Nakamori et al., 1993) but was 
also shown to inhibit metastasis in breast (Russell et al., 1998), melanoma (Baba et al., 1995) 
and prostate cancer (Lim et al., 1998). Similarly in HCC analyses, over-expression of NDKA 
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was also identified in comparative analysis between tumours and non-tumours (Li et al., 2005). 
A recent study also showed increased levels of NDKA in HepG2 liver cell lines infected with 
HBV-X gene (He et al., 2007).  However, NDKA expression levels are down-regulated in HCC 
tissues with intrahepatic metastasis (Iizuka et al., 1995; Fujimoto et al., 1998). These evidences 
suggest a dual function of NDKA with a high expression levels during tumour progression and 
a loss of expression levels during metastasis (Boissan and Lacombe, 2006). It is possible that 
the high levels of NDKA observed in this study are a reflection of the association to c-myc and 
HBV-X during tumour progression.  
 
5.4.2.3 Nucleophosmin    
 Another nuclear localized protein, nucleophosmin was identified to be up-regulated in 
only moderately differentiated HCC, consistent with western blot verification (Fig 4.13B). 
Over-expression of nucleophosmin has been noted in gastric cancer (Tanaka et al., 1992), colon 
cancer (Nozawa et al., 1996) and prostate cancer (Subong et al., 1999). Recently 
nucleophosmin levels were also examined in 103 human HCC tissues (Yun et al., 2007). The 
results showed correlated expression levels with other prognostic parameters such serum AFP 
levels and liver cirrhosis.  
Nucleophosmin is a direct target of c-myc transcription factor (Zeller et al., 2001; 
Grisendi et al., 2006) and was shown to correlate with transfection of HBV-X gene in liver cell 
lines (Li et al., 2009). High levels of nucleophosmin are believed to reflect cell’s commitment 
in mitogenesis (Feuerstein et al., 1988) and are proposed to play a role in tumourigenesis. The 
elevated levels of nucleophosmin in only moderately-differentiated HCC may reflect this 
commitment to HCC initiation in early stages. Its exact role in HCC remains to be understood.  
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5.4.3 Far-upstream binding proteins (FUBPs) 
Another c-myc associated protein of special interest is far upstream binding proteins 
(FUBPs). Unlike other c-myc related proteins discussed earlier, FUBPs are transcriptional 
activators of c-myc. Our study shows for the first time, the over-expression of two FUBP 
isoforms: FUBP1 and FUBP2 were identified in both moderately- and poorly-differentiated 
HCC (Fig.4.15). Li et al., (2005) had earlier reported up-regulation of only FUBP1 in HBV-
associated HCC. However, the significance of this observation was not elaborated further. 
 
5.4.3.1 Mechanism of FUBPs in regulating c-myc’s expression 
FUBPs consist of 3 members; FUBP1 was originally identified in 1990, along with 
closely related homologs FUBP2 and FUBP3 genes (Avigan et al., 1990; Bazar et al., 1995; 
Davis-Smyth et al., 1996). Although all 3 isoforms are situated on different chromosomes, their 
primary amino acid sequences are highly similar (Chung et al., 2006). All 3 proteins have four 
KH-DNA binding domains and have been shown to be able to bind with great affinity to a 
single stranded extended far upstream element (FUSE), about 1500 base pairs upstream of c-
myc’s promoter region.  
A working model describes that RNA polymerase II downstream of c-myc’s promoters 
is paused by transcriptional factor (TFIIH). In the presence of FUBPs bound to FUSE sequence, 
TFIIH releases RNA polymerase II and this in turn results in transcription of c-myc (He et al., 
2000; Lui et al., 2006). Presence of FUBPs thus regulates c-myc expression by “modulating the 
transition from transcription initiation to promoter escape” (He et al., 2000). This process can 
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be counteracted by FUBP interacting repressor (FIR) which can bind to FUBP and TFIIH. This 
results in inactivation of TFIIH and diminishes c-myc transcription (Liu et al., 2006).  
Binding of FUBPs to the FUSE sequence thus is an essential process in regulating the 
promoter activity of c-myc’s transcription (He et al., 2000, Chung et al., 2006). Dysregulation 
of FUBPs will result in aberrant c-myc’s expression levels. In vitro studies of FUBP knock-
down in osteosarcoma cell line (U2OS) also showed a significant decrease in c-myc mRNA 
levels and arrest in cell proliferation (He et al., 2000).  
FUBP expression levels were also observed to be tightly regulated with cell 
differentiation. Higher levels of FUBPs were reported in undifferentiated cells and expression 
levels declines upon cell differentiation. As observed by Wang et al., 1998, expression levels of 
FUBP decreases along development of various organs of embryonic mouse and chicken. In 
addition, ubiquitination of FUBP via p38 was necessary to lower c-myc expression levels for 
differentiation of lung cells (Kim et al., 2003). Over-expresion of FUBPs were also reported in 
several other studies such as DAOY medullablastoma cell line (Engidawork et al., 2006), 
melanoma cell lines induced by interferon-α (Craven et al., 2004) and in hypoxia induced stress 
and re-oxygenation of HeLa cervix carcinoma cells (Magagnin et al., 2007). The significance of 
these studies was however not elaborated. 
 
5.4.3.2 Over-expression of FUBPs  
In this study, 2-D DIGE approach detected the presence of multiple FUBP1 and FUBP2 
protein spots (Fig. 4.15). Despite the high similarity in their protein sequences, MS/MS spectra 
(Fig. 4.16B and D) illustrated that both isoforms have unique tryptic peptide sequences enabling 
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us to differentiate the two isoforms. Regulation level of each of these proteins spots are 
summarized in Table 4.4. The expression levels were also verified using western blotting (Fig. 
4.17). Multiple FUBPs protein spots with slightly varying pIs that ran along horizontal lines 
indicate the presence of post-translational modifications. The shift in pIs of these protein spots 
suggests the presence of various phosphorylation states of the protein. Indeed a total of 3 and 6 
phosphorylation sites are listed in the IPI database (Version 3.31) for FUBP1 and FUBP2 
respectively.  
Interestingly, we have found similar isoforms of FUBP1 and FUBP2 in HepG2 liver 
cells and they were found to be down-regulated when these cells were treated with butyrate, an 
anti-cancer agent (unpublished data). Butyrate has previously been shown to cause growth 
arrest and differentiation in liver cancer cells (Emanuele et al., 2004). A recent HCV study also 
revealed that FUBP is essential for efficient replication of the virus (Zhang et al., 2008). These 
results suggested FUBPs significance in HCC.  
 
5.4.3.3 Loss of FUBPs display preferential response 
 In this study, we observed correlated expression levels of FUBPs and c-myc in our HCC 
samples. Higher expression of c-myc was also more prominent in the poorly-differentiated 
tumour tissues paralleled with elevated levels of both FUBP1 and FUBP2 in these tissues (Fig. 
4.18). He et al., (2001) had also earlier showed using osteosarcoma cell lines (U2OS) that loss 
of FUBP resulted in lowered c-myc expression. This suggested that high expression of c-myc 
may be due to elevated FUBP expression observed in these HCC tissues analysed. 
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In consideration of evidence suggesting involvement of HBV in high expression level of 
c-myc, 2 different cell lines (HepG2 and Hep3B) with differing HBV properties were used for 
preliminary analysis. HepG2 is liver cell line has no known HBV and commonly used in 
numerous in vitro HCC studies. Hep3B another well characterized cell line on the hand, has 
HBV integrated genome and HBsAg present in the media (Tay et al., 1990).  
An in vitro model using siRNA transfection was conducted on these two cell lines to 
further characterize, FUBPs role in HBV-associated HCC. Despite, successful knock-down of 
FUBPs, HepG2 did not show any significant change in c-myc protein levels and cell viability 
(Fig.4.21 A and Fig. 4.22). In Hep3B, c-myc levels also remained unchanged in each transient 
knock-down of FUBP isoforms. siRNA transfection of all 3 FUBP isoforms simultaneously 
however showed slight down-regulation of c-myc expression level (Fig. 4.21 B). This 
observation is likely due to the compensatory effects of the FUBP isoforms.  
Most importantly, significant loss of cell viability was observed in Hep3B cells 
(compared to HepG2 cells) in all the siRNA transfections (Fig. 4.22). This observation suggests 
that FUBPs play an important role in viability of HBV-related HCC cells. It is however unclear 
if the minimal changes in c-myc expression levels detected in the western blots could explain 
the lowered cell viability observed. This preliminary analysis suggests that FUBPs are able to 
promote hepatocarcinogenesis in both c-myc dependent and independent pathways. 
 
5.4.3.4 Other possible roles of FUBPs  
Though most of the earlier studies on FUBPs had revolved around its possible roles with 
respect to c-myc, it is expected that as a transcriptional activator, FUBPs are also able to 
 173
modulate expression levels of other genes with an upstream FUSE sequence. A recent 
microarray analysis (Chung et al., 2006) conducted on individual FUBP knockdown showed 
that only a third of the 172 genes identified were common among all 3 isoforms. Another third 
of the genes detected showed distinct expression patterns regulated by each FUBPs. Although it 
is not clear, if the genes identified are directly controlled by FUBPs, this study suggests that 
each of the FUBP isoforms is capable of regulating a specific set of genes. Therefore it is likely 
that each of the FUBPs may regulate specific downstream activities in a c-myc independent 
manner. As described by Weber et al., 2008, over-expression of FUBP1 and FUBP3 was 
observed in renal, prostate and bladder cancer. This expression however only correlated with 
high levels of c-myc in renal cancer but not in prostate and bladder cancer. Thereby, suggesting 
other functions of FUBP in these tumours.  
In another study, Singer et al., (2009) showed FUBP1 as a potential inducer of stathmin 
in non-small cell lung cancer. Stathmin, involved in cell motility and division, was shown to 
decrease significantly upon FUBP1 siRNA transferction using Calu-1 (squamous cell 
carcinoma cell line) and Calu-6 (adenocarcinoma cell line). Most recently, the same group 
showed the same association between FUBP1, FUBP2 and stathmin in HCC cancer cell lines 
(Malz et al., 2009). The data from their study also further confirmed our observation that 
transient FUBP1 knock-down in Hep3B cells leads to loss of cell viability with marginal down-
regulation of c-myc. They also showed that FUBP activation is necessary for proliferation and 
motility of human liver cancer cells. In addition, over-expression of FUBPs in HCC 
significantly correlated to poor patient survival.  
These evidences further points to the importance of FUBPs in modulating the 
progression of HCC. It will thus be beneficial to evaluate the genes affected by FUBPs in a 
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HCC model so as to enable us to better understand the effects of its over-expression in addition 





This study represents the first single effort to combine three quantitative proteomic 
techniques to provide the most comprehensive analysis of proteome changes in liver 
tumourigenesis. A total of 344 regulated proteins were identified in both moderately- and 
poorly-differentiated HCC. The proteins identified varied significantly in the three techniques, 
suggests that these techniques are complementary and confirms that a combination of different 
approaches are essential to acquire adequate data in global profiling studies.  
Differentially expressed proteins obtained from this study thus signifies the completion 
of the first crucial step; identification of possible molecular players in initiating and promoting 
hepatocarcinoma. In this thesis, only three major clusters of proteins; metabolic proteins, stress 
related proteins and c-myc associated proteins were further elaborated. In all these clusters, we 
observed a prominent increase in number of dysregulated proteins from moderately- to poorly-
differentiated HCC. Stepwise abrogation of these pathways is an indicator of the loss of liver 
function as well as an attempt by the tumours to survive and proliferate.  
Most interestingly a significant number of proteins identified, including nuclear 
localized proteins, were associated with the proto-oncogene, c-myc. Though c-myc was not 
identified in our proteomics screening but its over-expression was later confirmed using 
western blotting. This finding is consistent with other HCC reports, where elevated levels of c-
myc have often been credited to chromosomal instability in the chromosome 8q or direct 
interaction of HBV-X protein. The identification of c-myc cluster of proteins thus reiterates the 
importance of this oncogene in HBV-related HCC as suggested by previous reports.  
The non-bias approach of proteomics also confers it the capability of identifying novel 
proteins that have not yet been well characterized in this area of study. To our knowledge this is 
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the first HCC study to report over-expressin of FUBP1 and FUBP2 in moderately- and poorly-
differentiated HCC. The abberation FUBPs were of particular interest due to their importance in 
“governing” the promoter sites for c-myc’s transcription factors. Unlike the other c-myc 
associated proteins identified, FUBPs have been credited as essential in ensuring the tight 
regulation of the oncogene. In vitro experiments to investigate its significance in liver 
tumourigenesis, showed that FUBPs are required to maintain cell viability of HBV-associated 
liver cell lines, Hep3B but not in HepG2 (a HBV null cell line). It is thus tempting to 
hypothesize that FUBPs are capable of increasing c-myc expression and also necessary in 
promoting hepatocarcinogenesis (Fig 6.1). Nevertheless, more work needs to be done to 
establish FUBPs exact molecular role and function. Cell lines and / or animal models will also 
be required to confirm its specificity in modulating the progression of HBV-associated HCC.  
It is hoped that c-myc and other prominent clusters of proteins that had been identified 
in this study will serve as a basis to extend our understanding in the molecular pathogenesis of 
HCC. Further characterization of their functions could provide insights to hepatocarcinoma and 
thus increase our ability for treatment and diagnosis of the disease.  
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Figure 6.1 : Schematic diagram illustrating the possible mechanisms that may be involved in the amplification of the proto-oncogene, c-myc 
and HCC tumourigenesis.  
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Table A : Significantly regulated proteins in moderately-differentiated HCC as identified by 













Table B : Significantly regulated proteins in poorly-differentiated HCC as identified by cICAT 
are listed below. 
 
* Number of peptides, standard deviation, total ion score C.I.%  and best ion score C.I.% of the 








Table A : Significantly regulated proteins in moderately-differentiated HCC as identified by 





Table B : Significantly regulated proteins in poorly-differentiated HCC as identified by iTRAQ 
are listed below 
 
 





* Number of peptides, standard deviation, total ion score C.I.%  and best ion score C.I.% of the 
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 ALDOB Fructose-bisphosphate aldolase B IPI00218407 39448.06 8 3 360.67 100 134.99 100 0 0 3
 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 2 176.13 100 93.57 100 0 0 2
 SELENBP1 53 kDa protein IPI00745729 53027.94 6.03 2 151.25 100 113.29 100 0 0 2
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 2 123.74 100 67.84 99.99721 0 0 2
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 1 124.11 100 124.11 100 0 0 1
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41324.39 6.47 1 123.18 100 124.6 100 0 0 1
 DAK Dihydroxyacetone kinase IPI00551024 58940.04 7.12 1 99.61 100 99.61 100 0 0 1
 PNPO 19 kDa protein IPI00793232 19465.84 6.92 1 92.37 100 92.37 100 0 0 1
 UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa 
protein, mitochondria IPI00296022 10731.94 4.39 1 84.22 99.99994 84.22 99.99994 0 0 1
 PAH Phenylalanine-4-hydroxylase IPI00017579 51829.46 6.15 1 84.01 99.99993 84.01 99.99993 0 0 1
 DCXR 26 kDa protein IPI00797249 25726.45 8.33 1 83.80005 99.99993 85.22 99.99995 0 0 1
 ASS1 Argininosuccinate synthetase 1 IPI00514341 19035.86 7.26 1 81.77 99.99989 81.77 99.99989 0 0 1
 GATM Isoform Cytoplasmic of Glycine amidinotransferase, 
mitochondrial precu IPI00216279 44854.47 6.61 1 80.56 99.99985 80.56 99.99985 0 0 1
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 79.13 99.99979 79.13 99.99979 0 0 1
 ERP29 Endoplasmic reticulum protein ERp29 precursor IPI00024911 28975.15 6.77 1 78.67 99.99977 78.67 99.99977 0 0 1
 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 75.6 99.99953 75.6 99.99953 0 0 1
 FTH1 Ferritin heavy chain IPI00554521 21212.29 5.3 1 69.13 99.99792 69.13 99.99792 0 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 131NT
 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 65.85 99.99558 65.85 99.99558 0 0 1
 C21orf33 Isoform Short of ES1 protein homolog, mitochondrial 
precursor IPI00218482 24741.95 8.29 1 53.53 99.92466 53.53 99.92466 0 0 1
 GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 1 52.97 99.91429 52.97 99.91429 0 0 1
 AK2 Isoform 1 of Adenylate kinase isoenzyme 2, mitochondrial IPI00215901 26460.77 7.67 1 48.86 99.77918 48.86 99.77918 0 0 1
 EPHX1 Epoxide hydrolase 1, microsomal IPI00640017 16373.31 5.85 1 48.33 99.75052 48.33 99.75052 0 0 1
 NQO2 NAD(P)H dehydrogenase, quinone 2 IPI00515016 21523.83 6.07 1 46.44004 99.61449 47.86 99.722 0 0 1
 GPT Alanine aminotransferase 1 IPI00217458 54602.15 6.77 1 45.96 99.56943 45.96 99.56943 0 0 1
 AKR1C1 Aldo-keto reductase family 1 member C1 IPI00029733 36765.02 8.02 1 44.09 99.33772 44.09 99.33772 0 0 1
 AOX1 Hypothetical protein AOX1 IPI00743616 147543.6 6.78 1 44.02 99.32696 44.02 99.32696 0 0 1
 COMT Isoform Soluble of Catechol O-methyltransferase IPI00375513 24433.38 5.15 1 42.5 99.04491 42.5 99.04491 0 0 1
 AKR1D1 CDNA FLJ25413 fis, clone TST03402, highly similar 
to 3-OXO-5-BETA- S IPI00065073 30242.66 8.11 1 39.83 98.23379 39.83 98.23379 0 0 1
 OAT Ornithine aminotransferase, mitochondrial precursor IPI00022334 48504.2 6.57 1 32.28 89.95286 32.28 89.95286 0 0 1
 ABAT 4-aminobutyrate aminotransferase, mitochondrial 
precursor IPI00009532 56402.59 8.17 1 31.65 88.38438 31.65 88.38438 0 0 1
 CRYZ 32 kDa protein IPI00647366 31508.5 8.59 1 31.22 87.17544 31.22 87.17544 0 0 1
 YSK4 132 kDa protein IPI00798105 131531.9 6.64 1 29.02 78.71654 29.02 78.71654 0 0 0
 BHMT2 Betaine--homocysteine S-methyltransferase 2 IPI00014363 40328.18 5.61 1 28.43 75.61952 28.43 75.61952 0 0 1
 GRHPR GRHPR protein (Fragment) IPI00550682 36801.01 5.95 2 77.61 99.99971 43.41 99.22546 0.003 0.218 2
 P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 2 79.33 99.9998 40.77 98.57753 0.006 0.556 2
 SORD Sorbitol dehydrogenase IPI00216057 38271.84 8.23 1 94.62 100 94.62 100 0.068 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 131NT
 CAT Catalase IPI00465436 59718.75 6.9 1 55.03004 99.94666 56.45 99.96154 0.111 0 1
 FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 36790.79 6.54 1 42.25004 98.98833 43.67 99.27047 0.167 0 1
 AKR1C3 Aldo-keto reductase family 1 member C3 IPI00291483 36820.84 8.05 1 28.95 78.37071 28.95 78.37071 0.238 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 58.43 99.97562 58.43 99.97562 0.261 0 1
 SAR1B GTP-binding protein SAR1b IPI00002149 22395.51 5.76 1 40.01 98.3055 40.01 98.3055 0.263 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 2 162.55 100 100.11 100 0.285 0.197 2
 PRDX1 11 kDa protein IPI00641244 10669.51 8.79 1 46.09 99.58213 46.09 99.58213 0.309 0 1
 PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 58.95 99.97837 58.95 99.97837 0.316 0 1
 C6orf115 similar to Protein C6orf115 IPI00740277 20388.71 6.38 1 47.62 99.70621 47.62 99.70621 0.342 0 1
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 44.77 99.43371 44.77 99.43371 0.35 0 1
 HBA2;HBA1 Alpha 2 globin variant (Fragment) IPI00853068 15270.94 8.72 1 95.46 100 95.46 100 0.387 0 1
 GLUD2 Glutamate dehydrogenase 2, mitochondrial precursor IPI00027146 61395.43 8.63 1 43.7 99.27549 43.7 99.27549 0.408 0 1
 CHDH Choline dehydrogenase, mitochondrial precursor IPI00168603 65360.13 8.67 1 31.34004 87.52507 32.76 91.00414 0.433 0 1
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 3 210.93 100 102.57 100 0.44 0.194 3
 C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 1 91.71 100 91.71 100 0.469 0 1
 HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 4 318.67 100 110.57 100 0.473 0.093 4
 MPST 3-mercaptopyruvate sulfurtransferase variant 
(Fragment) IPI00746782 34729.5 6.83 1 47.79 99.71748 47.79 99.71748 0.474 0 1
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 1 76.21 99.99959 76.21 99.99959 0.503 0 1
 HBD;HBB 15 kDa protein IPI00657660 15409.88 7.74 1 47.53 99.70005 47.53 99.70005 0.541 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 131NT
 GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 60.63 99.98531 60.63 99.98531 0.544 0 1
 CALR 37 kDa protein IPI00793605 36679.71 4.55 1 96.61 100 96.61 100 0.565 0 1
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 108.95 100 66.3 99.99602 0.578 0.022 2
 PDIA3 Protein disulfide-isomerase A3 precursor IPI00025252 56746.75 5.98 1 55.76 99.95491 55.76 99.95491 0.583 0 1
 SAR1A SAR1 gene homolog A IPI00644667 13653.07 6.49 1 32.91 91.30955 32.91 91.30955 0.595 0 1
 LASP1 Isoform 2 of LIM and SH3 domain protein 1 IPI00386803 35990.71 8.92 1 26.7 63.68866 26.7 63.68866 0.616 0 1
 B2M B2M protein IPI00796379 13687.95 6.06 1 70.68 99.99855 70.68 99.99855 0.622 0 1
 HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 13793.09 6.43 1 65.97 99.9957 65.97 99.9957 0.622 0 1
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 49.45004 99.80723 50.87 99.86099 0.639 0 1
 PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 59.36 99.98032 59.36 99.98032 0.674 0 1
 FGG Isoform Gamma-A of Fibrinogen gamma chain precursor IPI00219713 49464.97 5.7 1 61.9 99.98903 61.9 99.98903 0.678 0 1
 - Similar to Glyceraldehyde-3-phosphate dehydrogenase IPI00747273 12564.45 8.74 1 67.32 99.99685 67.32 99.99685 0.694 0 1
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 76.87 99.99965 76.87 99.99965 0.716 0 1
 HMGB1 High-mobility group box 1 IPI00644653 18299.33 9.72 1 44.49 99.39599 44.49 99.39599 1.495 0 1
 IGLV4-3 IGLV4-3 protein IPI00382938 25960.7 6.3 1 76.17 99.99959 76.17 99.99959 1.504 0 1
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 23496.76 4.93 1 26.95 65.71988 26.95 65.71988 1.515 0 1
 IGKC IGKC protein IPI00430808 25629.86 6.15 2 122.17 100 96.48 100 1.518 0.263 2
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 3 284.41 100 135.36 100 1.564 0.079 3
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase A IPI00419585 18000.88 7.68 2 181.79 100 127.21 100 1.57 0.31 2
Moderately Differentiated cICAT Individual Patients
Moderate Diff 131NT
 ALB Serum albumin IPI00022434 71529.53 6.33 18 1405.569 100 136.74 100 1.575 0.336 18
 PDIA6 Isoform 1 of Protein disulfide-isomerase A6 precursor IPI00644989 48091.26 4.95 1 88.05 100 88.05 100 1.582 0 1
 DCPS Scavenger mRNA-decapping enzyme DcpS IPI00335385 38585.02 5.93 1 35.18 94.84721 35.18 94.84721 1.59 0 1
 - Hypothetical protein DKFZp686C15213 IPI00426051 51066.19 7.85 2 136.92 100 98.93 100 1.672 0.059 2
 FHL1 Four and a half LIM domains 1 IPI00029028 23685.15 8.94 1 27.6 70.48503 27.6 70.48503 1.698 0 1
 UFC1 Ufm1-conjugating enzyme 1 IPI00294495 19446.02 6.9 1 45.85 99.55839 45.85 99.55839 1.803 0 1
 RAD23B UV excision repair protein RAD23 homolog B IPI00008223 43144.62 4.79 1 98.65 100 98.65 100 1.9 0 1
 LOC730278;LOC729659 similar to Putative S100 calcium-
binding protein A11 ps IPI00790691 11279.74 7.77 1 56.16 99.95888 56.16 99.95888 1.904 0 1
 ACTN4 Alpha-actinin-4 IPI00013808 104788.5 5.27 2 117.39 100 86.08 100 1.934 0.251 2
 VIM 50 kDa protein IPI00827679 49623.11 5.19 1 54.01 99.93254 54.01 99.93254 2.003 0 1
 GC vitamin D-binding protein precursor IPI00742696 52882.94 5.32 1 81.19 99.99987 81.19 99.99987 2.072 0 1
 CANX Calnexin precursor IPI00020984 67525.85 4.47 2 75.16 99.99948 39.68 98.17172 2.12 0.01 2
 APOH Beta-2-glycoprotein 1 precursor IPI00298828 38272.66 8.34 1 46.94 99.65641 46.94 99.65641 2.199 0 1
 RNH1 Ribonuclease/angiogenin inhibitor IPI00783491 49839.99 4.68 1 46.99 99.66034 46.99 99.66034 2.422 0 1
 EEF1G;LOC729998 similar to Elongation factor 1-gamma IPI00738381 50270.31 7.09 1 40.69 98.55109 40.69 98.55109 2.477 0 1
 RPSA Ribosomal protein SA IPI00413108 33292.65 4.79 1 130.15 100 130.15 100 2.542 0 1
 SSB Lupus La protein IPI00009032 46808.16 6.68 1 100.16 100 100.16 100 3.412 0 1
 RPS4X 14 kDa protein IPI00646114 14010.58 10.06 1 27.8 71.81342 27.8 71.81342 3.594 0 1
 TES Isoform 2 of Testin IPI00216425 46878.3 7.82 1 29.44 80.67843 29.44 80.67843 3.934 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 131NT
 TAGLN Transgelin IPI00216138 22596.43 8.87 1 54.29 99.93675 54.29 99.93675 4.626 0 1
 HP Haptoglobin precursor IPI00641737 46693.35 6.28 3 135.73 100 82.56 99.99991 17.625 1936.574 3
 - Hypothetical protein DKFZp686M24218 IPI00784998 52387.11 7.89 3 98.18001 100 37.99 97.302 29.941 2049.335 3
 IGHG1 IGHG1 protein IPI00448938 51362.63 8.69 2 175.85 100 98.93 100 152.493 13283.795 2
 HSP90AA1 Hsp89-alpha-delta-N IPI00604607 63211.62 5.03 2 132.14 100 93.38 100 159.32 8863.38 2
 EFEMP1 Isoform 2 of EGF-containing fibulin-like extracellular 
matrix protei IPI00220813 53686.69 4.9 1 34.62 94.13805 34.62 94.13805 4717.485 0 1
 IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 85.34 100 85.34 100 5126.801 0 1
 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A IPI00554737 65266.91 5 1 31.85 88.90717 31.85 88.90717 6165.208 0 1
 FLNA Filamin-A IPI00333541 280563.9 5.7 2 139.03 100 84.87 99.99994 6478.319 1890.214 2
 MYL9 Myosin regulatory light chain 2, smooth muscle isoform IPI00220278 19814.45 4.8 1 96.5 100 96.5 100 7243.278 0 1
 - PHAPI protein (Fragment) IPI00394706 15315.69 4.5 2 92.22 100 66.68 99.99635 8686.613 126.571 2
 FN1 Isoform 3 of Fibronectin precursor IPI00339223 259035.4 5.47 3 142.0295 100 68.71 99.99771 8730.836 3271.841 3
 VCP 89 kDa protein IPI00843748 89270.64 5.11 1 52.99004 99.91468 54.41 99.93848 9994.004 0 1
 TUBB Tubulin beta chain IPI00011654 49638.97 4.78 1 167.9 100 167.9 100 10062.12 0 1
 RNF113A RING finger protein 113A IPI00007343 38762.6 5.51 1 33.97 93.19164 33.97 93.19164 10245.76 0 1
 BAT1 Isoform 2 of Spliceosome RNA helicase BAT1 IPI00641829 50646.91 5.59 1 33.6 92.58617 33.6 92.58617 10364.71 0 1
 HSPG2 365 kDa protein IPI00747758 364402.6 6.07 2 143.98 100 74.25 99.99936 10654.38 702.065 2
 TRIM28 Isoform 2 of Transcription intermediary factor 1-beta IPI00438230 79423.48 5.67 1 54.04 99.93301 54.04 99.93301 10936.02 0 1
 SERPINA1 Alpha 1-antitrypsin IPI00790784 40237.62 5.26 1 41.64 98.83576 41.64 98.83576 11205.49 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 131NT
 ACTR2 actin-related protein 2 isoform a IPI00470573 45347.55 6.73 1 34.31 93.70433 34.31 93.70433 12043.56 0 1
 CD59 CD59 glycoprotein precursor IPI00011302 14167.79 6.02 1 51.29 99.8738 51.29 99.8738 14766.27 0 1
 LAMC1 Laminin subunit gamma-1 precursor IPI00298281 177492.5 5.01 1 28.85 77.8669 28.85 77.8669 32204.27 0 1
 FHL2 FHL2 isoform 5 IPI00396967 44147.85 8.51 1 54.79 99.94363 54.79 99.94363 38693.42 0 1






























 AKR1D1 CDNA FLJ25413 fis, clone TST03402, highly similar 
to 3-OXO-5-BETA- S IPI00065073 30242.66 8.11 2 132.08 100 93.09 100 0 0 2
 AGXT Serine--pyruvate aminotransferase IPI00009367 42982.44 8.61 2 120.34 100 75.38 99.99953 0 0 2
 HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 2 99.73 100 54.73 99.94494 0 0 2
 CMBL carboxymethylenebutenolidase-like IPI00383046 28030.17 6.71 2 74.52 99.99942 40.81 98.64219 0 0 2
 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 110.02 100 110.02 100 0 0 1
 FTH1 Ferritin heavy chain IPI00554521 21212.29 5.3 1 109.55 100 109.55 100 0 0 1
 PAH Phenylalanine-4-hydroxylase IPI00017579 51829.46 6.15 1 107.39 100 107.39 100 0 0 1
 AOX1 Hypothetical protein AOX1 IPI00743616 147543.6 6.78 1 102.15 100 102.15 100 0 0 1
 ASS1 Argininosuccinate synthetase 1 IPI00514341 19035.86 7.26 1 85.21 100 85.21 100 0 0 1
 GPT Alanine aminotransferase 1 IPI00217458 54602.15 6.77 1 49.1 99.7987 49.1 99.7987 0 0 1
 GSTZ1 glutathione transferase zeta 1 isoform 2 IPI00157928 19360.02 8.27 1 48.42 99.76458 48.42 99.76458 0 0 1
 ALAD delta-aminolevulinic acid dehydratase isoform a IPI00442121 39008.71 7.59 1 39.3 98.07762 39.3 98.07762 0 0 1
 GSTM1 28 kDa protein IPI00647885 27599.04 6.24 1 39.26 98.05983 39.26 98.05983 0 0 1
 NIT2 Nitrilase family member 2 IPI00549467 30588.56 6.82 1 38.96 97.92107 38.96 97.92107 0 0 1
 COMT Isoform Soluble of Catechol O-methyltransferase IPI00375513 24433.38 5.15 3 191.02 100 75.89 99.99958 0.001 0.03 3
 KRT1 Keratin, type II cytoskeletal 1 IPI00220327 65977.98 8.16 1 55.41 99.95292 55.41 99.95292 0.001 0 1
 GLUD2 Glutamate dehydrogenase 2, mitochondrial precursor IPI00027146 61395.43 8.63 2 162.06 100 99.29 100 0.004 0.127 2
Moderately Differentiated cICAT Individual Patients
Moderate Diff 196NT
 ALDOB Fructose-bisphosphate aldolase B IPI00218407 39448.06 8 2 259.04 100 129.97 100 0.005 0.105 2
 SORD Sorbitol dehydrogenase IPI00216057 38271.84 8.23 2 146.27 100 101.03 100 0.008 0.274 2
 SELENBP1 53 kDa protein IPI00745729 53027.94 6.03 2 194.04 100 141.37 100 0.009 0.304 2
 HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 5 407.49 100 109.1 100 0.027 1.413 5
 IGHG1 IGHG1 protein IPI00448938 51362.63 8.69 3 186.78 100 70.95 99.99869 0.047 2.133 3
 PYGL 97 kDa protein IPI00783313 97272.1 6.71 1 36.58 96.40383 36.58 96.40383 0.128 0 1
 CAT Catalase IPI00465436 59718.75 6.9 1 72.17004 99.99901 73.59 99.99928 0.15 0 1
 ALDH1L1 10-formyltetrahydrofolate dehydrogenase IPI00290553 98766.56 5.63 1 75.61 99.99955 75.61 99.99955 0.178 0 1
 SUOX 54 kDa protein IPI00853137 53851.08 5.35 1 46.74 99.65339 46.74 99.65339 0.317 0 1
 LTB4DH Leukotriene B4 12-hydroxydehydrogenase IPI00642248 19212.93 6.34 1 35.41 95.29196 35.41 95.29196 0.321 0 1
 PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61410.53 6.3 1 90.75 100 90.75 100 0.333 0 1
 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 IPI00012726 70738.09 9.31 1 95.84 100 95.84 100 0.356 0 1
 ABAT 4-aminobutyrate aminotransferase, mitochondrial 
precursor IPI00009532 56402.59 8.17 3 224.56 100 94.09 100 0.363 0.049 3
 DCXR 26 kDa protein IPI00797249 25726.45 8.33 1 46.87004 99.66362 48.29 99.75743 0.407 0 1
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 30355.86 8.55 1 70.17 99.99843 70.17 99.99843 0.421 0 1
 TAGLN Transgelin IPI00216138 22596.43 8.87 1 52.4 99.90585 52.4 99.90585 0.422 0 1
 ADK Isoform Long of Adenosine kinase IPI00290279 40519.66 6.24 1 71.47 99.99883 71.47 99.99883 0.454 0 1
 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 90.41 100 90.41 100 0.458 0 1
 HP Haptoglobin precursor IPI00641737 46693.35 6.28 3 220.39 100 85.59 100 0.478 0.074 3
Moderately Differentiated cICAT Individual Patients
Moderate Diff 196NT
 IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 97.78 100 97.78 100 0.509 0 1
 GRHPR Glyoxylate reductase/hydroxypyruvate reductase IPI00514020 43565.62 7.05 2 143.5 100 99.9 100 0.517 0.008 2
 BHMT Betaine--homocysteine S-methyltransferase 1 IPI00004101 44969.85 6.58 3 170.62 100 74.01 99.99935 0.534 0.173 3
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 83.32 99.99992 83.32 99.99992 0.536 0 1
 PPP1CA protein phosphatase 1, catalytic subunit, alpha 
isoform 3 IPI00027423 38606.37 6.2 1 41.66 98.88355 41.66 98.88355 0.545 0 1
 HGD Homogentisate 1,2-dioxygenase IPI00303174 49940.59 6.54 1 42.67 99.11521 42.67 99.11521 0.553 0 1
 HLA-DRB1;HLA-DRB5;LOC730415;hCG_1998957;HLA-
DRB4;HLA-DRB3 HLA class II hist IPI00005182 29970.06 7.71 1 39.25 98.05536 39.25 98.05536 0.567 0 1
 - 28 kDa protein IPI00472065 27488.58 6.54 1 60.74004 99.9862 62.16 99.99005 0.583 0 1
 C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 2 172.27 100 132.36 100 0.591 0.019 2
 EPHX1 Epoxide hydrolase 1, microsomal IPI00640017 16373.31 5.85 1 60.38 99.98501 60.38 99.98501 0.597 0 1
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 52737.86 6.3 2 137.98 100 71.49 99.99884 0.599 0.03 2
 ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 IPI00642144 22639.55 5.76 2 137.54 100 92.1 100 0.607 0.047 2
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 2 114.74 100 74.73 99.99945 0.612 0.128 2
 FAH 33 kDa protein IPI00793664 32625.4 7.12 1 38.23 97.54054 38.23 97.54054 0.614 0 1
 SEC14L3 SEC14-like protein 3 IPI00025260 46018.41 5.79 1 48.48 99.76781 48.48 99.76781 0.625 0 1
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 73.97 99.99934 73.97 99.99934 0.627 0 1
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 2 102.28 100 76.36 99.99962 0.641 0.027 2
 VIM 50 kDa protein IPI00827679 49623.11 5.19 1 45.95 99.58424 45.95 99.58424 0.648 0 1
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 108.71 100 110.13 100 0.677 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 196NT
 TF Transferrin variant (Fragment) IPI00798430 77029.59 6.68 3 235.8895 100 114.54 100 0.679 0.055 3
 LOC730278;LOC729659 similar to Putative S100 calcium-
binding protein A11 ps IPI00790691 11279.74 7.77 1 41.14 98.74154 41.14 98.74154 0.709 0 1
 SAR1B GTP-binding protein SAR1b IPI00002149 22395.51 5.76 1 82.21 99.9999 82.21 99.9999 1.49 0 1
 - 63 kDa protein IPI00792605 62706.83 10.91 1 55.85004 99.95746 57.27 99.96932 1.506 0 1
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41324.39 6.47 1 123.49 100 123.49 100 1.508 0 1
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 2 183.22 100 101.14 100 1.513 0.038 2
 CLGN Calmegin precursor IPI00024776 69994.44 4.58 1 57.46 99.97063 57.46 99.97063 1.521 0 1
 ALB Serum albumin IPI00022434 71529.53 6.33 13 1021.869 100 138.38 100 1.55 0.342 12
 PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 72886.97 4.96 2 165.67 100 102.64 100 1.556 0.064 2
 CTSB Cathepsin B precursor IPI00295741 37796.83 5.88 1 117.71 100 117.71 100 1.592 0 1
 BAT1 Isoform 2 of Spliceosome RNA helicase BAT1 IPI00641829 50646.91 5.59 1 42.85 99.15113 42.85 99.15113 1.608 0 1
 ACY3 HCBP1 IPI00382975 30891.26 6.79 1 67.51 99.9971 67.51 99.9971 1.638 0 1
 C6orf108 putative c-Myc-responsive isoform 2 IPI00395835 16177.23 6.31 1 43.34 99.2417 43.34 99.2417 1.638 0 1
 MYL9 Myosin regulatory light chain 2, smooth muscle isoform IPI00220278 19814.45 4.8 1 86.78 100 86.78 100 1.657 0 1
 UFC1 Ufm1-conjugating enzyme 1 IPI00294495 19446.02 6.9 1 68.11 99.99747 68.11 99.99747 1.667 0 1
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 2 221.62 100 133.29 100 1.757 0.015 2
 MTPN Myotrophin IPI00179589 12886.6 5.27 1 53.2 99.92169 53.2 99.92169 1.767 0 1
 PDIA6 Isoform 1 of Protein disulfide-isomerase A6 precursor IPI00644989 48091.26 4.95 1 118.57 100 118.57 100 1.864 0 1
 SYNCRIP Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00402182 65641.59 8.69 1 57.55 99.97124 57.55 99.97124 1.873 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 196NT
 HNRPR HNRPR protein IPI00644055 71170.32 8.23 1 57.55 99.97124 57.55 99.97124 1.873 0 1
 A1BG 41 kDa protein IPI00644018 40692.54 5.5 2 141.35 100 102.54 100 1.887 0.5 2
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 124.25 100 71.69 99.99889 1.918 0.162 2
 FIS1 Mitochondrial fission 1 protein IPI00007052 16927.02 8.84 1 49.82 99.82945 49.82 99.82945 1.921 0 1
 MBNL1 Isoform EXP42 of Muscleblind-like protein 1 IPI00021692 41789.99 9.16 1 39.67 98.23461 39.67 98.23461 1.941 0 1
 GATM Isoform Cytoplasmic of Glycine amidinotransferase, 
mitochondrial precu IPI00216279 44854.47 6.61 1 130.99 100 130.99 100 2.032 0 1
 HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 13793.09 6.43 1 88.04 100 88.04 100 2.074 0 1
 LYPLA1 Isoform 2 of Acyl-protein thioesterase 1 IPI00398727 22860.58 6.05 1 56.73 99.96526 56.73 99.96526 2.084 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 2 132.53 100 89.23 100 2.136 0.052 2
 HINT2 Histidine triad nucleotide-binding protein 2 IPI00000335 17151.24 9.2 1 46.1 99.59836 46.1 99.59836 2.146 0 1
 UGDH UDP-glucose 6-dehydrogenase IPI00031420 54989.25 6.73 1 54.45 99.94127 54.45 99.94127 2.169 0 1
 FLJ11151 Hypothetical protein FLJ11151 IPI00305010 35525.88 5.78 1 50.59 99.85716 50.59 99.85716 2.194 0 1
 ANXA2 annexin A2 isoform 1 IPI00418169 40385.72 8.53 1 71.33 99.9988 71.33 99.9988 2.214 0 1
 CUTA Isoform C of Protein CutA precursor IPI00554556 16821.85 5.15 1 66.43 99.99628 66.43 99.99628 2.224 0 1
 PRDX2 15 kDa protein IPI00794777 15128.81 5.82 1 73.96004 99.99934 75.38 99.99953 2.27 0 1
 UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa 
protein, mitochondria IPI00296022 10731.94 4.39 1 98.32 100 98.32 100 2.282 0 1
 PDLIM1 PDZ and LIM domain protein 1 IPI00010414 36049.04 6.56 2 115.73 100 91.07 100 2.364 0.31 2
 PEPD Xaa-Pro dipeptidase IPI00257882 54512.91 5.64 1 65 99.99483 65 99.99483 2.42 0 1
 HSPA1A;HSPA1B Heat shock 70kDa protein 1A IPI00647012 51914.69 5.35 1 36.07 95.95573 36.07 95.95573 2.496 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 196NT
 LASP1 Isoform 2 of LIM and SH3 domain protein 1 IPI00386803 35990.71 8.92 1 44.6 99.43266 44.6 99.43266 2.654 0 1
 CBX3;LOC653972 Chromobox protein homolog 3 IPI00297579 20798.35 5.23 1 34.74004 94.50667 36.16 96.03868 2.666 0 1
 TXN2 Thioredoxin, mitochondrial precursor IPI00017799 21811.28 8.85 1 86.97 100 86.97 100 2.759 0 1
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 3 218.29 100 103.66 100 2.945 0.75 3
 TMEM4 Isoform 1 of MIR-interacting saposin-like protein 
precursor IPI00443909 20639.17 4.81 1 92.87 100 92.87 100 2.981 0 1
 P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 3 190.35 100 86.11 100 3.168 3.193 3
 AARS 107 kDa protein IPI00784131 106643.1 5.33 1 95.36 100 95.36 100 3.178 0 1
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase 
A IPI00419585 18000.88 7.68 3 274.36 100 157.77 100 3.361 0.681 3
 FUBP1 Isoform 2 of Far upstream element-binding protein 1 IPI00644386 68861.11 7.74 1 46.2 99.6075 46.2 99.6075 3.6 0 1
 SSB Lupus La protein IPI00009032 46808.16 6.68 1 101.98 100 101.98 100 3.695 0 1
 LOC131691 similar to peptidylprolyl isomerase A isoform 1 IPI00741973 18098.81 6.41 1 45.27 99.51377 45.27 99.51377 4.351 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 3 230.71 100 109.64 100 29.697 1774.747 3
 APOH Beta-2-glycoprotein 1 precursor IPI00298828 38272.66 8.34 2 91.88 100 53.5 99.92691 83.341 2450.538 2
 ATOX1 Copper transport protein ATOX1 IPI00010863 7396.73 6.71 2 143.19 100 76.02 99.99959 115.681 3337.859 2
 HMGB1 High-mobility group box 1 IPI00644653 18299.33 9.72 2 110.68 100 76.02 99.99959 152.685 5106.955 2
 AKR1B10 Aldo-keto reductase family 1 member B10 IPI00105407 35997.82 7.12 1 111.12 100 111.12 100 2185.248 0 1
 C1QBP Protein IPI00795465 20360.71 4.1 1 86.62 100 86.62 100 3140.323 0 1
 GLO1 Lactoylglutathione lyase IPI00220766 20764.25 5.12 1 73.76 99.99931 73.76 99.99931 3330.002 0 1
 FN1 Isoform 12 of Fibronectin precursor IPI00556632 221308.4 5.84 7 413.8796 100 162.75 100 3399.395 25662.17 7
Moderately Differentiated cICAT Individual Patients
Moderate Diff 196NT
 TKT Transketolase IPI00643920 67834.72 7.58 2 146.94 100 79.7 99.99982 3850.95 1557.205 2
 PPA1 Pyrophosphatase (Inorganic) 1 IPI00643288 19968.92 5.07 1 47.94 99.73707 47.94 99.73707 3991.631 0 1
 NUDC 24 kDa protein IPI00646767 23916.97 5.47 1 54.95 99.94766 54.95 99.94766 4530.008 0 1
 FLJ14668 Hypothetical protein FLJ14668 IPI00303722 15630.66 7.56 1 81.85 99.99989 81.85 99.99989 4834.623 0 1
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 98.85 100 98.85 100 5588.454 0 1






























  GSTM1 28 kDa protein IPI00647885 27599.04 6.24 1 63.06 99.99193 63.06 99.99193 0 0 1
  IGHA1 Hypothetical protein DKFZp686G21220 (Fragment) IPI00423460 54354 6.15 1 47.09 99.68084 47.09 99.68084 0 0 0
  MGC29506 hypothetical protein LOC51237 IPI00102821 20681.23 5.37 1 41.07 98.72352 41.07 98.72352 0 0 1
  ALDOB Fructose-bisphosphate aldolase IPI00513830 24113.34 6.65 2 166.2 100 140.51 100 0.003 0.112 2
  SELENBP1 CDNA FLJ13813 fis, clone THYRO1000358, 
moderately similar to SELEN IPI00030385 25937 6.19 1 35.85 95.75366 35.85 95.75366 0.18 0 1
  LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 52737.86 6.3 1 37.46 97.06901 37.46 97.06901 0.239 0 1
  C6orf115 similar to Protein C6orf115 IPI00740277 20388.71 6.38 1 61.51 99.98847 61.51 99.98847 0.248 0 1
  GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 1 49.28 99.80724 49.28 99.80724 0.316 0 1
  ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 2 179.04 100 93.96 100 0.374 0.058 2
  SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 1 75.99 99.99959 75.99 99.99959 0.39 0 1
  CTSB Cathepsin B precursor IPI00295741 37796.83 5.88 1 35.42 95.31171 35.42 95.31171 0.396 0 1
  TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 46.77 99.65643 46.77 99.65643 0.401 0 1
  HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 73.47 99.99927 73.47 99.99927 0.444 0 1
  CAT Catalase IPI00465436 59718.75 6.9 1 32.56004 90.94246 33.98 93.46847 0.462 0 1
  PEPD Xaa-Pro dipeptidase IPI00257882 54512.91 5.64 1 36.86 96.63477 36.86 96.63477 0.487 0 1
  PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 1 54.78 99.94567 54.78 99.94567 0.497 0 1
  B2M B2M protein IPI00796379 13687.95 6.06 1 70.59 99.99857 70.59 99.99857 0.532 0 1
  HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 3 291.82 100 122.31 100 0.554 0.093 3
  HBB Hemoglobin delta Etolia variant IPI00830113 19482.91 8.32 2 84.55 99.99994 52.2 99.9016 0.569 0.008 2
Moderately Differentiated cICAT Individual Patients
Moderate Diff 199NT
  PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 53.9 99.93347 53.9 99.93347 0.599 0 1
  BLVRB Flavin reductase IPI00783862 22105.43 7.13 1 42.38 99.05591 42.38 99.05591 0.603 0 1
  TPI1 Isoform 2 of Triosephosphate isomerase IPI00451401 27109.05 8.48 2 154.56 100 104.08 100 0.614 0.108 2
  - 14 kDa protein IPI00788848 13799 5.24 1 103.43 100 104.85 100 0.619 0 1
  IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 41.38 98.81146 41.38 98.81146 0.626 0 1
  PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61410.53 6.3 1 34.48 94.17877 34.48 94.17877 0.629 0 1
  HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 86.26 100 86.26 100 0.635 0 1
  FTL Ferritin light chain IPI00852596 20007.1 5.51 1 62.34 99.99047 62.34 99.99047 0.642 0 1
  - 12 kDa protein IPI00797738 12027.62 6.81 3 108.04 100 59.33 99.98094 0.648 0.149 3
  ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 36.95 96.70379 36.95 96.70379 0.661 0 1
  IGHG1 Hypothetical protein DKFZp686O01196 IPI00423463 52579.41 8.46 2 101.12 100 54.84 99.94642 0.663 0.012 2
  PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 75.54 99.99954 75.54 99.99954 0.665 0 1
  CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 30355.86 8.55 1 46.67 99.64843 46.67 99.64843 0.667 0 1
  COMT Isoform Soluble of Catechol O-methyltransferase IPI00375513 24433.38 5.15 1 45.28 99.51581 45.28 99.51581 0.669 0 1
  NPC2 Epididymal secretory protein E1 precursor IPI00301579 16559.48 7.56 1 85.05 99.99995 85.05 99.99995 0.671 0 1
  AK2 Isoform 1 of Adenylate kinase isoenzyme 2, mitochondrial IPI00215901 26460.77 7.67 1 47.51 99.71026 47.51 99.71026 0.672 0 1
  GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 46.05 99.59448 46.05 99.59448 0.692 0 1
  HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 1 64.19 99.99378 64.19 99.99378 0.699 0 1
  PRDX1 11 kDa protein IPI00641244 10669.51 8.79 1 65.15 99.99501 65.15 99.99501 0.703 0 1
  C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 1 107.61 100 107.61 100 0.707 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 199NT
  PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase 
A IPI00419585 18000.88 7.68 2 120.28 100 66.9 99.99667 1.494 0.076 2
  SSB Lupus La protein IPI00009032 46808.16 6.68 1 98.89 100 98.89 100 1.521 0 1
  HSP90B1 Protein IPI00789430 26539.06 8.95 1 60.2 99.9844 60.2 99.9844 1.539 0 1
  GLO1 Lactoylglutathione lyase IPI00220766 20764.25 5.12 1 52.37 99.90537 52.37 99.90537 1.549 0 1
  P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 1 43.85 99.327 43.85 99.327 1.647 0 1
  LASP1 Isoform 2 of LIM and SH3 domain protein 1 IPI00386803 35990.71 8.92 1 37.62 97.17502 37.62 97.17502 1.724 0 1
  CES1 Isoform 1 of Liver carboxylesterase 1 precursor IPI00010180 62481.15 6.15 1 37.19 96.881 37.19 96.881 1.785 0 1
  FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 95.14 100 95.14 100 1.906 0 1
  TXNDC5;MUTED thioredoxin domain containing 5 isoform 2 IPI00395646 43641.51 5.77 1 39.21 98.04109 39.21 98.04109 1.956 0 1
  LOC440055 similar to ribosomal protein S12 IPI00456898 14588.54 6.43 1 62.41 99.99062 62.41 99.99062 2.036 0 1
  HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 3 180.71 100 84.67 99.99994 2.36 0.814 3
  UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa 
protein, mitochondria IPI00296022 10731.94 4.39 1 116.19 100 116.19 100 2.542 0 1
  PDIA3 Protein disulfide-isomerase A3 precursor IPI00025252 56746.75 5.98 1 60.36 99.98497 60.36 99.98497 2.695 0 1
  TKT Transketolase variant (Fragment) IPI00788802 67862.77 7.9 1 41.13 98.74103 41.13 98.74103 2.814 0 1
  FUBP1 Isoform 2 of Far upstream element-binding protein 1 IPI00644386 68861.11 7.74 1 38.26 97.56211 38.26 97.56211 3.8 0 1
  HSPA1A;HSPA1B Heat shock 70kDa protein 1A IPI00647012 51914.69 5.35 2 71.75 99.99891 45.19 99.50567 345.665 36059.63 2
  FN1 Isoform 12 of Fibronectin precursor IPI00556632 221308.4 5.84 3 151.2795 100 66.93 99.99669 3225.625 165571.7 3
  C1QBP Protein IPI00795465 20360.71 4.1 1 96.03 100 96.03 100 24539.93 0 1
  FLNB Isoform 2 of Filamin-B IPI00382696 275526.9 5.53 1 66.19 99.99607 66.19 99.99607 27210.4 0 1






























 GATM Isoform Cytoplasmic of Glycine amidinotransferase, 
mitochondrial precu IPI00216279 44854.47 6.61 1 96.18 100 96.18 100 0 0 1
 KRT9 Keratin, type I cytoskeletal 9 IPI00019359 62091.91 5.19 1 75.02 99.99947 75.02 99.99947 0 0 1
 DCXR 26 kDa protein IPI00797249 25726.45 8.33 1 72.63005 99.99909 74.05 99.99934 0 0 1
 DSG1 Desmoglein-1 precursor IPI00025753 113643.9 4.9 1 71.94 99.99893 71.94 99.99893 0 0 1
 PAH Phenylalanine-4-hydroxylase IPI00017579 51829.46 6.15 1 68.64 99.99772 68.64 99.99772 0 0 1
 SERPINB12 SERPINB12 protein IPI00643202 48415.18 5.25 1 62.72 99.99107 62.72 99.99107 0 0 1
 KRT10 57 kDa protein IPI00383111 56527.82 5.09 1 49.4 99.8083 49.4 99.8083 0 0 1
 ABAT 4-aminobutyrate aminotransferase, mitochondrial 
precursor IPI00009532 56402.59 8.17 2 156.5 100 81.66 99.99989 0.006 0.25 2
 KRT1 Keratin, type II cytoskeletal 1 IPI00220327 65977.98 8.16 2 277.83 100 161.16 100 0.034 0.011 2
 FTH1 Ferritin heavy chain IPI00554521 21212.29 5.3 1 124.95 100 124.95 100 0.181 0 1
 ALDOB Fructose-bisphosphate aldolase IPI00513830 24113.34 6.65 1 140.6 100 140.6 100 0.261 0 1
 CAT Catalase IPI00465436 59718.75 6.9 1 62.69004 99.99101 64.11 99.99352 0.268 0 1
 AK2 Isoform 1 of Adenylate kinase isoenzyme 2, mitochondrial IPI00215901 26460.77 7.67 1 64.64 99.99426 64.64 99.99426 0.273 0 1
 OTC Ornithine carbamoyltransferase, mitochondrial precursor IPI00295363 39909.67 8.75 1 56.36 99.9614 56.36 99.9614 0.273 0 1
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41324.39 6.47 1 42.54004 99.06973 43.96 99.32917 0.283 0 1
 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 94.28 100 94.28 100 0.292 0 1
 PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61410.53 6.3 1 46.49 99.62536 46.49 99.62536 0.309 0 1
 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 51.76 99.88867 51.76 99.88867 0.326 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 59.77 99.9824 59.77 99.9824 0.36 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 200NT
 HINT2 Histidine triad nucleotide-binding protein 2 IPI00000335 17151.24 9.2 1 44.64 99.4264 44.64 99.4264 0.377 0 1
 GLUD2 Glutamate dehydrogenase 2, mitochondrial precursor IPI00027146 61395.43 8.63 1 57.25 99.96855 57.25 99.96855 0.443 0 1
 HGD Homogentisate 1,2-dioxygenase IPI00303174 49940.59 6.54 1 59.1 99.97946 59.1 99.97946 0.451 0 1
 TPI1 Isoform 2 of Triosephosphate isomerase IPI00451401 27109.05 8.48 2 157.12 100 85.45 100 0.461 0.204 2
 - 11 kDa protein IPI00382841 11283.54 5.82 2 53.03 99.9169 29.41 80.87456 0.462 0.087 2
 C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 2 152.86 100 113.44 100 0.486 0.058 2
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 89.44 100 89.44 100 0.493 0 1
 RAD23B UV excision repair protein RAD23 homolog B IPI00008223 43144.62 4.79 1 63.37 99.99232 63.37 99.99232 0.527 0 1
 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 2 122.61 100 88.21 100 0.531 0.09 2
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 82.35 99.9999 82.35 99.9999 0.536 0 1
 PNPO 19 kDa protein IPI00793232 19465.84 6.92 1 48.71 99.7753 48.71 99.7753 0.551 0 1
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 1 57.41 99.96969 57.41 99.96969 0.553 0 1
 GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 63.26 99.99212 63.26 99.99212 0.554 0 1
 GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 1 49.83 99.82638 49.83 99.82638 0.559 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 3 244.08 100 107.84 100 0.578 0.059 3
 MPST 3-mercaptopyruvate sulfurtransferase variant (Fragment) IPI00746782 34729.5 6.83 1 75.07 99.99948 75.07 99.99948 0.614 0 1
 PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 65.63 99.99543 65.63 99.99543 0.625 0 1
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 1 62.18 99.98989 62.18 99.98989 0.629 0 1
 CALR 37 kDa protein IPI00793605 36679.71 4.55 1 63.99 99.99334 63.99 99.99334 0.643 0 1
 AKR1A1 Aldo-keto reductase family 1, member A1 IPI00647702 16506.3 5.84 1 42.93 99.14962 42.93 99.14962 0.644 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 200NT
 PRDM10 CDNA FLJ20227 fis, clone COLF5152 IPI00386081 105524.9 8.83 1 43.80005 99.304 45.22 99.49811 0.668 0 1
 SELENBP1 53 kDa protein IPI00745729 53027.94 6.03 1 43.38 99.23332 43.38 99.23332 0.695 0 1
 RBP4 Retinol binding protein 4, plasma IPI00480192 22929.13 5.77 1 50.34 99.84561 50.34 99.84561 0.704 0 1
 SYNCRIP Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00018140 69559.59 8.68 1 54.18 99.93623 54.18 99.93623 1.497 0 1
 TKT Transketolase variant (Fragment) IPI00788802 67862.77 7.9 1 55.44 99.95229 55.44 99.95229 1.525 0 1
 LOC730278;LOC729659 similar to Putative S100 calcium-
binding protein A11 ps IPI00790691 11279.74 7.77 1 71.72 99.99888 71.72 99.99888 1.608 0 1
 AMBP AMBP protein precursor IPI00022426 38973.98 5.95 1 42.71004 99.10545 44.13 99.35492 1.627 0 1
 TF Transferrin variant (Fragment) IPI00798430 77029.59 6.68 5 256.61 100 110.59 100 1.631 0.426 5
 A1BG 41 kDa protein IPI00644018 40692.54 5.5 2 103.92 100 57.29 99.96884 1.635 0.203 2
 PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 72886.97 4.96 1 71.75 99.99888 71.75 99.99888 1.66 0 1
 IGKC IGKC protein IPI00430808 25629.86 6.15 3 240.96 100 129.33 100 1.663 0.231 3
 ANXA2 annexin A2 isoform 1 IPI00418169 40385.72 8.53 1 52.2 99.8994 52.2 99.8994 1.67 0 1
 APOH Beta-2-glycoprotein 1 precursor IPI00298828 38272.66 8.34 3 118.14 100 55.69 99.95496 1.672 0.373 3
 FGB Fibrinogen beta chain precursor IPI00298497 55892.26 8.54 1 65.12 99.99486 65.12 99.99486 1.676 0 1
 UFC1 Ufm1-conjugating enzyme 1 IPI00294495 19446.02 6.9 2 80.88 99.99986 41.31 98.76516 1.824 0.198 2
 IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 73.52 99.99926 73.52 99.99926 1.84 0 1
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 110.31 100 56.04 99.95845 1.851 0.128 2
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 1 50.52 99.85188 50.52 99.85188 1.859 0 1
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 5 320.7 100 98.52 100 1.873 0.164 5
 LGALS1 Galectin-1 IPI00219219 14706.2 5.34 3 193.45 100 67.63 99.99712 1.906 0.099 3
Moderately Differentiated cICAT Individual Patients
Moderate Diff 200NT
 APOA2 Apolipoprotein A-II precursor IPI00021854 11167.9 6.26 1 68.16 99.99745 68.16 99.99745 1.95 0 1
 FHL1 Four and a half LIM domains 1 IPI00029028 23685.15 8.94 2 71.95 99.99893 40.25 98.4238 1.96 0.029 2
 - Hypothetical protein DKFZp686C15213 IPI00426051 51066.19 7.85 2 128.73 100 92.81 100 2.049 0.637 2
 IGHM IGHM protein IPI00472610 52633.11 7.5 3 200.34 100 92.81 100 2.065 0.586 3
 SERPINB6 Serpin peptidase inhibitor, clade B (Ovalbumin), 
member 6 IPI00513699 21231.33 6.89 1 42.54 99.06973 42.54 99.06973 2.14 0 1
 LYPLA1 Isoform 2 of Acyl-protein thioesterase 1 IPI00398727 22860.58 6.05 1 63.61 99.99273 63.61 99.99273 2.143 0 1
 IGHM Hypothetical protein DKFZp686I15212 IPI00418153 56983.02 8.39 2 66.11 99.99591 35.92 95.72819 2.238 0.447 2
 - 29 kDa protein IPI00791859 28830.89 5.65 1 49.49 99.81224 49.49 99.81224 2.269 0 1
 F2 70 kDa protein IPI00784409 69916.09 5.64 1 77.87 99.99973 77.87 99.99973 2.277 0 1
 CTSB Cathepsin B precursor IPI00295741 37796.83 5.88 1 93.1 100 93.1 100 2.291 0 1
 EEF1G;LOC729998 similar to Elongation factor 1-gamma IPI00738381 50270.31 7.09 1 45.21 99.49695 45.21 99.49695 2.326 0 1
 PGLYRP2 Isoform 2 of N-acetylmuramoyl-L-alanine amidase 
precursor IPI00394992 67957.49 7.62 1 67.82 99.99724 67.82 99.99724 2.472 0 1
 TAGLN Transgelin IPI00216138 22596.43 8.87 1 52.57 99.90761 52.57 99.90761 2.57 0 1
 - Hypothetical protein DKFZp686M24218 IPI00784998 52387.11 7.89 3 103.64 100 37.35 96.92665 2.583 0.789 3
 CP 20 kDa protein IPI00793108 20180.8 5.27 1 49.14 99.79648 49.14 99.79648 2.612 0 1
 ALB Serum albumin IPI00022434 71529.53 6.33 16 1299.41 100 131 100 2.648 14.824 15
 B2M B2M protein IPI00796379 13687.95 6.06 1 84.75 99.99994 84.75 99.99994 2.732 0 1
 GRN Isoform 1 of Granulins precursor IPI00296713 63499.84 6.43 1 48.4 99.75867 48.4 99.75867 2.796 0 1
 HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 2 137.77 100 103.75 100 3.362 0.101 2
 CD59 CD59 glycoprotein precursor IPI00011302 14167.79 6.02 1 55.07 99.94805 55.07 99.94805 3.983 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 200NT
 VTN Vitronectin precursor IPI00298971 54271.17 5.55 1 82.44 99.9999 82.44 99.9999 4.404 0 1
 UQCRC1 24 kDa protein IPI00792890 24089.1 5.51 1 61.58 99.9884 61.58 99.9884 4.479 0 1
 LUM Lumican precursor IPI00020986 38404.79 6.16 1 54.35 99.93868 54.35 99.93868 6.147 0 1
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 64.58 99.99418 64.58 99.99418 6.199 0 1
 P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 2 143.8 100 79.48 99.99981 77.276 6099.774 2
 RNH1 Ribonuclease/angiogenin inhibitor IPI00783491 49839.99 4.68 2 127.09 100 68.45 99.99761 135.005 5964.038 2
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-B;HLA-C HLA class 
I histocompatibility a IPI00472138 40312.04 5.9 2 69.97 99.99832 42.88 99.13978 168.042 4725.628 2
 EPHX1 Epoxide hydrolase 1 IPI00009896 52914.96 6.77 3 126.44 100 55.28 99.9505 567.814 20945.161 3
 AKR1B10 Aldo-keto reductase family 1 member B10 IPI00105407 35997.82 7.12 1 58.79 99.97794 58.79 99.97794 1568.221 0 1
 - CDNA FLJ41483 fis, clone BRTHA2002808, highly similar to 
GAMMA- INTERFERO IPI00446576 16995.2 4.57 1 53.24 99.92082 53.24 99.92082 2879.897 0 1
 TUBA1B Tubulin alpha-1B chain IPI00387144 50119.6 4.94 1 55.28 99.9505 55.28 99.9505 3088.856 0 1
 VIM 50 kDa protein IPI00827679 49623.11 5.19 1 93.62 100 93.62 100 3355.97 0 1
 ENO3 Beta-enolase IPI00218474 46957.32 7.59 1 53.5 99.92542 53.5 99.92542 4406.242 0 1
 FN1 Isoform 12 of Fibronectin precursor IPI00556632 221308.4 5.84 3 121.81 100 73.35 99.99923 4732.048 1377.937 3
 EFEMP1 Isoform 2 of EGF-containing fibulin-like extracellular 
matrix protei IPI00220813 53686.69 4.9 3 117.64 100 43.1 99.18227 5360.354 2518.163 3
 LGALS3BP 16 kDa protein IPI00794873 16452.93 5.74 1 66.18 99.99598 66.18 99.99598 6538.959 0 1
 RTN3 Isoform 5 of Reticulon-3 IPI00394896 26435.07 9.08 1 58.69 99.97743 58.69 99.97743 6823.166 0 1
 - 29 kDa protein IPI00177423 28641.2 8.34 1 58.69 99.97743 58.69 99.97743 6823.166 0 1
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-B;HLA-C HLA class 
I histocompatibility a IPI00472057 40336.98 5.67 2 52.56 99.9074 27.09 67.37043 6963.845 2945.924 2
 PRELP Prolargin precursor IPI00020987 43782.15 9.47 1 46.26 99.60499 46.26 99.60499 7718.268 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 200NT
 MYL9 Myosin regulatory light chain 2, smooth muscle isoform IPI00220278 19814.45 4.8 1 70.32 99.99845 70.32 99.99845 8926.424 0 1
 UCHL1 16 kDa protein IPI00657702 15680.62 5.19 1 79.18 99.9998 79.18 99.9998 12476.04 0 1






























 ALDOB Fructose-bisphosphate aldolase B IPI00218407 39448.06 8 2 188.78 100 137.28 100 0 0 2
 ABAT 4-aminobutyrate aminotransferase, mitochondrial 
precursor IPI00009532 56402.59 8.17 2 169.32 100 84.69 99.99994 0 0 2
 C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 2 118.84 100 87.61 100 0 0 2
 PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 72886.97 4.96 2 86.85 100 58.45 99.97596 0 0 2
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 2 79.21 99.9998 43.44 99.23808 0 0 2
 PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61410.53 6.3 1 83.76 99.99993 83.76 99.99993 0 0 1
 PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 72.96 99.99915 72.96 99.99915 0 0 1
 PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 71.12 99.9987 71.12 99.9987 0 0 1
 TXNDC5;MUTED thioredoxin domain containing 5 isoform 2 IPI00395646 43641.51 5.77 1 64.99005 99.99467 66.41 99.99615 0 0 1
 AKR1C1 Aldo-keto reductase family 1 member C1 IPI00029733 36765.02 8.02 1 59.3 99.98023 59.3 99.98023 0 0 1
 COMT Isoform Soluble of Catechol O-methyltransferase IPI00375513 24433.38 5.15 1 58.91 99.97838 58.91 99.97838 0 0 1
 PAH Phenylalanine-4-hydroxylase IPI00017579 51829.46 6.15 1 57.7 99.97143 57.7 99.97143 0 0 1
 P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 1 49.05 99.79063 49.05 99.79063 0 0 1
 PBLD 28 kDa protein IPI00396138 28133.41 6.55 1 45.79 99.55649 45.79 99.55649 0 0 1
 GSTZ1 glutathione transferase zeta 1 isoform 2 IPI00157928 19360.02 8.27 1 43.73 99.2873 43.73 99.2873 0 0 1
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 30355.86 8.55 1 43.53 99.25371 43.53 99.25371 0 0 1
 BHMT2 Betaine--homocysteine S-methyltransferase 2 IPI00014363 40328.18 5.61 1 43.03 99.16265 43.03 99.16265 0 0 1
 CHDH Choline dehydrogenase, mitochondrial precursor IPI00168603 65360.13 8.67 1 38.67004 97.71491 40.09 98.35219 0 0 1
 DCXR 26 kDa protein IPI00797249 25726.45 8.33 1 40.07005 98.3446 41.49 98.80627 0 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 203NT
 PDIA6 Isoform 1 of Protein disulfide-isomerase A6 precursor IPI00644989 48091.26 4.95 1 39.34 98.04157 39.34 98.04157 0 0 1
 PEBP1 22 kDa protein IPI00795288 21730.87 8.33 1 39.28 98.01433 39.28 98.01433 0 0 0
 ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 IPI00642144 22639.55 5.76 1 38.43 97.58506 38.43 97.58506 0 0 1
 AKR1D1 CDNA FLJ25413 fis, clone TST03402, highly similar 
to 3-OXO-5-BETA- S IPI00065073 30242.66 8.11 1 34.67 94.26006 34.67 94.26006 0 0 1
 GSTM1 glutathione S-transferase M1 isoform 2 IPI00152326 21238.76 7.67 1 31.76 88.78221 31.76 88.78221 0 0 1
 GFER Augmenter of liver regeneration IPI00472356 23463.22 8.01 1 30.99 86.60609 30.99 86.60609 0 0 1
 ALDH1L1 10-formyltetrahydrofolate dehydrogenase IPI00290553 98766.56 5.63 1 30.78 85.94253 30.78 85.94253 0 0 1
 IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 IPI00024254 55949.51 5.12 1 29.83 82.50527 29.83 82.50527 0 0 1
 NDUFV2 28 kDa protein IPI00646556 27889.3 8.15 1 28.5 76.23667 28.5 76.23667 0 0 1
 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 2 136.28 100 70.46 99.99849 0.002 0.103 2
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 3 151.98 100 82.84 99.99991 0.003 0.067 3
 SELENBP1 53 kDa protein IPI00745729 53027.94 6.03 2 130.17 100 93.82 100 0.003 0.081 2
 HP Haptoglobin precursor IPI00641737 46693.35 6.28 3 166.83 100 67.37 99.99692 0.004 0.135 3
 GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 2 138.82 100 73.29 99.99921 0.004 0.177 2
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 2 85.69 100 59.93 99.9829 0.006 0.098 2
 DAK Dihydroxyacetone kinase IPI00551024 58940.04 7.12 2 160.59 100 81.09 99.99987 0.007 0.237 2
 GATM Isoform Cytoplasmic of Glycine amidinotransferase, 
mitochondrial precu IPI00216279 44854.47 6.61 2 104.62 100 79.89 99.99983 0.008 0.329 2
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 85.95 100 85.95 100 0.045 0 1
 ATOX1 Copper transport protein ATOX1 IPI00010863 7396.73 6.71 1 117.87 100 117.87 100 0.054 0 1
 HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 13793.09 6.43 1 61.61 99.98839 61.61 99.98839 0.069 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 203NT
 ALB Serum albumin IPI00022434 71529.53 6.33 13 831.752 100 148.84 100 0.073 2.434 12
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 91.33005 100 92.75 100 0.099 0 1
 FAH Fumarylacetoacetase IPI00031708 46344.21 6.46 1 38.77 97.76691 38.77 97.76691 0.111 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 3 233.93 100 119.64 100 0.113 0.01 3
 HGD Homogentisate 1,2-dioxygenase IPI00303174 49940.59 6.54 1 45.24 99.49661 45.24 99.49661 0.138 0 1
 CAT Catalase IPI00465436 59718.75 6.9 1 55.70004 99.95472 57.12 99.96735 0.147 0 1
 MPST 3-mercaptopyruvate sulfurtransferase variant (Fragment) IPI00746782 34729.5 6.83 1 70.92 99.99864 70.92 99.99864 0.156 0 1
 SORD Sorbitol dehydrogenase IPI00216057 38271.84 8.23 1 57.23 99.96816 57.23 99.96816 0.164 0 1
 PNPO 19 kDa protein IPI00793232 19465.84 6.92 1 61.7 99.98863 61.7 99.98863 0.165 0 1
 AK2 Isoform 1 of Adenylate kinase isoenzyme 2, mitochondrial IPI00215901 26460.77 7.67 1 41.89 98.9113 41.89 98.9113 0.173 0 1
 UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa 
protein, mitochondria IPI00296022 10731.94 4.39 1 121.32 100 121.32 100 0.193 0 1
 C6orf108 putative c-Myc-responsive isoform 2 IPI00395835 16177.23 6.31 1 42.33 99.0162 42.33 99.0162 0.202 0 1
 TMEM4 Isoform 1 of MIR-interacting saposin-like protein 
precursor IPI00443909 20639.17 4.81 1 63.78 99.99295 63.78 99.99295 0.22 0 1
 ASGR2 Isoform 3 of Asialoglycoprotein receptor 2 IPI00150200 32529.64 5.46 1 39.7 98.19737 39.7 98.19737 0.231 0 1
 ACY1 15 kDa protein IPI00792542 15083.28 5.77 1 48.88 99.78228 48.88 99.78228 0.238 0 1
 GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 83.63 99.99993 83.63 99.99993 0.24 0 1
 CALR 37 kDa protein IPI00793605 36679.71 4.55 1 75.05 99.99947 75.05 99.99947 0.241 0 1
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 97.99 100 97.99 100 0.246 0 1
 TPI1 Isoform 1 of Triosephosphate isomerase IPI00465028 30771.7 5.65 4 324.78 100 92.69 100 0.268 0.049 4
 HINT2 Histidine triad nucleotide-binding protein 2 IPI00000335 17151.24 9.2 1 54.06 99.93394 54.06 99.93394 0.284 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 203NT
 HBB Hemoglobin delta Etolia variant IPI00830113 19482.91 8.32 2 102.19 100 65.42 99.99517 0.294 0.005 2
 - 11 kDa protein IPI00382841 11283.54 5.82 1 29.38 80.59528 29.38 80.59528 0.313 0 1
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 78.35 99.99975 78.35 99.99975 0.327 0 1
 OTC Ornithine carbamoyltransferase, mitochondrial precursor IPI00295363 39909.67 8.75 1 46.32 99.60744 46.32 99.60744 0.337 0 1
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 23496.76 4.93 1 105.65 100 105.65 100 0.347 0 1
 - 18 kDa protein IPI00745933 17925.71 6.21 3 166.5 100 74.6 99.99942 0.349 0.018 3
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 91.28 100 46.14 99.59083 0.351 0.023 2
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41324.39 6.47 1 116.01 100 117.43 100 0.355 0 1
 B2M B2M protein IPI00796379 13687.95 6.06 1 67.66 99.99712 67.66 99.99712 0.381 0 1
 EEF1G;LOC729998 similar to Elongation factor 1-gamma IPI00738381 50270.31 7.09 1 43.34 99.22034 43.34 99.22034 0.391 0 1
 LGALS1 Galectin-1 IPI00219219 14706.2 5.34 2 114.67 100 59.66 99.98181 0.396 0.182 2
 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 49.93 99.82904 49.93 99.82904 0.396 0 1
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 52737.86 6.3 1 52.3 99.90094 52.3 99.90094 0.406 0 1
 - 63 kDa protein IPI00792605 62706.83 10.91 1 45.43 99.51816 45.43 99.51816 0.406 0 1
 GCSH;LOC730107 Glycine cleavage system H protein, 
mitochondrial precursor IPI00011604 18898.67 4.91 1 30.19 83.89699 30.19 83.89699 0.412 0 1
 PDLIM1 PDZ and LIM domain protein 1 IPI00010414 36049.04 6.56 1 75.55 99.99953 75.55 99.99953 0.442 0 1
 HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 3 248.49 100 98.34 100 0.446 0.27 3
 KRT1 Keratin, type II cytoskeletal 1 IPI00220327 65977.98 8.16 1 61.46 99.98798 61.46 99.98798 0.447 0 1
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 2 89.65 100 45.82 99.55954 0.457 0.151 2
 AGXT Serine--pyruvate aminotransferase IPI00009367 42982.44 8.61 1 29.23 79.91336 29.23 79.91336 0.478 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 203NT
 HNRPR HNRPR protein IPI00644055 71170.4 8.23 2 76.47 99.99962 44.34 99.38069 0.485 0.131 2
 SYNCRIP Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00402182 65641.59 8.69 2 76.47 99.99962 44.34 99.38069 0.485 0.131 2
 HMGB1 High-mobility group box 1 IPI00644653 18299.33 9.72 1 39.36 98.05057 39.36 98.05057 0.485 0 1
 UFC1 Ufm1-conjugating enzyme 1 IPI00294495 19446.02 6.9 1 31.90942 89.16161 34.16 93.54484 0.522 0 1
 RAD23B UV excision repair protein RAD23 homolog B IPI00008223 43144.62 4.79 1 90.4 100 90.4 100 0.543 0 1
 TXNDC4 Thioredoxin domain-containing protein 4 precursor IPI00401264 46941.4 5.09 1 39.63 98.16808 39.63 98.16808 0.547 0 1
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 2 100.55 100 59.26 99.98005 0.55 0.374 2
 EPHX1 Epoxide hydrolase 1, microsomal IPI00640017 16373.31 5.85 1 30.03 83.29267 30.03 83.29267 0.559 0 1
 PRDX6 Peroxiredoxin-6 IPI00220301 25019.19 6 1 29.15 79.53992 29.15 79.53992 0.578 0 1
 FHL1 Four and a half LIM domains 1 IPI00029028 23685.15 8.94 1 29.41 80.72887 29.41 80.72887 0.617 0 1
 FGG Isoform Gamma-A of Fibrinogen gamma chain precursor IPI00219713 49464.97 5.7 1 40.77 98.59101 40.77 98.59101 0.631 0 1
 A1BG 41 kDa protein IPI00644018 40692.54 5.5 2 63.48 99.99245 34.65 94.23357 0.638 0.087 2
 TF Transferrin variant (Fragment) IPI00798430 77029.59 6.68 4 218.5901 100 103.56 100 0.645 0.249 4
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 46.95 99.66045 46.95 99.66045 0.682 0 1
 - Hypothetical protein DKFZp686C15213 IPI00426051 51066.19 7.85 1 26.94 65.96646 26.94 65.96646 1.646 0 1
 CLGN Calmegin precursor IPI00024776 69994.44 4.58 1 63.4 99.99231 63.4 99.99231 1.658 0 1
 HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 1 64.2 99.9936 64.2 99.9936 2.221 0 1
 APOA2 Apolipoprotein A-II precursor IPI00021854 11167.9 6.26 1 86.81 100 86.81 100 2.97 0 1
 CMBL carboxymethylenebutenolidase-like IPI00383046 28030.17 6.71 1 36.07 95.84178 36.07 95.84178 3.047 0 1
 VIM 50 kDa protein IPI00827679 49623.11 5.19 1 86.17 100 86.17 100 3.133 0 1
Moderately Differentiated cICAT Individual Patients
Moderate Diff 203NT
 TAGLN Transgelin IPI00216138 22596.43 8.87 1 36.58 96.30251 36.58 96.30251 4.751 0 1
 FN1 fibronectin 1 isoform 4 preproprotein IPI00414283 256351.1 5.53 1 44.62004 99.41937 46.04 99.5813 7.383 0 1
 MYL9 Myosin regulatory light chain 2, smooth muscle isoform IPI00220278 19814.45 4.8 1 27.73 71.62687 27.73 71.62687 5680.061 0 1
 AKR1B10 Aldo-keto reductase family 1 member B10 IPI00105407 35997.82 7.12 1 64.68 99.99427 64.68 99.99427 5861.212 0 1






























 CPS1 Isoform 2 of Carbamoyl-phosphate synthase [ammonia], 
mitochondrial pre IPI00397498 115964.1 5.67 5 194.44 100 61.38 99.98784 0 0 5
 UQCRC1 18 kDa protein IPI00792217 18454.07 7.66 1 52.86 99.91355 52.86 99.91355 0 0 1
 ADH1C Alcohol dehydrogenase 1C IPI00465343 39841.67 8.63 1 33.58004 92.67568 35 94.71832 0 0 1
 ADH4 Alcohol dehydrogenase 4 IPI00218899 40195.71 8.25 1 29.53 81.38891 29.53 81.38891 0 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 2 56.73004 99.96454 35.21 94.96764 0.002 0.185 2
 GAPDH 39 kDa protein IPI00788737 38766.83 8.76 2 66.36 99.99614 33.81 93.05341 0.005 0.28 2
 ASS1 Argininosuccinate synthetase 1 IPI00514341 19035.86 7.26 1 32.11 89.72524 32.11 89.72524 0.103 0 1
 ALDOB Fructose-bisphosphate aldolase IPI00513830 24113.34 6.65 1 102.93 100 102.93 100 0.104 0 1
 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 47.82 99.72409 47.82 99.72409 0.172 0 1
 AK2 Isoform 1 of Adenylate kinase isoenzyme 2, mitochondrial IPI00215901 26460.77 7.67 1 36.28 96.06656 36.28 96.06656 0.242 0 1
 - 11 kDa protein IPI00382841 11283.54 5.82 1 37.3 96.88992 37.3 96.88992 0.283 0 1
 PNPO 19 kDa protein IPI00793232 19465.84 6.92 1 67.52 99.99704 67.52 99.99704 0.295 0 1
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 30355.86 8.55 1 37.77 97.20892 37.77 97.20892 0.304 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 1 40.71 98.58169 40.71 98.58169 0.344 0 1
 PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 70.12 99.99838 70.12 99.99838 0.375 0 1
 UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa 
protein, mitochondria IPI00296022 10731.94 4.39 1 61.72 99.98876 61.72 99.98876 0.38 0 1
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 73.09 99.99918 37.59 97.09081 0.399 0.014 2
 TUBB4 Tubulin beta-4 chain IPI00023598 49553.9 4.78 2 60.29 99.98438 36.54 96.29514 0.421 0.022 2
 TUBB2A Tubulin beta-2A chain IPI00013475 49874.96 4.78 2 60.29 99.98438 36.54 96.29514 0.421 0.022 2
Poorly Differentiated cICAT Individual Patients
Poor Diff 120NT
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 2 69.22005 99.998 39.93 98.30265 0.423 0.019 2
 TXNDC5;MUTED thioredoxin domain containing 5 isoform 2 IPI00395646 43641.51 5.77 2 95.38005 100 69.55 99.99815 0.451 0.02 2
 CAT Catalase IPI00465436 59718.75 6.9 1 36.25004 96.03934 37.67 97.14391 0.484 0 1
 SELENBP1 CDNA FLJ13813 fis, clone THYRO1000358, 
moderately similar to SELEN IPI00030385 25937 6.19 1 31.08 86.97517 31.08 86.97517 0.508 0 1
 MDH2 Malate dehydrogenase, mitochondrial precursor IPI00291006 35508.76 8.92 1 42.12 98.97489 42.12 98.97489 0.52 0 1
 TPI1 Isoform 1 of Triosephosphate isomerase IPI00465028 30771.7 5.65 2 122.56 100 63.32 99.99222 0.545 0.051 2
 CTSB Cathepsin B precursor IPI00295741 37796.83 5.88 1 107.42 100 107.42 100 0.561 0 1
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 3 108.73 100 39.94 98.30655 0.566 0.217 3
 CLGN Calmegin precursor IPI00024776 69994.44 4.58 1 33.93 93.24272 33.93 93.24272 0.57 0 1
 AKR1C3 Aldo-keto reductase family 1 member C3 IPI00291483 36820.84 8.05 1 31.26 87.50398 31.26 87.50398 0.616 0 1
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 1 38.02 97.36505 38.02 97.36505 0.671 0 1
 HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 1 35.26 95.02524 35.26 95.02524 0.707 0 1
 FGG Isoform Gamma-A of Fibrinogen gamma chain precursor IPI00219713 49464.97 5.7 1 44.44 99.39914 44.44 99.39914 1.545 0 1
 LGALS1 Galectin-1 IPI00219219 14706.2 5.34 2 67.24 99.99685 43.93 99.32427 1.654 0.145 2
 VIM 50 kDa protein IPI00827679 49623.11 5.19 1 84.06 99.99993 84.06 99.99993 1.881 0 1
 HP Haptoglobin precursor IPI00641737 46693.35 6.28 4 188.82 100 72.93 99.99915 2.024 0.275 4
 FLNA filamin A, alpha IPI00302592 279843.5 5.69 1 36.13 95.92834 36.13 95.92834 2.068 0 1
 SERPINB6 Serpin peptidase inhibitor, clade B (Ovalbumin), 
member 6 IPI00513699 21231.33 6.89 1 58.6 99.97694 58.6 99.97694 2.234 0 1
 FHL1 Isoform 1 of Four and a half LIM domains protein 1 IPI00647207 31872.84 8.72 1 34.41 93.94977 34.41 93.94977 2.632 0 1
 IGHG1 Hypothetical protein DKFZp686K03196 IPI00423464 52327.11 8.84 4 209.7701 100 94.69 100 2.783 0.331 4
 HBA2;HBA1 Alpha 2 globin variant (Fragment) IPI00853068 15270.94 8.72 1 43.41 99.23832 43.41 99.23832 3.069 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 120NT
 - Hypothetical protein DKFZp686C15213 IPI00426051 51066.19 7.85 2 76.74001 99.99965 40.5 98.51142 3.09 0.155 2
 IGLV4-3 IGLV4-3 protein IPI00382938 25960.7 6.3 2 138.6 100 75.32 99.99951 3.51 0.544 2
 HBB Hemoglobin delta Etolia variant IPI00830113 19482.91 8.32 2 91.4 100 54.33 99.93837 3.625 0.103 2
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 62.83 99.99129 62.83 99.99129 3.629 0 1
 IGKC IGKC protein IPI00430808 25629.86 6.15 1 79.96 99.99983 79.96 99.99983 3.633 0 1
 TAGLN Transgelin IPI00216138 22596.43 8.87 1 37.12 96.75831 37.12 96.75831 3.702 0 1
 HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 3 271.53 100 108.66 100 3.994 0.221 3
 A1BG 41 kDa protein IPI00644018 40692.54 5.5 1 35.89 95.69699 35.89 95.69699 6.382 0 1
 TF Transferrin variant (Fragment) IPI00798430 77029.59 6.68 8 421.3802 100 92.64 100 8.548 143.573 8
 ALB Serum albumin IPI00022434 71529.53 6.33 18 1058.079 100 109.61 100 20.035 818.215 18
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 3 152.32 100 74.4 99.99939 1705.294 93062.586 3
 IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 34.65 94.27505 34.65 94.27505 10539.87 0 1
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 23496.76 4.93 1 42.1 98.97015 42.1 98.97015 12282.5 0 1
 SERPINA1 Alpha 1-antitrypsin IPI00790784 40237.62 5.26 1 57.26 99.96861 57.26 99.96861 15093.25 0 1






























  GSTM1 28 kDa protein IPI00647885 27599.04 6.24 1 29.62 81.89189 29.62 81.89189 0 0 1
  FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 36790.79 6.54 1 28.71004 77.67102 30.13 83.89825 0 0 1
  HBB Hemoglobin delta Etolia variant IPI00830113 19482.91 8.32 2 82.24 99.9999 56.23 99.96047 0.006 0.149 2
  ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 2 176.51 100 93.23 100 0.011 0.455 2
  EPHX1 Epoxide hydrolase 1 IPI00009896 52914.96 6.77 2 93.37 100 69.48 99.99813 0.011 0.316 2
  SPTA1 Spectrin, alpha, erythrocytic 1 IPI00641363 279501.7 4.95 1 33.51004 92.60618 34.93 94.66821 0.19 0 1
  HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 3 285.2 100 103.01 100 0.245 0.135 3
  PABPC4 Isoform 1 of Polyadenylate-binding protein 4 IPI00012726 70738.09 9.31 1 78.5 99.99977 78.5 99.99977 0.283 0 1
  PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 47.46 99.70224 47.46 99.70224 0.314 0 1
  SORD Sorbitol dehydrogenase IPI00216057 38271.84 8.23 1 42.79 99.12728 42.79 99.12728 0.324 0 1
  C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 1 62.78 99.99125 62.78 99.99125 0.333 0 1
  GOT2 Aspartate aminotransferase, mitochondrial precursor IPI00018206 47445.27 9.14 2 56.5 99.96286 29.9 83.02252 0.369 0.01 2
  HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 102.95 100 102.95 100 0.374 0 1
  ALDOB Fructose-bisphosphate aldolase B IPI00218407 39448.06 8 2 273.7 100 140.17 100 0.398 0.004 2
  SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 2 175.47 100 111.51 100 0.421 0.016 2
  PRDX2 15 kDa protein IPI00794777 15128.81 5.82 2 52.58004 99.90841 31.17 87.32719 0.441 0.02 2
  GFER Augmenter of liver regeneration IPI00472356 23463.22 8.01 1 28.16 74.65612 28.16 74.65612 0.442 0 1
Poorly Differentiated cICAT Individual Patients 
Poor Diff 126NT
  PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 1 111.67 100 111.67 100 0.45 0 1
  FTH1 Ferritin heavy chain IPI00554521 21212.29 5.3 1 105.74 100 105.74 100 0.46 0 1
  FTL Ferritin light chain IPI00852596 20007.1 5.51 1 95.55 100 95.55 100 0.549 0 1
  RAD23B UV excision repair protein RAD23 homolog B IPI00008223 43144.62 4.79 1 36 95.83252 36 95.83252 0.57 0 1
  GATM Isoform Cytoplasmic of Glycine amidinotransferase, 
mitochondrial precu IPI00216279 44854.47 6.61 1 66.35 99.99616 66.35 99.99616 0.577 0 1
  RAD23A UV excision repair protein RAD23 homolog A IPI00008219 39584.65 4.56 1 40.96 98.66993 40.96 98.66993 0.589 0 1
  - 14 kDa protein IPI00788848 13799 5.24 1 77.37005 99.9997 78.79 99.99978 0.601 0 1
  SPTAN1 283 kDa protein IPI00744706 283049.5 5.24 1 44.98 99.47292 44.98 99.47292 0.619 0 1
  HLA-DPA1 Major histocompatibility complex, class II, DP 
alpha 1 IPI00644713 24043.96 5.09 1 35.65 95.48276 35.65 95.48276 0.65 0 1
  CUTA Isoform C of Protein CutA precursor IPI00554556 16821.85 5.15 1 37.52004 97.06324 38.94 97.88226 0.67 0 1
  MYL9 Myosin regulatory light chain 2, smooth muscle isoform IPI00220278 19814.45 4.8 1 50.84 99.86327 50.84 99.86327 0.682 0 1
  ATOX1 Copper transport protein ATOX1 IPI00010863 7396.73 6.71 1 30.90004 86.51445 32.32 90.27537 0.688 0 1
  PYCARD Isoform 2 of Apoptosis-associated speck-like protein 
containing a CA IPI00221360 19956.4 5.66 1 59.7 99.98222 59.7 99.98222 0.691 0 1
  FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 83.07 99.99992 83.07 99.99992 0.693 0 1
  HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 1 57.03 99.96712 57.03 99.96712 0.835 0 1
  ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 55.59 99.9542 55.59 99.9542 1.486 0 1
  HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 70.3 99.99845 70.3 99.99845 1.5 0 1
  PLS3 Plastin-3 IPI00848312 70391.1 5.52 1 57.06 99.96735 57.06 99.96735 1.515 0 1
  IGHM IGHM protein IPI00472610 52633.11 7.5 3 190.54 100 83.13 99.99992 1.53 0.153 3
Poorly Differentiated cICAT Individual Patients 
Poor Diff 126NT
  APOA2 Apolipoprotein A-II precursor IPI00021854 11167.9 6.26 1 87.43 100 87.43 100 1.55 0 1
  B2M B2M protein IPI00796379 13687.95 6.06 1 82.7 99.99991 82.7 99.99991 1.581 0 1
  ALB Serum albumin IPI00022434 71529.53 6.33 12 1148.64 100 158 100 1.582 0.2 10
  UFC1 Ufm1-conjugating enzyme 1 IPI00294495 19446.02 6.9 2 58.85 99.97838 32.77 91.23255 1.634 0.235 2
  HPX Hemopexin precursor IPI00022488 51643.27 6.55 2 180.51 100 107.47 100 1.688 0.098 2
  EEF1G;LOC729998 similar to Elongation factor 1-gamma IPI00738381 50270.31 7.09 1 45.18 99.49665 45.18 99.49665 1.699 0 1
  LOC653879 similar to Complement C3 precursor IPI00739237 44900.89 4.94 1 38.63 97.72557 38.63 97.72557 1.706 0 1
  SSB Lupus La protein IPI00009032 46808.16 6.68 1 84.57 99.99994 84.57 99.99994 1.73 0 1
  IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 103.26 100 103.26 100 1.769 0 1
  PAH Phenylalanine-4-hydroxylase IPI00017579 51829.46 6.15 1 79.66 99.99982 79.66 99.99982 1.93 0 1
  TKT Transketolase variant (Fragment) IPI00788802 67862.77 7.9 1 67.56 99.99709 67.56 99.99709 2.354 0 1
  SYNCRIP Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00402182 65641.59 8.69 1 40.19004 98.41193 41.61 98.85482 2.358 0 1
  HSP90AA1 Hsp89-alpha-delta-N IPI00604607 63211.62 5.03 2 153.92 100 114.41 100 2.362 0.576 2
  VCP 89 kDa protein IPI00843748 89270.64 5.11 1 46.28004 99.60928 47.7 99.71824 2.549 0 1
  FLNA Filamin-A IPI00333541 280563.9 5.7 1 36.1 95.92739 36.1 95.92739 2.637 0 1
  FGB Fibrinogen beta chain precursor IPI00298497 55892.26 8.54 1 53.29 99.92222 53.29 99.92222 3.143 0 1
  UQCRC1 24 kDa protein IPI00792890 24089.1 5.51 1 40.77 98.61045 40.77 98.61045 3.182 0 1
  PML promyelocytic leukemia protein isoform 10 IPI00181058 64995.65 5.19 1 32.46004 90.58395 33.88 93.20995 3.533 0 1
  CYC1 Cytochrome c1 heme protein, mitochondrial precursor IPI00029264 35367 9.15 1 45.22 99.50126 45.22 99.50126 4.023 0 1
Poorly Differentiated cICAT Individual Patients 
Poor Diff 126NT
  HSPG2 365 kDa protein IPI00747758 364402.6 6.07 1 34.09 93.53046 34.09 93.53046 4.093 0 1
  AKR1B10 Aldo-keto reductase family 1 member B10 IPI00105407 35997.82 7.12 1 107.22 100 107.22 100 5.923 0 1
  FN1 Isoform 12 of Fibronectin precursor IPI00556632 221308.4 5.84 3 162.0301 100 77.76 99.99972 48.526 876.844 3
  HSPA4 Heat shock 70 kDa protein 4 IPI00002966 94240.29 5.18 2 63.02004 99.99172 39.07 97.94471 60.506 2978.441 2
  PGK1 Phosphoglycerate kinase 1 IPI00169383 44586.13 8.3 2 94.39 100 69.26 99.99803 79.731 1564.507 2
  - Hypothetical protein DKFZp686C15213 IPI00426051 51066.19 7.85 2 124.88 100 83.13 99.99992 90.973 5392.506 2
  NNMT Nicotinamide N-methyltransferase IPI00027681 29555.06 5.56 2 112.33 100 88.99 100 129.08 3325.475 2
  ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 23496.76 4.93 1 85.03 99.99995 85.03 99.99995 2141.019 0 1
  ACSL4 Isoform Short of Long-chain-fatty-acid--CoA ligase 4 IPI00219897 74387.9 8.33 1 30.3 84.51636 30.3 84.51636 2771.111 0 1
  TXN2 Thioredoxin, mitochondrial precursor IPI00017799 21811.28 8.85 1 70.13 99.99839 70.13 99.99839 3984.918 0 1
  ACTG1;PSPHL Actin, cytoplasmic 2 IPI00021440 41765.79 5.31 1 61.67 99.98871 61.67 99.98871 8330.845 0 1
  TUBB Tubulin beta chain IPI00011654 49638.97 4.78 1 47.42 99.69948 47.42 99.69948 9648.022 0 1






























 - CDNA FLJ46317 fis, clone TESTI4041832 IPI00443413 49623.29 10.33 1 29.97 83.27398 29.97 83.27398 0 0 0
 IGHG1 IGHG1 protein IPI00448938 51362.63 8.69 2 125.85 100 79.09 99.9998 0.012 0.751 2
 HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 2 70.14 99.99839 38.84 97.83034 0.018 1.369 2
 FGG Isoform Gamma-A of Fibrinogen gamma chain precursor IPI00219713 49464.97 5.7 1 64.96 99.9947 64.96 99.9947 0.488 0 1
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 86.51005 100 87.93 100 0.55 0 1
 ASS1 Argininosuccinate synthetase 1 IPI00514341 19035.86 7.26 1 82.81 99.99991 82.81 99.99991 0.556 0 1
 STOM Erythrocyte band 7 integral membrane protein IPI00219682 31710.74 7.71 1 41 98.68055 41 98.68055 0.596 0 1
 FGB Fibrinogen beta chain precursor IPI00298497 55892.26 8.54 1 45.05 99.48073 45.05 99.48073 0.637 0 1
 ALB Serum albumin IPI00022434 71529.53 6.33 10 645.8195 100 111.37 100 0.646 0.236 7
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 1 29.46 81.18983 29.46 81.18983 0.651 0 1
 CP 20 kDa protein IPI00793108 20180.8 5.27 1 29.13 79.70483 29.13 79.70483 0.653 0 1
 BHMT Betaine--homocysteine S-methyltransferase 1 IPI00004101 44969.85 6.58 1 58.13 99.97445 58.13 99.97445 0.661 0 1
 A1BG 41 kDa protein IPI00644018 40692.54 5.5 1 34.97 94.71077 34.97 94.71077 0.662 0 1
 IGKC IGKC protein IPI00430808 25629.86 6.15 1 79.94 99.99983 79.94 99.99983 0.677 0 1
 HBA2;HBA1 Alpha 2 globin variant (Fragment) IPI00853068 15270.94 8.72 1 64.41 99.99398 64.41 99.99398 0.695 0 1
 - Hypothetical protein DKFZp686M24218 IPI00784998 52387.11 7.89 3 113.97 100 47.39 99.69703 0.704 0.054 3
 CTSB Cathepsin B precursor IPI00295741 37796.83 5.88 1 52.65 99.90976 52.65 99.90976 1.465 0 1
 HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 13793.09 6.43 1 50.37 99.84746 50.37 99.84746 1.487 0 1
 CUTA Isoform C of Protein CutA precursor IPI00554556 16821.85 5.15 1 26.17 59.87707 26.17 59.87707 1.501 0 1
 - 14 kDa protein IPI00455040 14347.57 8.86 1 34.27 93.78569 34.27 93.78569 1.51 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 155NT
 RAD23B UV excision repair protein RAD23 homolog B IPI00008223 43144.62 4.79 1 67.25 99.99687 67.25 99.99687 1.559 0 1
 B2M B2M protein IPI00796379 13687.95 6.06 1 75.48 99.99953 75.48 99.99953 1.618 0 1
 SAR1A SAR1 gene homolog A IPI00644667 13653.07 6.49 1 33.33 92.284 33.33 92.284 1.642 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 2 71.97 99.99894 41.11 98.71355 1.662 0.255 2
 RAB21 Ras-related protein Rab-21 IPI00007755 24332.25 8.11 1 29.22 80.12108 29.22 80.12108 1.664 0 1
 IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 IPI00024254 55949.51 5.12 1 41.31 98.77145 41.31 98.77145 1.673 0 1
 HMGB1 High-mobility group box 1 IPI00644653 18299.33 9.72 1 26.16 59.78458 26.16 59.78458 1.686 0 1
 RAD23A UV excision repair protein RAD23 homolog A IPI00008219 39584.65 4.56 1 54.96 99.94699 54.96 99.94699 1.718 0 1
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 3 171.16 100 101.59 100 1.726 0.052 3
 PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 72886.97 4.96 2 99.8 100 56.77 99.96505 1.73 0.033 2
 SERPINB6 Serpin peptidase inhibitor, clade B (Ovalbumin), 
member 6 IPI00513699 21231.33 6.89 1 38.59 97.70177 38.59 97.70177 1.773 0 1
 ETFB Isoform 2 of Electron transfer flavoprotein subunit beta IPI00556451 37411 6.78 1 27.25 68.71093 27.25 68.71093 1.773 0 1
 HSP90B1 Protein IPI00789430 26539.06 8.95 1 74.12 99.99936 74.12 99.99936 1.788 0 1
 LOC389842 similar to Ran-specific GTPase-activating protein IPI00399212 35001.84 8.76 1 24.03942 34.46849 26.29 60.97054 1.806 0 1
 - Actinin alpha4 isoform IPI00845465 59542.11 4.82 1 69.07 99.99794 69.07 99.99794 1.807 0 1
 LASP1 Isoform 2 of LIM and SH3 domain protein 1 IPI00386803 35990.71 8.92 1 31.64 88.61344 31.64 88.61344 1.822 0 1
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 88.87 100 50.24 99.84282 1.858 0.219 2
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 59.97 99.98327 59.97 99.98327 1.859 0 1
 TES Isoform 2 of Testin IPI00216425 46878.3 7.82 1 28.6 77.0706 28.6 77.0706 1.864 0 1
 HSP90AA1 Hsp89-alpha-delta-N IPI00604607 63211.62 5.03 2 122.82 100 79.13 99.9998 1.969 0.19 2
 CDC42 Isoform 2 of Cell division control protein 42 homolog 
precursor IPI00016786 21245.02 6.15 1 43.29 99.22126 43.29 99.22126 1.977 0 1
 CLGN Calmegin precursor IPI00024776 69994.44 4.58 1 40.3 98.44978 40.3 98.44978 2.006 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 155NT
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41324.39 6.47 1 78.69 99.99978 78.69 99.99978 2.025 0 1
 C6orf115 similar to Protein C6orf115 IPI00740277 20388.71 6.38 1 41.92 98.93244 41.92 98.93244 2.034 0 1
 VCP 89 kDa protein IPI00843748 89270.64 5.11 1 37.19004 96.8276 38.61 97.71233 2.046 0 1
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase A IPI00419585 18000.88 7.68 3 151.52 100 61.03 99.9869 2.082 0.551 3
 LYPLA1 Isoform 2 of Acyl-protein thioesterase 1 IPI00398727 22860.58 6.05 1 46.76 99.64974 46.76 99.64974 2.169 0 1
 LGALS1 Galectin-1 IPI00219219 14706.2 5.34 1 35.59 95.41444 35.59 95.41444 2.195 0 1
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 1 77.99 99.99974 77.99 99.99974 2.206 0 1
 CALR 37 kDa protein IPI00793605 36679.71 4.55 1 54.75 99.94436 54.75 99.94436 2.215 0 1
 AARS 107 kDa protein IPI00784131 106643.1 5.33 1 48.86 99.78403 48.86 99.78403 2.256 0 1
 GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 1 57.9 99.97306 57.9 99.97306 2.291 0 1
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 70.22 99.99842 70.22 99.99842 2.293 0 1
 ERP29 Endoplasmic reticulum protein ERp29 precursor IPI00024911 28975.15 6.77 1 86.64 100 86.64 100 2.305 0 1
 PPP2CB Serine/threonine-protein phosphatase 2A catalytic 
subunit beta isofo IPI00429689 35552.33 5.21 1 40.94 98.6622 40.94 98.6622 2.486 0 1
 DCPS Scavenger mRNA-decapping enzyme DcpS IPI00335385 38585.02 5.93 1 32.26 90.12828 32.26 90.12828 2.616 0 1
 PYCARD Isoform 2 of Apoptosis-associated speck-like protein 
containing a CA IPI00221360 19956.4 5.66 1 34.12 93.56731 34.12 93.56731 2.647 0 1
 - CDNA FLJ41483 fis, clone BRTHA2002808, highly similar to 
GAMMA- INTERFERO IPI00446576 16995.2 4.57 1 55.96 99.95789 55.96 99.95789 2.653 0 1
 NPM1 Isoform 1 of Nucleophosmin IPI00549248 32554.84 4.64 1 31.5 88.2404 31.5 88.2404 2.684 0 1
 PEPD Xaa-Pro dipeptidase IPI00257882 54512.91 5.64 1 45.58 99.54039 45.58 99.54039 2.711 0 1
 CBX3;LOC653972 Chromobox protein homolog 3 IPI00297579 20798.35 5.23 1 54.07005 99.93493 55.49 99.95308 2.72 0 1
 CPOX Coproporphyrinogen III oxidase, mitochondrial precursor IPI00093057 50119.97 8.59 1 38.65004 97.73333 40.07 98.36547 2.883 0 1
 SSB Lupus La protein IPI00009032 46808.16 6.68 1 93.81 100 93.81 100 3.24 0 1
 - Similar to Glyceraldehyde-3-phosphate dehydrogenase IPI00747273 12564.45 8.74 1 45.06 99.48193 45.06 99.48193 3.874 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 155NT
 CNBP Isoform 3 of Cellular nucleic acid-binding protein IPI00430814 18400.04 8 1 48.69004 99.77541 50.11 99.83805 7.744 0 1
 TPI1 Isoform 1 of Triosephosphate isomerase IPI00465028 30771.7 5.65 3 154.12 100 59.12 99.97966 23.12 1066.058 3
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 84.68 99.99994 84.68 99.99994 3863.983 0 1
 ANP32A Acidic leucine-rich nuclear phosphoprotein 32 family 
member A IPI00025849 28568.28 3.99 1 54.61 99.94254 54.61 99.94254 4214.713 0 1
 P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 1 41.31 98.77145 41.31 98.77145 4728.755 0 1
 VIM 50 kDa protein IPI00827679 49623.11 5.19 1 92.83 100 92.83 100 6591.874 0 1
 ACP1 Isoform 1 of Low molecular weight phosphotyrosine 
protein phosphatase IPI00219861 18030.77 6.3 1 41.88 98.92256 41.88 98.92256 6934.492 0 1
 HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 83212.1 4.97 1 29.37 80.79596 29.37 80.79596 9725.499 0 1






























 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 36.01 95.70457 36.01 95.70457 0.341 0 1
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 1 87.27 100 87.27 100 0.391 0 1
 PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 61.72 99.98847 61.72 99.98847 0.417 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 1 62.62 99.99062 62.62 99.99062 0.447 0 1
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 3 158.04 100 63.16 99.99172 0.515 0.128 3
 AGPS Alkyldihydroxyacetonephosphate synthase, peroxisomal precursorIPI00010349 72865.75 6.99 1 29.45 80.54613 29.45 80.54613 0.525 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 43.67 99.26378 43.67 99.26378 0.535 0 1
 SPTA1 Spectrin, alpha, erythrocytic 1 IPI00641363 279501.7 4.95 1 29.80004 82.05259 31.22 87.05786 0.539 0 1
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial precursorIPI00013860 35305.76 8.38 1 55.69 99.95376 55.69 99.95376 0.543 0 1
 RAD23B UV excision repair protein RAD23 homolog B IPI00008223 43144.62 4.79 1 67.48 99.99694 67.48 99.99694 0.545 0 1
 UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondriaIPI00296022 10731.94 4.39 1 107.15 100 107.15 100 0.572 0 1
 TPI1 Isoform 2 of Triosephosphate isomerase IPI00451401 27109.05 8.48 2 131.33 100 73.91 99.9993 0.586 0.016 2
 CUTA Isoform C of Protein CutA precursor IPI00554556 16821.85 5.15 1 46.27004 99.59542 47.69 99.70825 0.628 0 1
 TMEM4 Isoform 1 of MIR-interacting saposin-like protein precursorIPI00443909 20639.17 4.81 1 46.74 99.63692 46.74 99.63692 0.669 0 1
 - 14 kDa protein IPI00788848 13799 5.24 1 108.14 100 109.56 100 0.673 0 1
 HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 13793.09 6.43 1 63.21 99.99182 63.21 99.99182 0.673 0 1
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 81.22 99.99987 81.22 99.99987 0.677 0 1
 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 1 81.79 99.99989 81.79 99.99989 0.693 0 1
 TXNDC4 Thioredoxin domain-containing protein 4 precursor IPI00401264 46941.4 5.09 1 79.73 99.99982 79.73 99.99982 0.698 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 157NT
 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 91.31 100 91.31 100 0.737 0 1
 PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61410.53 6.3 1 64.58 99.99403 64.58 99.99403 1.513 0 1
 SERPINB6 Serpin peptidase inhibitor, clade B (Ovalbumin), member 6IPI00513699 21231.33 6.89 1 51.66 99.88305 51.66 99.88305 1.55 0 1
 HPR Isoform 1 of Haptoglobin-related protein precursor IPI00477597 38982.65 6.42 1 53.67 99.92638 53.67 99.92638 1.559 0 1
 HBB Hemoglobin delta Etolia variant IPI00830113 19482.91 8.32 2 91.72 100 52.96 99.9133 1.565 0.164 2
 GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 45.89 99.55842 45.89 99.55842 1.666 0 1
 HSP90B1 Protein IPI00789430 26539.06 8.95 1 53.06 99.91528 53.06 99.91528 1.679 0 1
 CLGN Calmegin precursor IPI00024776 69994.44 4.58 1 43 99.14097 43 99.14097 1.711 0 1
 TKT Transketolase variant (Fragment) IPI00788802 67862.77 7.9 1 43.84 99.29204 43.84 99.29204 1.829 0 1
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 36.75 96.37752 36.75 96.37752 1.87 0 1
 CDC42 Isoform 2 of Cell division control protein 42 homolog precursorIPI00016786 21245.02 6.15 1 30.69 85.37803 30.69 85.37803 1.923 0 1
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase A IPI00419585 18000.88 7.68 1 49.19 99.79346 49.19 99.79346 1.95 0 1
 FLNA Filamin-A IPI00333541 280563.9 5.7 1 41.56 98.80324 41.56 98.80324 1.961 0 1
 GOT2 Aspartate aminotransferase, mitochondrial precursor IPI00018206 47445.27 9.14 1 76.51 99.99962 76.51 99.99962 2.049 0 1
 ACTN1 Actinin alpha 1 isoform b IPI00759776 105501.7 5.25 1 31.24 87.11732 31.24 87.11732 2.076 0 1
 APOA2 Apolipoprotein A-II precursor IPI00021854 11167.9 6.26 1 108.2 100 108.2 100 2.25 0 1
 ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 IPI00642144 22639.55 5.76 1 61.83 99.98875 61.83 99.98875 2.385 0 1
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 107.42 100 54.79 99.94311 2.437 0.167 2
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 94.8 100 94.8 100 2.606 0 1
 A1BG 41 kDa protein IPI00644018 40692.54 5.5 2 119.93 100 78.47 99.99976 2.626 0.569 2
Poorly Differentiated cICAT Individual Patients
Poor Diff 157NT
 AMBP AMBP protein precursor IPI00022426 38973.98 5.95 1 63.46004 99.99227 64.88 99.99443 2.714 0 1
 NNMT Nicotinamide N-methyltransferase IPI00027681 29555.06 5.56 1 77.62 99.9997 77.62 99.9997 2.743 0 1
 APOH Beta-2-glycoprotein 1 precursor IPI00298828 38272.66 8.34 1 44.36 99.37193 44.36 99.37193 2.761 0 1
 TXNDC5;MUTED thioredoxin domain containing 5 isoform 2 IPI00395646 43641.51 5.77 1 30.39 84.33227 30.39 84.33227 2.779 0 1
 CTSB Cathepsin B precursor IPI00295741 37796.83 5.88 1 68.95 99.99782 68.95 99.99782 2.824 0 1
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 5 404.4301 100 131.08 100 3.153 1.208 5
 FGG Isoform Gamma-A of Fibrinogen gamma chain precursor IPI00219713 49464.97 5.7 1 83.22 99.99992 83.22 99.99992 3.287 0 1
 SULT2A1 Bile salt sulfotransferase IPI00216133 33757.96 5.71 1 55.29 99.9493 55.29 99.9493 3.287 0 1
 STOM Erythrocyte band 7 integral membrane protein IPI00219682 31710.74 7.71 1 42.65 99.06888 42.65 99.06888 3.435 0 1
 TF Transferrin variant (Fragment) IPI00798430 77029.59 6.68 3 209.84 100 101.29 100 3.58 1.754 3
 GC vitamin D-binding protein precursor IPI00742696 52882.94 5.32 2 122.68 100 67.15 99.9967 4.145 0.547 2
 ALB Serum albumin IPI00022434 71529.53 6.33 14 1275.52 100 175.28 100 4.147 3.729 12
 LOC653879 similar to Complement C3 precursor IPI00739237 44900.89 4.94 1 45.08 99.46788 45.08 99.46788 4.278 0 1
 PDIA3 Protein disulfide-isomerase A3 precursor IPI00025252 56746.75 5.98 1 57.55 99.96987 57.55 99.96987 4.298 0 1
 FGB Fibrinogen beta chain precursor IPI00298497 55892.26 8.54 2 142.11 100 91.46 100 4.826 3.793 2
 IGKC IGKC protein IPI00430808 25629.86 6.15 2 174.84 100 105.13 100 4.902 2.918 2
 IGHM IGHM protein IPI00472610 52633.11 7.5 3 252.62 100 92.23 100 5.123 4.386 3
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 23496.76 4.93 1 110.22 100 110.22 100 5.489 0 1
 A2M Alpha-2-macroglobulin precursor IPI00478003 163174.8 6 1 47.45004 99.69168 48.87 99.77767 6.543 0 1
 IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 105.21 100 105.21 100 11.324 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 157NT
 FN1 fibronectin 1 isoform 4 preproprotein IPI00414283 256351.1 5.53 1 43.60004 99.25183 45.02 99.46048 21005.85 0 1






























 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 92.59 100 92.59 100 0 0 1
 CAST calpastatin isoform c IPI00302047 47014.15 4.72 1 54.82 99.94605 54.82 99.94605 0 0 1
 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 1 52.52 99.90839 52.52 99.90839 0 0 1
 NNMT Nicotinamide N-methyltransferase IPI00027681 29555.06 5.56 1 48.01 99.7412 48.01 99.7412 0 0 1
 - ABC1 protein IPI00784697 99637.02 8.07 1 38.22 97.53419 38.22 97.53419 0 0 0
 SELENBP1 53 kDa protein IPI00745729 53027.94 6.03 2 113.07 100 68.12 99.99748 0.008 0.256 2
 IFIT3 Interferon-induced protein with tetratricopeptide repeats 
3 IPI00024254 55949.51 5.12 2 74.04 99.99935 51.32 99.87923 0.009 0.666 2
 HLA-DRA major histocompatibility complex, class II, DR alpha 
precursor IPI00464948 28602.71 4.91 2 104.59 100 61.35 99.98801 0.022 1.417 2
 HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 3 263.16 100 108.96 100 0.046 2.072 3
 OTC Ornithine carbamoyltransferase, mitochondrial precursor IPI00295363 39909.67 8.75 1 54.04 99.93544 54.04 99.93544 0.165 0 1
 HGD Homogentisate 1,2-dioxygenase IPI00303174 49940.59 6.54 1 49.38 99.81122 49.38 99.81122 0.228 0 1
 TAGLN Transgelin IPI00216138 22596.43 8.87 1 49.44 99.81381 49.44 99.81381 0.276 0 1
 ALDOB Fructose-bisphosphate aldolase IPI00513830 24113.34 6.65 1 104.23 100 104.23 100 0.279 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 60.92 99.98676 60.92 99.98676 0.285 0 1
 - 63 kDa protein IPI00792605 62706.83 10.91 1 77.75 99.99973 77.75 99.99973 0.308 0 1
 TPI1 Isoform 1 of Triosephosphate isomerase IPI00465028 30771.7 5.65 5 391.53 100 117.53 100 0.336 8.167 5
 FTH1 Ferritin heavy chain IPI00554521 21212.29 5.3 1 94.4 100 94.4 100 0.36 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 187NT
 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 IPI00012726 70738.09 9.31 1 86.28 100 86.28 100 0.362 0 1
 MGC29506 hypothetical protein LOC51237 IPI00102821 20681.23 5.37 1 122.93 100 122.93 100 0.376 0 1
 SCP2 sterol carrier protein 2 isoform 2 IPI00433347 54380.39 6.25 1 66.31 99.99617 66.31 99.99617 0.439 0 1
 C6orf115 similar to Protein C6orf115 IPI00740277 20388.71 6.38 1 73.62 99.99929 73.62 99.99929 0.44 0 1
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 84.01 99.99993 84.01 99.99993 0.442 0 1
 GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 89.86 100 89.86 100 0.478 0 1
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 52737.86 6.3 1 74.55 99.99943 74.55 99.99943 0.488 0 1
 FABP3 Fatty acid-binding protein, heart IPI00219684 14848.73 6.29 1 47.25004 99.69171 48.67 99.77769 0.501 0 1
 B2M B2M protein IPI00796379 13687.95 6.06 1 107.28 100 107.28 100 0.55 0 1
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 102.82 100 102.82 100 0.561 0 1
 FIS1 Mitochondrial fission 1 protein IPI00007052 16927.02 8.84 1 56.64 99.96452 56.64 99.96452 0.561 0 1
 LOC730278;LOC729659 similar to Putative S100 calcium-
binding protein A11 ps IPI00790691 11279.74 7.77 1 83.07 99.99992 83.07 99.99992 0.565 0 1
 PDLIM1 PDZ and LIM domain protein 1 IPI00010414 36049.04 6.56 1 90.06 100 90.06 100 0.571 0 1
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 1 99.26 100 99.26 100 0.578 0 1
 IQGAP1 Ras GTPase-activating-like protein IQGAP1 IPI00009342 189133.8 6.08 1 48.66005 99.77718 50.08 99.83932 0.595 0 1
 ACTN1 Actinin alpha 1 isoform b IPI00759776 105501.7 5.25 1 43.61004 99.28722 45.03 99.486 0.597 0 1
 - 14 kDa protein IPI00788848 13799 5.24 2 190.51 100 129.76 100 0.617 0.107 2
 IGKC IGKC protein IPI00430808 25629.86 6.15 3 226.49 100 93.77 100 0.648 0.077 3
 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 42.91 99.16255 42.91 99.16255 0.659 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 187NT
 PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 96.41 100 96.41 100 0.662 0 1
 VIM 50 kDa protein IPI00827679 49623.11 5.19 1 107.69 100 107.69 100 0.666 0 1
 SORD Sorbitol dehydrogenase IPI00216057 38271.84 8.23 1 59.93 99.98337 59.93 99.98337 0.682 0 1
 HBB Hemoglobin delta Etolia variant IPI00830113 19482.91 8.32 2 65.67 99.99556 37.49 97.08284 0.688 0.007 2
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 2 128.62 100 69.01 99.99794 0.694 0.015 2
 DDTL D-dopachrome tautomerase-like IPI00472043 14186.27 5.89 1 41.44 98.82521 41.44 98.82521 0.698 0 1
 HP Haptoglobin precursor IPI00641737 46693.35 6.28 1 63.32 99.99238 63.32 99.99238 0.703 0 1
 CBX3;LOC653972 Chromobox protein homolog 3 IPI00297579 20798.35 5.23 1 70.28004 99.99847 71.7 99.99889 1.461 0 1
 NPC2 Epididymal secretory protein E1 precursor IPI00301579 16559.48 7.56 1 80.12 99.99984 80.12 99.99984 1.482 0 1
 PPP1CB Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit IPI00218236 37162.62 5.84 1 45.96 99.58508 45.96 99.58508 1.506 0 1
 LOC131691 similar to peptidylprolyl isomerase A isoform 1 IPI00741973 18098.81 6.41 1 39.15 98.00951 39.15 98.00951 1.506 0 1
 GLG1 79 kDa protein IPI00647145 79265.84 6.13 1 39.69004 98.24226 41.11 98.73246 1.543 0 1
 HNRPR HNRPR protein IPI00644055 71170.4 8.23 2 100.87 100 53.56 99.9279 1.551 0.145 2
 SYNCRIP Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00402182 65641.59 8.69 2 100.87 100 53.56 99.9279 1.551 0.145 2
 ALB Serum albumin IPI00022434 71529.53 6.33 14 839.7489 100 122.78 100 1.578 0.565 12
 MTPN Myotrophin IPI00179589 12886.6 5.27 1 105.3 100 105.3 100 1.599 0 1
 TF Transferrin variant (Fragment) IPI00798430 77029.59 6.68 6 332.8101 100 109.12 100 1.618 0.446 6
 FLJ11286 FLJ11286 protein IPI00383563 28987.22 6.47 2 72.21 99.99902 44.92 99.47282 1.633 0.169 2
 HNRPF Heterogeneous nuclear ribonucleoprotein F IPI00003881 45642.85 5.38 1 61.8 99.98919 61.8 99.98919 1.634 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 187NT
 PEPD Xaa-Pro dipeptidase IPI00257882 54512.91 5.64 1 60.85 99.98654 60.85 99.98654 1.646 0 1
 PTER Phosphotriesterase-related protein IPI00100933 38993.01 6.07 1 37.19 96.87421 37.19 96.87421 1.658 0 1
 APOD Apolipoprotein D precursor IPI00006662 21261.76 5.06 1 75.34 99.99952 75.34 99.99952 1.698 0 1
 - 11 kDa protein IPI00382841 11283.54 5.82 2 57.39 99.97015 32.66 91.12926 1.71 0.152 2
 - 12 kDa protein IPI00797738 12027.62 6.81 3 261.62 100 118.76 100 1.728 0.278 3
 CANX Calnexin precursor IPI00020984 67525.85 4.47 2 101.3 100 60.62 99.98581 1.756 0.088 2
 COMT Isoform Soluble of Catechol O-methyltransferase IPI00375513 24433.38 5.15 2 149.32 100 86.62 100 1.77 0.31 2
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 23496.76 4.93 2 176.62 100 104.11 100 1.785 0.182 2
 - 29 kDa protein IPI00411329 29377.25 9.14 2 108 100 70.74 99.99862 1.799 0.052 2
 DCPS Scavenger mRNA-decapping enzyme DcpS IPI00335385 38585.02 5.93 1 58.5 99.97688 58.5 99.97688 1.802 0 1
 PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 72.84 99.99915 72.84 99.99915 1.814 0 1
 ABAT 4-aminobutyrate aminotransferase, mitochondrial 
precursor IPI00009532 56402.59 8.17 2 162.2101 100 120.05 100 1.873 0.738 2
 PPP1CA protein phosphatase 1, catalytic subunit, alpha 
isoform 3 IPI00027423 38606.37 6.2 2 150.06 100 87.25 100 1.914 0.029 2
 HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 13793.09 6.43 1 87.67 100 87.67 100 2.044 0 1
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41324.39 6.47 1 71.56 99.99886 71.56 99.99886 2.071 0 1
 HNRPH2 Heterogeneous nuclear ribonucleoprotein H' IPI00026230 49232.29 5.89 1 61.04 99.98712 61.04 99.98712 2.095 0 1
 HSPA1A;HSPA1B Heat shock 70kDa protein 1A IPI00647012 51914.69 5.35 3 161.12 100 83.21 99.99992 2.097 0.513 3
 RBP4 Retinol binding protein 4, plasma IPI00480192 22929.13 5.77 1 65.87005 99.99576 67.29 99.99695 2.188 0 1
 - 14 kDa protein IPI00455040 14347.57 8.86 1 109.44 100 109.44 100 2.198 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 187NT
 OS9 33 kDa protein IPI00793206 32504.35 7.63 1 52.72 99.91251 52.72 99.91251 2.215 0 1
 SSB Lupus La protein IPI00009032 46808.16 6.68 1 108.34 100 108.34 100 2.274 0 1
 VCP 89 kDa protein IPI00843748 89270.64 5.11 1 72.53004 99.99909 73.95 99.99934 2.312 0 1
 CD59 CD59 glycoprotein precursor IPI00011302 14167.79 6.02 1 74.82 99.99946 74.82 99.99946 2.33 0 1
 PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 72886.97 4.96 2 165.46 100 84.08 99.99994 2.331 0.925 2
 EEF1G;LOC729998 similar to Elongation factor 1-gamma IPI00738381 50270.31 7.09 1 57.24 99.9691 57.24 99.9691 2.374 0 1
 ALDOA 45 kDa protein IPI00796333 45232.14 8.48 1 74.09 99.99936 74.09 99.99936 2.433 0 1
 ATOX1 Copper transport protein ATOX1 IPI00010863 7396.73 6.71 2 115.5 100 78.21 99.99975 2.484 0.684 2
 CUTA Isoform C of Protein CutA precursor IPI00554556 16821.85 5.15 1 62.19 99.99012 62.19 99.99012 2.492 0 1
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 2 179.01 100 103.17 100 2.566 0.018 2
 PML promyelocytic leukemia protein isoform 10 IPI00181058 64995.65 5.19 1 42.53004 99.08598 43.95 99.34089 2.611 0 1
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 106.29 100 106.29 100 2.795 0 1
 GLUD2 Glutamate dehydrogenase 2, mitochondrial precursor IPI00027146 61395.43 8.63 1 72.87942 99.99916 75.13 99.9995 2.96 0 1
 CPOX Coproporphyrinogen III oxidase, mitochondrial 
precursor IPI00093057 50119.97 8.59 1 60.34004 99.98487 61.76 99.98909 3.025 0 1
 TMEM4 Isoform 1 of MIR-interacting saposin-like protein 
precursor IPI00443909 20639.17 4.81 2 149.64 100 117.8 100 3.244 0.273 2
 SFRS6 Isoform SRP55-3 of Splicing factor, arginine/serine-rich 
6 IPI00215879 38395.63 11.01 1 40.4 98.50734 40.4 98.50734 3.525 0 1
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 1 58.47 99.97672 58.47 99.97672 3.905 0 1
 HMGB3 Non-histone chromosomal protein IPI00411540 17511 9.8 2 104.31 100 63.55 99.99277 4.124 1.707 2
 PLA2G12B Group XIIB secretory phospholipase A2-like 
protein precursor IPI00000240 21644.24 5.75 1 42.84 99.14894 42.84 99.14894 4.392 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 187NT
 HMGB1 High-mobility group box 1 IPI00644653 18299.33 9.72 2 140.49 100 75.11 99.9995 4.43 1.401 2
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase 
A IPI00419585 18000.88 7.68 3 268.27 100 129.9 100 17.831 593.948 3
 CTSZ CTSZ protein (Fragment) IPI00448792 33540.65 9.43 2 66.7 99.9965 39.59 98.20129 52.63 1454.771 2
 APOH Beta-2-glycoprotein 1 precursor IPI00298828 38272.66 8.34 2 61.35 99.98801 37.96 97.38206 102.734 4470.551 2
 RNH1 Ribonuclease/angiogenin inhibitor IPI00783491 49839.99 4.68 2 105.98 100 56.18 99.96056 104.433 3151.618 2
 FN1 fibronectin 1 isoform 4 preproprotein IPI00414283 256351.1 5.53 2 147.98 100 80.38 99.99985 116.699 5205.885 2
 CTSD 33 kDa protein IPI00852597 32543.31 5.88 4 335.28 100 107.84 100 120.467 3899.161 4
 FLJ11151 Hypothetical protein FLJ11151 IPI00305010 35525.88 5.78 2 209.39 100 124.35 100 153.946 6667.232 2
 GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 1 95.05 100 95.05 100 2111.703 0 1
 SFRS4 Splicing factor, arginine/serine-rich 4 IPI00000015 56645.27 11.52 1 39.4 98.12086 39.4 98.12086 2593.756 0 1
 TXN2 Thioredoxin, mitochondrial precursor IPI00017799 21811.28 8.85 1 44.86 99.46548 44.86 99.46548 3108.837 0 1
 TRIM28 Isoform 2 of Transcription intermediary factor 1-beta IPI00438230 79423.48 5.67 1 48.71 99.77973 48.71 99.77973 3132.645 0 1
 PPA1 Pyrophosphatase (Inorganic) 1 IPI00643288 19968.92 5.07 1 56.62 99.96436 56.62 99.96436 3643.519 0 1
 ITGB4BP Eukaryotic translation initiation factor 6 IPI00010105 26582.19 4.56 1 69.75 99.99827 69.75 99.99827 4020.212 0 1
 TIMM8B Mitochondrial import inner membrane translocase 
subunit Tim8 B IPI00001546 9337.54 5.02 1 108.12 100 108.12 100 4266.774 0 1
 LOC641827;LOC649440 Similar to eukaryotic translation 
elongation factor 1 b IPI00397392 24875.39 4.66 1 81.33 99.99988 81.33 99.99988 4544.575 0 1
 LGALS3BP 16 kDa protein IPI00794873 16452.93 5.74 1 60.52 99.98548 60.52 99.98548 4677.497 0 1
 PSAP Prosaposin IPI00219825 61651.56 5.11 1 75.9 99.99958 75.9 99.99958 5529.873 0 1
 PDIA6 Isoform 1 of Protein disulfide-isomerase A6 precursor IPI00644989 48091.26 4.95 1 120.75 100 120.75 100 7249.579 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 187NT
 GRN Isoform 1 of Granulins precursor IPI00296713 63499.84 6.43 1 54.04 99.93544 54.04 99.93544 8801.206 0 1






























 ABAT 4-aminobutyrate aminotransferase, mitochondrial 
precursor IPI00009532 56402.59 8.17 3 277.44 100 101.41 100 0 0 3
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 2 126 100 82.1 99.9999 0 0 2
 ALDOB Fructose-bisphosphate aldolase IPI00513830 24113.34 6.65 1 147 100 147 100 0 0 1
 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 99.97 100 99.97 100 0 0 1
 PNPO 19 kDa protein IPI00793232 19465.84 6.92 1 86.91 100 86.91 100 0 0 1
 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 1 84.42 99.99994 84.42 99.99994 0 0 1
 - 63 kDa protein IPI00792605 62706.83 10.91 1 76.76 99.99967 76.76 99.99967 0 0 1
 FTH1 Ferritin heavy chain IPI00554521 21212.29 5.3 1 62.72 99.99159 62.72 99.99159 0 0 1
 SHMT1 14 kDa protein IPI00008665 14332.98 5.62 1 50.16 99.84839 50.16 99.84839 0 0 1
 GATM Isoform Cytoplasmic of Glycine amidinotransferase, 
mitochondrial precu IPI00216279 44854.47 6.61 1 46.2 99.62267 46.2 99.62267 0 0 1
 PRDX6 Peroxiredoxin-6 IPI00220301 25019.19 6 1 40.65 98.6457 40.65 98.6457 0 0 1
 SORD Sorbitol dehydrogenase IPI00216057 38271.84 8.23 1 40.38 98.55883 40.38 98.55883 0 0 1
 GSTZ1 glutathione transferase zeta 1 isoform 2 IPI00157928 19360.02 8.27 1 36.56 96.52691 36.56 96.52691 0 0 1
 C6orf115 similar to Protein C6orf115 IPI00740277 20388.71 6.38 1 53.51 99.9299 53.51 99.9299 0.001 0 1
 GRHPR GRHPR protein (Fragment) IPI00550682 36801.01 5.95 2 117.23 100 78.4 99.99977 0.005 0.089 2
 SELENBP1 53 kDa protein IPI00745729 53027.94 6.03 2 155.88 100 124.13 100 0.006 0.099 2
 HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 2 188.14 100 106.58 100 0.013 1.085 2
 COMT Isoform Soluble of Catechol O-methyltransferase IPI00375513 24433.38 5.15 3 178.11 100 80.78 99.99987 0.02 0.526 3
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 3 194.71 100 98.65 100 0.047 1.822 3
Poorly Differentiated cICAT Individual Patients
Poor Diff 207NT
 BHMT2 Betaine--homocysteine S-methyltransferase 2 IPI00014363 40328.18 5.61 1 68.72 99.99789 68.72 99.99789 0.06 0 1
 DAK Dihydroxyacetone kinase IPI00551024 58940.04 7.12 1 43.23 99.25232 43.23 99.25232 0.113 0 1
 OTC Ornithine carbamoyltransferase, mitochondrial precursor IPI00295363 39909.67 8.75 1 44.73 99.47068 44.73 99.47068 0.148 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 74.49 99.99944 74.49 99.99944 0.212 0 1
 CAT Catalase IPI00465436 59718.75 6.9 1 55.09004 99.95128 56.51 99.96487 0.261 0 1
 GLUD2 Glutamate dehydrogenase 2, mitochondrial precursor IPI00027146 61395.43 8.63 1 52.18 99.90478 52.18 99.90478 0.293 0 1
 DDTL D-dopachrome tautomerase-like IPI00472043 14186.27 5.89 1 45.59 99.56577 45.59 99.56577 0.306 0 1
 C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 1 133.14 100 133.14 100 0.312 0 1
 PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61410.53 6.3 1 92.43 100 92.43 100 0.317 0 1
 PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 68.46 99.99776 68.46 99.99776 0.345 0 1
 HP Haptoglobin precursor IPI00641737 46693.35 6.28 2 155.35 100 79.87 99.99984 0.349 0.022 2
 P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 2 138.1 100 71.71 99.99894 0.354 0.284 2
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 88.1 100 88.1 100 0.389 0 1
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 52737.86 6.3 1 63.84 99.9935 63.84 99.9935 0.412 0 1
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 1 71.31 99.99884 71.31 99.99884 0.432 0 1
 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 110.42 100 110.42 100 0.434 0 1
 ATOX1 Copper transport protein ATOX1 IPI00010863 7396.73 6.71 1 39.63 98.28716 39.63 98.28716 0.482 0 1
 C6orf108 putative c-Myc-responsive isoform 2 IPI00395835 16177.23 6.31 1 47.23 99.70234 47.23 99.70234 0.506 0 1
 FIS1 Mitochondrial fission 1 protein IPI00007052 16927.02 8.84 1 49.61 99.82793 49.61 99.82793 0.513 0 1
 GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 1 95.3 100 95.3 100 0.523 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 207NT
 AKR1C3 Aldo-keto reductase family 1 member C3 IPI00291483 36820.84 8.05 1 36.95 96.8252 36.95 96.8252 0.534 0 1
 SAR1B GTP-binding protein SAR1b IPI00002149 22395.51 5.76 1 36.37 96.37159 36.37 96.37159 0.565 0 1
 - 29 kDa protein IPI00791859 28830.89 5.65 1 44.18 99.39922 44.18 99.39922 0.596 0 1
 CRYZ 32 kDa protein IPI00647366 31508.5 8.59 2 99.84 100 64.46 99.99437 0.597 0.032 2
 PDLIM1 PDZ and LIM domain protein 1 IPI00010414 36049.04 6.56 1 82.8 99.99992 82.8 99.99992 0.597 0 1
 - 12 kDa protein IPI00797738 12027.62 6.81 2 97.3 100 70.59 99.99863 0.628 0.084 2
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 132.96 100 73.11 99.99923 0.643 0.141 2
 HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 13793.09 6.43 1 81.29 99.99988 81.29 99.99988 0.651 0 1
 GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 74.49 99.99944 74.49 99.99944 0.651 0 1
 NDUFS5 NADH dehydrogenase [ubiquinone] iron-sulfur protein 
5 IPI00220063 12509.39 9.27 1 41.5 98.88643 41.5 98.88643 0.657 0 1
 B2M B2M protein IPI00796379 13687.95 6.06 1 76.28 99.99963 76.28 99.99963 0.666 0 1
 UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa 
protein, mitochondria IPI00296022 10731.94 4.39 1 106.17 100 106.17 100 0.667 0 1
 C1orf123 Uncharacterized protein C1orf123 IPI00016605 18036.81 4.93 1 39.25 98.13054 39.25 98.13054 0.668 0 1
 PRDM10 CDNA FLJ20227 fis, clone COLF5152 IPI00386081 105524.9 8.83 2 162.31 100 91.81 100 0.7 0.06 2
 PXN Isoform Beta of Paxillin IPI00335634 64491.84 5.73 1 57.06004 99.96905 58.48 99.97768 0.701 0 1
 CTSB Cathepsin B precursor IPI00295741 37796.83 5.88 1 98.13 100 98.13 100 0.707 0 1
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 1 35.58 95.64773 35.58 95.64773 1.465 0 1
 GC vitamin D-binding protein precursor IPI00742696 52882.94 5.32 1 56.04 99.96085 56.04 99.96085 1.499 0 1
 HGD Homogentisate 1,2-dioxygenase IPI00303174 49940.59 6.54 1 46.57 99.65349 46.57 99.65349 1.539 0 1
 RHOA Transforming protein RhoA precursor IPI00027500 21754.07 5.83 1 54.66 99.94621 54.66 99.94621 1.541 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 207NT
 HNRPR HNRPR protein IPI00644055 71170.4 8.23 2 86.74 100 51.17 99.87985 1.542 0.057 2
 SYNCRIP Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00402182 65641.59 8.69 2 86.74 100 51.17 99.87985 1.542 0.057 2
 TXNDC5;MUTED thioredoxin domain containing 5 isoform 2 IPI00395646 43641.51 5.77 1 41.55 98.89918 41.55 98.89918 1.548 0 1
 GRN Isoform 1 of Granulins precursor IPI00296713 63499.84 6.43 1 75.54 99.99956 75.54 99.99956 1.612 0 1
 PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 93.11 100 93.11 100 1.615 0 1
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase A IPI00419585 18000.88 7.68 2 119.5 100 60.64 99.98643 1.617 0.028 2
 SAR1A SAR1 gene homolog A IPI00644667 13653.07 6.49 1 60.44 99.98579 60.44 99.98579 1.675 0 1
 HSPD1 60 kDa heat shock protein, mitochondrial precursor IPI00784154 61016.38 5.7 2 162.23 100 100.16 100 1.742 0.149 2
 FUBP1 Isoform 2 of Far upstream element-binding protein 1 IPI00644386 68861.11 7.74 1 70.28 99.99853 70.28 99.99853 1.841 0 1
 HSP90B1 Protein IPI00789430 26539.06 8.95 1 122.38 100 122.38 100 1.848 0 1
 RAD23A UV excision repair protein RAD23 homolog A IPI00008219 39584.65 4.56 1 65.12 99.99516 65.12 99.99516 1.95 0 1
 LYPLA1 Isoform 2 of Acyl-protein thioesterase 1 IPI00398727 22860.58 6.05 1 36.43 96.42137 36.43 96.42137 2.001 0 1
 CLGN Calmegin precursor IPI00024776 69994.44 4.58 1 70.82 99.9987 70.82 99.9987 2.065 0 1
 FLJ14668 Hypothetical protein FLJ14668 IPI00303722 15630.66 7.56 1 48.94 99.79922 48.94 99.79922 2.229 0 1
 CBX3;LOC653972 Chromobox protein homolog 3 IPI00297579 20798.35 5.23 1 38.62004 97.83872 40.04 98.44147 2.334 0 1
 AKR1C1 Aldo-keto reductase family 1 member C1 IPI00029733 36765.02 8.02 1 50.99 99.87477 50.99 99.87477 2.383 0 1
 HMGB2 High mobility group protein B2 IPI00219097 24018.73 7.62 1 80.39 99.99986 80.39 99.99986 2.912 0 1
 SSB Lupus La protein IPI00009032 46808.16 6.68 1 102.7 100 102.7 100 3.093 0 1
 PAH Phenylalanine-4-hydroxylase IPI00017579 51829.46 6.15 1 87.09 100 87.09 100 3.104 0 1
 PDIA6 Isoform 1 of Protein disulfide-isomerase A6 precursor IPI00644989 48091.26 4.95 1 144.36 100 144.36 100 3.283 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 207NT
 TKT Transketolase variant (Fragment) IPI00788802 67862.77 7.9 1 52.64 99.91435 52.64 99.91435 3.356 0 1
 LOC646993 similar to high-mobility group box 3 IPI00376756 23728.83 8.94 1 66.36 99.99636 66.36 99.99636 4.214 0 1
 ALDOA 45 kDa protein IPI00796333 45232.14 8.48 1 52.41 99.90969 52.41 99.90969 5.64 0 1
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 70.34005 99.99855 71.76 99.99895 8.625 0 1
 IGHM IGHM protein IPI00472610 52633.11 7.5 3 198.07 100 87.67 100 22.746 838.009 3
 F2 70 kDa protein IPI00784409 69916.09 5.64 2 104.61 100 60.55 99.98614 135.449 5127.253 2
 UCHL1 16 kDa protein IPI00657702 15680.62 5.19 1 72.6 99.99914 72.6 99.99914 3093.871 0 1
 OAT Ornithine aminotransferase, mitochondrial precursor IPI00022334 48504.2 6.57 2 97.7 100 67.63 99.99729 3138.444 187.339 2
 BCAT2 Isoform A of Branched-chain-amino-acid 
aminotransferase, mitochondria IPI00396258 44259.06 8.88 1 41.45 98.87354 41.45 98.87354 3273.891 0 1
 C1QBP Protein IPI00795465 20360.71 4.1 1 113.88 100 113.88 100 4788.718 0 1
 LTF 73 kDa protein IPI00789477 73114.24 8.2 2 58.93005 99.97988 35.22 95.27158 4837.229 1249.721 2
 - Hypothetical protein DKFZp686M24218 IPI00784998 52387.11 7.89 1 82.47 99.99991 82.47 99.99991 5866.472 0 1
 FN1 Isoform 12 of Fibronectin precursor IPI00556632 221308.4 5.84 3 245.1195 100 106.7 100 6050.422 4977.344 3
 MMP9 Matrix metalloproteinase-9 precursor IPI00027509 78377.35 5.69 1 62.44 99.99103 62.44 99.99103 7784.208 0 1
 PRTN3 Myeloblastin precursor IPI00027409 27789.27 8.72 1 124.76 100 124.76 100 19980.05 0 1






























 ALDOB Fructose-bisphosphate aldolase IPI00513830 24113.34 6.65 1 139.09 100 139.09 100 0 0 1
 DCXR 26 kDa protein IPI00797249 25726.45 8.33 1 83.54005 99.99993 84.96 99.99995 0 0 1
 PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61410.53 6.3 1 79.15 99.9998 79.15 99.9998 0 0 1
 AKR1D1 CDNA FLJ25413 fis, clone TST03402, highly similar 
to 3-OXO-5-BETA- S IPI00065073 30242.66 8.11 1 79.1 99.9998 79.1 99.9998 0 0 1
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 30355.86 8.55 1 55.56 99.955 55.56 99.955 0 0 1
 GATM Isoform Cytoplasmic of Glycine amidinotransferase, 
mitochondrial precu IPI00216279 44854.47 6.61 1 53.98 99.93526 53.98 99.93526 0 0 1
 CHDH Choline dehydrogenase, mitochondrial precursor IPI00168603 65360.13 8.67 1 43.95004 99.34808 45.37 99.52989 0 0 1
 SUOX 54 kDa protein IPI00853137 53851.08 5.35 1 37.61 97.19329 37.61 97.19329 0 0 1
 CAT Catalase IPI00465436 59718.75 6.9 1 36.01004 95.9431 37.43 97.07451 0 0 1
 COQ9 36 kDa protein IPI00746245 35945.65 5.42 1 31.98 89.7388 31.98 89.7388 0 0 1
 TAGLN Transgelin IPI00216138 22596.43 8.87 1 30.26 84.75251 30.26 84.75251 0 0 1
 ECHS1 Enoyl-CoA hydratase, mitochondrial precursor IPI00024993 31367.13 8.34 1 68.45 99.99769 68.45 99.99769 0.001 0 1
 GSTZ1 glutathione transferase zeta 1 isoform 2 IPI00157928 19360.02 8.27 1 44.92 99.47857 44.92 99.47857 0.001 0 1
 TST Thiosulfate sulfurtransferase IPI00216293 33407.84 6.77 1 53.61 99.9295 53.61 99.9295 0.119 0 1
 PNPO 19 kDa protein IPI00793232 19465.84 6.92 1 79.31 99.99981 79.31 99.99981 0.125 0 1
 ABAT 4-aminobutyrate aminotransferase, mitochondrial 
precursor IPI00009532 56402.59 8.17 1 100.91 100 100.91 100 0.14 0 1
 GALM Aldose 1-epimerase IPI00060200 37742.13 6.18 1 51.67 99.8898 51.67 99.8898 0.151 0 1
 COMT Isoform Soluble of Catechol O-methyltransferase IPI00375513 24433.38 5.15 1 62.41 99.99071 62.41 99.99071 0.178 0 1
 SORD Sorbitol dehydrogenase IPI00216057 38271.84 8.23 1 67.71 99.99726 67.71 99.99726 0.184 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 215NT
 SOD1 Superoxide dismutase IPI00783680 15925.9 5.7 1 119.95 100 119.95 100 0.23 0 1
 GOT2 Aspartate aminotransferase, mitochondrial precursor IPI00018206 47445.27 9.14 1 90.98 100 90.98 100 0.288 0 1
 BLVRB Flavin reductase IPI00783862 22105.43 7.13 1 35.68 95.62278 35.68 95.62278 0.311 0 1
 HPR Isoform 1 of Haptoglobin-related protein precursor IPI00477597 38982.65 6.42 1 40.28 98.48226 40.28 98.48226 0.362 0 1
 AKR1A1 Aldo-keto reductase family 1, member A1 IPI00647702 16506.3 5.84 1 83.06 99.99992 83.06 99.99992 0.423 0 1
 C6orf115 similar to Protein C6orf115 IPI00740277 20388.71 6.38 1 40.23 98.46468 40.23 98.46468 0.45 0 1
 SCP2 sterol carrier protein 2 isoform 2 IPI00433347 54380.39 6.25 1 78.04 99.99975 78.04 99.99975 0.464 0 1
 AK2 Isoform 1 of Adenylate kinase isoenzyme 2, mitochondrial IPI00215901 26460.77 7.67 1 48.78 99.78561 48.78 99.78561 0.465 0 1
 SHMT1 14 kDa protein IPI00008665 14332.98 5.62 1 79.84 99.99983 79.84 99.99983 0.482 0 1
 C11orf54 Isoform 4 of Ester hydrolase C11orf54 IPI00760666 23158.41 6.3 1 106.56 100 106.56 100 0.511 0 1
 ORM2 Alpha-1-acid glycoprotein 2 precursor IPI00020091 23587.63 5.03 1 51.92004 99.89596 53.34 99.92498 0.512 0 1
 ARG1 Isoform 1 of Arginase-1 IPI00291560 34713.3 6.72 1 54.35 99.94054 54.35 99.94054 0.524 0 1
 B2M B2M protein IPI00796379 13687.95 6.06 1 86.21 100 86.21 100 0.547 0 1
 PGAM1;hCG_2015138;hCG_2015269 Phosphoglycerate 
mutase 1 IPI00549725 28785.83 6.67 1 46.22 99.61346 46.22 99.61346 0.58 0 1
 HCLS1 Hematopoietic lineage cell-specific protein IPI00026156 53964.98 4.74 1 75.49 99.99954 75.49 99.99954 0.589 0 1
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41324.39 6.47 1 103.96 100 105.38 100 0.625 0 1
 - 14 kDa protein IPI00788848 13799 5.24 1 122.62 100 124.04 100 0.629 0 1
 PCBD1 Pterin-4-alpha-carbinolamine dehydratase IPI00218568 11992.02 6.28 1 35.87 95.81015 35.87 95.81015 0.632 0 1
 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 
precursor IPI00013860 35305.76 8.38 1 65.78 99.99572 65.78 99.99572 0.664 0 1
 HBB Hemoglobin subunit beta IPI00654755 15988.29 6.75 3 287.9 100 118.13 100 0.673 0.051 3
 PARK7 Protein DJ-1 IPI00298547 19878.49 6.33 1 97.9 100 97.9 100 0.692 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 215NT
 ATOX1 Copper transport protein ATOX1 IPI00010863 7396.73 6.71 1 41.46004 98.84337 42.88 99.16594 0.694 0 1
 P4HB Protein disulfide-isomerase precursor IPI00010796 57080.67 4.76 1 65.66 99.9956 65.66 99.9956 1.462 0 1
 LOC389842 similar to Ran-specific GTPase-activating protein IPI00399212 35001.84 8.76 1 45.09942 99.49967 47.35 99.70201 1.479 0 1
 HPX Hemopexin precursor IPI00022488 51643.27 6.55 3 125.66 100 58.71 99.97821 1.499 0.251 3
 IGHA1 SNC66 protein IPI00383164 53631.38 6.22 1 90.46 100 90.46 100 1.51 0 1
 METAP2 CDNA FLJ34411 fis, clone HEART2002220, highly 
similar to METHIONINE IPI00300763 50477.81 5.2 1 31.22 87.77642 31.22 87.77642 1.611 0 1
 HSP90B1 Protein IPI00789430 26539.06 8.95 1 105.19 100 105.19 100 1.66 0 1
 TXNDC4 Thioredoxin domain-containing protein 4 precursor IPI00401264 46941.4 5.09 1 83.69005 99.99993 85.11 100 1.678 0 1
 CTSD 21 kDa protein IPI00658053 21476.66 5.48 2 115.58 100 66.13 99.99605 1.7 0.153 2
 TKT Transketolase variant (Fragment) IPI00788802 67862.77 7.9 1 50.18 99.84469 50.18 99.84469 1.731 0 1
 CALR 37 kDa protein IPI00793605 36679.71 4.55 2 155.73 100 80.11 99.99984 1.754 0.429 2
 CUTA Isoform C of Protein CutA precursor IPI00554556 16821.85 5.15 1 35.64 95.58228 35.64 95.58228 1.778 0 1
 LOC440055 similar to ribosomal protein S12 IPI00456898 14588.54 6.43 1 78.31 99.99976 78.31 99.99976 1.793 0 1
 IGHM IGHM protein IPI00472610 52633.11 7.5 3 225.59 100 85.19 100 1.854 0.656 3
 PDIA6 Isoform 1 of Protein disulfide-isomerase A6 precursor IPI00644989 48091.26 4.95 1 125.06 100 125.06 100 1.864 0 1
 SPTBN1 275 kDa protein IPI00794135 274658.8 5.39 1 42.8 99.15043 42.8 99.15043 1.871 0 1
 RAD23A UV excision repair protein RAD23 homolog A IPI00008219 39584.65 4.56 1 45.24 99.51561 45.24 99.51561 1.888 0 1
 RNF113A RING finger protein 113A IPI00007343 38762.6 5.51 1 31.13 87.52047 31.13 87.52047 1.908 0 1
 EIF1 Eukaryotic translation initiation factor 1 IPI00015077 12724.56 6.89 1 32.68 91.2663 32.68 91.2663 1.922 0 1
 HSP90AA1 Hsp89-alpha-delta-N IPI00604607 63211.62 5.03 1 58.22 99.97561 58.22 99.97561 1.95 0 1
 GPX1 16 kDa protein IPI00784231 16180.13 5.39 1 39.36 98.12415 39.36 98.12415 2.112 0 1
Poorly Differentiated cICAT Individual Patients
Poor Diff 215NT
 FAM10A4 Protein FAM10A4 IPI00218038 27389.69 5.01 1 91.75 100 91.75 100 2.209 0 1
 HNRPF Heterogeneous nuclear ribonucleoprotein F IPI00003881 45642.85 5.38 1 66.74 99.99657 66.74 99.99657 2.249 0 1
 - 14 kDa protein IPI00455040 14347.57 8.86 1 105.49 100 105.49 100 2.273 0 1
 LOC131691 similar to peptidylprolyl isomerase A isoform 1 IPI00741973 18098.81 6.41 1 47.8 99.73134 47.8 99.73134 2.311 0 1
 APOH Beta-2-glycoprotein 1 precursor IPI00298828 38272.66 8.34 2 91.37 100 48.84 99.78855 2.325 1.014 2
 SSB Lupus La protein IPI00009032 46808.16 6.68 1 111.45 100 111.45 100 2.409 0 1
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-trans isomerase 
A IPI00419585 18000.88 7.68 3 228.89 100 131.94 100 2.467 0.131 3
 SPTAN1 283 kDa protein IPI00744706 283049.5 5.24 1 31.77 89.23043 31.77 89.23043 2.501 0 1
 RAB21 Ras-related protein Rab-21 IPI00007755 24332.25 8.11 1 47.75 99.72823 47.75 99.72823 2.551 0 1
 PPP1CA protein phosphatase 1, catalytic subunit, alpha 
isoform 3 IPI00027423 38606.37 6.2 1 31.64 88.90318 31.64 88.90318 2.689 0 1
 - Glucose phosphate isomerase IPI00848316 63079.21 8.43 1 42.5 99.08967 42.5 99.08967 2.987 0 1
 GRN Isoform 1 of Granulins precursor IPI00296713 63499.84 6.43 1 34.64 94.43842 34.64 94.43842 2.987 0 1
 ERH Enhancer of rudimentary homolog IPI00029631 12251 5.63 1 91.13 100 91.13 100 3.077 0 1
 SYNCRIP Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00402182 65641.59 8.69 1 38.4 97.6601 38.4 97.6601 3.337 0 1
 HNRPR HNRPR protein IPI00644055 71170.32 8.23 1 38.4 97.6601 38.4 97.6601 3.337 0 1
 CBX3;LOC653972 Chromobox protein homolog 3 IPI00297579 20798.35 5.23 1 41.42004 98.83267 42.84 99.15822 3.467 0 1
 TES Isoform 2 of Testin IPI00216425 46878.3 7.82 1 33.35 92.51489 33.35 92.51489 3.676 0 1
 QSOX1 Isoform 2 of Sulfhydryl oxidase 1 precursor IPI00465016 66818.34 8.85 1 36.91 96.7024 36.91 96.7024 4.003 0 1
 NPC2 Epididymal secretory protein E1 precursor IPI00301579 16559.48 7.56 1 103.07 100 103.07 100 4.042 0 1
 - Actinin alpha4 isoform IPI00845465 59542.11 4.82 2 100.85 100 55.89 99.95829 78.278 2818.645 2
 GC vitamin D-binding protein precursor IPI00742696 52882.94 5.32 2 132.76 100 75.71 99.99957 79.725 2672.351 2
Poorly Differentiated cICAT Individual Patients
Poor Diff 215NT
 UFC1 Ufm1-conjugating enzyme 1 IPI00294495 19446.02 6.9 2 75.37 99.99953 38.45 97.68688 86.823 1482.113 2
 FN1 fibronectin 1 isoform 4 preproprotein IPI00414283 256351.1 5.53 2 119.8 100 75.17 99.99951 114.055 1540.07 2
 AFP Alpha-fetoprotein precursor IPI00022443 68632.99 5.48 1 56.98 99.96755 56.98 99.96755 1259.6 0 1
 - 29 kDa protein IPI00411329 29377.25 9.14 1 41.79 98.92799 41.79 98.92799 2161.134 0 1
 F2 70 kDa protein IPI00784409 69916.09 5.64 1 75.09005 99.9995 76.51 99.99964 2389.757 0 1
 BCAT2 Isoform A of Branched-chain-amino-acid 
aminotransferase, mitochondria IPI00396258 44259.06 8.88 1 75.13 99.9995 75.13 99.9995 4244.754 0 1
 UCHL1 16 kDa protein IPI00657702 15680.62 5.19 1 114.95 100 114.95 100 7205.28 0 1
 FTL Ferritin light chain IPI00852596 20007.1 5.51 1 72.98 99.99918 72.98 99.99918 7712.681 0 1





























 POSTN Isoform 2 of Periostin precursor IPI00218585 96544.46875 7.87 1 72.84999847 99.99949111 72.84999847 99.99949111 24.73917341 0 1
 COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 1 94.27999878 100 94.27999878 100 13.94230409 0 1
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 3 199.3300018 100 85.90000153 100 8.586292956 5.86325591 3
 PRELP Prolargin precursor IPI00020987 46264.33984 9.47 4 194.1799927 100 52.11999893 99.93979572 7.653537067 1.69200739 4
 LUM 23 kDa protein IPI00794403 25919.60938 8.52 2 117.8000031 100 83.20999908 100 6.796665649 1.2258881 2
 BGN CDNA FLJ35635 fis, clone 
SPLEN2011805, highly similar to 
BONE/CARTILAGE
IPI00385748 39528 6.31 3 209.9899902 100 95.19999695 100 6.215801838 1.66310797 3
 TAGLN Transgelin IPI00216138 25234.73047 8.87 3 131.3200073 100 52.47000122 99.94445728 5.633770241 0.56875397 3
 SERPINA1 Alpha-1-antitrypsin precursor IPI00553177 51885.51172 5.37 5 290.7799988 100 92.73999786 100 5.39849275 2.35972142 5
 HBB Hemoglobin subunit beta IPI00654755 17808.5 6.75 12 1000.98999 100 138.6000061 100 5.232844264 1.52721961 21
 HBD;HBB Hemoglobin subunit delta IPI00473011 17865.5 7.85 9 700.250061 100 122.2799988 100 5.137607915 1.35573786 15
 ANXA4 annexin IV IPI00793199 39558.51953 5.84 5 271.6499939 100 80.65000153 99.99991554 5.111776365 0.5293396 5
 HBG2;HBE1;HBG1 Hemoglobin subunit 
gamma-2 IPI00554676 18034.5293 6.64 2 84.23000336 100 42.65000153 99.46712281 4.735193958 0.50201534 4
 IGHM Hypothetical protein DKFZp686I15212 IPI00418153 62655.28125 8.39 6 272.8399963 100 61.43999863 99.99295911 4.691345142 1.06612521 6
 ALB Isoform 1 of Serum albumin precursor IPI00745872 79715.90625 5.92 27 1632.174438 100 114.9700012 100 4.62106406 1.5109062 32
 IGHM IGHM protein IPI00761159 57955.55078 7.53 5 298.8899841 100 84.55000305 100 4.40607813 1.10746392 5
 IGLV4-3 IGLV4-3 protein IPI00382938 28252.89063 6.3 2 185.9199982 100 102.6100006 100 4.403126611 0.24181286 2
 IGHG1 Hypothetical protein 
DKFZp686O01196 IPI00423463 58171.78906 8.46 5 327.5700073 100 90.12000275 100 4.191251943 0.85220869 5
 VIM Vimentin IPI00418471 56977.44141 5.06 18 1041.103394 100 88.40000153 100 4.021581911 1.67800105 19
 HBA2;HBA1 Alpha 2 globin variant 
(Fragment) IPI00853068 17045.16992 8.72 6 448.1199951 100 115.8700027 100 3.979262515 1.24917404 17
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 IGHA1 IGHA1 protein IPI00166866 57142.32031 6.26 5 299.2399902 100 90.12000275 100 3.6498017 0.50412413 6
 FGB Fibrinogen beta chain precursor IPI00298497 61772.66016 8.54 3 124.1999969 100 50.40999985 99.91074608 3.536530728 0.91573108 3
 FN1 Isoform 1 of Fibronectin precursor IPI00022418 276716.375 5.45 13 709.7888184 100 86.59999847 100 3.462952784 2.30017338 13
 APOA1 Apolipoprotein A-I precursor IPI00021841 34071.30859 5.56 1 73.94999695 99.99960497 73.94999695 99.99960497 3.403968799 0 1
 TPM1 Isoform 1 of Tropomyosin alpha-1 
chain IPI00014581 38351.23828 4.69 3 143.8999939 100 52.59000015 99.94597096 3.398269777 0.56957008 3
 ANXA5 Annexin A5 IPI00329801 39272.76172 4.94 4 236.8000031 100 78.11000061 99.99984843 3.369572778 1.19881208 5
 ANXA2 Annexin A2 IPI00455315 43516.26953 7.57 10 572.848938 100 98.91999817 100 3.363958056 2.4820809 10
 FGA Isoform 2 of Fibrinogen alpha chain 
precursor IPI00029717 76032.28906 8.23 4 250.3699951 100 77.08999634 99.9998083 3.336872651 0.63220092 4
 HP HP protein IPI00478493 43017.64844 6.13 4 237.230011 100 65.5 99.99723543 3.325875204 4.97E-02 4
 FLNA Filamin-A IPI00333541 305957.375 5.7 7 399.6499939 100 66.12999725 99.99760874 3.228230673 1.51878973 7
 ACTC1 Actin, alpha cardiac muscle 1 IPI00023006 45148.14063 5.23 11 690.1700439 100 89.95999908 100 3.184060246 1.02347845 16
 TPM4 Isoform 1 of Tropomyosin alpha-4 
chain IPI00010779 32340.88086 4.67 3 139.1000061 100 52.59000015 99.94597096 3.127817741 0.15999281 3
 DKFZp686D0972 hypothetical protein 
LOC345651 IPI00003269 44988.21875 5.39 3 188.4899902 100 85.37000275 100 3.059748262 0.6669657 5
 KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 2 82.63000488 99.99994647 47.43000031 99.82273326 3.035711072 2.88735499 2
 ACTG1;PSPHL Actin, cytoplasmic 2 IPI00021440 44922.05859 5.31 11 876.7299805 100 183.1100006 100 2.960014502 0.70981878 16
 LGALS3 Galectin-3 IPI00465431 27514.25 8.58 2 109.3899994 100 66.76000214 99.99793164 2.954685262 1.4307495 2
 TAGLN2 24 kDa protein IPI00647915 26448.48047 8.41 2 103.4100037 100 52.18999863 99.94075831 2.900969417 0.27883642 2
 MYL6 17 kDa protein IPI00744444 18920.58008 4.54 4 319.519989 100 121.7900009 100 2.900669059 0.42276586 4
 - FK506 binding protein12 IPI00759644 10743.65039 7.66 1 57.41999817 99.98223245 57.41999817 99.98223245 2.831240881 0 1
 IGKC IGKC protein IPI00430808 27732.05078 6.15 1 59.65999985 99.98939215 59.65999985 99.98939215 2.817046457 0 1
 TF Transferrin variant (Fragment) IPI00798430 87365.92188 6.68 7 335.3499756 100 63.74000168 99.99585402 2.800448633 0.45973711 7
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 VTN Vitronectin precursor IPI00298971 57939.35156 5.55 5 235.7200012 100 59.11999893 99.98798767 2.748669358 1.68572324 5
 CFL2 Cofilin-2 IPI00413344 22273.21094 7.66 1 86.23000336 100 86.23000336 100 2.739273765 0 1
 FGG Isoform Gamma-A of Fibrinogen 
gamma chain precursor IPI00219713 55011.35938 5.7 1 68.5 99.99861443 68.5 99.99861443 2.712322423 0 1
 YWHAZ 14-3-3 protein zeta/delta IPI00021263 30890.03906 4.73 4 243.2644501 100 89.68000031 100 2.628808383 0.90830703 4
 COL6A3 alpha 3 type VI collagen isoform 3 
precursor IPI00072917 345457.3438 6.47 9 391.0899963 100 66.15000153 99.99761973 2.624296983 0.34231047 9
 C3 Complement C3 precursor (Fragment) IPI00783987 204689.0469 6.02 3 150.0100098 100 63.34999847 99.99546448 2.59791271 2.0189775 3
 TPM3 Isoform 2 of Tropomyosin alpha-3 
chain IPI00218319 32655.08008 4.75 5 228.7500153 100 52.59000015 99.94597096 2.58023618 1.4557494 5
 MIF 12 kDa protein IPI00790382 12661.19043 9.3 1 54.97999954 99.96883786 54.97999954 99.96883786 2.562223341 0 1
 COL6A2 Isoform 2C2A of Collagen alpha-
2(VI) chain precursor IPI00220613 105910.7031 5.38 2 88.63000488 100 53.79000092 99.95901479 2.549904919 0.34120876 2
 ALDOA 45 kDa protein IPI00796333 49776.48828 8.48 2 88.41999817 100 51.41999817 99.92926612 2.548405251 1.10671595 2
 HNRPK Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein K IPI00216049 54486.71875 5.39 3 124.0444489 100 46.47999954 99.77938891 2.499644615 0.20842101 3
 YWHAQ 14-3-3 protein theta IPI00018146 30857.03906 4.68 4 235.4799957 100 101.9700012 100 2.461015947 1.13243823 4
 MYH9 Myosin-9 IPI00019502 257357.9844 5.5 13 642.8356323 100 83.44999695 100 2.443700343 0.63621378 13
 CLU clusterin isoform 1 IPI00400826 62857.89844 6.24 1 81.48999786 99.9999304 81.48999786 99.9999304 2.437651022 0 1
 NPM1 Isoform 1 of Nucleophosmin IPI00549248 37589.32031 4.64 2 109.8000031 100 71.08000183 99.99923506 2.28037521 0.58978655 2
 RPLP0 60S acidic ribosomal protein P0 IPI00556485 30148.58984 8.36 1 87.63999939 100 87.63999939 100 2.254593957 0 1
 YWHAB Isoform Short of 14-3-3 protein 
beta/alpha IPI00759832 30949.07031 4.76 4 227.0299988 100 93.51999664 100 2.242713675 0.66149536 4
 PRDX2 16 kDa protein IPI00375400 18010.59961 6.13 4 206.1399994 100 59.18000031 99.98815249 2.218273587 0.85746089 4
 LMNA Isoform C of Lamin-A/C IPI00216952 70902.15625 6.4 10 581.2044678 100 81.94999695 99.99993739 2.10317443 0.46903256 10
 ARHGDIA 28 kDa protein IPI00794402 30709 4.94 2 133.9499969 100 77.98999786 99.99984418 2.075286947 0.21774244 3
 TUBB Tubulin beta chain IPI00011654 52311.16016 4.78 8 527.8399658 100 110.8499985 100 2.053343412 0.38342978 9
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 SFN Isoform 2 of 14-3-3 protein sigma IPI00411765 26671.25 4.77 3 133.5099945 100 58.81000137 99.98709889 2.048069958 0.54740592 3
 NME2;NME1 Nucleoside diphosphate kinase 
B IPI00026260 19395.17969 8.52 4 209.3000183 100 75.76000214 99.99973961 1.965538636 0.31367589 5
 MSN Moesin IPI00219365 76942.64063 6.08 3 127.3899994 100 53.52999878 99.95648616 1.878474485 0.38922797 3
 TUBB2C Tubulin beta-2C chain IPI00007752 52471.19141 4.79 7 477.6399841 100 110.8499985 100 1.869995021 0.52699208 8
 LOC388720 similar to ubiquitin and 
ribosomal protein S27a precursor IPI00397808 21877.69922 9.53 2 131.0500031 100 82.11000061 99.99993966 1.865550563 8.02E-02 2
 HSPB1 Heat shock protein beta-1 IPI00025512 23966.66992 5.98 1 59.36999893 99.98865963 59.36999893 99.98865963 1.846010606 0 1
 TXNDC5;MUTED thioredoxin domain 
containing 5 isoform 2 IPI00395646 48461.78125 5.77 2 73.72000122 99.99958349 39.97999954 99.01456648 1.840502319 0.15917387 2
 ACTN1 Actinin alpha 1 isoform b IPI00759776 114216.3906 5.25 5 242.2799988 100 67.08000183 99.99807856 1.829901396 0.61640486 5
 SERPINB6 serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), me IPI00749398 46902.42188 5.18 1 57.54000092 99.98271668 57.54000092 99.98271668 1.819866301 0 1
 COL6A1 Collagen alpha-1(VI) chain 
precursor IPI00291136 117302.5391 5.26 2 97.58999634 100 60.84999847 99.99193457 1.748738158 0.3712096 2
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-
trans isomerase A IPI00419585 20345.10938 7.68 5 333.5 100 86.23999786 100 1.744204797 0.24561571 7
 TUBA1A Tubulin alpha-1A chain IPI00180675 53535.80078 4.94 4 298.480011 100 94.84999847 100 1.740585972 0.75456982 4
 - Calnexin (Fragment) IPI00383227 35238.5 4.62 2 105.1200027 100 61.08000183 99.9923506 1.689373411 0.63732366 2
 HNRPA2B1 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 IPI00414696 38478.16016 8.67 3 168.5644531 100 78.44000244 99.99985952 1.67488093 0.37154405 3
 ACTN4 Alpha-actinin-4 IPI00013808 113653.2031 5.27 7 397.9899902 100 71.55999756 99.9993151 1.674049454 0.4237082 7
 UBE1 Ubiquitin-activating enzyme E1 IPI00645078 126424.8516 5.49 2 94.44999695 100 50.75999832 99.91765685 1.647823861 0.41987788 2
 APOE Apolipoprotein E precursor IPI00021842 38239.98828 5.65 3 240.2999878 100 107.5899963 100 1.619775042 0.820529 3
 HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55078 9.27 2 84.23999786 100 46.47999954 99.77938891 1.606419355 0.37644307 2
 HSPA8 Isoform 1 of Heat shock cognate 71 
kDa protein IPI00003865 78958.95313 5.37 10 581.6243896 100 119.1800003 100 1.603052718 0.39414573 10
 LGALS1 Galectin-1 IPI00219219 16278.33008 5.34 2 105.0299988 100 61.34000015 99.99279511 1.577602815 1.10001871 2
 PRDX5 Isoform Cytoplasmic+peroxisomal of 
Peroxiredoxin-5, mitochondrial pre IPI00759663 19174.23047 6.73 1 62.63999939 99.99465894 62.63999939 99.99465894 1.577557478 0 1
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 EEF1A1 Elongation factor 1-alpha IPI00025447 54739.5 9.12 3 202.6699982 100 75.75 99.99973901 1.53799621 0.11003678 3
 KRT8 Keratin, type II cytoskeletal 8 IPI00554648 58423.62891 5.52 17 1084.158813 100 102.9000015 100 1.52673046 0.41951301 17
 VIL2 Ezrin IPI00843975 77526.5 5.94 3 123.7044373 100 53.52999878 99.95648616 1.509889126 0.21942795 3
 HIST1H2BL Histone H2B type 1-L IPI00018534 16967.94922 10.31 2 104.4000015 100 60.99000168 99.99219043 1.47182726 6.52E-03 2
 KRT79 keratin 6L IPI00241841 62350.57031 6.75 3 162.3000031 100 63.45999908 99.99557791 1.469764863 0.28791603 3
 RPN1 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 67 kDa IPI00025874 78729.54688 5.87 1 54.65999985 99.96645504 54.65999985 99.96645504 1.461471264 0 1
 - CD68 antigen variant (Fragment) IPI00555602 45637.91016 5.46 2 123.75 100 86.23999786 100 1.458704192 0.38333857 2
 TRAP1 57 kDa protein IPI00646055 62264.05859 7.21 1 78.47000122 99.99986048 78.47000122 99.99986048 1.450983949 0 1




IPI00453473 13088.62012 11.36 3 110.8499985 100 42.18999863 99.40758312 1.428364607 0.16201299 3
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00026602 42374.19922 6.09 2 104.5 100 63.65000153 99.99576721 1.420031869 3.75E-03 2
 HSP90AB4P Heat shock protein 90Bd IPI00555565 66222.17969 4.65 2 111.5200043 100 66.55000305 99.99782916 1.419040562 0.39267435 2
 HNRPH1 Heterogeneous nuclear 
ribonucleoprotein H IPI00013881 51876.64844 5.89 2 72.22000122 99.99941166 38.95999908 98.75368628 1.416454573 0.88825641 2
 SPTBN1 Isoform Short of Spectrin beta 
chain, brain 1 IPI00328230 275951.75 5.31 2 97.84444427 100 57.93999863 99.98423742 1.400994605 0.28779376 2
 S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 1 55.36999893 99.97151427 55.36999893 99.97151427 1.390751509 0 1
 ETFB Isoform 2 of Electron transfer 
flavoprotein subunit beta IPI00556451 41287.32813 6.78 3 150.4199982 100 58.50999832 99.9861762 0.697228645 0.39979414 3
 FASN Fatty acid synthase IPI00847250 287598.7813 5.99 8 360.3233032 100 54.15000153 99.96227518 0.687337132 0.47749635 8
 GOT2 Aspartate aminotransferase, 
mitochondrial precursor IPI00018206 52087.64844 9.14 2 107.4900055 100 59.08000183 99.98787653 0.686418834 0.33327916 2
 MDH2 Malate dehydrogenase, mitochondrial 
precursor IPI00291006 39765.08984 8.92 6 415.8644409 100 101.9499969 100 0.675011095 0.13145124 6
 HSD17B10 Isoform 1 of 3-hydroxyacyl-CoA 
dehydrogenase type-2 IPI00017726 28818.30078 7.66 3 111.1999969 100 40.88999939 99.20085176 0.668171251 0.26174848 3
 PHB2 7 kDa protein IPI00797822 7920.140137 10.24 1 52.16999817 99.94048486 52.16999817 99.94048486 0.666970392 0 1
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 AKR1A1 Alcohol dehydrogenase IPI00220271 39850.12891 6.32 1 54.59444046 99.96594482 55.77000046 99.97402071 0.66565588 0 1
 IDH2 Isocitrate dehydrogenase [NADP], 
mitochondrial precursor IPI00011107 56573.30859 8.88 4 189.734436 100 72.62999725 99.99946466 0.655839281 0.14599748 5
 ETFA 24 kDa protein IPI00792673 27117.09961 8.77 1 106.0100021 100 106.0100021 100 0.65360585 0 1
 RRBP1 Isoform 1 of Ribosome-binding 
protein 1 IPI00220967 178629.8125 8.73 4 207.9299927 100 82.16000366 99.99994035 0.650604345 0.32651136 4
 IDH1 Isocitrate dehydrogenase [NADP] 
cytoplasmic IPI00027223 52332.01172 6.53 7 393.4299927 100 87.31999969 100 0.64561385 0.21956547 9
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 58388.32813 6.3 4 240.5899963 100 75.94999695 99.99975075 0.637108662 0.20139225 4
 DLD Dihydrolipoyl dehydrogenase, 
mitochondrial precursor IPI00015911 60048.35938 7.59 1 74.77999878 99.99967369 74.77999878 99.99967369 0.63147561 0 1
 PCBD1 Pterin-4-alpha-carbinolamine 
dehydratase IPI00218568 12902.16992 6.28 4 171.4400024 100 50.50999832 99.91277772 0.629212162 0.22606579 4
 ATP5B ATP synthase subunit beta, 
mitochondrial precursor IPI00303476 59980.98828 5.26 9 558.6644287 100 85.80000305 100 0.625194422 0.21726058 9
 ASL 50 kDa protein IPI00514772 52806.57031 5.99 2 88.28678894 100 53.31000137 99.95422513 0.62373624 0.39021388 2
 NNT NAD(P) transhydrogenase, 
mitochondrial precursor IPI00337541 123493.2578 8.31 1 67.37000275 99.99820267 67.37000275 99.99820267 0.620804467 0 1
 CAT Catalase IPI00465436 64367.17969 6.9 9 523.9500122 100 93.44999695 100 0.618483152 0.31605441 9
 MAOA Amine oxidase [flavin-containing] A IPI00008483 65674.00781 7.94 2 121.6100006 100 69.40000153 99.99887377 0.614364555 5.47E-02 2
 ATP5A1 ATP synthase subunit alpha, 
mitochondrial precursor IPI00440493 64270.03906 9.16 5 347.4799805 100 100.2099991 100 0.608422953 0.17922405 5
 PNPO 13 kDa protein IPI00792667 13812.58008 8.93 2 102.4300003 100 55.63999939 99.9732313 0.599260864 7.07E-02 2
 TST Thiosulfate sulfurtransferase IPI00216293 35752.05859 6.77 7 425.1444397 100 112.0299988 100 0.598467154 0.24498046 7
 ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial precursor IPI00011416 38661.62109 8.16 2 121.8300018 100 76.01999664 99.99975474 0.596524608 0.15325824 2
 FMO5 Dimethylaniline monooxygenase [N-
oxide-forming] 5 IPI00215760 66454.40625 8.41 1 82.66999817 99.99994696 82.66999817 99.99994696 0.591069761 0 1
 ALDH7A1 similar to antiquitin IPI00786942 63780.78125 8.25 2 85.83999634 100 43.5 99.56184549 0.586066426 0.03649206 2
 HADHB Trifunctional enzyme beta subunit, 
mitochondrial precursor IPI00022793 56777.03906 9.45 2 107.9500046 100 72.62000275 99.99946343 0.582252881 0.13210817 2
 HSD17B4 Peroxisomal multifunctional 
enzyme type 2 IPI00019912 88068.99219 8.96 1 73.22000122 99.99953267 73.22000122 99.99953267 0.580812275 0 1
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 DECR1 2,4-dienoyl-CoA reductase, 
mitochondrial precursor IPI00003482 40019.14844 9.35 3 174.25 100 76.26999664 99.99976846 0.562595463 0.36139741 3
 NIPSNAP1 Protein NipSnap1 IPI00304435 36019.10938 9.35 3 166.4599915 100 85.98999786 100 0.553891129 9.99E-02 4
 CYP2E1 Cytochrome P450 2E1 IPI00007282 61500.80078 8.27 2 66.94000244 99.99801561 33.52000046 95.63858674 0.549995499 0.11496567 2
 FAH 33 kDa protein IPI00793664 34681.60938 7.12 2 72.22999573 99.99941301 38.34999847 98.56574148 0.531857008 0.17621473 2
 OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.05859 8.75 5 314.8244324 100 106.8799973 100 0.494445138 0.43966706 5
 DBI Isoform 2 of Acyl-CoA-binding protein IPI00218836 13802.13965 5.41 2 95.23000336 100 53.24000168 99.95348135 0.477903985 6.60E-02 2
 HADHA Trifunctional enzyme subunit alpha, 
mitochondrial precursor IPI00031522 93913.70313 9.16 4 216.5699921 100 74 99.99960949 0.477601944 8.88E-02 4
 GALK1 CDNA FLJ26554 fis, clone 
LNF01773, highly similar to Galactokinase IPI00442827 44445.10938 6.81 3 137.9000092 100 60.79999924 99.99184118 0.464813636 3.48E-02 3
 HMGCL 19 kDa protein IPI00514407 21853.41016 8.9 1 90.19000244 100 90.19000244 100 0.46208774 0 1
 PPIF Peptidyl-prolyl cis-trans isomerase, 
mitochondrial precursor IPI00026519 24750.41992 9.48 1 61.11000061 99.99240326 61.11000061 99.99240326 0.461369297 0 1
 PEBP1 Phosphatidylethanolamine-binding 
protein 1 IPI00219446 23439.92969 7.01 6 469.8399963 100 178.5599976 100 0.456541289 0.27485665 6
 MAT1A S-adenosylmethionine synthetase 
isoform type-1 IPI00021772 47392.28906 5.86 3 197.9244385 100 90.23000336 100 0.449442837 0.17599103 3
 SELENBP1 53 kDa protein IPI00745729 57664.26953 6.03 4 205.5900116 100 66.86000061 99.99797872 0.447974117 0.1067351 4
 UNQ501 MBC3205 IPI00063130 22277.99023 8.91 1 61.65999985 99.9933069 61.65999985 99.9933069 0.440068717 0 1
 ACAT2 Acetyl-CoA acetyltransferase, 
cytosolic IPI00291419 44906.64063 6.47 1 75.80999756 99.99974259 75.80999756 99.99974259 0.438262714 0 1
 QPRT 17 kDa protein IPI00853023 17914 7.71 2 109.3199997 100 59.18000031 99.98815249 0.436531711 1.36E-02 2
 HAO1 Hydroxyacid oxidase 1 IPI00006934 44682.82031 8.2 3 186.6900024 100 89.73000336 100 0.431740451 0.60183539 3
 ALDH4A1 Aldehyde dehydrogenase 4 family, 
member A1 IPI00647328 65056.12109 7.62 8 435.2200012 100 69.44000244 99.9988841 0.429279272 0.32235099 8
 ACADSB Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial IPI00024623 52051.67969 6.53 3 158.3899994 100 61.31999969 99.99276185 0.426572636 0.24722753 3
 SARDH Sarcosine dehydrogenase, 
mitochondrial precursor IPI00034308 106218.8125 6.8 1 55.95000076 99.97507546 55.95000076 99.97507546 0.425445538 0 1
 ALDH1A1 Retinal dehydrogenase 1 IPI00218914 60949.39063 6.3 5 261.1199951 100 87.58999634 100 0.423539563 0.1460814 5
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 BDH1 D-beta-hydroxybutyrate 
dehydrogenase, mitochondrial precursor IPI00025341 41766.75 9.11 2 73.09999847 99.99951957 37.18999863 98.12661334 0.421559339 0.92456341 2
 GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78125 6.61 10 666.2999878 100 140.7599945 100 0.417691823 0.32497638 10
 UGDH UDP-glucose 6-dehydrogenase IPI00031420 60869.64844 6.73 3 171.8099976 100 74.59999847 99.99965988 0.416727125 0.29226343 3
 GOT1 Aspartate aminotransferase, 
cytoplasmic IPI00219029 49570.83984 6.52 3 118.25 100 44.95999908 99.68694015 0.412082325 2.92E-02 3
 ACAA1 3-ketoacyl-CoA thiolase, peroxisomal 
precursor IPI00012828 47604.07031 8.76 5 251.6999817 100 59.43000031 99.98881522 0.410764537 0.47707915 5
 PBLD 28 kDa protein IPI00396138 30189.60938 6.55 2 81.55000305 99.99993135 42.31999969 99.42505366 0.41053028 0.17336574 2
 ECHS1 Enoyl-CoA hydratase, mitochondrial 
precursor IPI00024993 35335.42969 8.34 6 381.5900269 100 108.0100021 100 0.409662277 0.32684795 6
 ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.07813 8.72 7 371.9800415 100 70.38999939 99.99910334 0.40550038 0.17201491 8
 ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 3 145.6699982 100 53.16999817 99.95272544 0.405146892 0.37622485 3
 LOC645619 similar to Adenylate kinase 
isoenzyme 4, mitochondrial IPI00738805 27444.46094 8.47 2 69.98000336 99.99901457 35.90000153 97.47868485 0.4044644 5.89E-02 2
 APOC3 13 kDa protein IPI00657670 13861.62012 7.9 1 85.61000061 100 85.61000061 100 0.385339561 0 1
 GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 13 880.25 100 88.37000275 100 0.374184054 0.20381043 15
 EPHX1 Epoxide hydrolase 1 IPI00009896 57419.37891 6.77 3 217.8299866 100 118.5999985 100 0.373561952 0.60567448 3
 AOX1 Hypothetical protein AOX1 IPI00743616 161854.2031 6.78 2 107.6999969 100 64.90000153 99.99682585 0.372177265 0.22202264 2
 FTCD Isoform A of Formimidoyltransferase-
cyclodeaminase IPI00001441 62321.57813 5.58 4 177.4000092 100 51.59999847 99.93213788 0.367568394 0.13668904 4
 BHMT2 Betaine--homocysteine S-
methyltransferase 2 IPI00014363 43910.42969 5.61 3 123.2244415 100 47.00999832 99.80473363 0.366104567 8.33E-02 3
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 33322.12891 8.55 2 161.0100098 100 84.68000031 100 0.360663046 1.71E-02 2
 ACSL1 Isoform 1 of Long-chain-fatty-acid--
CoA ligase 1 IPI00012728 85201.29688 6.81 5 262.4100037 100 79.12999725 99.99988015 0.350712007 0.2083006 6
 UGT2B7 similar to UDP-
glucuronosyltransferase 2B7 precursor IPI00787584 65314.41016 8.41 3 179.3999939 100 72.83000183 99.99948876 0.350464401 5.67E-02 3
 ALDH2 Mitochondrial aldehyde 
dehydrogenase 2 variant (Fragment) IPI00792207 61065.96094 6.63 6 348.1699829 100 73.36000061 99.99954749 0.349704915 0.2526833 6
 PHGDH Phosphoglycerate dehydrogenase IPI00642548 56869.67969 6.47 2 92.38000488 100 53.13999939 99.95239776 0.348773711 0.15128801 2
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 UGT2B17 UDP-glucuronosyltransferase 
2B17 precursor IPI00026932 67707.59375 8.76 1 72.83000183 99.99948876 72.83000183 99.99948876 0.344443216 0 1
 DAK Dihydroxyacetone kinase IPI00551024 63392.42188 7.12 2 157.9900055 100 111 100 0.343111969 0.1550338 2
 UGP2 Isoform 1 of UTP--glucose-1-
phosphate uridylyltransferase IPI00329331 63091.28906 8.16 6 343.2444458 100 76.88999939 99.99979926 0.330030961 0.04786195 6
 ACAA2 3-ketoacyl-CoA thiolase, 
mitochondrial IPI00001539 46153.96875 8.32 9 505.5700073 100 83.16999817 100 0.324916873 0.36626289 9
 SCP2 sterol carrier protein 2 isoform 2 IPI00433347 61608.94141 6.25 3 146.6900024 100 69.51999664 99.99890446 0.324680292 0.18338335 3
 - 105 kDa protein IPI00794900 115433.2422 7.3 9 364.6000061 100 51.72999954 99.93413915 0.313543115 0.13859138 9
 - 14 kDa protein IPI00788848 15907.24023 5.24 6 355 100 93.44000244 100 0.308022587 0.25488216 8
 ACY1 Aminoacylase-1 IPI00009268 48344.23047 5.77 6 283.1600037 100 59.18999863 99.98817973 0.304239303 0.198984 6
 DCXR 26 kDa protein IPI00797249 27252.58984 8.33 5 316.0800171 100 83.98000336 100 0.302553084 6.53E-02 5
 CES2 carboxylesterase 2 isoform 1 IPI00332828 72247.0625 6.03 4 227.7000122 100 89.77999878 100 0.300215897 0.17998687 4
 PGM1 Phosphoglucomutase 1 IPI00844159 66935.90625 6.2 6 377.908905 100 95.12999725 100 0.295493085 0.14418012 6
 AGXT Serine--pyruvate aminotransferase IPI00009367 46426.73047 8.61 4 230.2799988 100 93.05999756 100 0.293665918 0.13669913 4
 GRHPR GRHPR protein (Fragment) IPI00550682 39375.17188 5.95 2 158.3444366 100 108.4499969 100 0.293602584 8.13E-02 2
 PCK2 Phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial precursor IPI00294380 74737.8125 7.56 11 640.1799927 100 89.26999664 100 0.277302395 0.29336983 11
 BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.23828 6.58 5 270.7444458 100 80.41000366 99.99991075 0.274906278 9.66E-02 5
 SORD Sorbitol dehydrogenase IPI00216057 42378.10938 8.23 3 181.2599945 100 94.58999634 100 0.270098791 0.3130166 3
 PCK2 mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor IPI00797038 74784.85938 7.57 11 683.4800415 100 89.26999664 100 0.263132145 0.24532861 11
 KHK Isoform C of Ketohexokinase IPI00216136 35220.62891 5.91 3 190.984436 100 93.37999725 100 0.256727697 0.19976701 3
 SOD1 Superoxide dismutase IPI00783680 17838.08984 5.7 3 240.7100067 100 112.2600021 100 0.251869937 3.19E-02 3
 HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 2 124.6999969 100 62.97999954 99.99506113 0.247159478 0.19447979 2
 AKR1C3 Aldo-keto reductase family 1 
member C3 IPI00291483 41031.17969 8.05 4 177.6499939 100 59.72000122 99.9895377 0.246116768 0.25465726 4
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 131NT
 HMGCS2 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial precursor IPI00008934 61333.76953 8.4 6 345.9000244 100 73.31999969 99.9995433 0.237872579 0.32943531 6
 MAOB Amine oxidase [flavin-containing] B IPI00328156 63747.53125 7.2 2 124.8000031 100 69.40000153 99.99887377 0.235839557 0.32826859 2
 FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 3 175.0299988 100 70.54000092 99.99913378 0.229416426 0.23496863 3
 ASS1 Argininosuccinate synthase IPI00640430 24839.67969 6.84 5 223.0700073 100 51.79999924 99.93519219 0.227907106 0.16759224 5
 SULT1A1 Sulfotransferase 1A1 IPI00300026 47814.69922 8.61 3 127.7600021 100 44.54999924 99.65594541 0.226966471 0.10918505 3
 UGT1A10;UGT1A6 UDP-
glucuronosyltransferase 1-10 precursor IPI00233885 64734.48828 6.88 1 65.73000336 99.99737803 65.73000336 99.99737803 0.219405261 0 1
 ARG1 Isoform 1 of Arginase-1 IPI00291560 38451.66016 6.72 2 127.0699997 100 73.52999878 99.99956486 0.217653848 0.13533258 2
 ACAT1 Acetyl-CoA acetyltransferase, 
mitochondrial precursor IPI00030363 49865.05859 8.98 5 392.9812317 100 124.1800003 100 0.212100424 0.11219495 5
 CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 44 2904.68335 100 134.6900024 100 0.206313584 0.24030259 48
 CYB5A Isoform 1 of Cytochrome b5 IPI00397860 16616.71094 4.88 5 431.980011 100 172.6000061 100 0.203474699 0.11502888 5
 ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor IPI00009532 61418.91016 8.17 2 109.7700043 100 60.58000183 99.99141724 0.199781537 0.10749474 2
 ACSM2A 23 kDa protein IPI00334599 25689.23047 9.04 2 110.0800018 100 64.44999695 99.99647931 0.183556482 3.79E-02 2
 RDH16 Microsomal NAD+-dependent retinol 
dehydrogenase 4 variant (Fragment) IPI00555683 23832.68945 7.67 2 94.77999878 100 53.36000061 99.9547491 0.176448788 0.14233921 2
 ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03125 8.25 6 388.0499878 100 82.48999786 99.99994471 0.176143371 0.16239362 7
 ADH1A Alcohol dehydrogenase 1A IPI00218896 45320.80859 8.26 7 474.1499939 100 111.1399994 100 0.154116622 0.21712908 7
 CES1 carboxylesterase 1 isoform c precursor IPI00607693 68199.60938 6.15 11 701.250061 100 98.52999878 100 0.153944084 0.10184486 11
 GSTA1 Glutathione S-transferase A1 IPI00657682 29261.05078 8.91 6 325.7600098 100 76.02999878 99.9997553 0.118478966 5.38E-02 6
 ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 6 435.9699707 100 111.1399994 100 0.116125176 0.11188744 6
 ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 8 572.3044434 100 94.22000122 100 9.27E-02 5.59E-02 9
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FN1 Isoform 1 of Fibronectin precursor IPI00022418 276716.375 5.45 13 709.7888184 100 86.59999847 100 4.69164933 2.22023028 13
GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78125 6.61 10 666.2999878 100 140.7599945 100 3.333623381 0.98232625 10
APOE Apolipoprotein E precursor IPI00021842 38239.98828 5.65 3 240.2999878 100 107.5899963 100 3.046027758 0.46707844 3
KRT79 keratin 6L IPI00241841 62350.57031 6.75 3 162.3000031 100 63.45999908 99.99557791 2.880781091 0.16000436 3
POSTN Isoform 2 of Periostin precursor IPI00218585 96544.46875 7.87 1 72.84999847 99.99949111 72.84999847 99.99949111 2.857461154 0 1
ANXA2 Annexin A2 IPI00455315 43516.26953 7.57 10 572.848938 100 98.91999817 100 2.585622379 1.46772622 10
KRT8 Keratin, type II cytoskeletal 8 IPI00554648 58423.62891 5.52 17 1084.158813 100 102.9000015 100 2.540204083 0.54444182 17
KRT18 Keratin, type I cytoskeletal 18 IPI00784347 51196.89844 5.34 8 415.4400024 100 66.73000336 99.9979173 2.531720197 0.32916576 8
TKT Transketolase variant (Fragment) IPI00788802 74607.24219 7.9 2 86.19999695 100 52.22000122 99.94116616 2.487795152 1.29598718 2
VTN Vitronectin precursor IPI00298971 57939.35156 5.55 5 235.7200012 100 59.11999893 99.98798767 2.429800561 0.70269433 5
HSPE1 10 kDa heat shock protein, 
mitochondrial IPI00220362 12653.11035 8.89 5 282.7600098 100 79.84999847 99.99989846 2.385210982 0.44461367 6
ETFA 24 kDa protein IPI00792673 27117.09961 8.77 1 106.0100021 100 106.0100021 100 2.147704605 0 1
QPRT 17 kDa protein IPI00853023 17914 7.71 2 109.3199997 100 59.18000031 99.98815249 2.135853724 0.35892407 2
VDAC1 20 kDa protein IPI00790304 22855.44922 6.74 1 56.52000046 99.97814115 56.52000046 99.97814115 2.130542782 0 1
HSPD1 60 kDa heat shock protein, 
mitochondrial precursor IPI00784154 68931.10156 5.7 11 582.317749 100 90.54000092 100 2.102235323 0.42340338 11
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial precursor IPI00011416 38661.62109 8.16 2 121.8300018 100 76.01999664 99.99975474 2.101764842 0.38254505 2
HSPA6 Heat shock 70 kDa protein 6 IPI00339269 77112.71094 5.81 4 267.0200195 100 106.0800018 100 2.023154679 0.17015218 4
CTSD Protein IPI00853455 44335.46875 5.38 2 80.71000671 99.9999167 41.24000168 99.26272906 2.003697141 0.69992828 2
HSPA1A;HSPA1B heat shock 70kDa protein 1A IPI00845339 77569.67969 5.48 6 344.0700073 100 106.0800018 100 1.943532971 0.22384396 6
- 14 kDa protein IPI00788848 15907.24023 5.24 6 355 100 93.44000244 100 1.939587243 0.32338065 8
NME2;NME1 Nucleoside diphosphate kinase B IPI00026260 19395.17969 8.52 4 209.3000183 100 75.76000214 99.99973961 1.892010973 0.50216313 5
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 196NT
ETFB Isoform 2 of Electron transfer flavoprotein 
subunit beta IPI00556451 41287.32813 6.78 3 150.4199982 100 58.50999832 99.9861762 1.828168752 5.98E-02 3
PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-
trans isomerase A IPI00419585 20345.10938 7.68 5 333.5 100 86.23999786 100 1.818516558 0.15396059 7
CLU clusterin isoform 1 IPI00400826 62857.89844 6.24 1 81.48999786 99.9999304 81.48999786 99.9999304 1.794800336 0 1
SLC25A3 Isoform B of Phosphate carrier 
protein, mitochondrial precursor IPI00215777 44188.96875 9.43 1 47.31000137 99.81776695 47.31000137 99.81776695 1.791957852 0.31032646 2
HSPA9 Stress-70 protein, mitochondrial 
precursor IPI00007765 81497.46094 5.87 5 262.230011 100 79.87999725 99.99989916 1.786205156 0.14479074 5
CTSB Cathepsin B precursor IPI00295741 40882.91016 5.88 2 107.3899994 100 63.43000031 99.99554726 1.736327274 0.33277556 2
TRAP1 57 kDa protein IPI00646055 62264.05859 7.21 1 78.47000122 99.99986048 78.47000122 99.99986048 1.719844252 0 1
OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.05859 8.75 5 314.8244324 100 106.8799973 100 1.693001507 0.16591354 5
HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55078 9.27 2 84.23999786 100 46.47999954 99.77938891 1.688249892 0.71554639 2
CFL2 Cofilin-2 IPI00413344 22273.21094 7.66 1 86.23000336 100 86.23000336 100 1.667398984 0 1
HIST1H2BL Histone H2B type 1-L IPI00018534 16967.94922 10.31 2 104.4000015 100 60.99000168 99.99219043 1.632490136 0.30528719 2
ALDOA 45 kDa protein IPI00796333 49776.48828 8.48 2 88.41999817 100 51.41999817 99.92926612 1.631140522 9.87E-02 2
FASN Fatty acid synthase IPI00847250 287598.7813 5.99 8 360.3233032 100 54.15000153 99.96227518 1.61588821 0.70267146 8
AKR1C3 Aldo-keto reductase family 1 member 
C3 IPI00291483 41031.17969 8.05 4 177.6499939 100 59.72000122 99.9895377 1.599582689 0.18146628 4
TAGLN2 24 kDa protein IPI00647915 26448.48047 8.41 2 103.4100037 100 52.18999863 99.94075831 1.593187528 0.12643353 2
GLO1 Lactoylglutathione lyase IPI00220766 23684.51953 5.12 2 109.3800049 100 58.40999985 99.98585421 1.566522854 1.91E-02 2
LOC645619 similar to Adenylate kinase 
isoenzyme 4, mitochondrial IPI00738805 27444.46094 8.47 2 69.98000336 99.99901457 35.90000153 97.47868485 1.559443183 0.32351742 2
TUFM Tu translation elongation factor, 
mitochondrial IPI00027107 54583.71875 7.26 4 190.5800171 100 53.54000092 99.95658626 1.550602393 0.33587243 4
TUBB2C Tubulin beta-2C chain IPI00007752 52471.19141 4.79 7 477.6399841 100 110.8499985 100 1.543717441 0.44777039 8
HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.0625 4.97 9 578.8600464 100 116.1500015 100 1.535131392 0.46092414 10
NIPSNAP1 Protein NipSnap1 IPI00304435 36019.10938 9.35 3 166.4599915 100 85.98999786 100 1.526254931 0.33494911 4
LGALS3 Galectin-3 IPI00465431 27514.25 8.58 2 109.3899994 100 66.76000214 99.99793164 1.502722393 0.10067532 2
HSD17B10 Isoform 1 of 3-hydroxyacyl-CoA 
dehydrogenase type-2 IPI00017726 28818.30078 7.66 3 111.1999969 100 40.88999939 99.20085176 1.498503375 0.17842609 3
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 196NT
TUBA1A Tubulin alpha-1A chain IPI00180675 53535.80078 4.94 4 298.480011 100 94.84999847 100 1.497069006 0.33278022 4
PRDX5 Isoform Cytoplasmic+peroxisomal of 
Peroxiredoxin-5, mitochondrial pre IPI00759663 19174.23047 6.73 1 62.63999939 99.99465894 62.63999939 99.99465894 1.488526809 0 1
GALK1 CDNA FLJ26554 fis, clone LNF01773, 
highly similar to Galactokinase IPI00442827 44445.10938 6.81 3 137.9000092 100 60.79999924 99.99184118 1.48296436 5.00E-02 3
IDH1 Isocitrate dehydrogenase [NADP] 
cytoplasmic IPI00027223 52332.01172 6.53 7 393.4299927 100 87.31999969 100 1.479247309 0.24414522 9
TUBB Tubulin beta chain IPI00011654 52311.16016 4.78 8 527.8399658 100 110.8499985 100 1.464613681 0.45259364 9
NPM1 Isoform 1 of Nucleophosmin IPI00549248 37589.32031 4.64 2 109.8000031 100 71.08000183 99.99923506 1.454446488 9.87E-02 2
TST Thiosulfate sulfurtransferase IPI00216293 35752.05859 6.77 7 425.1444397 100 112.0299988 100 1.446275178 0.18044383 7
HNRPA2B1 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 IPI00414696 38478.16016 8.67 3 168.5644531 100 78.44000244 99.99985952 1.431830561 0.21967077 3
LOC728188;PGAM4 Probable 
phosphoglycerate mutase 4 IPI00374975 31633.05078 6.19 1 71.55000305 99.99931352 71.55000305 99.99931352 1.428008208 0 1
LOC388720 similar to ubiquitin and ribosomal 
protein S27a precursor IPI00397808 21877.69922 9.53 2 131.0500031 100 82.11000061 99.99993966 1.422628587 0.10192314 2
GAPDH Glyceraldehyde 3-phosphate 
dehydrogenase IPI00789134 31015.36914 6.45 4 310.7200012 100 121.7099991 100 1.416487881 0.10665591 4
EEF1A1 Elongation factor 1-alpha IPI00025447 54739.5 9.12 3 202.6699982 100 75.75 99.99973901 1.409278367 8.94E-02 3
YWHAZ 14-3-3 protein zeta/delta IPI00021263 30890.03906 4.73 4 243.2644501 100 89.68000031 100 1.400213751 0.15106071 4
HIST1H4E;HIST1H4I;HIST1H4D;HIST1H4L;HI
ST1H4J;HIST1H4A;HIST1H4F;HIST1H4H;HIS IPI00453473 13088.62012 11.36 3 110.8499985 100 42.18999863 99.40758312 1.394397322 1.11001555 3
HSP90AA1 Isoform 1 of Heat shock protein 
HSP 90-alpha IPI00784295 96593.6875 4.94 8 548.6000366 100 121.8899994 100 1.390073383 0.26487711 9
LGALS1 Galectin-1 IPI00219219 16278.33008 5.34 2 105.0299988 100 61.34000015 99.99279511 0.708939818 0.42029336 2
HP HP protein IPI00478493 43017.64844 6.13 4 237.230011 100 65.5 99.99723543 0.700163902 3.99E-02 4
KHK Isoform C of Ketohexokinase IPI00216136 35220.62891 5.91 3 190.984436 100 93.37999725 100 0.698774669 4.40E-02 3
FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 3 175.0299988 100 70.54000092 99.99913378 0.662081159 7.75E-02 3
LDHA Isoform 2 of L-lactate dehydrogenase A 
chain IPI00607708 40851.19922 7.94 2 113.9799957 100 60.00999832 99.9902135 0.661987272 0.24257114 2
ARG1 Isoform 1 of Arginase-1 IPI00291560 38451.66016 6.72 2 127.0699997 100 73.52999878 99.99956486 0.659918001 6.69E-02 2
CES1 carboxylesterase 1 isoform c precursor IPI00607693 68199.60938 6.15 11 701.250061 100 98.52999878 100 0.657871606 8.26E-02 11
SARDH Sarcosine dehydrogenase, 
mitochondrial precursor IPI00034308 106218.8125 6.8 1 55.95000076 99.97507546 55.95000076 99.97507546 0.646929345 0 1
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 196NT
ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 3 145.6699982 100 53.16999817 99.95272544 0.644839622 0.12906938 3
COL6A3 alpha 3 type VI collagen isoform 3 
precursor IPI00072917 345457.3438 6.47 9 391.0899963 100 66.15000153 99.99761973 0.63258632 0.10401701 9
COL6A2 Isoform 2C2A of Collagen alpha-2(VI) 
chain precursor IPI00220613 105910.7031 5.38 2 88.63000488 100 53.79000092 99.95901479 0.630573742 0.1086929 2
GRHPR GRHPR protein (Fragment) IPI00550682 39375.17188 5.95 2 158.3444366 100 108.4499969 100 0.628703184 0.16419832 2
COL6A1 Collagen alpha-1(VI) chain precursor IPI00291136 117302.5391 5.26 2 97.58999634 100 60.84999847 99.99193457 0.616586669 6.78E-02 2
ACADSB Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial IPI00024623 52051.67969 6.53 3 158.3899994 100 61.31999969 99.99276185 0.611672916 6.76E-02 3
PRDX6 Peroxiredoxin-6 IPI00220301 27847.49023 6 5 201.4100037 100 45.15000153 99.70034113 0.609208833 5.88E-02 5
ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 8 572.3044434 100 94.22000122 100 0.594610734 6.74E-02 9
ALDH4A1 Aldehyde dehydrogenase 4 family, 
member A1 IPI00647328 65056.12109 7.62 8 435.2200012 100 69.44000244 99.9988841 0.589857644 0.11958453 8
UNQ501 MBC3205 IPI00063130 22277.99023 8.91 1 61.65999985 99.9933069 61.65999985 99.9933069 0.58968704 0 1
HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 2 124.6999969 100 62.97999954 99.99506113 0.585925567 0.21657136 2
ASL 50 kDa protein IPI00514772 52806.57031 5.99 2 88.28678894 100 53.31000137 99.95422513 0.584426323 0.14270184 2
SCP2 sterol carrier protein 2 isoform 2 IPI00433347 61608.94141 6.25 3 146.6900024 100 69.51999664 99.99890446 0.569728249 7.47E-02 3
AKR1A1 Alcohol dehydrogenase IPI00220271 39850.12891 6.32 1 54.59444046 99.96594482 55.77000046 99.97402071 0.563907492 0 1
ACSL1 Isoform 1 of Long-chain-fatty-acid--CoA 
ligase 1 IPI00012728 85201.29688 6.81 5 262.4100037 100 79.12999725 99.99988015 0.556263548 8.21E-02 6
ACSM2A 23 kDa protein IPI00334599 25689.23047 9.04 2 110.0800018 100 64.44999695 99.99647931 0.544518871 0.11531382 2
SULT1A1 Sulfotransferase 1A1 IPI00300026 47814.69922 8.61 3 127.7600021 100 44.54999924 99.65594541 0.541971508 1.73E-02 3
GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 13 880.25 100 88.37000275 100 0.540100997 9.46E-02 15
AOX1 Hypothetical protein AOX1 IPI00743616 161854.2031 6.78 2 107.6999969 100 64.90000153 99.99682585 0.526519389 6.89E-02 2
GSTA1 Glutathione S-transferase A1 IPI00657682 29261.05078 8.91 6 325.7600098 100 76.02999878 99.9997553 0.524475848 7.68E-02 6
SELENBP1 53 kDa protein IPI00745729 57664.26953 6.03 4 205.5900116 100 66.86000061 99.99797872 0.521206877 7.90E-02 4
ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.07813 8.72 7 371.9800415 100 70.38999939 99.99910334 0.520113907 0.1492127 8
BLVRB Flavin reductase IPI00783862 23637.61914 7.13 2 104.2700043 100 59.13999939 99.98804286 0.50956855 1.61E-02 2
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 196NT
PCK2 Phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial precursor IPI00294380 74737.8125 7.56 11 640.1799927 100 89.26999664 100 0.498647454 0.14971569 11
ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor IPI00009532 61418.91016 8.17 2 109.7700043 100 60.58000183 99.99141724 0.497844373 2.20E-02 2
CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 44 2904.68335 100 134.6900024 100 0.495179104 9.14E-02 48
PCK2 mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor IPI00797038 74784.85938 7.57 11 683.4800415 100 89.26999664 100 0.493318438 0.14003596 11
HAO1 Hydroxyacid oxidase 1 IPI00006934 44682.82031 8.2 3 186.6900024 100 89.73000336 100 0.489075782 8.77E-02 3
CAT Catalase IPI00465436 64367.17969 6.9 9 523.9500122 100 93.44999695 100 0.483585722 0.23064285 9
AGXT Serine--pyruvate aminotransferase IPI00009367 46426.73047 8.61 4 230.2799988 100 93.05999756 100 0.470013626 3.98E-02 4
SOD1 Superoxide dismutase IPI00783680 17838.08984 5.7 3 240.7100067 100 112.2600021 100 0.461226296 3.01E-02 3
CYP2E1 Cytochrome P450 2E1 IPI00007282 61500.80078 8.27 2 66.94000244 99.99801561 33.52000046 95.63858674 0.458716174 7.87E-03 2
FTCD Isoform A of Formimidoyltransferase-
cyclodeaminase IPI00001441 62321.57813 5.58 4 177.4000092 100 51.59999847 99.93213788 0.455871169 0.21765755 4
TAGLN Transgelin IPI00216138 25234.73047 8.87 3 131.3200073 100 52.47000122 99.94445728 0.455016768 0.04230213 3
FTL Ferritin light chain IPI00852596 21925.33984 5.51 2 98.58000183 100 52.33000183 99.94263763 0.437876205 0.13707333 2
SORD Sorbitol dehydrogenase IPI00216057 42378.10938 8.23 3 181.2599945 100 94.58999634 100 0.434298367 3.18E-02 3
UGT2B17 UDP-glucuronosyltransferase 2B17 
precursor IPI00026932 67707.59375 8.76 1 72.83000183 99.99948876 72.83000183 99.99948876 0.425171731 0 1
- 105 kDa protein IPI00794900 115433.2422 7.3 9 364.6000061 100 51.72999954 99.93413915 0.422328867 8.83E-02 9BGN CDNA FLJ35635 fis, clone 
SPLEN2011805, highly similar to 
BONE/CARTILAGE IPI00385748 39528 6.31 3 209.9899902 100 95.19999695 100 0.411923531 0.12898124 3
PBLD 28 kDa protein IPI00396138 30189.60938 6.55 2 81.55000305 99.99993135 42.31999969 99.42505366 0.41065073 0.13784584 2
ACAT1 Acetyl-CoA acetyltransferase, 
mitochondrial precursor IPI00030363 49865.05859 8.98 5 392.9812317 100 124.1800003 100 0.405856689 5.74E-02 5
UGT2B7 similar to UDP-
glucuronosyltransferase 2B7 precursor IPI00787584 65314.41016 8.41 3 179.3999939 100 72.83000183 99.99948876 0.399178773 0.14185989 3
UGP2 Isoform 1 of UTP--glucose-1-phosphate 
uridylyltransferase IPI00329331 63091.28906 8.16 6 343.2444458 100 76.88999939 99.99979926 0.395002156 6.19E-02 6
LUM 23 kDa protein IPI00794403 25919.60938 8.52 2 117.8000031 100 83.20999908 100 0.38313986 0.16077867 2
DCXR 26 kDa protein IPI00797249 27252.58984 8.33 5 316.0800171 100 83.98000336 100 0.374224565 0.19731429 5
PRELP Prolargin precursor IPI00020987 46264.33984 9.47 4 194.1799927 100 52.11999893 99.93979572 0.287182882 9.76E-02 4
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 196NT
RDH16 Microsomal NAD+-dependent retinol 
dehydrogenase 4 variant (Fragment) IPI00555683 23832.68945 7.67 2 94.77999878 100 53.36000061 99.9547491 0.273090626 0.11530921 2
ASS1 Argininosuccinate synthase IPI00640430 24839.67969 6.84 5 223.0700073 100 51.79999924 99.93519219 0.272135418 7.38E-02 5
COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 3 199.3300018 100 85.90000153 100 0.239121932 0.1238869 3
ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03125 8.25 6 388.0499878 100 82.48999786 99.99994471 0.145050483 0.09963193 7
ADH1A Alcohol dehydrogenase 1A IPI00218896 45320.80859 8.26 7 474.1499939 100 111.1399994 100 0.128981463 7.98E-02 7
COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 1 94.27999878 100 94.27999878 100 0.128894413 0 1
ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 6 435.9699707 100 111.1399994 100 0.126775249 8.31E-02 6






























FN1 Isoform 1 of Fibronectin precursor IPI00022418 276716.375 5.45 9 441.6544189 100 82.48999786 99.99994479 3.487115298 1.530472082 11
AKR1D1 CDNA FLJ25413 fis, clone 
TST03402, highly similar to 3-OXO-5-BETA- 
STEROID 4-DEHYDROGENASE
IPI00065073 33300.88672 8.11 1 54.40000153 99.96443706 54.40000153 99.96443706 3.280508179 0 1
LOC645619 similar to Adenylate kinase 
isoenzyme 4, mitochondrial IPI00738805 27444.46094 8.47 2 70.94000244 99.99921114 37.63999939 98.31345503 2.761734166 0.744524299 2
GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78125 6.61 6 364.9199829 100 89.69000244 100 2.594049314 0.375845991 6
AKR1C3 Aldo-keto reductase family 1 member 
C3 IPI00291483 41031.17969 8.05 4 198.3399963 100 63.93000031 99.99603724 2.528213075 0.471764218 4
HSPD1 60 kDa heat shock protein, 
mitochondrial precursor IPI00784154 68931.10156 5.7 7 437.0189209 100 101.2300034 100 2.404382961 0.771539451 8
HSPA1A;HSPA1B heat shock 70kDa protein 
1A IPI00845339 77569.67969 5.48 7 414.2700195 100 118.5800018 100 2.392320022 0.948908078 7
HSPA6 Heat shock 70 kDa protein 6 IPI00339269 77112.71094 5.81 5 327.7600098 100 118.5800018 100 2.338145577 1.038025901 5
HSPE1 10 kDa heat shock protein, 
mitochondrial IPI00220362 12653.11035 8.89 6 309.730011 100 65.75 99.99739386 2.250237954 0.623933664 9
HMGCS2 Hydroxymethylglutaryl-CoA synthase, 
mitochondrial precursor IPI00008934 61333.76953 8.4 4 159.3999939 100 50.04999924 99.90317267 2.249225517 0.791181495 5
UGDH UDP-glucose 6-dehydrogenase IPI00031420 60869.64844 6.73 3 159.980011 100 68.37000275 99.9985744 2.138718845 1.023191528 3
HSPA9 Stress-70 protein, mitochondrial 
precursor IPI00007765 81497.46094 5.87 4 237.5700073 100 98.48000336 100 2.001890086 0.986582545 4
HADHB Trifunctional enzyme beta subunit, 
mitochondrial precursor IPI00022793 56777.03906 9.45 4 165.1699982 100 49.88999939 99.8995389 1.996888928 0.507476913 5
SOD2 manganese superoxide dismutase 
isoform B precursor IPI00607577 22864.7793 8.36 2 99.51000214 100 63.49000168 99.99561472 1.941866614 0.195455917 2
NCL Isoform 1 of Nucleolin IPI00604620 89719.57031 4.6 1 59.61999893 99.9893095 59.61999893 99.9893095 1.93485054 0 1
LOC388720 similar to ubiquitin and ribosomal 
protein S27a precursor IPI00397808 21877.69922 9.53 2 119.4199982 100 67.08000183 99.99808134 1.872844837 0.111362025 2
CES1 carboxylesterase 1 isoform c precursor IPI00607693 68199.60938 6.15 12 712.789978 100 97.69999695 100 1.855502926 0.30434818 13
GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 9 532 100 87.05000305 100 1.855199834 0.332353267 12
HSPA8 Isoform 1 of Heat shock cognate 71 
kDa protein IPI00003865 78958.95313 5.37 8 423.2900085 100 104.3099976 100 1.832232068 0.340100389 8
MDH2 Malate dehydrogenase, mitochondrial 
precursor IPI00291006 39765.08984 8.92 2 108.9799957 100 68.69999695 99.99867871 1.79912193 0.206352254 2
CS citrate synthase precursor, isoform b IPI00383539 50469.26172 6.74 2 74.97000122 99.99968811 38.63999939 98.66032971 1.709230926 0.666050215 2
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 199NT
HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.0625 4.97 6 382.5299988 100 93.37999725 100 1.689681444 0.308332847 6
GANAB Isoform 3 of Neutral alpha-glucosidase 
AB precursor IPI00441414 99842.15625 5.43 2 129.8999939 100 69.69999695 99.99895046 1.671290838 5.73E-02 2
PC Pyruvate carboxylase, mitochondrial 
precursor IPI00299402 138358.0469 6.37 1 71.01999664 99.99922554 71.01999664 99.99922554 1.654663251 0 1
CALR Protein IPI00794237 19298.58594 4.47 1 68.75444031 99.99869517 69.93000031 99.9990046 1.616554253 0 1
TRAP1 57 kDa protein IPI00646055 62264.14453 7.21 1 93.29000092 100 93.29000092 100 1.609612229 0 1
FDX1 Adrenodoxin, mitochondrial precursor IPI00019326 20618.73047 5.51 2 99.33999634 100 59.38000107 99.9887021 1.597678239 0.393800917 2
EIF4A1 Eukaryotic initiation factor 4A-I IPI00025491 49332.85938 5.32 1 76.16000366 99.99976286 76.16000366 99.99976286 1.593613043 0 1
GALK1 CDNA FLJ26554 fis, clone LNF01773, 
highly similar to Galactokinase IPI00442827 44445.10938 6.81 1 51.36000061 99.92838602 51.36000061 99.92838602 1.588110518 0 1
ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 1 61.16999817 99.99251834 61.16999817 99.99251834 1.556089548 0 1
- Ig kappa chain V-III region SIE IPI00387115 12435.95996 8.7 1 50.31999969 99.90900911 50.31999969 99.90900911 1.552926352 0 1
ETFA 24 kDa protein IPI00792673 27117.09961 8.77 1 94.65000153 100 94.65000153 100 1.5364581 0 1
COX5B Cytochrome c oxidase subunit 5B, 
mitochondrial precursor IPI00021785 14879.07031 9.07 1 52.40000153 99.94363653 52.40000153 99.94363653 1.518099412 0 1
- FK506 binding protein12 IPI00759644 10743.65039 7.66 1 67.72000122 99.99834424 67.72000122 99.99834424 1.492913987 0 1
IMMT Isoform 3 of Mitochondrial inner 
membrane protein IPI00470829 88364.21094 6.31 1 79.62000275 99.9998931 79.62000275 99.9998931 1.490259692 0 1
ETFB Isoform 2 of Electron transfer 
flavoprotein subunit beta IPI00556451 41287.32813 6.78 3 121.7099991 100 46.27999878 99.76932635 1.476080466 0.193093175 3
HSPB1 Heat shock protein beta-1 IPI00025512 23966.66992 5.98 2 116.0499954 100 81.83999634 99.99993588 1.455065695 6.71E-02 2
LMNA Isoform C of Lamin-A/C IPI00216952 70902.15625 6.4 9 479.0600281 100 96.04000092 100 1.436005451 0.266331249 9
HNRPA2B1 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 IPI00414696 38478.16016 8.67 3 183.4744415 100 68.37999725 99.99857768 1.432510692 5.45E-02 3
ENO1 Isoform MBP-1 of Alpha-enolase IPI00759806 41357.21094 5.93 2 133.6600037 100 82.93000031 100 1.4168123 2.63E-02 2
HSPA5 HSPA5 protein IPI00003362 81398.29688 5.07 7 336.980011 100 59.56999969 99.98918571 1.407969116 0.275111092 7
CALR 37 kDa protein IPI00793605 41138.14063 4.55 4 292.8500061 100 95.69000244 100 1.407363696 0.185347952 4
ACO2 Aconitase 2, mitochondrial IPI00790739 96473.60938 6.97 2 92.36000061 100 53.18999863 99.95301081 1.401811635 0.311801625 2
KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 2 95.88000488 100 55.40000153 99.97175135 0.705240784 0.182244284 3
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 199NT
PGM1 Phosphoglucomutase 1 IPI00844159 66935.90625 6.2 1 56.79000092 99.97948848 56.79000092 99.97948848 0.703240934 0 1
MDH1 Malate dehydrogenase, cytoplasmic IPI00291005 41195.46094 6.91 2 88.06999969 100 47.68999863 99.83327605 0.695662402 0.106523689 2
ANXA4 annexin IV IPI00793199 39558.51953 5.84 1 66.23999786 99.99767192 66.23999786 99.99767192 0.679906941 0 1
CTSB Cathepsin B precursor IPI00295741 40882.91016 5.88 1 60.79999924 99.991853 60.79999924 99.991853 0.679439918 0 1
CA1 22 kDa protein IPI00796435 23598.06055 7.1 2 120.6900024 100 78.69999695 99.99986787 0.677581592 0.323301754 2
BLVRB Flavin reductase IPI00783862 23637.61914 7.13 2 98.02999878 100 51.36999893 99.9285507 0.656692705 0.10878359 2
CYP2C9 Cytochrome P450 2C9 IPI00007219 61374.14063 8.13 1 58.72999954 99.98687806 58.72999954 99.98687806 0.644867428 0 1
ACY1 Aminoacylase-1 IPI00009268 48344.23047 5.77 2 102.6600037 100 59.47000122 99.98893382 0.636258713 7.19E-02 2
GGTLA1 Isoform 2 of Gamma-
glutamyltransferase 5 precursor IPI00339373 61051.73828 7.67 1 52.38000107 99.94337636 52.38000107 99.94337636 0.61143345 0 1
- Histone 2, H3, pseudogene 2 IPI00455457 17482.80078 11.27 2 64.17999268 99.99625891 32.16999817 94.05710513 0.609401873 1.47E-02 2
BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.23828 6.58 3 135.5444489 100 60.06000137 99.99033954 0.605661601 0.124221284 3
HBG2;HBE1;HBG1 Hemoglobin subunit 
gamma-2 IPI00554676 18034.5293 6.64 2 117.3000031 100 59.5 99.98901 0.597563382 5.23E-02 6
HIST3H3 Histone H3.1t IPI00216402 17606.75 11.13 2 71.22999573 99.9992621 39.06000137 98.78382036 0.593159983 0.030970553 2
LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 58388.32813 6.3 4 210.3900146 100 87.55000305 100 0.587386985 0.142071743 4
HBA2;HBA1 Alpha 2 globin variant (Fragment) IPI00853068 17045.16992 8.72 5 468.5 100 154.5599976 100 0.579116026 0.117389209 20
CAT Catalase IPI00465436 64367.17969 6.9 6 286.1144409 100 64.13999939 99.9962243 0.564990742 0.107718904 6
HBD;HBB Hemoglobin subunit delta IPI00473011 17865.5 7.85 9 751.6900024 100 127.4800034 100 0.534643197 0.103774477 24
S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 1 65.37999725 99.99716209 65.37999725 99.99716209 0.531443647 0 1
HBB Hemoglobin subunit beta IPI00654755 17808.5 6.75 13 1154.079956 100 127.4800034 100 0.529018809 0.106601313 30
MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C 41 kDa protein IPI00004672 42978.55078 5.91 1 50.18000031 99.90602814 50.18000031 99.90602814 0.518442417 0 1
GPT Alanine aminotransferase 1 IPI00217458 57510.32813 6.77 1 64.27999878 99.99634407 64.27999878 99.99634407 0.508426217 0 1
HBD Hemoglobin Lepore-Baltimore (Fragment) IPI00829896 12794.0498 6.17 8 654.4799805 100 127.4800034 100 0.503446252 9.16E-02 18
GSTA2 Glutathione S-transferase A2 IPI00745233 29104 8.51 4 192.9399872 100 63.34000015 99.99546061 0.491035057 0.127008813 4
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 199NT
DCXR 26 kDa protein IPI00797249 27252.58984 8.33 2 100.3399963 100 53.93999863 99.96046352 0.490472152 7.11E-02 2
KHK Isoform C of Ketohexokinase IPI00216136 35220.62891 5.91 2 73.91000366 99.9996019 43.31000137 99.5429142 0.477136614 0.165093833 2
CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 30 1745.524536 100 108.4700012 100 0.473984526 0.119502488 31
FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 2 132.8800049 100 70.26999664 99.99907955 0.431392685 0.115631656 3
UGP2 Isoform 2 of UTP--glucose-1-phosphate 
uridylyltransferase IPI00395676 61684.64063 7.69 2 75.56999969 99.99972836 41.09000015 99.23792476 0.427843059 0.13356807 2
COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 2 110.9899979 100 59.91999817 99.99002304 0.41446507 9.92E-02 2
ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 5 354.6199951 100 88.48999786 100 0.407071247 7.90E-02 5
COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 2 165.0800018 100 104.8799973 100 0.364272738 0.214838564 2
HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 1 58.65999985 99.98666485 58.65999985 99.98666485 0.341732609 0 1
ASS1 Argininosuccinate synthase IPI00640430 24839.67969 6.84 3 122.1900024 100 53.63999939 99.95763591 0.341630088 0.109785502 3
- 105 kDa protein IPI00794900 115433.2422 7.3 2 86.55000305 100 51.61999893 99.93254751 0.327526764 9.99E-02 2
ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 7 426.7044373 100 111.5999985 100 0.28944962 0.127992437 9
DEFA3 Neutrophil defensin 3 precursor IPI00021827 10946.21973 5.71 2 67.43000031 99.9982299 33.84000015 95.95426112 0.269986635 6.04E-02 2
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 FDX1 Adrenodoxin, mitochondrial precursor IPI00019326 20618.73047 5.51 2 99.33999634 100 59.38000107 99.9887021 20.0779693 3.243283157 2
 CYP11B1 cytochrome P450, family 11, 
subfamily B, polypeptide 1 isoform 2 pr IPI00167781 52252.19922 8.89 2 87.00444031 100 50.79999924 99.91852996 19.5190535 4.545414295 2
 AKR1B1 Aldose reductase IPI00413641 39896.82031 6.51 3 122.8499985 100 59.70999908 99.98952876 15.2378072 5.92131971 3
 FDXR Isoform Long of NADPH:adrenodoxin 
oxidoreductase, mitochondrial precur IPI00221118 57594.57813 8.67 5 235.1499939 100 69.37999725 99.99887021 5.32286014 2.784525834 5
 HBG2;HBE1;HBG1 Hemoglobin subunit 
gamma-2 IPI00554676 18034.5293 6.64 2 117.3000031 100 59.5 99.98901 4.34617298 0.712485189 6
 TPP1 Isoform 3 of Tripeptidyl-peptidase 1 
precursor IPI00554538 62032.14844 5.94 2 146.3399963 100 85.87999725 100 4.1776737 1.604676874 2
 HBB Hemoglobin subunit beta IPI00654755 17808.5 6.75 13 1154.079956 100 127.4800034 100 3.92374306 2.569823908 30
 HBA2;HBA1 Alpha 2 globin variant (Fragment) IPI00853068 17045.16992 8.72 5 468.5 100 154.5599976 100 3.85949225 1.759290529 20
 HBD;HBB Hemoglobin subunit delta IPI00473011 17865.5 7.85 9 751.6900024 100 127.4800034 100 3.55122879 2.779269289 24
 HBD Hemoglobin Lepore-Baltimore 
(Fragment) IPI00829896 12794.0498 6.17 8 654.4799805 100 127.4800034 100 3.30995209 2.269645048 18
 CA1 22 kDa protein IPI00796435 23598.06055 7.1 2 120.6900024 100 78.69999695 99.99986787 3.05340875 3.638452979 2
 HSPD1 60 kDa heat shock protein, 
mitochondrial precursor IPI00784154 68931.10156 5.7 7 437.0189209 100 101.2300034 100 2.97814028 1.033906592 8
 HSPE1 10 kDa heat shock protein, 
mitochondrial IPI00220362 12653.11035 8.89 6 309.730011 100 65.75 99.99739386 2.72746901 0.947192228 9
 VIL2 Ezrin IPI00843975 77526.5 5.94 2 96.58999634 100 51.29999924 99.92738975 2.69835761 0.904637588 2
 HSPA9 Stress-70 protein, mitochondrial 
precursor IPI00007765 81497.46094 5.87 4 237.5700073 100 98.48000336 100 2.59049674 0.448583396 4
 ASAH1 ASAH1 protein IPI00059685 48400.71094 7.52 2 70.68000031 99.99916 36.27999878 97.69326351 2.57945488 0.785334516 2
 SERPINB6 serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), me IPI00749398 46902.42188 5.18 1 73.79000092 99.99959 73.79000092 99.99959074 2.3665219 0 1
 DLD Dihydrolipoyl dehydrogenase, 
mitochondrial precursor IPI00015911 60048.35938 7.59 1 67.94000244 99.99843 67.94000244 99.99842603 2.36154782 0 1
 FGB Fibrinogen beta chain precursor IPI00298497 61772.66016 8.54 3 126.1300049 100 53.13000107 99.95235715 2.32625421 0.219844022 3
 PAPSS2 Isoform B of Bifunctional 3'-
phosphoadenosine 5'-phosphosulfate synt IPI00220873 76578.32813 8.18 1 61.13999939 99.99247 61.13999939 99.99246648 2.31873375 0 1
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 200NT
 FGA Isoform 2 of Fibrinogen alpha chain 
precursor IPI00029717 76032.28906 8.23 2 173.0100098 100 91.41000366 100 2.26689511 0.326301945 3
 PRDX2 16 kDa protein IPI00375400 18010.59961 6.13 4 218.9100037 100 79.73999786 99.99989601 2.21949693 0.783754503 4
 HSPA6 Heat shock 70 kDa protein 6 IPI00339269 77112.71094 5.81 5 327.7600098 100 118.5800018 100 2.21007407 0.430648475 5
 HSPA1A;HSPA1B heat shock 70kDa protein 
1A IPI00845339 77569.67969 5.48 7 414.2700195 100 118.5800018 100 2.12533543 0.395428783 7
 RDX Radixin IPI00017367 78406.29688 6.03 2 104.2144394 100 54.09000015 99.96180576 2.10524166 8.79E-02 2
 VIL2 Cytovillin 2 (Fragment) IPI00384282 18443.30078 9.32 1 51.29999924 99.92739 51.29999924 99.92738975 2.02085574 0 1
 PEBP1 Phosphatidylethanolamine-binding 
protein 1 IPI00219446 23439.92969 7.01 6 290.5799866 100 79.95999908 99.99990115 2.01120544 0.328686366 7
 HSPB6 Heat-shock protein beta-6 IPI00022433 19439.91992 7.9 1 51.83000183 99.93573 51.83000183 99.93573157 1.98811072 0 1
 HIBADH 3-hydroxyisobutyrate dehydrogenase, 
mitochondrial precursor IPI00013860 38652.03125 8.38 1 72.51999664 99.99945 72.51999664 99.99945173 1.93354793 0 1
 DLST Dihydrolipoyllysine-residue 
succinyltransferase component of 2- oxoglu IPI00420108 52917.75 9.01 2 95.69999695 100 62.45000076 99.99442817 1.84077688 0.301294237 2
 NME2;NME1 Nucleoside diphosphate kinase 
B IPI00026260 19395.17969 8.52 3 134.3600006 100 67.33999634 99.99819283 1.80766451 0.27114135 3
 PGK1 Phosphoglycerate kinase 1 IPI00169383 51100.66016 8.3 2 79.06999969 99.99988 43.93000031 99.60372394 1.80377091 0.128355825 3
 PRDX3 peroxiredoxin 3 isoform b IPI00374151 27924.48047 7.04 2 66.33999634 99.99772 35.93000031 97.49966711 1.7731312 0.186533349 2
 PARK7 Protein DJ-1 IPI00298547 22464.75 6.33 3 190.6999969 100 80.77999878 99.99991815 1.76730078 0.126417256 3
 IMMT Isoform 3 of Mitochondrial inner 
membrane protein IPI00470829 88364.21094 6.31 1 79.62000275 99.99989 79.62000275 99.9998931 1.71882258 0 1
 ANXA5 Annexin A5 IPI00329801 39272.76172 4.94 5 275.3099976 100 89.29000092 100 1.71813522 0.236741215 5
 ACADVL Isoform 2 of Very-long-chain specific 
acyl-CoA dehydrogenase, mitoch IPI00178744 78527.97656 9.06 2 84.43000031 100 52.02000046 99.93848262 1.70162525 0.183194585 2
 HSPA8 Isoform 1 of Heat shock cognate 71 
kDa protein IPI00003865 78958.95313 5.37 8 423.2900085 100 104.3099976 100 1.69971483 0.442463165 8
 hCG_2015269 similar to Phosphoglycerate 
mutase 1 (Phosphoglycerate mutase i IPI00453476 31706.10938 6.67 2 96.81999969 100 51.50999832 99.93081722 1.6992601 6.60E-02 2
 CS citrate synthase precursor, isoform b IPI00383539 50469.26172 6.74 2 74.97000122 99.99969 38.63999939 98.66032971 1.69325536 0.624091275 2
 - FK506 binding protein12 IPI00759644 10743.65039 7.66 1 67.72000122 99.99834 67.72000122 99.99834424 1.67101887 0 1
 HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.0625 4.97 6 382.5299988 100 93.37999725 100 1.63770625 0.542045666 6
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 200NT
 MDH2 Malate dehydrogenase, mitochondrial 
precursor IPI00291006 39765.08984 8.92 2 108.9799957 100 68.69999695 99.99867871 1.62501412 2.78E-02 2
 SPTBN1 Isoform Short of Spectrin beta chain, 
brain 1 IPI00328230 275951.75 5.31 2 69.13444519 99.9988 35.97999954 97.52828775 1.59769178 0.116097345 2
 HNRPA2B1 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 IPI00414696 38478.16016 8.67 3 183.4744415 100 68.37999725 99.99857768 1.55473451 9.47E-02 3
 HSP90AA1 Isoform 1 of Heat shock protein 
HSP 90-alpha IPI00784295 96593.6875 4.94 7 401.8800049 100 93.37999725 100 1.5363124 0.27533818 7
 YWHAG 14-3-3 protein gamma IPI00220642 31015.18945 4.8 4 195.6199951 100 65.08999634 99.99696612 1.52296308 0.716977505 5
 TPM3 Isoform 2 of Tropomyosin alpha-3 chain IPI00218319 32655.08008 4.75 2 84 100 47.56000137 99.82821006 1.52071787 0.51817041 3
 TPM4 Isoform 1 of Tropomyosin alpha-4 chain IPI00010779 32340.88086 4.67 3 131.7900085 100 48.59999847 99.86479336 1.4859766 0.426875432 4
 MSN Moesin IPI00219365 76942.64063 6.08 2 98.42443848 100 51.29999924 99.92738975 1.46340782 0.557447884 2
 ATP5B ATP synthase subunit beta, 
mitochondrial precursor IPI00303476 59980.98828 5.26 6 317.6644592 100 79.31999969 99.99988545 1.45716526 0.534449321 6
 S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 1 65.37999725 99.99716 65.37999725 99.99716209 1.43111454 0 1
 YWHAZ 14-3-3 protein zeta/delta IPI00021263 30890.03906 4.73 4 233.2299805 100 82.76999664 99.99994824 1.40385995 0.474095802 5
 TUFM Tu translation elongation factor, 
mitochondrial IPI00027107 54583.71875 7.26 4 190.6499939 100 70.38999939 99.99910464 1.400834 0.195583744 5
 TRAP1 57 kDa protein IPI00646055 62264.14453 7.21 1 93.29000092 100 93.29000092 100 1.39096819 0 1
 UGT1A10;UGT1A6 UDP-
glucuronosyltransferase 1-10 precursor IPI00233885 64734.48828 6.88 2 92.33000183 100 47.15000153 99.81120186 0.70832374 0.11236795 3
 ALDH2 Mitochondrial aldehyde 
dehydrogenase 2 variant (Fragment) IPI00792207 61065.96094 6.63 4 178.8300018 100 60.02000046 99.99025015 0.70086969 9.21E-02 4
 PGM1 Phosphoglucomutase 1 IPI00844159 66935.90625 6.2 1 56.79000092 99.97949 56.79000092 99.97948848 0.67844088 0 1
 DBI Isoform 2 of Acyl-CoA-binding protein IPI00218836 13802.13965 5.41 2 78.49000549 99.99986 47.95000076 99.84296452 0.67356881 0.468389318 2
 COL6A3 alpha 3 type VI collagen isoform 3 
precursor IPI00072917 345457.3438 6.47 15 639.0344849 100 68.26000214 99.99853783 0.67194973 0.158312144 15
 ACAA1 17 kDa protein IPI00790196 18819 9.39 2 95.22000122 100 58.45999908 99.98603638 0.66614352 0.143166834 2
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 2 110.9899979 100 59.91999817 99.99002304 0.66469585 0.118793491 2
 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial IPI00001539 46153.96875 8.32 5 276.7399902 100 85.08000183 100 0.66459384 0.346219958 5
 ALDH1A1 Retinal dehydrogenase 1 IPI00218914 60949.39063 6.3 5 216 100 54.45999908 99.96492498 0.64280386 0.280001415 5
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 200NT
 TST Thiosulfate sulfurtransferase IPI00216293 35752.05859 6.77 6 306.3644409 100 80.23000336 99.9999071 0.62546074 0.319512346 6
 SCP2 sterol carrier protein 2 isoform 2 IPI00433347 61608.94141 6.25 1 73.46443939 99.99956 74.63999939 99.99966349 0.62491901 0 1
 UGP2 Isoform 2 of UTP--glucose-1-phosphate 
uridylyltransferase IPI00395676 61684.64063 7.69 2 75.56999969 99.99973 41.09000015 99.23792476 0.62202285 0.12838789 2
 ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 1 61.16999817 99.99252 61.16999817 99.99251834 0.62121347 0 1
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 58388.32813 6.3 4 210.3900146 100 87.55000305 100 0.60627287 0.127901868 4
 GSTO1 Glutathione transferase omega-1 IPI00019755 31234.35938 6.23 1 56.38999939 99.97751 56.38999939 99.97750956 0.59766343 0 1
 EHHADH Peroxisomal bifunctional enzyme IPI00216164 86466.10156 9.22 3 142.6100006 100 72 99.99938199 0.59202575 0.148665904 3
 PDIA4 Protein disulfide-isomerase A4 
precursor IPI00009904 82667.8125 4.96 4 157.3600006 100 55.02000046 99.96916828 0.58048645 0.263627762 4
 UGDH UDP-glucose 6-dehydrogenase IPI00031420 60869.64844 6.73 3 159.980011 100 68.37000275 99.9985744 0.57196598 0.28190222 3
 CAT Catalase IPI00465436 64367.17969 6.9 6 286.1144409 100 64.13999939 99.9962243 0.56456156 0.225109723 6
 FASN Fatty acid synthase IPI00847250 287598.7813 5.99 2 104.1900024 100 60.38999939 99.9910464 0.555684 0.376295845 2
 GSTA2 Glutathione S-transferase A2 IPI00745233 29104 8.51 4 192.9399872 100 63.34000015 99.99546061 0.55484335 0.170097667 4
 ACADS Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor IPI00027701 47857.05859 8.13 1 54.95000076 99.96867 54.95000076 99.9686673 0.53320085 0 1
 ECHS1 Enoyl-CoA hydratase, mitochondrial 
precursor IPI00024993 35335.42969 8.34 4 247.7799988 100 76.30000305 99.99977039 0.53309522 0.265723652 4
 ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.07813 8.72 2 75.59999847 99.99973 45.27000046 99.70892975 0.52783435 0.097173422 2
 GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 9 532 100 87.05000305 100 0.52717968 0.256583702 12
 SULT2A1 Bile salt sulfotransferase IPI00216133 37496.32813 5.71 1 35.65999985 97.33929 35.65999985 97.33928793 0.49699235 5.49E-02 2
 GALK1 CDNA FLJ26554 fis, clone LNF01773, 
highly similar to Galactokinase IPI00442827 44445.10938 6.81 1 51.36000061 99.92839 51.36000061 99.92838602 0.49670223 0 1
 ANXA4 annexin IV IPI00793199 39558.51953 5.84 1 66.23999786 99.99767 66.23999786 99.99767192 0.49433877 0 1
 RRBP1 Isoform 1 of Ribosome-binding protein 
1 IPI00220967 178629.8125 8.73 2 92.01000214 100 51.31000137 99.92755678 0.48021297 0.160008974 2
 CYP2C9 Cytochrome P450 2C9 IPI00007219 61374.14063 8.13 1 58.72999954 99.98688 58.72999954 99.98687806 0.47279856 0 1
 PC Pyruvate carboxylase, mitochondrial 
precursor IPI00299402 138358.0469 6.37 1 71.01999664 99.99923 71.01999664 99.99922554 0.46704795 0 1
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 200NT
 CES2 carboxylesterase 2 isoform 1 IPI00332828 72247.0625 6.03 1 61.04999924 99.99231 61.04999924 99.99230873 0.46436769 0 1
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 33322.12891 8.55 2 160.5400085 100 86.30000305 100 0.4477089 0.112624062 2
 AKR1C3 Aldo-keto reductase family 1 member 
C3 IPI00291483 41031.17969 8.05 4 198.3399963 100 63.93000031 99.99603724 0.43815841 0.263827719 4
 AGXT Serine--pyruvate aminotransferase IPI00009367 46426.73047 8.61 2 87.47000122 100 56.11999893 99.97606695 0.42967645 0.158243779 2
 PCK2 Phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial precursor IPI00294380 74737.8125 7.56 8 377.519989 100 59.34000015 99.98859756 0.42267296 0.249940893 9
 UGT2B17 UDP-glucuronosyltransferase 2B17 
precursor IPI00026932 67707.59375 8.76 1 62.15999985 99.99404 62.15999985 99.99404341 0.42169992 0 1
 GPT Alanine aminotransferase 1 IPI00217458 57510.32813 6.77 1 64.27999878 99.99634 64.27999878 99.99634407 0.41174066 0 1
 ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor IPI00009532 61418.91016 8.17 1 64.84999847 99.99679 64.84999847 99.99679375 0.41136028 0 1
 HMGCS2 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial precursor IPI00008934 61333.76953 8.4 4 159.3999939 100 50.04999924 99.90317267 0.40378244 0.816362544 5
 OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.05859 8.75 3 197.2000122 100 109.9100037 100 0.39893402 0.30165356 3
 LOC645619 similar to Adenylate kinase 
isoenzyme 4, mitochondrial IPI00738805 27444.46094 8.47 2 70.94000244 99.99921 37.63999939 98.31345503 0.39828753 0.126782541 2
 ASS1 Argininosuccinate synthase IPI00640430 24839.67969 6.84 3 122.1900024 100 53.63999939 99.95763591 0.39349609 0.099698287 3
 FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 2 132.8800049 100 70.26999664 99.99907955 0.38934455 0.187888274 3
 UGT2B4 UDP-glucuronosyltransferase 2B4 
precursor IPI00301491 66843.75 8.7 2 138.9700012 100 76.80999756 99.99979583 0.38891897 3.28E-02 2
 ALDH4A1 Aldehyde dehydrogenase 4 family, 
member A1 IPI00647328 65056.12109 7.62 5 248.8899994 100 86.48999786 100 0.37204929 0.107857862 5
 MAT1A S-adenosylmethionine synthetase 
isoform type-1 IPI00021772 47392.28906 5.86 2 127.1544418 100 83.33999634 100 0.34340523 0.119832949 2
 DCXR 26 kDa protein IPI00797249 27252.58984 8.33 2 100.3399963 100 53.93999863 99.96046352 0.32498072 0.16360878 2
 FTL Ferritin light chain IPI00852596 21925.33984 5.51 2 105.5099945 100 54.77999878 99.96741648 0.32494578 6.32E-02 2
 CYB5A Isoform 1 of Cytochrome b5 IPI00397860 16616.71094 4.88 4 379.5599976 100 183.6000061 100 0.32475639 0.174978719 5
 BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.23828 6.58 3 135.5444489 100 60.06000137 99.99033954 0.3175794 0.239291426 3
 ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 5 354.6199951 100 88.48999786 100 0.30077176 0.167153887 5
 - 14 kDa protein IPI00788848 15907.24023 5.24 5 308.8699951 100 93.13999939 100 0.29774664 0.314847323 6
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 200NT
 ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03125 8.25 2 82.66000366 99.99995 43.86999893 99.59821107 0.29671189 3.62E-03 2
 GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78125 6.61 6 364.9199829 100 89.69000244 100 0.29328238 0.122597401 6
 HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 1 58.65999985 99.98666 58.65999985 99.98666485 0.27811037 0 1
 AKR1D1 CDNA FLJ25413 fis, clone 
TST03402, highly similar to 3-OXO-5-BETA- 
STEROID 4-DEHYDROGENASE
IPI00065073 33300.88672 8.11 1 54.40000153 99.96444 54.40000153 99.96443706 0.26220713 0 1
 KRT8 Keratin, type II cytoskeletal 8 IPI00554648 58423.62891 5.52 12 681.9089355 100 86.61000061 100 0.25766139 0.13024774 12
 ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 7 426.7044373 100 111.5999985 100 0.25307092 0.155003019 9
 KRT18 Keratin, type I cytoskeletal 18 IPI00784347 51196.89844 5.34 10 420.6199951 100 67.43000031 99.9982299 0.24618872 0.200161765 11
 - 105 kDa protein IPI00794900 115433.2422 7.3 2 86.55000305 100 51.61999893 99.93254751 0.23882092 0.15006211 2
 CES1 carboxylesterase 1 isoform c precursor IPI00607693 68199.60938 6.15 12 712.789978 100 97.69999695 100 0.23456105 0.289282143 13
 CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 30 1745.524536 100 108.4700012 100 0.23079239 0.217635843 31
 ACY1 Aminoacylase-1 IPI00009268 48344.23047 5.77 2 102.6600037 100 59.47000122 99.98893382 0.19060681 9.14E-02 2
 KHK Isoform C of Ketohexokinase IPI00216136 35220.62891 5.91 2 73.91000366 99.9996 43.31000137 99.5429142 0.18216674 0.173504471 2
 KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 2 95.88000488 100 55.40000153 99.97175135 0.15999566 8.66E-02 3
 ARG1 Isoform 1 of Arginase-1 IPI00291560 38451.66016 6.72 1 58.56000137 99.98635 58.56000137 99.98635424 0.07846065 0 1






























 LTBP2 Latent-transforming growth factor beta-
binding protein 2 precursor IPI00292150 207622.5469 5.08 1 62.54000092 99.99492142 62.54000092 99.99492142 104.658011 0 1
 MT1X Metallothionein-1X IPI00008753 8279.200195 8.38 2 128.0400085 100 84.55000305 100 23.9242234 19.45809266 2
 MT1H;MT1P2 Metallothionein-1H IPI00008750 8394.240234 8.49 2 105.9499969 100 62.45999908 99.994827 21.2395437 12.95268355 2
 MT1E Metallothionein-1E IPI00025461 8225.160156 8.38 2 118.9500046 100 84.55000305 100 20.5229264 2.29E+01 2
 MT1M Metallothionein-1M IPI00642651 8033.149902 8.05 2 122.9000015 100 84.55000305 100 19.0680509 2.43E+01 2
 - Metallothionein-1F IPI00746270 15151.62012 8.17 2 105.6300049 100 71.23000336 99.99931334 18.8218372 17.66684305 2
 PRELP Prolargin precursor IPI00020987 46264.33984 9.47 8 448.0200195 100 84.88999939 100 12.7707615 2.670195955 8
 FBLN5 Full-length cDNA clone CS0DI085YI08 
of Placenta of Homo sapiens IPI00382428 56833.08984 4.57 3 132.1799927 100 56.20000076 99.97813537 8.65992717 6.679735521 3
 OGN Osteoglycin IPI00515092 34941.69141 8.49 4 177.2900085 100 49.52999878 99.8984354 8.20476636 2.306501125 4
 ASPN ASPN protein IPI00418431 49081.85938 6.03 3 112.2100067 100 42.58000183 99.49679837 7.52104415 2.804192992 3
 AKR1B10 Aldo-keto reductase family 1 
member B10 IPI00105407 41078.28125 7.12 7 490.6300049 100 97.18000031 100 6.84119627 2.656214326 7
 LUM Lumican precursor IPI00020986 42425.12891 6.16 9 529.9744263 100 85.91999817 100 6.81407128 2.426430431 9
 POSTN Isoform 2 of Periostin precursor IPI00218585 96544.46875 7.87 1 62.83000183 99.99524947 62.83000183 99.99524947 6.70785702 0 1
 COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 2 131.8500061 100 85.20999908 100 6.52690877 1.448670728 2
 BGN Biglycan preproprotein variant 
(Fragment) IPI00643384 45356.82031 7.16 7 529.0999756 100 138.6000061 100 6.37695415 2.563716411 7
 CFL1 24 kDa protein IPI00784459 28091.64063 8.13 3 230.4200134 100 90.93000031 100 6.13607265 20.27122084 3
 DCN Isoform A of Decorin precursor IPI00012119 44030.19922 8.75 3 204.0944519 100 89.51000214 100 5.99276418 1.162174019 3
 TAGLN Transgelin IPI00216138 25234.73047 8.87 7 393.2200317 100 96.01000214 100 5.44227728 7.678081372 8
 CSRP1 Cysteine and glycine-rich protein 1 IPI00442073 24699.9707 8.9 3 297.3399963 100 168.1399994 100 5.43849809 3.155947561 3
 CLU clusterin isoform 1 IPI00400826 62857.89844 6.24 3 200.7744446 100 92.27999878 100 5.28852796 3.599673089 3
 LSP1 50 kDa protein IPI00554652 54843.82031 5.42 1 92.48000336 100 92.48000336 100 5.23139084 0 1
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 4 287.7600098 100 98.44000244 100 4.89498933 1.891593154 4
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 203NT
 NID1 Isoform 2 of Nidogen-1 precursor IPI00384542 127664.8828 5.29 2 121.8199997 100 77.61000061 99.99984197 4.78397404 2.612946878 2
 IGFBP7 Insulin-like growth factor-binding 
protein 7 precursor IPI00016915 32243.50977 8.25 1 61.40000153 99.99339699 61.40000153 99.99339699 4.45164234 0 1
 FLNA Filamin-A IPI00333541 305957.375 5.7 29 2074.378174 100 134.0500031 100 4.22114196 2.073562741 29
 HIST2H2AB Histone H2A type 2-B IPI00216730 16003.11035 10.88 2 73.97000122 99.99963462 41.65000153 99.3766355 3.94987782 0.530556835 2
 VIM Vimentin IPI00418471 56977.44141 5.06 25 1802.358765 100 136.3699951 100 3.91551457 1.264033399 25
 CALD1 Isoform 2 of Caldesmon IPI00218694 76226.46875 6.37 4 288.1199951 100 107.3099976 100 3.87340549 1.637916455 4
 COL14A1 Isoform 3 of Collagen alpha-1(XIV) 
chain precursor IPI00402215 195721.9844 5.16 5 381.1444397 100 135.8600006 100 3.83547973 2.46855347 5
 HSPB6 Heat-shock protein beta-6 IPI00022433 19439.91992 7.9 2 77.02999878 99.99981939 45.70000076 99.75467481 3.63087591 0.153739909 2
 ANXA2 Annexin A2 IPI00455315 43516.26953 7.57 13 894.2489624 100 142.4600067 100 3.5744064 1.896433874 14
 HSPG2 Basement membrane-specific 
heparan sulfate proteoglycan core protein IPI00024284 487110.1563 6.06 3 105.0067749 100 37.59999847 98.4160467 3.50153407 0.157090052 3
 ARHGDIB 13 kDa protein IPI00791712 14875.75977 4.69 1 116.0599976 100 116.0599976 100 3.49527137 0 1
 MARCKS Myristoylated alanine-rich C-kinase 
substrate IPI00219301 35850.28125 4.47 1 90.79000092 100 90.79000092 100 3.45338156 0 1
 GSTP1 19 kDa protein IPI00793319 20948.17969 5.67 2 137.4700012 100 90.75 100 3.44526495 4.76E-02 2
 ALB Isoform 1 of Serum albumin precursor IPI00745872 79715.90625 5.92 40 2784.528809 100 195.3800049 100 3.36749049 1.169666579 54
 CRIP2 Cysteine-rich protein 2 IPI00006034 26434.21094 9.01 1 53.93000031 99.96312414 53.93000031 99.96312414 3.36661396 0 1
 TAGLN2 24 kDa protein IPI00647915 26448.48047 8.41 7 509.8900146 100 106.1100006 100 3.33269828 1.839249697 7
 SERPINA1 Alpha-1-antitrypsin precursor IPI00553177 51885.51172 5.37 14 954.3599243 100 115.3000031 100 3.25645762 1.270569399 14
 TPM1 Isoform 3 of Tropomyosin alpha-1 chain IPI00216135 38040.28906 4.72 7 411.734436 100 95.33000183 100 3.20212438 1.126004174 7
 ANXA1 Annexin A1 IPI00549413 25333.10938 5.39 4 285.1400146 100 112.1699982 100 3.1737076 0.866148037 4
 TPM4 Isoform 1 of Tropomyosin alpha-4 chain IPI00010779 32340.88086 4.67 8 505.9144287 100 95.33000183 100 3.08817283 0.64967053 8
 GSN Isoform 2 of Gelsolin precursor IPI00646773 87445.10938 5.58 3 122.9599991 100 43.18000031 99.56172955 3.07178112 0.921114052 3
 CNN3 Calponin-3 IPI00216682 40129.14844 5.69 1 55.27000046 99.97291417 55.27000046 99.97291417 3.06800245 0 1
 VTN Vitronectin precursor IPI00298971 57939.35156 5.55 6 280.3200073 100 73.66000366 99.99960759 3.06759651 1.177036838 6
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 203NT
 SERPINH1 CDNA FLJ16712 fis, clone 
UTERU2032279, highly similar to 47 kDa HE IPI00442080 30003.93945 9.62 1 62.81000137 99.99522754 62.81000137 99.99522754 3.03424554 0 1
 MYH11 smooth muscle myosin heavy chain 11 
isoform SM2B IPI00744256 254257.9219 5.44 8 545.8088989 100 144.9100037 100 2.99247621 1.827895861 8
 LMNA Isoform C of Lamin-A/C IPI00216952 70902.15625 6.4 20 1336.18457 100 129.7400055 100 2.9795141 0.562513271 20
 LOC646913 similar to cell division cycle 10 
isoform 1 IPI00737735 61445.96875 7.55 1 94.05999756 100 94.05999756 100 2.9734518 0 1
 ACTG2 Actin, gamma-enteric smooth muscle IPI00025416 45052.03906 5.31 16 1215.809937 100 171.8300018 100 2.9447524 2.362217172 22
 LMNB1 Lamin-B1 IPI00217975 72358.14844 5.11 2 114.4199982 100 79.47000122 99.99989702 2.90208586 0.85401967 2
 YWHAZ 14-3-3 protein zeta/delta IPI00021263 30890.03906 4.73 10 767.694458 100 147.3800049 100 2.87645589 0.6446227 11
 SET Isoform 2 of Protein SET IPI00301311 35108.05859 4.12 1 66.54000092 99.99797818 66.54000092 99.99797818 2.87522486 0 1
 MIF 12 kDa protein IPI00790382 12661.19043 9.3 2 110.0899963 100 58.97999954 99.98847231 2.81211438 0.230462546 3
 PKM2 Isoform M2 of Pyruvate kinase 
isozymes M1/M2 IPI00479186 63832.46094 7.96 5 329.75 100 109.0699997 100 2.79179249 1.791310373 5
 FUS Fus-like protein (Fragment) IPI00260715 55689.03125 9.46 2 144.7799988 100 72.94999695 99.99953789 2.79090173 1.061129248 2
 IGKC IGKC protein IPI00430808 27732.05078 6.15 4 405.3300171 100 169.0700073 100 2.78447743 0.383220055 4
 TPM2 Isoform 2 of Tropomyosin beta chain IPI00220709 38056.12109 4.63 7 450.6799927 100 95.33000183 100 2.76924719 1.409365656 7
 ACTC1 Actin, alpha cardiac muscle 1 IPI00023006 45148.14063 5.23 16 1231.529907 100 171.8300018 100 2.75318541 1.942606295 23
 - Hypothetical protein IPI00807428 26545.32031 5.66 4 380.25 100 124.9400024 100 2.73325627 0.699173395 4
 MYL6 17 kDa protein IPI00744444 18920.58008 4.54 6 504 100 135.4100037 100 2.71287517 0.70382937 8
 HNRPL heterogeneous nuclear 
ribonucleoprotein L isoform b IPI00465225 54634.78125 7.22 1 91.26999664 100 91.26999664 100 2.71155933 0 1
 IGLV3-25 IGLV3-25 protein IPI00550162 27143.41992 5.23 4 379.6399841 100 124.9400024 100 2.67936233 0.745953638 4
 ITGB1 integrin beta 1 isoform 1A precursor IPI00645194 99377.10938 5.27 1 104.6800003 100 104.6800003 100 2.67136079 0 1
 HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55078 9.27 5 350.9200134 100 115.3700027 100 2.64361214 0.86223201 5
 ANXA5 Annexin A5 IPI00329801 39272.76172 4.94 10 643.960022 100 112.4300003 100 2.62216781 1.267939925 10
 COL6A3 alpha 3 type VI collagen isoform 3 
precursor IPI00072917 345457.3438 6.47 35 1893.973511 100 127.8799973 100 2.61710408 0.884991847 36
 
HIST1H2BI;HIST1H2BG;HIST1H2BF;HIST1H2
BC;HIST1H2BE H2B histone family, membe
IPI00020101 16921.91016 10.31 5 357.2099915 100 107.5100021 100 2.61105341 0.435735167 8
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 203NT
 COL6A2 Isoform 2C2 of Collagen alpha-2(VI) 
chain precursor IPI00304840 117254.4375 5.85 4 192.9400024 100 75.01999664 99.99971309 2.55851357 0.694370684 4
 COL6A3 alpha 3 type VI collagen isoform 4 
precursor IPI00072918 345401.0313 6.48 35 1887.693481 100 127.8799973 100 2.54926238 0.8218367 36
 GGTLA1 Isoform 2 of Gamma-
glutamyltransferase 5 precursor IPI00339373 61051.73828 7.67 2 126.8100052 100 85.98000336 100 2.53733169 2.09E-01 2
 SFPQ Isoform Long of Splicing factor, proline- 
and glutamine-rich IPI00010740 81090.10938 9.45 3 224.2399902 100 111.5100021 100 2.53502581 0.429913032 3
 HPX Hemopexin precursor IPI00022488 55409.48047 6.55 2 119.8600006 100 75.11000061 99.99971898 2.52604094 6.33E-01 2
 SERPINF1 25 kDa protein IPI00796279 26706.00977 5.84 1 63.97000122 99.99634622 63.97000122 99.99634622 2.52410869 0 1
 - Hypothetical protein IPI00784807 56014.51953 6.56 6 367.8200073 100 84.55000305 100 2.50599106 1.295226003 6
 CTSS Cathepsin S precursor IPI00299150 42009.60938 8.61 2 102.1800003 100 68.06999969 99.99857852 2.46678877 0.894047237 2
 - Ig kappa chain V-III region SIE IPI00387115 12435.95996 8.7 1 79.19999695 99.99989042 79.19999695 99.99989042 2.43874871 0 1
 - Ig kappa chain V-III region B6 IPI00387113 12295.89063 9.34 1 77.33677673 99.99983171 79.19999695 99.99989042 2.43874871 0 1
 MYH10 Isoform 2 of Myosin-10 IPI00479307 260063.1719 5.46 11 768.4022217 100 144.9100037 100 2.43613307 0.452570188 11
 LCP1 Plastin-2 IPI00010471 77185.35938 5.2 7 353.4099731 100 76.11000061 99.99977678 2.42810102 0.908979286 7
 VCL Isoform 2 of Vinculin IPI00307162 135558.7656 5.5 5 314.5144348 100 106.8600006 100 2.42535015 0.843440365 5
 TPM3 tropomyosin 3 isoform 1 IPI00183968 38592.33984 4.68 5 321.2999878 100 95.33000183 100 2.42269262 1.191990153 5
 ARL6IP5 PRA1 family protein 3 IPI00007426 23184.64063 9.77 1 52.77000046 99.95183382 52.77000046 99.95183382 2.40448552 0 1
 IGHM IGHM protein IPI00761159 57955.55078 7.53 10 806.7399292 100 132.1900024 100 2.40113246 0.913000549 10
 HLA-DPB1 HLA class II histocompatibility 
antigen, DP(W4) beta chain precurs IPI00103082 30666.89063 8.83 1 62.77999878 99.99519446 62.77999878 99.99519446 2.39997254 0 1
 AHNAK AHNAK nucleoprotein isoform 1 IPI00021812 748355.625 5.8 4 224.1851196 100 89.66999817 100 2.39476711 1.2683173 4
 NPM1 Isoform 1 of Nucleophosmin IPI00549248 37589.32031 4.64 6 362.230011 100 104.3899994 100 2.37286745 0.490212817 6
 - Hypothetical protein DKFZp686M24218 IPI00784998 57403.42969 7.89 4 245.0899963 100 84.55000305 100 2.37068051 0.763240113 4
 - MHC-F3 REPEAT, fibronectin type III 
REPEAT=CLONE 3.9KF3-2 IPI00743608 191267.9063 4.89 3 132.1712341 100 56.95999908 99.98164551 2.34470743 0.487972031 3
 IGHG1 Hypothetical protein DKFZp686P15220 IPI00645363 56996.17188 8.13 10 825.8999634 100 132.1900024 100 2.34429502 0.874852037 10
 IGHA1 IGHA1 protein IPI00166866 57142.32031 6.26 6 370.0299988 100 105.3799973 100 2.34145908 2.18E-01 7
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 203NT
 ACTG1;PSPHL Actin, cytoplasmic 2 IPI00021440 44922.05859 5.31 16 1344.609985 100 214.6799927 100 2.33200543 0.680408253 22
 DKFZp686D0972 hypothetical protein 
LOC345651 IPI00003269 44988.21875 5.39 6 360.3200073 100 85.76000214 100 2.31383247 0.366666094 8
 XRCC5 ATP-dependent DNA helicase 2 
subunit 2 IPI00220834 92329.03906 5.55 2 71.95999908 99.99941958 40.38000107 99.16489302 2.3136101 6.09E-01 2
 G3BP2 Isoform B of Ras GTPase-activating 
protein-binding protein 2 IPI00179890 53856.42969 5.27 1 55.70000076 99.97546748 55.70000076 99.97546748 2.30879692 0 1
 ACTN2 Alpha-actinin-2 IPI00019884 112024.9219 5.31 6 276.4533386 100 66.94999695 99.99816032 2.25631397 0.258964121 7
 TF Transferrin variant (Fragment) IPI00798430 87365.92188 6.68 25 1678.903442 100 111.4899979 100 2.24823666 0.504521273 25
 HNRPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 IPI00419373 42922.89844 9.1 4 364.6300049 100 172.4499969 100 2.24647791 0.274565562 4
 COL4A2 Collagen type IV alpha 2 IPI00477950 179684.2344 8.86 2 91.20999908 100 58.72999954 99.98778925 2.24080758 1.64E-02 2
 APOA1 Apolipoprotein A-I precursor IPI00021841 34071.30859 5.56 6 287.7000122 100 65.45999908 99.99740736 2.23609317 0.36530168 6
 FN1 Isoform 1 of Fibronectin precursor IPI00022418 276716.375 5.45 11 526.9788818 100 64.12999725 99.99647838 2.19600038 1.034150409 11
 C20orf77 Uncharacterized protein C20orf77 IPI00009659 41289.62109 5.73 1 58.81000137 99.98801213 58.81000137 99.98801213 2.17422432 0 1
 - FK506 binding protein12 IPI00759644 10743.65039 7.66 1 54.33000183 99.96636883 54.33000183 99.96636883 2.14425899 0 1
 COL6A1 Collagen alpha-1(VI) chain precursor IPI00291136 117302.5391 5.26 4 258.6099854 100 100.1800003 100 2.14081077 1.219080756 5
 COL18A1 Isoform 3 of Collagen alpha-1(XVIII) 
chain precursor IPI00414694 141995.6406 6.04 3 141.230011 100 66.54000092 99.99797818 2.13652519 0.832744318 3
 MYH9 Myosin-9 IPI00019502 257357.9844 5.5 42 3132.524414 100 144.9100037 100 2.12479204 0.656929606 43
 IGHM Hypothetical protein DKFZp686I15212 IPI00418153 62655.28125 8.39 7 379.1400146 100 84.55000305 100 2.122753 0.627275333 7
 XRCC6 70 kDa protein IPI00465430 78696.84375 6.23 3 193.5500031 100 94.98000336 100 2.11794227 1.102584544 3
 APCS Serum amyloid P-component precursor IPI00022391 27335.35938 6.1 2 148.230011 100 79.61000061 99.99990029 2.10981998 0.376387643 2
 YWHAQ 14-3-3 protein theta IPI00018146 30857.03906 4.68 6 311.9400024 100 88.83000183 100 2.10728475 0.535643449 6
 CAP1 Adenylyl cyclase-associated protein IPI00639931 58646.21094 8.24 2 136.5599976 100 73.62000275 99.99960396 2.09801547 0.240358481 2
 HIST3H2A Histone H2A type 3 IPI00031562 16129.2002 11.05 4 242.1699829 100 135.9299927 100 2.08742194 1.343221694 5
 HDGF Hepatoma-derived growth factor IPI00020956 30896.2793 4.7 2 118.7844391 100 72.22000122 99.99945331 2.08417928 0.414675489 2
 SFN Isoform 2 of 14-3-3 protein sigma IPI00411765 26671.25 4.77 4 189.7100067 100 54.90000153 99.97050543 2.07517412 0.362938173 4
Moderately Differentiated iTRAQ Individual Patients
Moderate Diff 203NT
 SRP9 Hypothetical protein DKFZp564M2223 IPI00419797 8474.950195 6.81 1 52.93999863 99.95368279 52.93999863 99.95368279 2.0519497 0 1
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C Isoform 1 of HLA class I histoco IPI00472448 42869.39063 5.77 5 242.5700073 100 61.74000168 99.99389421 2.0391788 0.138453578 5
 HNRPH2 Heterogeneous nuclear 
ribonucleoprotein H' IPI00026230 51910.53125 5.89 5 268.5 100 99.12999725 100 2.03819639 0.51560158 5
 KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 6 295.4400024 100 65.37999725 99.99735916 2.03661785 2.618510416 6
 TTR 13 kDa protein IPI00646384 14770.61035 5.34 3 221.7900085 100 95.23999786 100 2.02328728 0.223763829 3
 EWSR1 CDNA FLJ32119 fis, clone 
PEBLM1000034, highly similar to RNA-
BINDING PROTEIN EWS
IPI00065554 65261.13281 9.43 1 53.86000061 99.96252496 53.86000061 99.96252496 2.0220847 0 1
 ACTN1 Actinin alpha 1 isoform b IPI00759776 114216.3906 5.25 20 1306.753296 100 139.1100006 100 2.01879239 0.42815741 21
 HNRPH1 HNRPH1 protein IPI00479191 53875.41016 6.33 5 288.3544312 100 99.12999725 100 2.01536292 0.559324779 5






























 AKR1B10 Aldo-keto reductase family 1 
member B10 IPI00105407 41078.28125 7.12 7 490.6300049 100 97.18000031 100 7.123890909 1.692446185 7
 PGM2 Phosphoglucomutase-2 IPI00550364 75710.97656 6.28 2 153.0200043 100 102.2600021 100 4.448052748 2.146895462 3
 LOC728320 similar to lactotransferrin IPI00788271 62413.83984 6.43 2 136.8300018 100 76.44000244 99.99979311 3.779153087 1.074014684 2
 HBD Hemoglobin Lepore-Baltimore 
(Fragment) IPI00829896 12794.0498 6.17 9 727.8300171 100 137.0299988 100 3.625005948 1.39880615 11
 HBB Hemoglobin subunit beta IPI00654755 17808.5 6.75 13 1234.580078 100 139.4900055 100 3.31471078 1.418526684 18
 OS9 amplified in osteosarcoma isoform 4 
precursor IPI00604451 80767.53125 4.81 1 65.12999725 99.99720268 65.12999725 99.99720268 3.314359622 0 1
 SLC4A1 Erythroid anion exchange protein IPI00788779 68660.35938 4.78 2 90.36000061 100 47.61999893 99.84233245 3.279293312 1.209274147 2
 DEFA3 Neutrophil defensin 3 precursor IPI00021827 10946.21973 5.71 2 66.11000061 99.99776775 33.18999863 95.62737376 3.254040647 0.342414917 2
 HBD;HBB Hemoglobin subunit delta IPI00473011 17865.5 7.85 13 1094.660034 100 137.0299988 100 3.246160908 0.679019173 15
 S100A8 Protein S100-A8 IPI00007047 12745.88965 6.51 6 342.2744751 100 77.48000336 99.99983717 3.219759622 0.766994811 6
 NUCB2 Nucleobindin-2 precursor IPI00009123 57484.05078 5.03 2 126.3499985 100 71.94999695 99.99941824 2.899157565 1.007252253 2
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472282 42025.16016 5.89 4 205.4544373 100 61.74000168 99.99389421 2.843580489 0.817836584 4
 HBG2;HBE1;HBG1 Hemoglobin subunit 
gamma-2 IPI00554676 18034.5293 6.64 2 84.96000671 100 51.81000137 99.93991832 2.815035465 0.172274998 2
 S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 5 422.9100037 100 134.5599976 100 2.762495753 0.71043372 5
 RPN2 Ribophorin II IPI00383680 72001.89063 5.7 1 69.76999664 99.99903896 69.76999664 99.99903896 2.607302498 0 1
 HBA2;HBA1 Alpha 2 globin variant (Fragment) IPI00853068 17045.16992 8.72 6 582.5 100 229.7299957 100 2.591589199 0.761376222 19
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00026602 42374.19922 6.09 4 204.0400085 100 61.74000168 99.99389421 2.579925886 1.05386237 4
 PKM2 Isoform M2 of Pyruvate kinase 
isozymes M1/M2 IPI00479186 63832.46094 7.96 5 329.75 100 109.0699997 100 2.54574153 0.639404747 5
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472138 41982.19141 5.9 5 276.2000122 100 63.97000122 99.99634622 2.537511395 0.853799057 5
 SEL1L Isoform 2 of Sel-1 homolog precursor IPI00555723 36763.62891 4.77 1 91.08999634 100 91.08999634 100 2.519071293 0 1
 LSP1 50 kDa protein IPI00554652 54843.82031 5.42 1 92.48000336 100 92.48000336 100 2.509160472 0 1
 PYGB Glycogen phosphorylase, brain form IPI00004358 105395.1719 6.4 2 87.47000122 100 54.81999969 99.96995707 2.385929941 0.212140518 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 LYZ Lysozyme C precursor IPI00019038 17902.35938 9.38 2 120.5200043 100 89.75 100 2.376883312 0.293678474 2
 UBE1L2 Isoform 2 of Ubiquitin-activating 
enzyme E1-like protein 2 IPI00827491 73283.60156 7.29 2 94.93000031 100 48.06999969 99.85785151 2.367610106 0.363398914 2
 WARS tryptophanyl-tRNA synthetase isoform 
b IPI00412737 53848.82813 6.03 3 121.7200012 100 50.18999863 99.91275464 2.316721901 0.453871478 3
 PKLR Pyruvate kinase L IPI00743713 67899.96875 7.6 4 254.7200012 100 81.97000122 99.99994209 2.30529557 0.481581329 4
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C Isoform 1 of HLA class I histoco IPI00472448 42869.39063 5.77 5 242.5700073 100 61.74000168 99.99389421 2.305110095 0.281869015 5
 CA1 Carbonic anhydrase 1 IPI00215983 31634.69922 6.59 3 257.0899963 100 101.2900009 100 2.290426165 0.829497613 3
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472903 42843.35156 6.52 5 250.7000122 100 61.74000168 99.99389421 2.284441765 0.500516039 5
 SERPINB1 Leukocyte elastase inhibitor IPI00027444 47127.14063 5.9 2 170.8600006 100 118.9499969 100 2.270544388 0.715635753 2
 GBP1 Interferon-induced guanylate-binding 
protein 1 IPI00028564 76194.35156 5.97 5 276.7299805 100 81.90000153 99.99994115 2.238426637 0.234848304 5
 EIF5 Eukaryotic translation initiation factor 5 IPI00022648 56760.42188 5.41 1 66.48000336 99.99795006 66.48000336 99.99795006 2.186656479 0 1
 CCT6A chaperonin containing TCP1, subunit 
6A isoform b IPI00552590 59959.64844 6.85 1 61.59999847 99.99369417 61.59999847 99.99369417 2.167958591 0 1
 CANX Calnexin precursor IPI00020984 75958.53906 4.47 7 465.5144348 100 83.55000305 100 2.145721468 0.30738692 7
 PDIA4 Protein disulfide-isomerase A4 
precursor IPI00009904 82667.8125 4.96 17 1002.425659 100 142.8500061 100 2.138753623 0.433052752 17
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00644631 43142.39063 6.5 3 129.2600098 100 63.97000122 99.99634622 2.100769075 6.65E-02 3
 MIF 12 kDa protein IPI00790382 12661.19043 9.3 2 110.0899963 100 58.97999954 99.98847231 2.100398253 0.126610338 3
 PDIA4 Protein IPI00852792 21271.91992 8.33 5 274.0899963 100 86.45999908 100 2.087016322 0.250960018 5
 VARS similar to Valyl-tRNA synthetase (Valine-
-tRNA ligase) (ValRS) (Protei IPI00646425 42804.14844 9.44 1 57.88000107 99.98514946 57.88000107 99.98514946 2.078790881 0 1
 EEF1G;LOC729998 similar to Elongation 
factor 1-gamma IPI00738381 55298.73828 7.09 6 307.8099976 100 82.68000031 100 2.078047461 0.5442416 6
 NME1;NME2 Nucleoside diphosphate kinase IPI00604590 36163.17969 8.7 8 503.9377747 100 113.2799988 100 2.052168598 0.354718509 8
 ARPC2 Actin-related protein 2/3 complex 
subunit 2 IPI00005161 38147.87109 6.84 1 65.26999664 99.99729141 65.26999664 99.99729141 2.048490828 0 1
 ARL6IP5 PRA1 family protein 3 IPI00007426 23184.64063 9.77 1 52.77000046 99.95183382 52.77000046 99.95183382 2.048039321 0 1
 HSPA5 HSPA5 protein IPI00003362 81398.29688 5.07 22 1967.191406 100 151.8399963 100 2.036456694 0.232681477 23
 - CDNA FLJ41483 fis, clone BRTHA2002808, 
highly similar to GAMMA- INTERFERO IPI00446576 17847.26953 4.57 1 55.33000183 99.97328581 55.33000183 99.97328581 2.034800619 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472222 42679.30078 6.02 5 281.7744446 100 94.26999664 100 2.024358367 0.294927 5
 PDIA3 55 kDa protein IPI00657680 62595.51953 6.42 19 1612.418823 100 192.4400024 100 2.011223819 0.341646378 20
 RAN 26 kDa protein IPI00792352 29358.91016 8.51 3 139.8299866 100 67 99.99818138 2.000303418 0.324738723 3
 FGB Fibrinogen beta chain precursor IPI00298497 61772.66016 8.54 11 732.4000244 100 115.3000031 100 1.993790379 0.310594438 11
 STAT1 Isoform Beta of Signal transducer and 
activator of transcription 1-al IPI00218188 91515.17188 6.02 6 361.9700317 100 79.08000183 99.99988735 1.983432364 0.492587584 6
 PSMA4 Proteasome subunit beta type IPI00789638 30677.13086 6.91 1 63.59999847 99.99602129 63.59999847 99.99602129 1.966454743 0 1
 SRP9 Hypothetical protein DKFZp564M2223 IPI00419797 8474.950195 6.81 1 52.93999863 99.95368279 52.93999863 99.95368279 1.95624833 0 1
 LCP1 Plastin-2 IPI00010471 77185.35938 5.2 7 353.4099731 100 76.11000061 99.99977678 1.948382673 0.46354034 7
 FDPS Farnesyl diphosphate synthase IPI00101405 51970.89063 5.83 4 331.4300232 100 117.8700027 100 1.923686938 0.647013125 4
 - Farnesyl pyrophosphate synthetase like-4 
protein (Fragment) IPI00382869 42840.89844 4.87 4 252.730011 100 102.9800034 100 1.923686938 0.647013125 4
 C3 Complement C3 precursor (Fragment) IPI00783987 204689.0469 6.02 8 397.230011 100 75.95999908 99.99976893 1.917471773 0.354338109 9
 HNRPAB Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A/B IPI00329355 41002.28906 9.04 2 94.48999786 100 54.22999954 99.96558544 1.914916618 0.360357999 2
 CCT5 T-complex protein 1 subunit epsilon IPI00010720 66337.35156 5.45 3 162.7399902 100 82.09999847 99.9999438 1.909663205 0.17252162 3
 GBP2 GBP2 protein IPI00848358 76021.07813 5.54 2 132.6799927 100 75.37999725 99.99973592 1.900440109 0.033929903 2
 PDIA6 Isoform 1 of Protein disulfide-isomerase 
A6 precursor IPI00644989 52733.64063 4.95 9 570.8900146 100 108.1800003 100 1.893954218 0.617604415 11
 HSP90B1 Endoplasmin precursor IPI00027230 104018.3516 4.76 23 1668.059937 100 138.4100037 100 1.887056529 0.388206162 24
 NAPB Beta-soluble NSF attachment protein IPI00748037 37843.85938 5.32 2 79.61000061 99.99990029 43.75 99.61563643 1.886482472 0.2151396 2
 ARHGDIB 13 kDa protein IPI00791712 14875.75977 4.69 1 116.0599976 100 116.0599976 100 1.872277198 0 1
 CCT2 T-complex protein 1 subunit beta IPI00297779 63200.62109 6.01 2 158.8399963 100 89.55999756 100 1.865851694 1.87E-02 2
 CTSS Cathepsin S precursor IPI00299150 42009.60938 8.61 2 102.1800003 100 68.06999969 99.99857852 1.859019847 0.214055188 2
 EPHX1 Epoxide hydrolase 1 IPI00009896 57419.37891 6.77 13 796.0800781 100 102.8399963 100 1.854227328 0.456533738 14
 EWSR1 CDNA FLJ32119 fis, clone 
PEBLM1000034, highly similar to RNA-
BINDING PROTEIN EWS
IPI00065554 65261.13281 9.43 1 53.86000061 99.96252496 53.86000061 99.96252496 1.852724885 0 1
 ARPC3 12 kDa protein IPI00796102 13215.08008 8.52 2 77 99.99981814 40.08000183 99.10516691 1.837952912 5.15E-02 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00646225 42792.37891 6.02 5 265.6544189 100 94.26999664 100 1.837015265 0.24886544 5
 XRCC5 ATP-dependent DNA helicase 2 
subunit 2 IPI00220834 92329.03906 5.55 2 71.95999908 99.99941958 40.38000107 99.16489302 1.830851987 0.18427055 2
 PPIB peptidylprolyl isomerase B precursor IPI00646304 27661.94922 9.42 10 713.3944702 100 105.7900009 100 1.815333042 0.168546768 11
 SAMHD1 SAM domain and HD domain-
containing protein 1 IPI00294739 79521.28906 6.69 3 119.7599945 100 43.88000107 99.62697142 1.805975726 0.614678945 3
 RAB1B Ras-related protein Rab-1B IPI00008964 24743.49023 5.55 1 81.81999969 99.99994006 81.81999969 99.99994006 1.80286808 0 1
 CCT8 T-complex protein 1 subunit theta IPI00784090 66090.99219 5.42 1 70.30999756 99.99915132 70.30999756 99.99915132 1.802445244 0 1
 HYOU1 Hypoxia up-regulated protein 1 
precursor IPI00000877 122683.2188 5.16 7 475.25 100 139.1399994 100 1.793325289 0.402444295 7
 SERPINB6 serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), me IPI00749398 46902.42188 5.18 1 69.33000183 99.99893649 69.33000183 99.99893649 1.792798806 0 1
 DDOST dolichyl-diphosphooligosaccharide-
protein glycosyltransferase precurs IPI00297084 54075.30078 6.09 2 96.75 100 50.77999878 99.9238373 1.788077331 0.436364235 2
 HNRPU heterogeneous nuclear 
ribonucleoprotein U isoform a IPI00644079 101350.8203 5.76 3 183.8200073 100 84.73000336 100 1.779424994 0.699230604 3
 LMAN2 Vesicular integral-membrane protein 
VIP36 precursor IPI00009950 43071.33984 6.46 2 115.7400055 100 57.97000122 99.98545405 1.769161746 0.130659921 2
 MARCKS Myristoylated alanine-rich C-kinase 
substrate IPI00219301 35850.28125 4.47 1 90.79000092 100 90.79000092 100 1.761123681 0 1
 TMEM4 Isoform 1 of MIR-interacting saposin-
like protein precursor IPI00443909 22355.31055 4.81 1 63.38000107 99.99581455 63.38000107 99.99581455 1.752790913 0 1
 CFL1 24 kDa protein IPI00784459 28091.64063 8.13 3 230.4200134 100 90.93000031 100 1.747577969 0.241923967 3
 HSD17B4 Peroxisomal multifunctional enzyme 
type 2 IPI00019912 88068.99219 8.96 10 579.4000244 100 122.5 100 1.741526205 0.217869352 10
 FUS Fus-like protein (Fragment) IPI00260715 55689.03125 9.46 2 144.7799988 100 72.94999695 99.99953789 1.727308752 0.125416197 2
 PRDX2 16 kDa protein IPI00375400 18010.59961 6.13 7 430.25 100 116.0800018 100 1.722672783 0.280553283 7
 CCT3 chaperonin containing TCP1, subunit 3 
isoform c IPI00552715 61849.64844 6.1 3 153.3900146 100 62.06000137 99.99432792 1.717416452 0.358002051 3
 APOE Apolipoprotein E precursor IPI00021842 38239.98828 5.65 7 451.1099854 100 114.8099976 100 1.696669467 0.260778943 7
 CKAP4 CKAP4 protein (Fragment) IPI00433214 72955.86719 9.34 4 349.0400085 100 132.6600037 100 1.693948501 0.490005217 4
 UBE2L3 ubiquitin-conjugating enzyme E2L 3 
isoform 2 IPI00386512 15678.38965 8.56 1 68.70999908 99.99877329 68.70999908 99.99877329 1.684709928 0 1
 ECGF1 50 kDa protein IPI00852987 52423.58984 5.36 2 115.1900024 100 59.70999908 99.99025589 1.678616426 0.241869527 2
 GUSB Isoform Short of Beta-glucuronidase 
precursor IPI00219516 72974.11719 6.48 2 81.22999573 99.99993133 48.04999924 99.85719537 1.676991052 4.82E-02 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 ACTR3 Actin-like protein 3 IPI00028091 51165.26953 5.61 2 134.019989 100 67.20999908 99.99826722 1.676107829 0.110372498 2
 METTL7A Methyltransferase-like protein 7A 
precursor IPI00022300 30730.71094 8.7 2 153.6300049 100 113.4000015 100 1.668445027 8.81E-02 2
 FKBP1A Peptidyl-prolyl cis-trans isomerase IPI00647507 12759.03027 9.17 1 87.26999664 100 87.26999664 100 1.667848134 0 1
 TUBB2A Tubulin beta-2A chain IPI00013475 52501.16016 4.78 15 1204.310059 100 162.5500031 100 1.66702441 0.324620613 19
 ENO1 Isoform alpha-enolase of Alpha-enolase IPI00465248 53031.82031 7.01 9 704.8300171 100 114.75 100 1.663599099 0.556065902 9
 RPN1 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 67 kDa IPI00025874 78729.54688 5.87 3 145.2399902 100 60.29999924 99.99149367 1.660330083 9.80E-02 3
 HLA-DPB1 HLA class II histocompatibility 
antigen, DP(W4) beta chain precurs IPI00103082 30666.89063 8.83 1 62.77999878 99.99519446 62.77999878 99.99519446 1.659716825 0 1
 - Elongation factor 1-alpha IPI00472724 57485.78125 9.15 8 534.1099854 100 159.0899963 100 1.657829732 0.223293158 8
 SET Isoform 2 of Protein SET IPI00301311 35108.05859 4.12 1 66.54000092 99.99797818 66.54000092 99.99797818 1.654555515 0 1
 HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55078 9.27 5 350.9200134 100 115.3700027 100 1.647061187 0.258954283 5
 HNRPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 IPI00419373 42922.89844 9.1 4 364.6300049 100 172.4499969 100 1.637812338 0.261979499 4
 YWHAZ 14-3-3 protein zeta/delta IPI00021263 30890.03906 4.73 10 767.694458 100 147.3800049 100 1.635589819 0.333753224 11
 CAPZB Capping protein (Actin filament) 
muscle Z-line, beta IPI00642256 32963.14844 6.45 4 238.2600098 100 67.91000366 99.99852517 1.633026798 0.259294356 4
 LMNB1 Lamin-B1 IPI00217975 72358.14844 5.11 2 114.4199982 100 79.47000122 99.99989702 1.626918706 0.395887233 2
 TUBB Tubulin beta chain IPI00011654 52311.16016 4.78 18 1517.410034 100 162.5500031 100 1.600245678 0.212054029 22
 RPL3 RPL3 protein IPI00642267 33597.94141 10.17 1 55.58000183 99.97478018 55.58000183 99.97478018 1.593345198 0 1
 TUBA1B Similar to Tubulin alpha-ubiquitous 
chain IPI00792677 49578.05859 4.96 8 602.0299683 100 105.6200027 100 1.591544625 0.272330093 8
 SSR4 Protein IPI00646864 13775.66992 6.69 2 95.76000214 100 57.68000031 99.98444958 1.586927813 0.104710569 2
 CAPRIN1 membrane component chromosome 
11 surface marker 1 isoform 1 IPI00150961 82632.4375 5.14 1 93.27999878 100 93.27999878 100 1.57978274 0 1
 RHOA Transforming protein RhoA precursor IPI00027500 24622.31055 5.83 3 148.7000122 100 74.91000366 99.99970573 1.575018385 0.132446577 3
 GANAB Isoform 3 of Neutral alpha-
glucosidase AB precursor IPI00441414 99842.15625 5.43 8 467.0700073 100 120.5899963 100 1.57360297 0.213494531 8
 TXNDC4 Thioredoxin domain-containing 
protein 4 precursor IPI00401264 50287.66016 5.09 4 190.2900085 100 65.73999786 99.99756924 1.573438936 0.23722306 4
 EEF1D eukaryotic translation elongation factor 
1 delta isoform 1 IPI00642971 77348.54688 6.02 3 256.4200134 100 112.2600021 100 1.57157341 0.18012651 3
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 SND1 Staphylococcal nuclease domain-
containing protein 1 IPI00140420 110982.1797 6.74 3 198.8800049 100 98.45999908 100 1.571370555 5.32E-02 3
 YWHAG 14-3-3 protein gamma IPI00220642 31015.18945 4.8 6 305.3500061 100 81.72000122 99.99993866 1.569419143 0.175399453 6
 ANXA5 Annexin A5 IPI00329801 39272.76172 4.94 10 643.960022 100 112.4300003 100 1.565566175 0.420239581 10
 GSN Isoform 2 of Gelsolin precursor IPI00646773 87445.10938 5.58 3 122.9599991 100 43.18000031 99.56172955 1.555542318 0.162631652 3
 TMED10 Transmembrane emp24 domain-
containing protein 10 precursor IPI00028055 27690.30078 6.97 3 119.1699982 100 43.88999939 99.62782921 1.554334324 9.40E-02 3
 P4HB Protein disulfide-isomerase precursor IPI00010796 64315.26953 4.76 23 1598.709961 100 126.6200027 100 1.548710343 0.238274646 25
 - 31 kDa protein IPI00165486 34730.76172 9.96 1 57.5 99.98379152 57.5 99.98379152 1.534565075 0 1
 TPP1 Isoform 3 of Tripeptidyl-peptidase 1 
precursor IPI00554538 62032.14844 5.94 2 108.3499985 100 61.45999908 99.99348758 1.525824822 0.14558524 2
 SSBP1 Single-stranded DNA-binding protein, 
mitochondrial precursor IPI00029744 18545.23047 9.59 1 60.54000092 99.991951 60.54000092 99.991951 1.524386572 0 1
 - 30 kDa protein IPI00472119 35896.37109 9.78 1 57.56000137 99.98401392 57.56000137 99.98401392 1.522094277 0 1
 AADAC Arylacetamide deacetylase IPI00383879 49123.19141 8.75 2 188.3144531 100 117.9400024 100 1.519739058 6.85E-02 2
 IDH1 Isocitrate dehydrogenase [NADP] 
cytoplasmic IPI00027223 52332.01172 6.53 15 1231.119873 100 119.1299973 100 1.517181492 0.186849873 16
 PSME1 29 kDa protein IPI00479722 32701.33008 5.27 5 252.9244385 100 74 99.99963714 1.51517464 0.162943307 5
 SFN Isoform 2 of 14-3-3 protein sigma IPI00411765 26671.25 4.77 4 189.7100067 100 54.90000153 99.97050543 1.510126619 0.113427678 4
 UBA52 ubiquitin and ribosomal protein L40 
precursor IPI00456429 17541.21094 9.87 3 238.2799988 100 125.8199997 100 1.506173048 0.213686634 3
 ATIC Bifunctional purine biosynthesis protein 
PURH IPI00289499 70461.78906 6.27 2 89.55999756 100 49.04999924 99.88656625 1.505165246 0.276951631 2
 CSTB Cystatin-B IPI00021828 12618.79004 6.96 3 206.7600098 100 90.56999969 100 1.499930481 0.189615146 3
 CALR Protein IPI00794237 19298.58008 4.47 3 291.7744446 100 149.8500061 100 1.499731813 0.124424466 4
 TUBB3 Tubulin beta-3 chain IPI00013683 53216.46094 4.83 11 954.8900146 100 162.5500031 100 1.498445038 0.266654383 12
 EEF2 Elongation factor 2 IPI00186290 105563.6484 6.41 5 335.8600159 100 114.25 100 1.494151093 0.391063665 5
 UGDH UDP-glucose 6-dehydrogenase IPI00031420 60869.64844 6.73 7 445.5599976 100 123.0299988 100 1.487731171 0.338008222 7
 PSME2 proteasome activator subunit 2 IPI00746205 30834.65039 5.54 5 328.8600159 100 108.9800034 100 1.487402722 0.286986874 6
 PSMB1 Proteasome subunit beta type 1 
precursor IPI00025019 28672.58008 8.27 1 64.75 99.99694689 64.75 99.99694689 1.486049343 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 PFN1 Profilin-1 IPI00216691 16766.75 8.44 6 549.4399414 100 135.8699951 100 1.485521972 0.269390985 6
 ILF3 Isoform 1 of Interleukin enhancer-binding 
factor 3 IPI00298788 105105.8906 8.86 1 60.36999893 99.99162967 60.36999893 99.99162967 1.484554131 0 1
 PSMA1 Isoform Long of Proteasome subunit 
alpha type 1 IPI00472442 32610.50977 6.51 2 69.42999268 99.9989607 36.50999832 97.96416589 1.483274333 0.289929946 2
 CALR 37 kDa protein IPI00793605 41138.14063 4.55 8 696.8199463 100 149.8500061 100 1.483042681 0.320696253 9
 TUBB2C Tubulin beta-2C chain IPI00007752 52471.19141 4.79 17 1414.25 100 162.5500031 100 1.478723236 0.394178225 21
 HNRPM Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein M IPI00383296 79706.89844 8.94 3 153.4100037 100 65.18000031 99.9972347 1.478241028 0.15196225 3
 FN1 Isoform 1 of Fibronectin precursor IPI00022418 276716.375 5.45 11 526.9788818 100 64.12999725 99.99647838 1.471742451 0.496467701 11
 HNRPL heterogeneous nuclear 
ribonucleoprotein L isoform b IPI00465225 54634.78125 7.22 1 91.26999664 100 91.26999664 100 1.469265951 0 1
 CLTC Isoform 2 of Clathrin heavy chain 1 IPI00455383 203165.7031 5.48 5 260.1999817 100 89.83999634 100 1.463700961 0.25263785 5
 LOC641827;LOC649440 Similar to eukaryotic 
translation elongation factor 1 b IPI00397392 28469.74023 4.66 2 166.6399994 100 120.8700027 100 1.456239998 0.167810707 2
 RAB10 Ras-related protein Rab-10 IPI00016513 25878.90039 8.59 1 54.18000031 99.96518694 54.18000031 99.96518694 1.44043929 0 1
 FGG Isoform Gamma-A of Fibrinogen gamma 
chain precursor IPI00219713 55011.35938 5.7 5 500.0499878 100 134.6600037 100 1.439582455 0.362254194 5
 HSP90AB4P Heat shock protein 90Bd IPI00555565 66222.17969 4.65 3 160.8899994 100 74.90000153 99.99970505 1.439329108 8.30E-02 3
 - CD68 antigen variant (Fragment) IPI00555602 45637.91016 5.46 2 162.3099976 100 92.26000214 100 1.439298407 0.160670772 2
 LOC652826 similar to 26S protease regulatory 
subunit 6B IPI00738042 51256.71875 5.17 1 62.45999908 99.994827 62.45999908 99.994827 1.437973319 0 1
 CAP1 Adenylyl cyclase-associated protein IPI00639931 58646.21094 8.24 2 136.5599976 100 73.62000275 99.99960396 1.432156379 0.226279047 2
 GPI Glucose-6-phosphate isomerase IPI00027497 68475.72656 8.43 6 396.6500244 100 88.26000214 100 1.430878738 0.134030316 6
 RPS29 ribosomal protein S29 isoform 2 IPI00639942 9222.080078 10.08 1 60.09999847 99.99109278 60.09999847 99.99109278 1.428291613 0 1
 PYGL 97 kDa protein IPI00783313 107098.9297 6.71 10 617.7299805 100 107.4899979 100 1.425746226 0.407381088 10
 HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.0625 4.97 16 961.0300293 100 114.0599976 100 1.423396462 0.353215844 17
 PAICS phosphoribosylaminoimidazole 
carboxylase, phosphoribosylaminoimidazol IPI00815732 53853.98828 7.86 1 59.75 99.99034522 59.75 99.99034522 1.420894208 0 1
 YWHAQ 14-3-3 protein theta IPI00018146 30857.03906 4.68 6 311.9400024 100 88.83000183 100 1.419688879 0.210138503 6
 HLA-DRA major histocompatibility complex, 
class II, DR alpha precursor IPI00464948 30468.91016 4.91 2 121.6200027 100 85.83000183 100 1.418710128 0.37020355 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 HNRPH1 HNRPH1 protein IPI00479191 53875.41016 6.33 5 288.3544312 100 99.12999725 100 1.417129537 0.18195718 5
 TUBA1C Tubulin alpha-1C chain IPI00218343 53295.64844 4.96 8 576.9599609 100 96.26999664 100 1.4134727 0.455975793 8
 NCL Isoform 1 of Nucleolin IPI00604620 89719.57031 4.6 6 308.8599854 100 76.70999908 99.99980558 1.411614405 0.367224258 6
 TGM2 Isoform 1 of Protein-glutamine gamma-
glutamyltransferase 2 IPI00294578 82951.92188 5.11 9 564.0100098 100 96.11000061 100 1.410509044 0.278126164 10
 NDUFS2 NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial IPI00025239 56146.01172 7.21 1 65.11000061 99.99718977 65.11000061 99.99718977 1.404833937 0 1
 VIL2 Cytovillin 2 (Fragment) IPI00384282 18443.30078 9.32 4 202.1444244 100 59.50999832 99.98979666 1.403527879 0.105225389 5
 MSN Moesin IPI00219365 76942.64063 6.08 15 970.904541 100 128.3999939 100 1.402689312 0.138648159 17
 GBE1 1,4-alpha-glucan-branching enzyme IPI00296635 85817.03906 5.87 4 227.6300049 100 101.1299973 100 1.397669327 0.266686131 4
 LMAN1 ERGIC-53 protein precursor IPI00026530 62207.39063 6.3 5 304.928894 100 140.9199982 100 1.396233488 0.118257977 5
 EFHD2 EF-hand domain family, member D2 IPI00552365 32619.2207 5.26 2 78.59443665 99.99987402 43.91999817 99.63039111 1.391297994 0.371903582 2
 FMO5 Dimethylaniline monooxygenase [N-
oxide-forming] 5 IPI00215760 66454.40625 8.41 3 184.4499969 100 71.70999908 99.99938519 0.709903875 9.56E-02 3
 AK3 GTP:AMP phosphotransferase IPI00478236 20052.85938 8.73 4 274.3399963 100 101.1800003 100 0.709408981 8.70E-02 4
 MYH10 Isoform 2 of Myosin-10 IPI00479307 260063.1719 5.46 11 768.4022217 100 144.9100037 100 0.708849958 0.543628596 11
 SERPINF1 25 kDa protein IPI00796279 26706.00977 5.84 1 63.97000122 99.99634622 63.97000122 99.99634622 0.707564514 0 1
 CYP2C8 45 kDa protein IPI00843846 49430.42188 8.91 2 66.67999268 99.99804231 33.66999817 96.08490412 0.707068352 0.121367153 2
 DPYS Dihydropyrimidinase IPI00028910 62048.10938 6.81 4 200.9299927 100 63.56000137 99.99598448 0.705557091 0.172436273 4
 ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial precursor IPI00011416 38661.62109 8.16 3 155.1600037 100 72.68000031 99.99950825 0.705521696 0.134118312 3
 - 105 kDa protein IPI00794900 115433.2422 7.3 11 662.0700073 100 105.5100021 100 0.704733875 0.185420773 12
 COMT Isoform Soluble of Catechol O-
methyltransferase IPI00375513 26915.57031 5.15 3 192.7400055 100 83.06999969 100 0.703304949 0.174481279 3
 HADHA Trifunctional enzyme subunit alpha, 
mitochondrial precursor IPI00031522 93913.70313 9.16 14 1023.834351 100 106.2200012 100 0.696449442 0.16805208 14
 ADH5 Alcohol dehydrogenase class 3 IPI00746777 45140.69141 7.45 3 149.6299896 100 60.16999817 99.99123519 0.696433267 9.83E-03 3
 TUFM Tu translation elongation factor, 
mitochondrial IPI00027107 54583.71875 7.26 5 355.9200134 100 121.3099976 100 0.68858296 0.127606501 5
 POR Hypothetical protein DKFZp686G04235 IPI00792395 82665.85938 5.38 4 224.5899963 100 74.80000305 99.99969818 0.683497704 0.082151649 4
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 HP Haptoglobin precursor IPI00641737 52573.75 6.28 9 601.0400391 100 89.75 100 0.682809915 0.118559096 9
 ACY1 Aminoacylase-1 IPI00009268 48344.23047 5.77 8 442.0400391 100 92.38999939 100 0.680613529 0.135348474 8
 PDLIM5 PDZ and LIM domain 5 isoform e IPI00103146 26878.82031 9.93 1 62.52999878 99.99490971 62.52999878 99.99490971 0.680148321 0 1
 ASPN ASPN protein IPI00418431 49081.85938 6.03 3 112.2100067 100 42.58000183 99.49679837 0.679656027 5.15E-02 3
 NDUFAB1 Acyl carrier protein, mitochondrial 
precursor IPI00022442 18696.14063 4.82 2 109.3999939 100 72.27999878 99.99946081 0.679066493 0.061676869 2
 ATP5O ATP synthase O subunit, 
mitochondrial precursor IPI00007611 26090.96094 9.97 2 76.22000122 99.99978236 44.70999908 99.69186409 0.678946988 0.114995202 2
 MDH2 Malate dehydrogenase, mitochondrial 
precursor IPI00291006 39765.08984 8.92 13 938.9788208 100 132.3899994 100 0.673156752 8.05E-02 13
 HSPE1 10 kDa heat shock protein, 
mitochondrial IPI00220362 12653.11035 8.89 7 409.1000366 100 79.08000183 99.99988735 0.671865854 0.071045973 8
 MT1X Metallothionein-1X IPI00008753 8279.200195 8.38 2 128.0400085 100 84.55000305 100 0.669831346 0.290858872 2
 SERPINC1 SERPINC1 protein IPI00844156 32447.10938 9.03 1 93.75 100 93.75 100 0.668372987 0 1
 AIFM1 Isoform 3 of Apoptosis-inducing factor 
1, mitochondrial precursor IPI00157908 72532.10938 9.03 4 302.9499817 100 95.19999695 100 0.668207494 0.118614694 4
 CYP2D7P1 Cytochrome P450 IPI00418408 60228.42188 8.59 1 59.20000076 99.98904173 59.20000076 99.98904173 0.660998292 0 1
 PPIF Peptidyl-prolyl cis-trans isomerase, 
mitochondrial precursor IPI00026519 24750.41992 9.48 2 96.66000366 100 58.97999954 99.98847231 0.660376281 7.86E-03 2
 AK2 Isoform 2 of Adenylate kinase isoenzyme 
2, mitochondrial IPI00218988 28472.61914 7.71 3 217.8199921 100 79.13999939 99.99988889 0.660273141 0.036265494 3
 MT1E Metallothionein-1E IPI00025461 8225.160156 8.38 2 118.9500046 100 84.55000305 100 0.659852271 0.272426604 2
 ACO1 Iron-responsive element-binding protein 
1 IPI00008485 105951.1797 6.23 7 397.25 100 93.86000061 100 0.655598098 0.168110263 7
 PHB Prohibitin variant (Fragment) IPI00791634 31847.21094 6.02 4 198.4200134 100 60.79000092 99.99240125 0.654964161 8.44E-02 4
 COX4I1 Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial precursor IPI00006579 22634.39063 9.52 3 184.4199982 100 76.25 99.99978386 0.654863622 0.226997347 3
 SOD1 Superoxide dismutase IPI00783680 17838.08984 5.7 4 223.6600037 100 105.1299973 100 0.653589343 2.63E-02 5
 BCKDHA CDNA FLJ45695 fis, clone 
FEBRA2013570, highly similar to 2- oxoisova IPI00444329 57253.05859 6.09 1 60.38000107 99.99164893 60.38000107 99.99164893 0.652488042 0 1
 ACAA1 3-ketoacyl-CoA thiolase, peroxisomal 
precursor IPI00012828 47604.07031 8.76 5 341.3900146 100 106.0999985 100 0.652013255 0.326294671 5
 ACADVL Isoform 2 of Very-long-chain specific 
acyl-CoA dehydrogenase, mitoch IPI00178744 78527.97656 9.06 2 98.63999939 100 51.63999939 99.93751982 0.650976908 2.00E-02 2
 GLUL Glutamine synthetase IPI00010130 45423.51172 6.43 1 57.79999924 99.98487337 57.79999924 99.98487337 0.650677891 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 120NT
 MAT1A S-adenosylmethionine synthetase 
isoform type-1 IPI00021772 47392.28906 5.86 5 278.5844421 100 85.16999817 100 0.649028921 0.120258391 5
 ACADM Hypothetical protein 
DKFZp686M24262 IPI00513827 55018.78906 7.94 3 145.5699921 100 78.76999664 99.99987901 0.643608556 5.43E-02 3
 COX6C Cytochrome c oxidase polypeptide VIc 
precursor IPI00015972 9927.879883 10.38 2 116.1100006 100 58.75999832 99.98787331 0.636859867 0.199775587 2
 QPRT 17 kDa protein IPI00853023 17914 7.71 1 55.06999969 99.97163765 55.06999969 99.97163765 0.636228468 0 1
 OGDH oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) isoform 1 IPI00098902 124171.8594 6.4 2 129.1199951 100 86.63999939 100 0.636106362 0.171345692 2
 ASL 50 kDa protein IPI00514772 52806.57031 5.99 7 422.3667908 100 81 99.9999276 0.634559644 8.01E-02 7
 NIT2 Nitrilase family member 2 IPI00549467 33646.80078 6.82 3 176.2399902 100 74.56999969 99.99968177 0.633058787 0.168699829 3
 ALDH3A2 Isoform 2 of Fatty aldehyde 
dehydrogenase IPI00394758 63761.19141 9.06 1 78.23999786 99.99986331 78.23999786 99.99986331 0.63012025 0 1
 SUCLG1 succinate-CoA ligase, GDP-forming, 
alpha subunit IPI00759493 39717.12109 9.01 3 220.9200134 100 119.0500031 100 0.628229097 2.19E-02 3
 KRT10 57 kDa protein IPI00383111 60122.17188 5.09 2 70.30999756 99.99915132 36 97.71049171 0.628064365 0.336423222 2
 PHB2 Prohibitin-2 IPI00027252 36156.25 9.83 3 147.1699982 100 52.86000061 99.95282171 0.626564015 0.175493665 3
 CYP1A2 Isoform 1 of Cytochrome P450 1A2 IPI00719591 62467.67188 9.18 1 82.29000092 99.9999462 82.29000092 99.9999462 0.622057257 0 1
 SUCLG2 Succinyl-CoA ligase [GDP-forming] 
beta-chain, mitochondrial precurso IPI00096066 51941.89844 6.15 8 465.4588928 100 83.80000305 100 0.621125826 0.430143742 8
 ACO2 Aconitase 2, mitochondrial IPI00790739 96473.60938 6.97 2 125.0844421 100 85.44999695 100 0.616294678 5.11E-02 2
 CALD1 Isoform 2 of Caldesmon IPI00218694 76226.46875 6.37 4 288.1199951 100 107.3099976 100 0.615760202 9.79E-02 4
 EPHX2 Epoxide hydrolase 2 IPI00104341 68213.03906 5.91 1 62.13999939 99.99443145 62.13999939 99.99443145 0.612473552 0 1
 LTB4DH Leukotriene B4 12-
hydroxydehydrogenase IPI00643630 9274.419922 9.4 3 268.9200134 100 103.9800034 100 0.60449042 4.38E-02 3
 AOX1 Hypothetical protein AOX1 IPI00743616 161854.2031 6.78 11 534.8544922 100 108.5800018 100 0.600030347 0.285428294 11
 COL6A2 Isoform 2C2 of Collagen alpha-2(VI) 
chain precursor IPI00304840 117254.4375 5.85 4 192.9400024 100 75.01999664 99.99971309 0.595130883 0.134443954 4
 ALDH8A1 aldehyde dehydrogenase 8A1 
isoform 2 IPI00172476 51159.08984 5.97 2 93.44000244 100 51.66999817 99.93794991 0.590137413 3.72E-02 2
 ETFA Electron transfer flavoprotein subunit 
alpha, mitochondrial precursor IPI00010810 39221.92969 8.62 6 639.1044312 100 153.6499939 100 0.588809851 9.74E-02 7
 GCSH;LOC730107 Glycine cleavage system 
H protein, mitochondrial precursor IPI00011604 20522.83984 4.91 1 51.47000122 99.93502563 51.47000122 99.93502563 0.581687169 0 1
 ETFB Isoform 2 of Electron transfer 
flavoprotein subunit beta IPI00556451 41287.32813 6.78 5 248.4299927 100 55.77999878 99.97591524 0.574464202 0.147273966 5
Poorly Differentiated iTRAQ Individual Patients
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 CRYL1 Lambda-crystallin IPI00645031 36297.23828 5.68 2 66.19999695 99.99781354 34.09000015 96.4457972 0.572842951 1.67E-03 2
 - HDCMB21P IPI00384863 14111.21973 5.17 1 92.70999908 100 92.70999908 100 0.571261218 0 1
 COL6A3 alpha 3 type VI collagen isoform 4 
precursor IPI00072918 345401.0313 6.48 35 1887.693481 100 127.8799973 100 0.563478974 0.23673822 36
 HADHB Trifunctional enzyme beta subunit, 
mitochondrial precursor IPI00022793 56777.03906 9.45 8 515.9699707 100 94.51999664 100 0.562244657 0.110463435 8
 SLC27A5 Bile acyl-CoA synthetase IPI00016827 78658.29688 7.81 2 71.59888458 99.99936926 40.20999908 99.13155502 0.561489058 1.41E-02 2
 COL6A3 alpha 3 type VI collagen isoform 3 
precursor IPI00072917 345457.3438 6.47 35 1893.973511 100 127.8799973 100 0.560801078 0.235707359 36
 HSPB6 Heat-shock protein beta-6 IPI00022433 19439.91992 7.9 2 77.02999878 99.99981939 45.70000076 99.75467481 0.560728068 0.12795191 2
 KRT79 keratin 6L IPI00241841 62350.57031 6.75 4 202.9299927 100 61.38000107 99.99336651 0.560202029 0.149295629 4
 AKR7A3 Aflatoxin B1 aldehyde reductase 
member 3 IPI00293721 39376.69141 6.67 5 244.0900116 100 60.40999985 99.99170642 0.560046812 0.278333522 5
 ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.07813 8.72 15 1078.744385 100 132.8600006 100 0.558758958 0.139314367 16
 COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 2 131.8500061 100 85.20999908 100 0.558443576 2.22E-02 2
 ALDH5A1 aldehyde dehydrogenase 5A1 
precursor, isoform 1 IPI00336008 63482.35938 8.41 1 52.31000137 99.94645214 52.31000137 99.94645214 0.553893937 0 1
 PC Pyruvate carboxylase, mitochondrial 
precursor IPI00299402 138358.0469 6.37 11 651.5643921 100 112.0999985 100 0.552496157 0.127067577 11
 FTL Ferritin light chain IPI00852596 21925.33984 5.51 7 496.5900269 100 94.73999786 100 0.547436401 7.69E-02 7
 OGN Osteoglycin IPI00515092 34941.69141 8.49 4 177.2900085 100 49.52999878 99.8984354 0.546735988 0.238702858 4
 PPA1 CDNA FLJ45159 fis, clone 
BRAWH3043295, highly similar to Inorganic pyr IPI00444797 17858.00977 8.71 1 86.70999908 100 86.70999908 100 0.54653992 0 1
 HAGH Hydroxyacylglutathione hydrolase IPI00745553 32141.91016 6.86 2 136.4299927 100 87.30999756 100 0.546189968 0.342022528 2
 SORD Sorbitol dehydrogenase IPI00216057 42378.10938 8.23 5 276.1699829 100 81.12000275 99.99992957 0.545841347 0.1071126 5
 MT-CO2 Cytochrome c oxidase subunit 2 IPI00017510 26406.33008 4.67 1 106.5599976 100 106.5599976 100 0.545428153 0 1
 PCBD1 Pterin-4-alpha-carbinolamine 
dehydratase IPI00218568 12902.16992 6.28 4 209.3899994 100 65.72000122 99.99755802 0.532763254 0.162697763 4
 MUT Methylmalonyl-CoA mutase, 
mitochondrial precursor IPI00024934 90636.34375 6.48 2 128.0700073 100 96.76000214 100 0.52869817 7.01E-02 2
 ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 15 1184.474365 100 141.0700073 100 0.518644944 8.18E-02 17
 GSTA1 Glutathione S-transferase A1 IPI00657682 29261.05078 8.91 11 671.8044434 100 130.4600067 100 0.516008977 0.116624691 12
Poorly Differentiated iTRAQ Individual Patients
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 GSTA2 Glutathione S-transferase A2 IPI00745233 29104 8.51 11 686.0444336 100 130.4600067 100 0.515643674 0.116368807 12
 UQCRH Ubiquinol-cytochrome c reductase 
complex 11 kDa protein, mitochondria IPI00296022 11826.04004 4.39 1 67.86000061 99.99850809 67.86000061 99.99850809 0.513484015 0 1
 CES2 carboxylesterase 2 isoform 1 IPI00332828 72247.0625 6.03 8 456.0800171 100 103.1900024 100 0.513480209 8.19E-02 8
 ALDH2 Mitochondrial aldehyde 
dehydrogenase 2 variant (Fragment) IPI00792207 61065.96094 6.63 7 435.7000122 100 96.18000031 100 0.511926767 0.118996751 8
 HGD Homogentisate 1,2-dioxygenase IPI00303174 54236.85938 6.54 5 318.4799805 100 74.81999969 99.99969957 0.510809195 7.60E-02 5
 ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 11 744.1188965 100 110.1600037 100 0.508596793 0.29913287 11
 SHMT1 Isoform 2 of Serine 
hydroxymethyltransferase, cytosolic IPI00220668 53489.17969 7.59 1 88.37999725 100 88.37999725 100 0.507727081 0 1
 FBLN5 Full-length cDNA clone CS0DI085YI08 
of Placenta of Homo sapiens IPI00382428 56833.08984 4.57 3 132.1799927 100 56.20000076 99.97813537 0.505664441 9.02E-02 3
 RDH16 Retinol dehydrogenase 16 IPI00289551 38852.73828 8.83 3 163.0044403 100 67.73000336 99.99846276 0.502669767 0.406188699 3
 ECHS1 Enoyl-CoA hydratase, mitochondrial 
precursor IPI00024993 35335.42969 8.34 11 870.3544312 100 134.75 100 0.499812613 6.65E-02 11
 NDUFA4 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 4 IPI00011770 10562.08984 9.42 3 160.7200012 100 75.68000031 99.99975354 0.494365543 8.02E-02 3
 COL6A1 Collagen alpha-1(VI) chain precursor IPI00291136 117302.5391 5.26 4 258.6099854 100 100.1800003 100 0.490695131 0.134964348 5
 SDHA Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondri IPI00305166 77793.53125 7.06 5 349.6200256 100 100.5699997 100 0.490293863 0.200222067 5
 BPHL Isoform 1 of Valacyclovir hydrolase 
precursor IPI00384428 35828.30078 9.2 1 51.68000031 99.93809265 51.68000031 99.93809265 0.486897 0 1
 KRT18 Keratin, type I cytoskeletal 18 IPI00784347 51196.89844 5.34 16 850.7600098 100 94.44000244 100 0.485844446 0.106923598 18
 BAAT Bile acid CoA:amino acid N-
acyltransferase IPI00017819 48856.32031 6.49 5 356.1700134 100 113.3000031 100 0.482728015 0.103011503 5
 - MHC-F3 REPEAT, fibronectin type III 
REPEAT=CLONE 3.9KF3-2 IPI00743608 191267.9063 4.89 3 132.1712341 100 56.95999908 99.98164551 0.481714567 0.220730978 3
 KRT8 Keratin, type II cytoskeletal 8 IPI00554648 58423.62891 5.52 26 1823.793457 100 156.5399933 100 0.480256368 0.15353718 26
 SFXN1 Sideroflexin-1 IPI00009368 37842.55078 9.22 1 53.63000107 99.96048681 53.63000107 99.96048681 0.479781645 0 1
 SFXN3 sideroflexin 3 IPI00793874 38103.92188 9.25 1 53.43000031 99.9586246 53.43000031 99.9586246 0.479781645 0 1
 ALDH1B1 Aldehyde dehydrogenase X, 
mitochondrial precursor IPI00103467 62178.58984 6.36 5 338.539978 100 118.3899994 100 0.476440031 9.83E-02 5
 COL14A1 Isoform 3 of Collagen alpha-1(XIV) 
chain precursor IPI00402215 195721.9844 5.16 5 381.1444397 100 135.8600006 100 0.470622489 0.257324199 5
 PHGDH Phosphoglycerate dehydrogenase IPI00642548 56869.67969 6.47 2 112.0400009 100 71.95999908 99.99941958 0.469667239 0.195750831 2
Poorly Differentiated iTRAQ Individual Patients
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 CYP2E1 Cytochrome P450 2E1 IPI00007282 61500.80078 8.27 6 336.0299988 100 72.08000183 99.9994354 0.459706211 0.336680882 6
 KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 6 295.4400024 100 65.37999725 99.99735916 0.456963995 0.195414024 6
 ALDH4A1 Aldehyde dehydrogenase 4 family, 
member A1 IPI00647328 65056.12109 7.62 11 746.3499756 100 102.4700012 100 0.455714328 5.83E-02 11
 HEBP1 Heme-binding protein 1 IPI00148063 23623.80078 5.71 1 52.02000046 99.94275439 52.02000046 99.94275439 0.452278296 0 1
 C21orf33 Isoform Long of ES1 protein 
homolog, mitochondrial precursor IPI00024913 31020.9707 8.5 3 303.1544495 100 137.2200012 100 0.44612891 2.17E-02 3
 HMGCL 19 kDa protein IPI00514407 21853.41016 8.9 1 88.65000153 100 88.65000153 100 0.445642072 0 1
 ASS1 Argininosuccinate synthase IPI00020632 56147.66016 8.6 10 658.1799927 100 139.2599945 100 0.438203818 0.203211714 10
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 4 287.7600098 100 98.44000244 100 0.43527248 0.223062965 4
 SDHB Succinate dehydrogenase [ubiquinone] 
iron-sulfur subunit, mitochondria IPI00294911 35997.07813 9.03 2 116.4100037 100 84.76000214 100 0.429081515 7.26E-02 2
 DCI Isoform 2 of 3,2-trans-enoyl-CoA 
isomerase, mitochondrial precursor IPI00398758 32932.46875 9.07 2 136.6000061 100 100.1100006 100 0.428459758 0.011239714 2
 FTCD Isoform C of Formimidoyltransferase-
cyclodeaminase IPI00218976 64571.53125 5.24 6 364.9444275 100 104.5899963 100 0.426107298 0.291685228 6
 ACOT1 Acyl-coenzyme A thioesterase 1 IPI00333838 49306.28906 6.9 1 79.73000336 99.99990301 79.73000336 99.99990301 0.419423437 0 1
 ADI1 Isoform 1 of 1,2-dihydroxy-3-keto-5-
methylthiopentene dioxygenase IPI00651738 23402.88086 5.43 1 69.87000275 99.99906083 69.87000275 99.99906083 0.417946208 0 1
 DBT Lipoamide acyltransferase component of 
branched-chain alpha-keto acid d IPI00003944 59823.44141 8.71 3 253.0500031 100 114.3300018 100 0.41653184 3.88E-02 3
 BGN Biglycan preproprotein variant 
(Fragment) IPI00643384 45356.82031 7.16 7 529.0999756 100 138.6000061 100 0.414329618 0.292252371 7
 GLYAT Isoform 1 of Glycine N-acyltransferase IPI00402759 37221.21094 8.38 3 123.1199951 100 51.84000015 99.9403319 0.414070373 2.33E-02 3
 GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 20 1495.669922 100 102.6399994 100 0.413532409 0.134364046 20
 FAHD2A Fumarylacetoacetate hydrolase 
domain-containing protein 2A IPI00329742 37730.39063 8.48 1 90.91999817 100 90.91999817 100 0.41232654 0 1
 CYP2C9 Cytochrome P450 2C9 IPI00007219 61374.14063 8.13 4 184.980011 100 79.22000122 99.99989092 0.406128629 0.187510942 4
 PCK2 mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor IPI00797038 74784.85938 7.57 21 1416.350098 100 147.8399963 100 0.402712008 0.118873868 22
 ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor IPI00009532 61418.91016 8.17 8 609.6400146 100 135.1499939 100 0.402705094 0.120273234 8
 GRHPR Glyoxylate reductase/hydroxypyruvate 
reductase IPI00037448 38271.94141 7.01 8 678.5844727 100 146.9900055 100 0.402661675 0.141361989 8
 BDH1 D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial precursor IPI00025341 41766.75 9.11 6 276.8944397 100 73.88999939 99.99962783 0.399764781 9.77E-02 6
Poorly Differentiated iTRAQ Individual Patients
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 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial IPI00001539 46153.96875 8.32 13 1005.26001 100 155.6999969 100 0.398372899 0.165019982 14
 HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 4 284.8699951 100 84.55000305 100 0.395929352 8.53E-02 4
 CYP3A5 Cytochrome P450 3A5 IPI00025831 63206.72266 8.86 1 70.5 99.99918765 70.5 99.99918765 0.393749205 0 1
 COX5A Cytochrome c oxidase subunit 5A, 
mitochondrial precursor IPI00025086 18053.88086 6.3 3 204.5699921 100 112.3799973 100 0.377587665 4.11E-02 3
 TAGLN Transgelin IPI00216138 25234.73047 8.87 7 393.2200317 100 96.01000214 100 0.375624993 0.110354396 8
 GOT2 Aspartate aminotransferase, 
mitochondrial precursor IPI00018206 52087.64844 9.14 6 484.5700073 100 167.9900055 100 0.366842272 0.071128545 6
 FABP1 FABP1 protein (Fragment) IPI00010290 18729.4707 9.52 7 470.559967 100 121.6399994 100 0.363843824 0.140424786 11
 ALDH1L2 Aldehyde dehydrogenase family 1 
member L2 IPI00298308 112632.0703 6.13 2 157.6699982 100 110.1600037 100 0.360466816 5.07E-02 2
 OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.05859 8.75 9 531.4944458 100 106.7699966 100 0.35217937 0.140004678 9
 DAK Dihydroxyacetone kinase IPI00551024 63392.42188 7.12 5 456.0200195 100 180.9900055 100 0.350158309 0.42096784 5
 SULT2A1 Bile salt sulfotransferase IPI00216133 37496.32813 5.71 10 744.4200439 100 124.8899994 100 0.343372164 9.33E-02 11
 DCN Isoform A of Decorin precursor IPI00012119 44030.19922 8.75 3 204.0944519 100 89.51000214 100 0.343058336 0.158672975 3
 ARG1 Isoform 2 of Arginase-1 IPI00398768 39380.19922 6.72 6 397.0599976 100 111.8499985 100 0.342711174 0.241772841 6
 DCXR 26 kDa protein IPI00797249 27252.58984 8.33 4 262.4100037 100 110.0100021 100 0.340316501 0.116913804 4
 FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 6 549.8900146 100 118.0100021 100 0.338723414 0.103589414 6
 BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.23828 6.58 14 775.5488892 100 126.4800034 100 0.337667181 0.111413602 14
 HADH Isoform 2 of Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial precu IPI00298406 47125.23047 9.34 5 377.3800049 100 114.0500031 100 0.327374691 9.15E-02 5
 ECHDC2 Enoyl coenzyme A hydratase domain-
containing protein 2 IPI00384676 32534.50977 9.03 2 89.79000092 100 56.33000183 99.97878016 0.324639167 4.52E-02 2
 PRELP Prolargin precursor IPI00020987 46264.33984 9.47 8 448.0200195 100 84.88999939 100 0.324486836 0.323152772 8
 GNMT Glycine N-methyltransferase IPI00215925 35681.57031 6.55 2 69.83000183 99.99905214 36.93000031 98.15182884 0.324368536 3.66E-02 2
 ACADSB Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial IPI00024623 52051.67969 6.53 3 223.0599976 100 91.02999878 100 0.323251694 0.13380618 3
 CYB5A Isoform 1 of Cytochrome b5 IPI00397860 16616.71094 4.88 6 572.4099731 100 227.0399933 100 0.318273955 3.96E-02 6
 LUM Lumican precursor IPI00020986 42425.12891 6.16 9 529.9744263 100 85.91999817 100 0.317284738 0.239601669 9
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 LTBP2 Latent-transforming growth factor beta-
binding protein 2 precursor IPI00292150 207622.5469 5.08 1 62.54000092 99.99492142 62.54000092 99.99492142 0.316430123 0 1
 CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 63 4790.559082 100 157.8999939 100 0.296128713 8.97E-02 70
 PAH Phenylalanine-4-hydroxylase IPI00017579 56707.82031 6.15 1 69.76000214 99.99903674 69.76000214 99.99903674 0.282829783 0 1
 PBLD MAWD binding protein isoform b IPI00651719 33923.37891 6.5 3 224.3500061 100 118.0999985 100 0.281783128 0.093163638 3
 CYP3A4 Cytochrome P450 3A4 IPI00465138 63244.41016 8.27 2 107.8800049 100 70.5 99.99918765 0.278803614 0.114945566 2
 SULT1A1 Sulfotransferase 1A1 IPI00300026 47814.69922 8.61 7 510.0544128 100 127.8099976 100 0.275130539 2.78E-02 7
 ADH1C Alcohol dehydrogenase 1C IPI00465343 45428 8.63 11 791.6699829 100 120.9300003 100 0.273645349 0.195502242 12
 NNMT Nicotinamide N-methyltransferase IPI00027681 33091.32031 5.56 2 90.05000305 100 49.61999893 99.9005185 0.272222291 0.018431746 2
 GPT Alanine aminotransferase 1 IPI00217458 57510.32813 6.77 3 193.9199982 100 84.44999695 100 0.268620924 6.38E-02 3
 ACSL1 Isoform 1 of Long-chain-fatty-acid--
CoA ligase 1 IPI00012728 85201.29688 6.81 9 539.8499756 100 103.1100006 100 0.268495774 8.19E-02 9
 ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 11 887.3900146 100 120.9300003 100 0.261623901 0.105814352 13
 ADH1A Alcohol dehydrogenase 1A IPI00218896 45320.80859 8.26 13 1029.309937 100 120.9300003 100 0.260818255 0.175423462 15
 HPD 40 kDa protein IPI00795913 44884.14063 5.93 4 245.9500122 100 80.48000336 99.99991839 0.25954813 0.144771824 4
 CTH Isoform 2 of Cystathionine gamma-lyase IPI00221301 42918.19141 6.43 1 58.97000122 99.98844574 58.97000122 99.98844574 0.252362398 0 1
 COQ9 Isoform 1 of Ubiquinone biosynthesis 
protein COQ9, mitochondrial precu IPI00470631 37064.78125 5.61 1 134.4299927 100 134.4299927 100 0.237080354 0 1
 REEP6 Receptor expression-enhancing 
protein 6 IPI00647161 22153.98047 8.74 1 110.3899994 100 110.3899994 100 0.228044335 0 1
 ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03125 8.25 10 680.0299683 100 96.80000305 100 0.224337989 0.162764303 11
 GGTLA1 Isoform 2 of Gamma-
glutamyltransferase 5 precursor IPI00339373 61051.73828 7.67 2 126.8100052 100 85.98000336 100 0.218421715 0.160263842 2






























 DEFA3 Neutrophil defensin 3 precursor IPI00021827 10946.21973 5.71 2 75.76000214 99.99976171 42.81000137 99.52999851 7.856763064 0.11414292 2
 AKR1B10 Aldo-keto reductase family 1 
member B10 IPI00105407 41078.28125 7.12 7 509.4899902 100 91.45999908 100 7.773800844 10.0275884 7
 COL14A1 Isoform 3 of Collagen alpha-1(XIV) 
chain precursor IPI00402215 195721.9844 5.16 1 101.0599976 100 101.0599976 100 6.505353851 0 1
 BGN CDNA FLJ35635 fis, clone 
SPLEN2011805, highly similar to 
BONE/CARTILAGE
IPI00385748 39528 6.31 5 245.0299988 100 68.23000336 99.99865073 6.364955502 3.16732957 5
 COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 2 130.4900055 100 87.87000275 100 6.073615549 1.03064137 2
 PRELP Prolargin precursor IPI00020987 46264.33984 9.47 3 139.0700073 100 50.68999863 99.9234228 5.986039846 4.6455314 3
 LYZ Lysozyme C precursor IPI00019038 17902.35938 9.38 1 95.75 100 95.75 100 5.557095071 0 1
 TAGLN Transgelin IPI00216138 25234.73047 8.87 3 206.8999939 100 92 100 5.359155604 2.44506301 3
 LUM Lumican precursor IPI00020986 42425.12891 6.16 7 367.3844604 100 67.23999786 99.99830527 4.829051829 3.96004274 7
 DCN Isoform A of Decorin precursor IPI00012119 44030.19922 8.75 2 118.9944382 100 68.26999664 99.9986631 4.636626341 3.62943916 2
 LSP1 50 kDa protein IPI00554652 54843.82031 5.42 1 85.93000031 100 85.93000031 100 4.445154074 0 1
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 25840.99023 4.93 3 179.0500031 100 68.11000061 99.99861293 4.019642008 0.7518576 4
 UBA52 ubiquitin and ribosomal protein L40 
precursor IPI00456429 17541.21094 9.87 6 366.0700073 100 139.6600037 100 3.999801025 0.86418169 6
 LTF 73 kDa protein IPI00789477 80974.52344 8.2 3 156.7799988 100 77.13999939 99.99982658 3.909418845 1.64333493 3
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 3 209.4100037 100 73.65000153 99.99961265 3.827926465 2.41995572 3
 CLU clusterin isoform 1 IPI00400826 62857.89844 6.24 2 92.61444092 100 58.84999847 99.98830233 3.659645102 0.64027381 2
 FGB Fibrinogen beta chain precursor IPI00298497 61772.66016 8.54 12 830.1599731 100 110.4000015 100 3.463031404 1.48047343 12
 ACSL4 Isoform Short of Long-chain-fatty-acid--
CoA ligase 4 IPI00219897 83902.50781 8.33 3 134.4499969 100 46.13999939 99.78167703 3.410263795 2.37826278 3
 LAMA4 Isoform 2 of Laminin subunit alpha-4 
precursor IPI00735310 218700.1875 5.93 1 70.91999817 99.99927373 70.91999817 99.99927373 3.379817119 0 1
 ALB Isoform 1 of Serum albumin precursor IPI00745872 79715.90625 5.92 41 2774.008789 100 179.8800049 100 3.353519341 1.11709249 49
 FLNA Filamin-A IPI00333541 305957.375 5.7 11 666.2888184 100 115.1999969 100 3.302385298 1.47261963 11
 ANXA2 Annexin A2 IPI00455315 43516.26953 7.57 10 580.9888916 100 124.4499969 100 3.075363312 1.18083811 10
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 126NT
 FN1 fibronectin 1 isoform 2 preproprotein IPI00845263 280315.25 5.36 18 1097.723389 100 111.7300034 100 3.054956222 1.61314633 18
 SERPINA1 Alpha-1-antitrypsin precursor IPI00553177 51885.51172 5.37 13 969.6444702 100 130.0099945 100 3.036878306 1.17773054 16
 S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 6 487.2399902 100 139.8899994 100 2.951139672 0.46197809 6
 SOD2 manganese superoxide dismutase 
isoform A precursor IPI00847322 27176.83984 8.35 6 414.6799927 100 122.3499985 100 2.855297856 0.46280991 6
 IGHM IGHM protein IPI00761159 57955.55078 7.53 10 906.2800903 100 136.2599945 100 2.838502697 0.7595165 11
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 155NT
Protein Name Accession Number Protein MW Protein PI
Peptide 
Count Total Ion Score
Total Ion Score 
C.I. % Best Ion Score











COL14A1 Isoform 3 of Collagen alpha-1(XIV) 
chain precursor IPI00402215 195721.9844 5.16 1 101.0599976 100 101.0599976 100 2.072425955 0 1
RPS14 40S ribosomal protein S14 IPI00026271 18272.75 10.07 1 69.23999786 99.9989307 69.23999786 99.9989307 1.679352185 0 1
ECGF1 50 kDa protein IPI00852987 52423.58984 5.36 1 58.63000107 99.9876945 58.63000107 99.9876945 1.582487717 0 1
LSP1 50 kDa protein IPI00554652 54843.82031 5.42 1 85.93000031 100 85.93000031 100 1.567364877 0 1
AGL Isoform 6 of Glycogen debranching 
enzyme IPI00219066 185998.375 6.26 1 69.20999908 99.99892329 69.20999908 99.99892329 1.521345765 0 1
COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 2 130.4900055 100 87.87000275 100 1.510999423 0.03921568 2
CSTB Cystatin-B IPI00021828 12618.79004 6.96 2 83.93000031 100 50.38999939 99.91794606 1.496362852 5.67E-02 3
PRSS1 Trypsin-1 precursor IPI00011694 29161.24023 6.08 1 81.45999908 99.99993586 81.45999908 99.99993586 1.470828836 0 1
TGFBI Transforming growth factor-beta-
induced protein ig-h3 precursor IPI00018219 80036.35156 7.62 2 111.3500061 100 77.58000183 99.99984329 1.449882512 0.37291565 2
SEC31A Isoform 4 of Protein transport protein 
Sec31A IPI00515103 138953.7344 7.03 3 141.0188904 100 51.18000031 99.93159319 1.428385418 0.18288652 3
GSTP1 Glutathione S-transferase P IPI00219757 25397.2207 5.43 1 104.0800018 100 104.0800018 100 1.403326044 0 1
RPL28 Ribosomal protein L28 variant 
(Fragment) IPI00816097 11793.78027 10.42 1 78.51000214 99.9998735 78.51000214 99.9998735 0.693904468 0 1
RAP1A Ras-related protein Rap-1A precursor IPI00019345 23841.94922 6.38 2 136.5200043 100 78.5 99.99987321 0.693302948 0.10799761 2
RPL14 RPL14 protein IPI00555744 29336.74023 10.94 2 91.94000244 100 49.11000061 99.88982088 0.68544742 0.21269961 2
RPS29 ribosomal protein S29 isoform 2 IPI00639942 9222.080078 10.08 1 56.15999985 99.97826802 56.15999985 99.97826802 0.66280005 0 1
CLU clusterin isoform 1 IPI00400826 62857.89844 6.24 2 92.61444092 100 58.84999847 99.98830233 0.662329599 6.43E-02 2
APOC3 13 kDa protein IPI00657670 13861.62012 7.9 1 64.51000214 99.9968224 64.51000214 99.9968224 0.656835827 0 1
UQCRH Ubiquinol-cytochrome c reductase 
complex 11 kDa protein, mitochondria IPI00296022 11826.04004 4.39 1 73.61000061 99.99960907 73.61000061 99.99960907 0.639803629 0 1
HIST1H1B Histone H1.5 IPI00217468 32071.38086 10.91 1 92.31999969 100 92.31999969 100 0.628362736 0 1
SNTB1 Isoform 2 of Beta-1-syntrophin IPI00216858 44616.67188 9.13 1 56.08000183 99.977864 56.08000183 99.977864 0.61594014 0 1
DDX21 Isoform 2 of Nucleolar RNA helicase 2 IPI00477179 91110.35156 9.42 2 132.9199982 100 93.43000031 100 0.607575762 0.11629702 2
PLG Plasminogen precursor IPI00019580 99918.28125 7.04 3 127.2900085 100 59.29999924 99.98945372 0.60073279 0.1163334 3
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 155NT
- Ig kappa chain V-III region SIE IPI00387115 12435.95996 8.7 1 58.79000092 99.9881396 58.79000092 99.9881396 0.585375145 0 1
- Ig kappa chain V-III region B6 IPI00387113 12295.89063 9.34 1 56.92678452 99.98178535 58.79000092 99.9881396 0.585375145 0 1
FGG Isoform Gamma-A of Fibrinogen gamma 
chain precursor IPI00219713 55011.35938 5.7 9 500.9499817 100 84.5 100 0.567892953 0.20829345 9
FGA Isoform 2 of Fibrinogen alpha chain 
precursor IPI00029717 76032.28906 8.23 11 840.444458 100 133.3000031 100 0.521675923 0.19703553 12
FGB Fibrinogen beta chain precursor IPI00298497 61772.66016 8.54 12 830.1599731 100 110.4000015 100 0.461917825 9.78E-02 12






























 FGB Fibrinogen beta chain precursor IPI00298497 61772.66016 8.54 21 1354.390137 100 113.9700012 100 12.41724255 5.9032913 26
 - Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment) IPI00783024 15665.44043 9.65 1 91.43000031 100 91.43000031 100 10.10147016 0 1
 POSTN Isoform 2 of Periostin precursor IPI00218585 96544.46875 7.87 1 70.58000183 99.99924036 70.58000183 99.99924036 9.961197502 0 1
 FGG Isoform Gamma-A of Fibrinogen gamma 
chain precursor IPI00219713 55011.35938 5.7 14 825.9499512 100 124.9800034 100 9.310750424 3.5919684 14
 DEFA3 Neutrophil defensin 3 precursor IPI00021827 10946.21973 5.71 4 150.5100098 100 42.83000183 99.5475116 9.054118193 6.7386449 4
 FGA Isoform 2 of Fibrinogen alpha chain 
precursor IPI00029717 76032.28906 8.23 25 1683.264526 100 121.5500031 100 8.873750269 4.8371029 27
 S100P Protein S100-P IPI00017526 12023.44043 4.75 1 102.4000015 100 102.4000015 100 7.21369809 0 1
 IGHG2 Hypothetical protein DKFZp686I04196 
(Fragment) IPI00399007 50615.94141 7.63 7 463.8200378 100 116.6100006 100 6.729833394 6.0572009 8
 FN1 Isoform 1 of Fibronectin precursor IPI00022418 276716.375 5.45 20 1147.833252 100 89.23999786 100 6.705884937 4.4933018 21
 SERPINA3 Isoform 1 of Alpha-1-
antichymotrypsin precursor IPI00847635 51646.92188 5.33 7 438.1344604 100 125.1999969 100 6.455902983 1.9635636 7
 IGHA1 CDNA FLJ25298 fis, clone STM07683, 
highly similar to Protein Tro alph IPI00386524 56728.32813 6.21 11 724.1699829 100 131.3699951 100 6.436333584 1.6584694 13
 IGL@ IGL@ protein IPI00658130 27441.46094 8.14 5 431.1600037 100 123.9300003 100 6.409485481 1.869191 5
 IGHA2 Hypothetical protein DKFZp686C02218 
(Fragment) IPI00642017 57449.87891 6.67 9 571.6900024 100 134.4400024 100 6.376704938 1.7254594 11
 - Hypothetical protein IPI00807428 26545.32031 5.66 4 396.3999939 100 123.9300003 100 6.335395908 2.5007228 4
 IGHM Hypothetical protein DKFZp686I15212 IPI00418153 62655.28125 8.39 8 585.1699829 100 121.8600006 100 6.186590908 2.5441143 9
 SERPINA1 Alpha-1-antitrypsin precursor IPI00553177 51885.51172 5.37 10 685.5 100 125.5599976 100 6.157651046 1.2727903 10
 MPO Isoform H14 of Myeloperoxidase 
precursor IPI00236554 77088.74219 9.3 5 247.3599854 100 66.40000153 99.99801113 6.095339518 2.4020806 5
 IGHM IGHM protein IPI00761159 57955.55078 7.53 10 917.5299683 100 145.4600067 100 6.023900665 3.9470889 12
 FKBP5 51 kDa protein IPI00743671 59312.21094 5.79 1 71.45999908 99.99937969 71.45999908 99.99937969 5.753093099 0 1
 IGKV1-5 IGKV1-5 protein IPI00419424 28320.14063 6.3 7 651.9500122 100 142.8000031 100 5.642667893 1.9932317 8
 GC Vitamin D-binding protein precursor IPI00555812 60697.32813 5.4 4 192.0644379 100 72.72000122 99.9995359 5.527661656 1.8702396 4
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 CLU clusterin isoform 1 IPI00400826 62857.89844 6.24 2 108.4644394 100 77.80999756 99.99985625 5.494775625 1.2567174 2
 IGHG4 Ig gamma-4 chain C region IPI00829814 39932.16016 7.18 7 371.6900024 100 93.20999908 100 5.453336664 4.5451462 7
 PLG Plasminogen precursor IPI00019580 99918.28125 7.04 6 383.6099854 100 92.73000336 100 5.403589844 1.203747 6
 IGL@ IGL@ protein IPI00745660 27232.34961 7.59 4 343.9200134 100 123.9300003 100 5.397535835 0.9828402 4
 IGHM IGHM protein IPI00479708 73773.75 6.86 6 337.1399841 100 130.2899933 100 5.33276366 3.1217384 6
 LTF 73 kDa protein IPI00789477 80974.52344 8.2 3 104.1800003 100 36.65000153 98.12238095 5.324688968 2.8622551 4
 IGHG1 Hypothetical protein DKFZp686P15220 IPI00645363 56996.17188 8.13 10 916.4799805 100 145.4600067 100 5.294315363 3.1276834 12
 CP Ceruloplasmin precursor IPI00017601 132466.3281 5.44 5 324.809967 100 118.5 100 5.06778401 4.0739102 5
 ANXA1 Annexin A1 IPI00218918 43626.42969 6.57 4 350.3200073 100 118.4100037 100 4.807958823 1.8914651 4
 ALB Isoform 1 of Serum albumin precursor IPI00745872 79715.90625 5.92 43 2745.158447 100 115.1600037 100 4.784888043 1.9857847 59
 - Ig kappa chain V-III region SIE IPI00387115 12435.95996 8.7 1 77.12000275 99.9998315 77.12000275 99.9998315 4.747285583 0 1
 - Ig kappa chain V-III region B6 IPI00387113 12295.89063 9.34 1 75.25678253 99.99974122 77.12000275 99.9998315 4.747285583 0 1
 APOA4 apolipoprotein A-IV precursor IPI00847179 49520.91016 5.28 7 295.5844421 100 56.18000031 99.97907779 4.619751947 2.0154697 7
 LBP Lipopolysaccharide-binding protein 
precursor IPI00032311 56800.25 6.23 2 143.1199951 100 75.59999847 99.99976088 4.600992044 1.433581 2
 C9 Complement component C9 precursor IPI00022395 69800.9375 5.43 2 92.00999451 100 59.50999832 99.99028131 4.499831492 0.7558639 2
 AZGP1 alpha-2-glycoprotein 1, zinc IPI00166729 37445.41016 5.71 2 101.1967773 100 59.52999878 99.99032596 4.496562314 1.6212749 2
 APOA4 Apolipoprotein A-IV precursor IPI00304273 49547.92188 5.28 7 292.2544556 100 56.18000031 99.97907779 4.412591559 1.3277459 7
 A2M Alpha-2-macroglobulin precursor IPI00478003 177285.7656 6 9 436.3699951 100 63.31000137 99.99594858 4.381167572 2.0328209 9
 VTN Vitronectin precursor IPI00298971 57939.35156 5.55 8 471.8200073 100 107.4599991 100 4.34201784 2.0699817 8
 LYZ Lysozyme C precursor IPI00019038 17902.35938 9.38 2 128.1699982 100 92.77999878 100 4.208624448 0.4487407 2
 APOA1 Apolipoprotein A-I precursor IPI00021841 34071.30859 5.56 8 417.7588806 100 67.41000366 99.99842381 3.978969929 2.7917361 8
 C3 Complement C3 precursor (Fragment) IPI00783987 204689.0469 6.02 12 661.1099854 100 88.48000336 100 3.880763376 2.0592109 12
 - 10 kDa protein IPI00259410 11159.19043 6.23 1 58.93000031 99.98889272 58.93000031 99.98889272 3.880414106 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 - Ig kappa chain V-I region DEE IPI00387025 12753.91992 9.43 1 57.75444031 99.98543993 58.93000031 99.98889272 3.880414106 0 1
 - Ig kappa chain V-I region OU IPI00387098 12437.78027 9.94 1 57.75444031 99.98543993 58.93000031 99.98889272 3.880414106 0 1
 CFH Complement factor H IPI00515041 146209.4219 6.35 3 136.8000031 100 53.09000015 99.95738057 3.875536229 0.3569699 3
 GSN Isoform 2 of Gelsolin precursor IPI00646773 87445.10938 5.58 8 365.710022 100 67.58000183 99.99848432 3.804021154 1.3196541 8
 SERPINC1 SERPINC1 protein IPI00844156 32447.10938 9.03 4 201.3600006 100 94.70999908 100 3.733905731 1.7263869 4
 TTR 13 kDa protein IPI00646384 14770.61035 5.34 2 140.5200043 100 91.56999969 100 3.663669704 0.1973862 2
 LSM8 U6 snRNA-associated Sm-like protein 
LSm8 IPI00219871 10684.41016 4.34 1 68.25 99.998701 68.25 99.998701 3.619554939 0 1
 HRG Histidine-rich glycoprotein precursor IPI00022371 63635.03125 7.09 1 59.49000168 99.99023646 59.49000168 99.99023646 3.584225627 0 1
 CFB Isoform 2 of Complement factor B 
precursor (Fragment) IPI00218508 74644.8125 6.11 2 87.40000153 100 46.90999985 99.82314895 3.580169145 0.4672555 2
 SERPINC1 Antithrombin III variant IPI00032179 58498.30859 6.11 3 115.7700043 100 42.33000183 99.49229966 3.438398746 1.282044 3
 IFITM1 Interferon-induced transmembrane 
protein 1 IPI00300620 14931.44043 7.78 2 192.5400085 100 112.5299988 100 3.398483901 2.3756874 3
 SERPINH1 Serpin H1 precursor IPI00032140 51543.67969 8.75 5 412.0200195 100 145.7799988 100 3.362311968 1.6429696 5
 C4B;C4A complement component 4B 
preproprotein IPI00418163 205105.2656 6.89 4 163.0944366 100 49.29999924 99.89799823 3.354061032 0.5958582 5
 HPX Hemopexin precursor IPI00022488 55409.48047 6.55 3 166.0299988 100 91.66999817 100 3.332318829 1.7609427 4
 SERPINB1 Leukocyte elastase inhibitor IPI00027444 47127.14063 5.9 2 93.13999939 100 57.5 99.98456141 3.313973483 0.6418931 2
 APOB Apolipoprotein B-100 precursor IPI00022229 567947.0625 6.61 5 253.0844421 100 92.09999847 100 3.155435562 1.1254397 5
 S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 5 473.7599792 100 143.7299957 100 3.106782863 0.6319131 8
 F2 70 kDa protein IPI00784409 75432.22656 5.64 2 93.02999878 100 59.70000076 99.99069733 3.101762834 0.5591597 2
 S100A8 Protein S100-A8 IPI00007047 12745.88965 6.51 5 246.9644623 100 57.88999939 99.98588738 3.026061989 0.4060154 5
 HP Haptoglobin precursor IPI00641737 52573.75 6.28 12 821.3200073 100 109.9599991 100 2.998685157 0.4106641 14
 RTN4 Isoform 2 of Reticulon-4 IPI00298289 42931.25 4.71 1 82.09999847 99.99994647 82.09999847 99.99994647 2.914596692 0 1
 HNRPH1 HNRPH1 protein IPI00479191 53875.41016 6.33 6 476.8544312 100 147.8399963 100 2.905955321 1.3974767 7
 TF Transferrin variant (Fragment) IPI00798430 87365.92188 6.68 22 1126.348877 100 98.70999908 100 2.875403865 1.0882451 22
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 LGALS1 Galectin-1 IPI00219219 16278.33008 5.34 2 152.7799988 100 90.55000305 100 2.863065894 0.1346352 2
 RCN3 Reticulocalbin-3 precursor IPI00101037 38766.19922 4.74 2 105.1900024 100 56.11000061 99.97873783 2.842719805 2.9776675 2
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 25840.99023 4.93 3 261.8900146 100 106.5100021 100 2.804392111 0.2972795 3
 - 2,3-bisphosphoglycerate mutase variant 
(Fragment) IPI00556284 18558.81055 6.59 1 74.06999969 99.9996599 74.06999969 99.9996599 2.795621774 0 1
 AHSG 29 kDa protein IPI00795830 31274.16992 4.77 2 60.70999908 99.99262762 30.79999924 92.77882762 2.66793087 2.6643007 2
 LSP1 50 kDa protein IPI00554652 54843.82031 5.42 1 87.08000183 100 87.08000183 100 2.667818628 0 1
 APOE Apolipoprotein E precursor IPI00021842 38239.98828 5.65 5 346.5999756 100 121.8099976 100 2.624189174 0.6842099 5
 LUM 23 kDa protein IPI00794403 25919.60938 8.52 3 212.9199982 100 92.41000366 100 2.604090243 0.1795785 3
 PRKDC Isoform 2 of DNA-dependent protein 
kinase catalytic subunit IPI00376215 508806.4375 6.81 1 84.68000031 100 84.68000031 100 2.600128958 0 1
 HNRPH2 Heterogeneous nuclear 
ribonucleoprotein H' IPI00026230 51910.53125 5.89 6 436.9400024 100 147.8399963 100 2.570387801 1.9086134 7
 ARPC2 Actin-related protein 2/3 complex 
subunit 2 IPI00005161 38147.87109 6.84 5 198.3944397 100 52.09000015 99.94634532 2.489408673 0.7672243 5
 NAP1L1 43 kDa protein IPI00789029 47959.44141 4.45 2 114.3499985 100 72.48999786 99.99951066 2.488313587 1.5962477 2
 TRIM28 Isoform 2 of Transcription 
intermediary factor 1-beta IPI00438230 85861.78906 5.67 2 159.1699982 100 106.3499985 100 2.486671601 0.329186 2
 PSMC3 26S protease regulatory subunit 6A IPI00018398 54730.94141 5.13 3 120.4000015 100 56.70999908 99.98148142 2.464893055 0.887885 3
 A1BG 41 kDa protein IPI00644018 42068.62109 5.5 2 68.49000549 99.99877084 38.83000183 98.86340052 2.431373771 0.1697634 2
 YWHAZ 14-3-3 protein zeta/delta IPI00021263 30890.03906 4.73 9 615.1844482 100 142.6799927 100 2.430456858 0.964619 9
 COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968.0469 9.08 2 150.8000031 100 86.65000153 100 2.412886112 0.5153256 2
 FSCN1 FSCN1 protein IPI00747810 59288.51172 7.93 2 83.77999878 100 51.22000122 99.93444474 2.351865211 3.83E-02 2
 ANXA7 Isoform 2 of Annexin A7 IPI00021771 52673.87891 6.25 1 77.56999969 99.99984808 77.56999969 99.99984808 2.301853704 0 1
 CKAP4 CKAP4 protein (Fragment) IPI00433214 72955.86719 9.34 10 674.2144775 100 99.13999939 100 2.287005397 1.4223606 10
 - Rheumatoid factor D5 light chain (Fragment) IPI00816799 13282.5498 9.15 1 61.18000031 99.99338382 61.18000031 99.99338382 2.280691044 0 1
 BGN CDNA FLJ35635 fis, clone 
SPLEN2011805, highly similar to 
BONE/CARTILAGE
IPI00385748 39528 6.31 4 198.6600037 100 68.30999756 99.99871883 2.279520057 0.9537916 4
 DDX3Y ATP-dependent RNA helicase DDX3Y IPI00293616 78372.53125 7.24 2 128.5800018 100 76.30999756 99.99979695 2.236079067 0.4423616 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 STX7 Isoform 2 of Syntaxin-7 IPI00552913 29491.90039 5.02 1 67.40000153 99.99842018 67.40000153 99.99842018 2.233677757 0 1
 COL6A3 alpha 3 type VI collagen isoform 4 
precursor IPI00072918 345401.0313 6.48 31 1747.334717 100 110.0500031 100 2.230964967 1.0447581 33
 GSTP1 Glutathione S-transferase P IPI00219757 25397.2207 5.43 3 164.3399963 100 66.19999695 99.99791739 2.174025472 0.3151039 3
 ARPC3 12 kDa protein IPI00796102 13215.08008 8.52 2 81.86999512 99.99994356 48.81999969 99.88607798 2.170654826 0.6971714 2
 HNRPM Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein M IPI00383296 79706.89844 8.94 3 279.6699829 100 137.0299988 100 2.165247577 0.5364623 3
 ARHGDIB 13 kDa protein IPI00791712 14875.75977 4.69 2 168.4499969 100 128.8600006 100 2.16009022 0.2719841 2
 NID2 NID2 protein IPI00293033 111838.1875 5.38 2 93.08999634 100 54.43000031 99.96869544 2.145019197 0.616331 2
 B2M B2M protein IPI00796379 15076.12988 6.06 2 156.0100098 100 83.06999969 100 2.144708521 0.111012 2
 ACTR3 Actin-like protein 3 IPI00028091 51165.26953 5.61 3 120.8099976 100 47.50999832 99.84596912 2.108060764 0.3238271 3
 CYBB Cytochrome b-245 heavy chain IPI00218646 71069.92188 8.9 1 91.33000183 100 91.33000183 100 2.105822832 0 1
 VIM Vimentin IPI00418471 56977.44141 5.06 23 1567.598633 100 114.6600037 100 2.104318013 0.7306668 26
 GART Isoform Long of Trifunctional purine 
biosynthetic protein adenosine-3 IPI00025273 118791.6875 6.26 2 73.77000427 99.99963558 40.43000031 99.213665 2.091232779 0.3315155 2
 HNRPF Heterogeneous nuclear 
ribonucleoprotein F IPI00003881 48367.07813 5.38 4 221.8399963 100 109.75 100 2.072902227 0.5381524 4
 C1S 75 kDa protein IPI00743907 81580.29688 5.2 1 73.19000244 99.99958351 73.19000244 99.99958351 2.063512627 0 1
 EIF4A1 Eukaryotic initiation factor 4A-I IPI00025491 49332.85938 5.32 6 392.460022 100 118.6399994 100 2.059831144 1.0682674 7
 RAC1 Isoform B of Ras-related C3 botulinum 
toxin substrate 1 precursor IPI00219675 26798.57031 8.87 3 112.2099991 100 44.45999908 99.6891093 2.05560662 0.7959509 3
 ERH Enhancer of rudimentary homolog IPI00029631 13541.16016 5.63 2 135.75 100 96.52999878 100 2.052781748 0.5445948 2
 RBM8A Isoform 2 of RNA-binding protein 8A IPI00216659 21665.92969 5.64 1 111.5599976 100 111.5599976 100 2.043273795 0 1
 MYH14 Isoform 5 of Myosin-14 IPI00029818 180709.0469 6.27 4 274.0744324 100 91.20999908 100 2.038690192 0.3858594 4
 PKM2 58 kDa protein IPI00784179 63980.44141 7.95 7 317.2000122 100 69.29000092 99.99897763 2.033596032 1.8681983 7
 CCT7 chaperonin containing TCP1, subunit 7 
isoform b IPI00552072 40821.19141 6.04 1 72.73999786 99.99953804 72.73999786 99.99953804 2.029156189 0 1
 HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55078 9.27 8 431.0100098 100 96.29000092 100 2.024902077 1.6538914 8
 HNRPU heterogeneous nuclear 
ribonucleoprotein U isoform a IPI00644079 101350.8203 5.76 5 259.6799927 100 70.44000244 99.99921547 2.008647525 0.82917 5
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 TAGLN Transgelin IPI00216138 25234.73047 8.87 5 302.4500122 100 89.48000336 100 2.005715396 0.1842202 5
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 4 270.4700012 100 104.8799973 100 1.99853832 0.5335837 4
 MARCKS Myristoylated alanine-rich C-kinase 
substrate IPI00219301 35850.28125 4.47 1 96.12000275 100 96.12000275 100 1.994727871 0 1
 PCNA Proliferating cell nuclear antigen IPI00021700 31474.51953 4.57 2 83.98999786 100 42.63999939 99.52727595 1.981602596 2.1532418 2
 HNRPH3 Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein H3 IPI00216492 36558.57031 6.36 3 217.6100006 100 79.33000183 99.9998987 1.978276332 0.6832766 3
 IGF2BP2 Insulin-like growth factor 2 mRNA-
binding protein 2 IPI00180983 67944.92969 8.22 1 68.97000122 99.99889946 68.97000122 99.99889946 1.968549684 0 1
 IGF2BP3 64 kDa protein IPI00746216 71308.52344 9.12 1 68.97000122 99.99889946 68.97000122 99.99889946 1.968549684 0 1
 FLNA Filamin-A IPI00333541 305957.375 5.7 17 991.5889282 100 112.0699997 100 1.927150925 0.7789952 17
 DKFZp686D0972 hypothetical protein 
LOC345651 IPI00003269 44988.21875 5.39 6 366.0299683 100 86.11000061 100 1.919147952 0.5525134 8
 GBP5 CTCL tumor antigen GBP-5ta 
(Fragment) IPI00645391 61674.92188 5.52 2 89.22999573 100 58.25999832 99.98703992 1.908707005 0.1065657 2
 YWHAH 14-3-3 protein eta IPI00216319 31363.33008 4.76 6 292.8800049 100 64.13999939 99.99665337 1.906021069 0.4418584 6
 CPNE1 53 kDa protein IPI00852917 56975.76172 5.52 2 119.5 100 86.37000275 100 1.903531477 0.6271852 2
 HNRPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 IPI00419373 42922.89844 9.1 4 374.2299805 100 178.1799927 100 1.898002176 1.1872072 5
 YWHAG 14-3-3 protein gamma IPI00220642 31015.18945 4.8 7 386.2000122 100 73.48999786 99.99961131 1.896552192 0.5344562 7
 ACTG1;PSPHL Actin, cytoplasmic 2 IPI00021440 44922.05859 5.31 17 1177.290039 100 135.5800018 100 1.880646106 0.5297015 27
 PSMD3 26S proteasome non-ATPase 
regulatory subunit 3 IPI00011603 66216 8.47 2 98.75 100 66.81999969 99.99819446 1.871599504 0.0403988 2
 HMOX1 33 kDa protein IPI00747450 35080.30078 8.72 1 58.81000137 99.98858154 58.81000137 99.98858154 1.856586533 0 1
 NONO Non-POU domain-containing octamer-
binding protein IPI00304596 58321.69141 9.01 5 213.7644501 100 52.49000168 99.95106637 1.847189697 0.578229 5
 PTGES3 19 kDa protein IPI00789101 21682.35938 4.76 2 124.1699982 100 78.91999817 99.99988867 1.837413842 6.60E-02 2
 SFPQ Isoform Long of Splicing factor, proline- 
and glutamine-rich IPI00010740 81090.10938 9.45 5 249.9644318 100 65.47000122 99.99753619 1.834075517 0.6930046 5
 ANXA11 Annexin A11 IPI00552303 19910.25 7.63 2 112.3600006 100 63.65999985 99.99626227 1.826493533 0.3563469 2
 MYH10 Isoform 2 of Myosin-10 IPI00479307 260063.1719 5.46 9 456.8056335 100 104.7799988 100 1.819013661 0.9204365 9
 MYH9 Myosin-9 IPI00019502 257357.9844 5.5 45 2882.604248 100 127.2200012 100 1.818237774 0.5821137 46
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 YWHAQ 14-3-3 protein theta IPI00018146 30857.03906 4.68 8 405.230011 100 91.94000244 100 1.80847221 0.5204737 8
 
HIST1H2BI;HIST1H2BG;HIST1H2BF;HIST1H2
BC;HIST1H2BE H2B histone family, membe
IPI00020101 16921.91016 10.31 4 270.0700073 100 102.5400009 100 1.80170744 0.4890485 11
 PA2G4 41 kDa protein IPI00794875 47417.53125 6.82 4 233.8500061 100 79.51999664 99.99990304 1.799023917 0.3213148 4
 ACTG2 Actin, gamma-enteric smooth muscle IPI00025416 45052.03906 5.31 12 786.8900146 100 115.3899994 100 1.798472192 0.5372273 19
 EIF4A3 Eukaryotic initiation factor 4A-III IPI00009328 50527.51172 6.3 2 124.3899994 100 71.06999969 99.99932141 1.798107646 0.4579668 3
 MYL6 17 kDa protein IPI00744444 18920.58008 4.54 5 482.3500061 100 131.6999969 100 1.77027477 0.2367583 6
 OTUB1 Hypothetical protein DKFZp564E242 IPI00000581 34180.75 4.9 1 95.68000031 100 95.68000031 100 1.763256892 0 1
 ACTC1 Actin, alpha cardiac muscle 1 IPI00023006 45148.14063 5.23 12 800.7900391 100 115.3899994 100 1.760549247 0.4735275 21
 YWHAB Isoform Short of 14-3-3 protein 
beta/alpha IPI00759832 30949.07031 4.76 8 409.40448 100 96.88999939 100 1.759109233 0.6086951 8
 DHX9 ATP-dependent RNA helicase A IPI00844578 151431.7344 6.41 5 250.1688995 100 62.77000046 99.99541217 1.755607852 0.4352823 6
 SFN Isoform 2 of 14-3-3 protein sigma IPI00411765 26671.25 4.77 4 213.9900055 100 64.13999939 99.99665337 1.754667943 0.3838283 4
 ARPC4 actin related protein 2/3 complex 
subunit 4 isoform b IPI00607772 10554.03027 6.84 2 87.73999786 100 56.97999954 99.98259766 1.74827399 7.23E-03 2
 COL6A1 Collagen alpha-1(VI) chain precursor IPI00291136 117302.5391 5.26 7 492.5200195 100 110.4700012 100 1.746920651 0.1496196 7
 NDUFS2 NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial IPI00025239 56146.01172 7.21 1 62.25 99.99482861 62.25 99.99482861 1.743114543 0 1
 HCLS1 Hematopoietic lineage cell-specific 
protein IPI00026156 59241.48828 4.74 5 207.5399933 100 54.18999863 99.96691678 1.732525816 1.0277794 5
 HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.0625 4.97 30 1951.044434 100 115.0299988 100 1.73181602 0.9471513 33
 PKLR Pyruvate kinase L IPI00743713 67899.96875 7.6 3 140.9700012 100 69.29000092 99.99897763 1.723734413 0.6054856 3
 MATR3 100 kDa protein IPI00789551 110688.2734 5.71 2 94.50999451 100 54.47999954 99.96905377 1.723535818 7.26E-02 2
 NCL Isoform 1 of Nucleolin IPI00604620 89719.57031 4.6 10 590.4199829 100 103.3899994 100 1.722700593 0.8444746 11
 - Transforming growth factor, beta-induced, 
68kDa variant (Fragment) IPI00556324 27690.46094 5.33 1 77.80000305 99.99985592 77.80000305 99.99985592 1.721331012 0 1
 PFN1 Profilin-1 IPI00216691 16766.75 8.44 8 600.2699585 100 142.2599945 100 1.714901522 0.734022 8
 KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 7 341.1699829 100 83.98000336 100 1.710563791 0.8207215 7
 PFKM CDNA FLJ44241 fis, clone 
THYMU3008436, highly similar to 6- 
phosphofru
IPI00465179 101419.0313 8.2 1 56.61999893 99.98109365 56.61999893 99.98109365 1.706116229 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 LMNB1 LMNB1 protein IPI00790831 48786.14063 4.99 6 246.4799805 100 68.48999786 99.99877084 1.700971254 0.4200787 6
 ALDOA Fructose-bisphosphate aldolase A IPI00465439 43651.62891 8.3 10 774.1444092 100 120.5299988 100 1.693642539 0.7375481 10
 ILK Integrin-linked protein kinase IPI00013219 55688.23828 8.3 1 72.62000275 99.99952509 72.62000275 99.99952509 1.683716652 0 1
 CLTC Isoform 2 of Clathrin heavy chain 1 IPI00455383 203165.7031 5.48 8 418.0299988 100 73.05999756 99.99957085 1.674421285 0.9930723 9
 ANXA2 Annexin A2 IPI00455315 43516.26953 7.57 14 874.848877 100 104.6299973 100 1.673743489 0.4657385 14
 HIST3H3 Histone H3.1t IPI00216402 17606.75 11.13 4 167.8199921 100 54.75999832 99.97098599 1.66937617 0.3689901 4
 EIF4A2 Isoform 2 of Eukaryotic initiation factor 
4A-II IPI00409717 49956.14063 5.33 4 318.9299927 100 118.6399994 100 1.666609992 1.2554873 5
 COL6A2 Isoform 2C2A of Collagen alpha-2(VI) 
chain precursor IPI00220613 105910.7031 5.38 3 195.9599915 100 74.73999786 99.99970852 1.664949191 0.4251385 3
 TUBB Tubulin beta chain IPI00011654 52311.16016 4.78 18 1291.790039 100 144.4199982 100 1.659437419 0.6396325 21
 LCP1 Plastin-2 IPI00010471 77185.35938 5.2 8 366.1999817 100 72.69999695 99.99953376 1.655249558 0.5203204 8
 NUMA1 Isoform 1 of Nuclear mitotic apparatus 
protein 1 IPI00292771 260878.9688 5.63 2 121.7400055 100 63.68000031 99.99627945 1.651112674 0.1357461 2
 STAT1 Isoform Beta of Signal transducer and 
activator of transcription 1-al IPI00218188 91515.17188 6.02 6 272.4599915 100 69.06999969 99.99892451 1.650141086 0.9811945 6
 SAA1;SAA2 Serum amyloid A protein 
precursor IPI00552578 14433.66992 6.28 3 307.8399963 100 156.3099976 100 1.649195549 0.4554382 3
 TUBA1B Similar to Tubulin alpha-ubiquitous 
chain IPI00792677 49578.05859 4.96 11 934.1499634 100 165.2400055 100 1.645599936 0.5736838 13
 DYNLL1 Dynein light chain 1, cytoplasmic IPI00019329 12081.2998 6.89 2 84.43000031 100 45.15000153 99.73477926 1.643114846 6.73E-02 2
 EMILIN1 EMILIN-1 precursor IPI00013079 109415.4531 5.1 2 136.2799988 100 92.22000122 100 1.639988624 0.5416282 2
 APOC3 13 kDa protein IPI00657670 13861.62012 7.9 1 109.9199982 100 109.9199982 100 1.628990486 0 1
 DYNC1I2 Isoform 2B of Cytoplasmic dynein 1 
intermediate chain 2 IPI00302712 77936.72656 5.1 1 66.86000061 99.99821101 66.86000061 99.99821101 1.621869371 0 1
 ARF5 17 kDa protein IPI00853337 18726.14063 6.74 1 73.23999786 99.99958827 73.23999786 99.99958827 1.596322024 0 1
 SAA1;SAA2 serum amyloid A2 IPI00006146 14428.79004 9.2 3 245.9299927 100 94.40000153 100 1.593610038 0.5222085 3
 ARF3 ADP-ribosylation factor 3 IPI00215917 22649.98047 6.84 2 81.80000305 99.99994264 44.75 99.70919114 1.589681557 0.250007 2
 RAN 26 kDa protein IPI00792352 29358.91016 8.51 3 182.4000092 100 85.73999786 100 1.587407123 0.6179264 3
 ANXA5 Annexin A5 IPI00329801 39272.76172 4.94 12 753.3899536 100 105.2900009 100 1.582858736 0.4432637 12
Poorly Differentiated iTRAQ Individual Patients
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 CTSS Cathepsin S precursor IPI00299150 42009.60938 8.61 1 63.11000061 99.99575764 63.11000061 99.99575764 1.582598874 0 1
 LGALS3BP Galectin-3-binding protein 
precursor IPI00023673 68905.42969 5.13 4 212.230011 100 94.05000305 100 1.579800053 0.3402115 4
 BCAP31 21 kDa protein IPI00639976 22905.44922 8.94 3 135.6300049 100 58.34999847 99.98730573 1.57895904 0.6957274 3
 PLEC1 plectin 1 isoform 6 IPI00186711 568646.6875 5.74 9 372.9801331 100 65.80000305 99.99771647 1.578606393 0.7132134 9
 DSTN 15 kDa protein IPI00643237 18687.19922 8.84 1 55.95999908 99.97799062 55.95999908 99.97799062 1.573136108 0 1
 RPS7 40S ribosomal protein S7 IPI00013415 25713.66016 10.09 2 97.09999847 100 48.88999939 99.88789946 1.562806921 0.1929502 2
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00743359 42850.23828 6.08 3 115.8099976 100 42.18000031 99.47445779 1.560256705 0.4772893 3
 YWHAE 14-3-3 protein epsilon IPI00000816 32029.69922 4.63 8 505.2099609 100 132.5399933 100 1.556450597 0.5594842 8
 FUBP1 Isoform 2 of Far upstream element-
binding protein 1 IPI00644386 73175.53125 7.74 3 119.7200012 100 45.81999969 99.77269569 1.55643709 0.5860938 3
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00742968 42765.21875 5.91 4 152.1199951 100 45.75 99.76900231 1.555103368 0.3854709 4
 HIST1H1D Histone H1.3 IPI00217466 31265.17969 11.02 2 105.9199982 100 71.88999939 99.99943817 1.552994885 0.233981 2
 TUBB2A Tubulin beta-2A chain IPI00013475 52501.16016 4.78 14 1052.599976 100 144.4199982 100 1.540607386 0.5591041 17
 PDHB Isoform 2 of Pyruvate dehydrogenase 
E1 component subunit beta, mitocho IPI00549885 40188.14063 5.64 1 87.01000214 100 87.01000214 100 1.540355886 0 1
 HLA-DRB1;HLA-
DRB5;LOC730415;hCG_1998957;HLA-
DRB4;HLA-DRB3 MHC ClassII HLA-D
IPI00815988 14149.65039 5.91 3 153.1999969 100 76.62999725 99.99981137 1.538129854 0.7516925 3
 HMGB1 High mobility group protein B1 IPI00419258 31352.75977 5.62 2 186.3544464 100 96.87000275 100 1.535736102 1.0810478 2
 TNS3 tensin 3 IPI00658152 166503.375 6.34 1 74.55000305 99.99969549 74.55000305 99.99969549 1.533971904 0 1
 CCT2 T-complex protein 1 subunit beta IPI00297779 63200.62109 6.01 3 197.9300079 100 69.55000305 99.99903704 1.526447327 0.3281597 3
 TUBB2C Tubulin beta-2C chain IPI00007752 52471.19141 4.79 17 1309.77002 100 144.4199982 100 1.524432112 0.5128577 20
 TMPO Isoform Gamma of Lamina-associated 
polypeptide 2, isoforms beta/gamma IPI00181409 43512.75 9.18 1 57.25 99.98364662 57.25 99.98364662 1.51749335 0 1
 TUBB3 Tubulin beta-3 chain IPI00013683 53216.46094 4.83 11 828.3200073 100 144.4199982 100 1.517015114 0.4999962 12
 APCS Serum amyloid P-component precursor IPI00022391 27335.35938 6.1 1 71.68000031 99.99941033 71.68000031 99.99941033 1.5152239 0 1
 NHP2L1 NHP2-like protein 1 IPI00026167 15932.73047 8.72 2 77.66000366 99.9998512 40.93000031 99.2991782 1.514569261 0.1277811 2
 SNRP70 Isoform 3 of U1 small nuclear 
ribonucleoprotein 70 kDa IPI00219484 21454.14063 7.82 1 58.11444092 99.98659819 59.29000092 99.98977631 1.510611353 0 1
Poorly Differentiated iTRAQ Individual Patients
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 SAMHD1 SAM domain and HD domain-
containing protein 1 IPI00294739 79521.28906 6.69 6 352.8399963 100 97.97000122 100 1.508418286 0.3213406 6
 TUBB6 43 kDa protein IPI00643158 44746.64063 4.71 7 327.5299988 100 83.66000366 100 1.50533307 0.5064512 7
 PTBP1 polypyrimidine tract-binding protein 1 
isoform a IPI00183626 64630.35156 9.21 2 118.6999969 100 69.20999908 99.99895862 1.501639526 7.44E-02 2
 - Tryptophanyl-tRNA synthetase (Fragment) IPI00383754 12867.94043 4.57 1 62.81444168 99.99545887 63.99000168 99.99653576 1.499615305 0 1
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472284 42123.23047 5.77 6 278.3599854 100 76.51999664 99.99980653 1.495260368 0.3147671 6
 HNRPD Isoform 3 of Heterogeneous nuclear 
ribonucleoprotein D0 IPI00220684 37704.55859 8.23 3 179.5599976 100 79.04000092 99.99989171 1.494500722 0.3398456 4
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472676 42024.01172 5.55 6 292.5099792 100 76.51999664 99.99980653 1.489127242 0.3215919 6
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472943 42316.07031 5.84 3 134.269989 100 50.02000046 99.91358133 1.485178178 0.5127508 3
 ALDH16A1 Aldehyde dehydrogenase family 16 
member A1 IPI00217920 87917.74219 6.35 1 74 99.99965437 74 99.99965437 1.482258431 0 1
 TUBB6 TUBB6 protein IPI00646779 52874.32813 4.8 9 606.7999878 100 144.4199982 100 1.474440062 0.5173359 10
 MCCC2 Isoform 2 of Methylcrotonoyl-CoA 
carboxylase beta chain, mitochondria IPI00789428 61882.76172 7.59 3 144.8500061 100 63.04000092 99.99568871 1.466712228 2.0151389 3
 RPS3 40S ribosomal protein S3 IPI00011253 29833.74023 9.68 2 98.37999725 100 63.09999847 99.99574786 1.465484638 0.1581078 2
 PFKL Liver phosphofructokinase isoform a IPI00784216 96819.92188 8.17 2 106.9300003 100 59.36000061 99.98993978 1.462342175 0.2437741 2
 HLA-DRA major histocompatibility complex, 
class II, DR alpha precursor IPI00464948 30468.91016 4.91 2 123.0800018 100 78.25 99.9998701 1.459834572 0.5707349 2
 UBE1 Ubiquitin-activating enzyme E1 IPI00645078 126424.8516 5.49 2 105.7799988 100 65.90000153 99.99776845 1.449224297 4.68E-02 2
 XRCC6 ATP-dependent DNA helicase 2 
subunit 1 IPI00644712 78669.82813 6.23 4 244.4944305 100 98.86000061 100 1.448476068 0.716455 4
 DYNC1H1 532 kDa protein IPI00477531 576722 6.03 4 157.3933105 100 55.36000061 99.97472986 1.447052939 0.3254075 4
 LOC653888 similar to Actin-related protein 2/3 
complex subunit 1B IPI00737530 45280.69141 9.11 1 87.95999908 100 87.95999908 100 1.44286733 0 1
 HSPG2 Basement membrane-specific 
heparan sulfate proteoglycan core protein IPI00024284 487110.1563 6.06 7 277.0344238 100 54.72999954 99.97078488 1.442045774 1.2560232 7
 COL14A1 Isoform 3 of Collagen alpha-1(XIV) 
chain precursor IPI00402215 195721.9844 5.16 2 73.08999634 99.99957381 37.04000092 98.28364332 1.441838496 0.2369642 2
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00718924 42211.23828 5.96 6 281.6699829 100 76.51999664 99.99980653 1.440332069 0.2296209 6
 SCAMP3 Isoform 2 of Secretory carrier-
associated membrane protein 3 IPI00306383 37073.82813 7.53 2 113.1800079 100 68.44000244 99.99875661 1.438629459 9.34E-02 2
 RHOA Transforming protein RhoA precursor IPI00027500 24622.31055 5.83 2 99.72000122 100 55.41999817 99.97507657 1.432768417 0.8001399 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 - Elongation factor 1-alpha IPI00472724 57485.78125 9.15 11 706.2999878 100 110.4199982 100 1.430951474 0.5253133 12
 - 140 kDa protein IPI00829641 149651.875 7.92 3 206.5200043 100 80.63999939 99.99992508 1.429835322 0.2047226 3
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472282 42025.16016 5.89 6 267.5244446 100 76.51999664 99.99980653 1.426254021 0.4222042 6
 TPM4 Isoform 1 of Tropomyosin alpha-4 chain IPI00010779 32340.88086 4.67 8 475.269989 100 102.9800034 100 1.423207559 0.3668562 8
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472903 42843.35156 6.52 5 220.2600098 100 50.02000046 99.91358133 1.420413722 0.4989142 5
 HSP90AB4P Heat shock protein 90Bd IPI00555565 66222.17969 4.65 7 425.6400146 100 103.3799973 100 1.417303742 0.8307596 7
 OSTF1 Osteoclast-stimulating factor 1 IPI00414836 26502.21094 5.46 1 79.80999756 99.9999093 79.80999756 99.9999093 1.416332798 0 1
 RCN1 Reticulocalbin-1 precursor IPI00015842 42898.60156 4.86 3 134.0799866 100 53.45999908 99.96086118 1.410986976 0.8203622 3
 COTL1 Coactosin-like protein IPI00017704 18043.26953 5.54 2 102.9499969 100 53.81000137 99.96389166 1.405608029 0.4405755 2
 HNRPL heterogeneous nuclear 
ribonucleoprotein L isoform b IPI00465225 54634.78125 7.22 5 330.8099976 100 90.86000061 100 1.395462 0.7600105 5
 ECGF1 46 kDa protein IPI00853163 47964.32813 5.35 2 117.0200043 100 58.99000168 99.98904512 0.709960587 0.2917728 2
 - 17 kDa protein IPI00794543 18448.19922 4.06 4 180.6399994 100 53.84000015 99.96414022 0.709538955 0.2530146 5
 DDAH1 NG,NG-dimethylarginine 
dimethylaminohydrolase 1 IPI00220342 34258.19922 5.53 2 109.4100037 100 57.08000183 99.98299379 0.708909642 9.18E-02 2
 RPL10 Ribosomal protein L10 IPI00646899 30498.25 10.2 3 116.25 100 47.00999832 99.82717451 0.705977674 0.1780875 3
 PSME1 29 kDa protein IPI00479722 32701.33008 5.27 5 246.464447 100 71 99.99931038 0.703753652 0.2267562 5
 SLC25A13 Mitochondrial aspartate-glutamate 
carrier protein IPI00007084 80339.20313 8.79 2 67.47999573 99.99844901 35.45999908 97.53050741 0.701523198 3.42E-02 2
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 44906.64063 6.47 2 119.5299988 100 77.04000092 99.99982836 0.700233296 8.50E-02 2
 COX4I1 COX4I1 protein IPI00645361 10672.90039 8.64 3 152.1500092 100 79.16000366 99.99989466 0.700031485 0.3279608 3
 LTB4DH NADP-dependent leukotriene B4 12-
hydroxydehydrogenase IPI00292657 40639.17188 8.45 3 169.0899963 100 81.90000153 99.99994395 0.697922439 0.2437829 3
 PPIB peptidylprolyl isomerase B precursor IPI00646304 27661.94922 9.42 8 450.2444458 100 85.15000153 100 0.689899124 0.1151863 10
 PSMB2 Proteasome subunit beta type 2 IPI00028006 24687.88086 6.51 2 76.77000427 99.99981736 44.40999985 99.68550941 0.680048896 0.1599511 2
 ATP5A1 ATP synthase subunit alpha, 
mitochondrial precursor IPI00440493 64270.03906 9.16 14 811.444458 100 127.6500015 100 0.678550992 0.2904419 15
 RPS13 40S ribosomal protein S13 IPI00221089 19947.99023 10.53 4 197.3200073 100 71.76999664 99.99942243 0.675449132 0.2256954 4
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 RPS2 40S ribosomal protein S2 IPI00013485 35134.92969 10.25 4 180.7644348 100 74.16999817 99.99966764 0.674202045 0.6080656 4
 MAT2B Isoform 1 of Methionine 
adenosyltransferase 2 subunit beta IPI00002324 40396.42188 6.9 2 109.7099991 100 56.90999985 99.98231489 0.672663819 0.2057659 2
 NIPSNAP1 Protein NipSnap1 IPI00304435 36019.10938 9.35 3 156.9400024 100 75.05999756 99.99972923 0.671390681 0.6969326 3
 SELENBP1 53 kDa protein IPI00745729 57664.26953 6.03 3 122.3199997 100 48.38000107 99.87393123 0.671347102 0.5708795 3
 CALR Protein IPI00794237 19298.58008 4.47 4 199.644455 100 67.76000214 99.99854586 0.667621437 0.232172 5
 RPL28 Ribosomal protein L28 variant 
(Fragment) IPI00816097 11793.78027 10.42 1 64.56999969 99.99696885 64.56999969 99.99696885 0.663855491 0 1
 MTCH2 Mitochondrial carrier homolog 2 IPI00003833 35542.96875 8.25 4 147.0400085 100 42.33000183 99.49229966 0.663473899 0.3389921 4
 KRT18 Keratin, type I cytoskeletal 18 IPI00784347 51196.89844 5.34 15 897.7000122 100 157.1699982 100 0.658860386 0.3229556 16
 COMT Isoform Soluble of Catechol O-
methyltransferase IPI00375513 26915.57031 5.15 4 180.1600037 100 55.77999878 99.97705924 0.656672586 0.2613248 4
 TXNDC5;MUTED thioredoxin domain 
containing 5 isoform 2 IPI00395646 48461.78125 5.77 8 427.9144592 100 124.4400024 100 0.655687571 0.2581076 8
 ATP5B ATP synthase subunit beta, 
mitochondrial precursor IPI00303476 59980.98828 5.26 15 1113.828857 100 133.5500031 100 0.654245025 0.2564786 16
 SORD Sorbitol dehydrogenase IPI00216057 42378.10938 8.23 2 84.18000031 100 46.40999985 99.80156985 0.654096842 0.6565632 2
 H6PD GDH/6PGL endoplasmic bifunctional 
protein precursor IPI00607861 93328.71875 6.84 4 199.3499908 100 69.16000366 99.99894657 0.653421097 0.1725092 4
 COX6C Cytochrome c oxidase polypeptide VIc 
precursor IPI00015972 9927.879883 10.38 4 213.6199951 100 79.45999908 99.99990169 0.650299096 0.3014299 4
 RPL4 60S ribosomal protein L4 IPI00003918 56250.17969 11.07 2 110.6888809 100 60.06000137 99.99143736 0.643630448 0.1652094 2
 FLJ21963 hypothetical protein LOC79611 IPI00002245 81861.02344 8.84 4 171.519989 100 60.43000031 99.99213665 0.637623756 0.5362779 4
 hCG_1640785 hypothetical protein 
LOC401206 IPI00401105 17395.9707 10.06 2 96.19000244 100 58.09999847 99.98655355 0.635795235 5.92E-02 2
 ACOT1 Acyl-coenzyme A thioesterase 1 IPI00333838 49306.28906 6.9 2 108.1200027 100 55.54000092 99.97575582 0.633956785 0.1934598 2
 CALR 37 kDa protein IPI00793605 41138.14063 4.55 9 613.4599609 100 119.5299988 100 0.633365462 0.2472835 10
 ATP5O ATP synthase O subunit, 
mitochondrial precursor IPI00007611 26090.96094 9.97 3 136.8300018 100 59.06000137 99.98922028 0.633134907 0.5895055 3
 TBCA Tubulin-specific chaperone A IPI00217236 15052.96973 5.25 1 80.80999756 99.99992795 80.80999756 99.99992795 0.632750341 0 1
 VDP General vesicular transport factor p115 IPI00743314 117492.7188 4.85 1 117.6399994 100 117.6399994 100 0.631387915 0 1
 BAAT Bile acid CoA:amino acid N-
acyltransferase IPI00017819 48856.32031 6.49 2 115.2200012 100 75.95999908 99.99977991 0.628377233 0.4548838 2
Poorly Differentiated iTRAQ Individual Patients
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 PARK7 Protein DJ-1 IPI00298547 22464.75 6.33 5 252.5 100 69.95999908 99.99912379 0.624540853 0.2164835 6
 SUCLG1 succinate-CoA ligase, GDP-forming, 
alpha subunit IPI00759493 39717.12109 9.01 4 317.9500122 100 103.5100021 100 0.624498481 0.2163542 4
 PSMA4 Proteasome subunit beta type IPI00789638 30677.13086 6.91 1 72.26000214 99.99948405 72.26000214 99.99948405 0.621435134 0 1
 RRBP1 Isoform 1 of Ribosome-binding protein 
1 IPI00220967 178629.8125 8.73 9 593.3644409 100 128 100 0.620036407 0.2720343 9
 HADHA Trifunctional enzyme subunit alpha, 
mitochondrial precursor IPI00031522 93913.70313 9.16 18 1015.214417 100 86.76999664 100 0.618746666 0.3539562 19
 MAOA Amine oxidase [flavin-containing] A IPI00008483 65674.00781 7.94 4 194.8500061 100 56.27000046 99.9795069 0.617648444 0.5761415 4
 TPI1 Isoform 1 of Triosephosphate isomerase IPI00465028 34025.98828 5.65 9 789.1199951 100 118.0400009 100 0.614538423 0.2342444 9
 GSTO1 Glutathione transferase omega-1 IPI00019755 31234.35938 6.23 3 140.8699951 100 65.12999725 99.99733555 0.610431327 0.1127696 3
 HSPA5 HSPA5 protein IPI00003362 81398.29688 5.07 25 2094.601318 100 141.3300018 100 0.609786135 0.3513689 28
 PDIA4 Protein disulfide-isomerase A4 
precursor IPI00009904 82667.8125 4.96 19 1037.39563 100 115.0999985 100 0.609272723 0.3742005 19
 SLC25A3 Isoform B of Phosphate carrier 
protein, mitochondrial precursor IPI00215777 44188.96875 9.43 2 86.86000061 100 54.77000046 99.97105273 0.606985706 0.146756 2
 CSTB Cystatin-B IPI00021828 12618.79004 6.96 3 223.1999969 100 95.09999847 100 0.605079798 0.1317777 3
 GPI Glucose-6-phosphate isomerase IPI00027497 68475.72656 8.43 4 201.3800049 100 83.58000183 100 0.603494576 0.1654314 4
 GGTLA1 Isoform 2 of Gamma-
glutamyltransferase 5 precursor IPI00339373 61051.73828 7.67 2 115.5200043 100 73.97000122 99.99965198 0.598232936 0.2437469 2
 - 14 kDa protein IPI00455040 16069.75977 8.86 1 85.73000336 100 85.73000336 100 0.596104915 0.2578946 2
 PSMB4 Proteasome subunit beta type 4 
precursor IPI00555956 30095.63086 5.72 1 63.95000076 99.99650371 63.95000076 99.99650371 0.595278334 0 1
 AKR1A1 Alcohol dehydrogenase IPI00220271 39850.12891 6.32 8 335.4844055 100 64.26999664 99.99675206 0.594544498 0.3388224 8
 PRDX4 Protein IPI00639945 19604.41992 5.56 2 143.9100037 100 78.26000214 99.9998704 0.593714379 8.47E-02 2
 PRDX6 Peroxiredoxin-6 IPI00220301 27847.49023 6 10 643.0400391 100 128.3000031 100 0.592424759 0.4994095 10
 CMPK cytidylate kinase IPI00219953 29138.61914 8.14 4 270.5400085 100 93.48000336 100 0.589409251 0.2379775 4
 LMAN1 ERGIC-53 protein precursor IPI00026530 62207.39063 6.3 4 274.3800049 100 128.4499969 100 0.587250838 7.27E-02 4
 PSMA3 Isoform 1 of Proteasome subunit alpha 
type 3 IPI00419249 31335.35938 5.19 1 66.55000305 99.99807865 66.55000305 99.99807865 0.587213411 0 1
 PDIA4 Protein IPI00852792 21271.91992 8.33 6 305.4400024 100 86.51000214 100 0.585293111 0.1233382 6
Poorly Differentiated iTRAQ Individual Patients
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 MAT1A S-adenosylmethionine synthetase 
isoform type-1 IPI00021772 47392.28906 5.86 5 238.8744507 100 86.52999878 100 0.584329845 0.3511509 5
 HSPA9 Stress-70 protein, mitochondrial 
precursor IPI00007765 81497.46094 5.87 15 1009.074463 100 120.0699997 100 0.582349001 0.3419179 15
 FTL Ferritin light chain IPI00852596 21925.33984 5.51 5 342.6799927 100 92.97000122 100 0.578543496 0.2297759 5
 HYOU1 Hypoxia up-regulated protein 1 
precursor IPI00000877 122683.2188 5.16 7 415.25 100 80.76000214 99.99992712 0.571204972 0.3064075 7
 - 25 kDa protein IPI00412122 28146.10938 5.48 1 71.98999786 99.99945096 71.98999786 99.99945096 0.569920376 0 1
 SDHB Succinate dehydrogenase [ubiquinone] 
iron-sulfur subunit, mitochondria IPI00294911 35997.07813 9.03 2 70.75 99.99926952 41.16999817 99.33685604 0.569495287 3.25E-02 2
 FKBP2 FK506-binding protein 2 precursor IPI00002535 17649.5293 9.24 4 248.9899902 100 92.48999786 100 0.568843863 0.1313032 4
 HINT1 Histidine triad nucleotide-binding 
protein 1 IPI00239077 15325.28027 6.43 3 246.1499939 100 98.5 100 0.559835694 0.5945098 3
 MAOB Amine oxidase [flavin-containing] B IPI00328156 63747.53125 7.2 3 113.6699982 100 42.02999878 99.4559889 0.559769523 0.1652405 3
 HADHB Trifunctional enzyme beta subunit, 
mitochondrial precursor IPI00022793 56777.03906 9.45 8 446.4799805 100 85.72000122 100 0.554907365 0.1521809 8
 RPLP2 60S acidic ribosomal protein P2 IPI00008529 13242.07031 4.42 1 94.69000244 100 94.69000244 100 0.549054121 0 1
 - CALRETICULIN=CALCIUM binding protein 
(Fragment) IPI00383751 26354.40039 4.45 5 398.019989 100 119.5299988 100 0.548444226 0.2686494 5
 AK3 GTP:AMP phosphotransferase IPI00478236 20052.85938 8.73 2 117.5599976 100 72.27999878 99.99948642 0.547042121 0.3086591 2
 EIF3S10 EIF3S10 protein (Fragment) IPI00386403 51034.98047 6.24 1 62.02000046 99.99454735 62.02000046 99.99454735 0.54692606 0 1
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 33322.12891 8.55 7 415.6700134 100 96.26000214 100 0.545126887 0.3470988 7
 CNDP2 53 kDa protein IPI00646632 58467.37891 5.66 12 831.8200073 100 143.2700043 100 0.543299371 0.2616244 12
 PPIF Peptidyl-prolyl cis-trans isomerase, 
mitochondrial precursor IPI00026519 24750.41992 9.48 2 94.19999695 100 56.33000183 99.97978809 0.53960438 0.2276606 2
 CYP4F2 Cytochrome P450 4F2 IPI00019160 63921.05859 6.6 2 96.68000031 100 53.95000076 99.96503709 0.537991178 2.33E-02 2
 CRYZ Quinone oxidoreductase IPI00000792 38778.89063 8.56 4 282.1300049 100 136.2400055 100 0.537260357 0.193974 5
 HDHD3 Haloacid dehalogenase-like hydrolase 
domain-containing protein 3 IPI00009931 29030.5293 6.21 2 145.4799957 100 83.97000122 100 0.532809137 0.5128546 2
 C5orf33 hypothetical protein LOC133686 
isoform 1 IPI00845432 52310.35156 8.46 2 125.7099991 100 74.59999847 99.99969897 0.531246871 7.35E-02 2
 ALDOC 16 kDa protein IPI00789171 18438.7207 7.74 3 225.0944519 100 119.3600006 100 0.529430692 1.3628115 3
 - 24 kDa protein IPI00747151 25497.4707 8.59 1 70.16999817 99.99916515 70.16999817 99.99916515 0.52294488 0 1
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 ETFB Isoform 2 of Electron transfer 
flavoprotein subunit beta IPI00556451 41287.32813 6.78 6 258.9599915 100 50.45999908 99.92190779 0.520850789 0.5893814 6
 ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 3 135.6988831 100 64.37000275 99.996826 0.520285275 8.18E-02 3
 TGM2 Isoform 1 of Protein-glutamine gamma-
glutamyltransferase 2 IPI00294578 82951.92188 5.11 9 502.7399902 100 71.41999817 99.99937395 0.518355287 0.1696458 9
 ARG1 Isoform 2 of Arginase-1 IPI00398768 39380.19922 6.72 3 109.0600052 100 42.08000183 99.46221653 0.517708326 9.18E-03 3
 MDH1 Malate dehydrogenase, cytoplasmic IPI00291005 41195.46094 6.91 2 88.31999969 100 53.47999954 99.96104101 0.515299458 0.1197618 2
 UNQ501 MBC3205 IPI00063130 22277.99023 8.91 1 78.47000122 99.99987652 78.47000122 99.99987652 0.51330587 0 1
 PECI Peroxisomal 3,2-trans-enoyl-CoA 
isomerase IPI00639841 48775.80078 9.13 3 167.6699982 100 69.70999908 99.99907187 0.512863655 0.3277265 3
 AKR7A3 Aflatoxin B1 aldehyde reductase 
member 3 IPI00293721 39376.69141 6.67 4 184.1999969 100 59.41999817 99.9900778 0.510574105 0.4268619 4
 EHHADH Peroxisomal bifunctional enzyme IPI00216164 86466.10156 9.22 5 201.9244385 100 47.52999878 99.84667684 0.509688146 0.315607 5
 PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 66969.02344 6.3 9 556.8944092 100 84.62000275 100 0.506107448 0.4262223 9
 NNT NAD(P) transhydrogenase, mitochondrial 
precursor IPI00337541 123493.2578 8.31 6 286.5700073 100 70.95999908 99.999304 0.505580126 0.4705573 6
 ASL argininosuccinate lyase isoform 3 IPI00607563 52220 5.82 3 204.2899933 100 104.8399963 100 0.503857536 0.4147404 3
 CPT2 Carnitine O-palmitoyltransferase 2, 
mitochondrial precursor IPI00012912 79760.85938 8.38 3 159.0399933 100 87.09999847 100 0.503164303 0.2232465 3
 LDHAL6A L-lactate dehydrogenase A-like 6A IPI00148061 40792.55078 6.51 2 83.77999878 100 53.88999939 99.9645507 0.502956422 8.89E-02 2
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 58388.32813 6.3 11 675.194397 100 86.12999725 100 0.500703053 0.5535931 11
 PYGL 97 kDa protein IPI00783313 107098.9297 6.71 7 371.960022 100 74.45999908 99.99968911 0.497331683 0.1438407 7
 HSDL2 Hydroxysteroid dehydrogenase-like 
protein 2 IPI00414384 51500.05078 8.07 2 130.7600098 100 66.23000336 99.99793173 0.496676682 0.4643452 2
 NNMT Nicotinamide N-methyltransferase IPI00027681 33091.32031 5.56 2 81.08000183 99.9999323 48.75999832 99.88449313 0.496517605 7.75E-03 2
 ADH5 Alcohol dehydrogenase class 3 IPI00746777 45140.69141 7.45 3 166.0499878 100 74.87999725 99.99971777 0.494034083 0.1671787 3
 DBT Lipoamide acyltransferase component of 
branched-chain alpha-keto acid d IPI00003944 59823.44141 8.71 2 95.1499939 100 60.72999954 99.99266149 0.492313503 0.3117282 2
 MT1X Metallothionein-1X IPI00008753 8279.200195 8.38 2 126.2200012 100 91.13999939 100 0.492172477 5.80E-02 2
 SDHA Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondri IPI00305166 77793.53125 7.06 7 333.210022 100 66.87000275 99.99821513 0.492049902 0.1779117 7
 PCCB Hypothetical protein IPI00387103 34520.42188 4.61 1 60.76443863 99.99271946 61.93999863 99.99444598 0.485108568 0 1
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 AKR1C3 Aldo-keto reductase family 1 member 
C3 IPI00291483 41031.17969 8.05 6 283.6900024 100 69.58000183 99.99904367 0.483249334 0.3538979 7
 AKR1B1 Aldo-keto reductase family 1, 
member B1 variant (Fragment) IPI00556258 32725.51953 6.54 1 64.26999664 99.99675206 64.26999664 99.99675206 0.482063754 0 1
 CAT Catalase IPI00465436 64367.17969 6.9 9 586.8799438 100 92.09999847 100 0.474786979 0.2565191 9
 HAO1 Hydroxyacid oxidase 1 IPI00006934 44682.82031 8.2 3 167.6299896 100 63.11999893 99.99576739 0.473177436 0.6801375 3
 RPS5 40S ribosomal protein S5 IPI00008433 25448.32031 9.73 1 131.8699951 100 131.8699951 100 0.467551933 0 1
 P4HB Protein disulfide-isomerase precursor IPI00010796 64315.26953 4.76 22 1451.75 100 133.8200073 100 0.467384977 0.2417369 26
 SDHALP2 SDHALP2 protein IPI00479656 17968.10938 6.14 2 89.30999756 100 49.00999832 99.89095449 0.464925415 0.2353338 2
 KIAA1598 Protein KIAA1598 IPI00448751 84444.75781 5.37 1 59.45999908 99.99016877 59.45999908 99.99016877 0.456801315 0 1
 FIS1 Mitochondrial fission 1 protein IPI00007052 19709.33008 8.84 1 81.41000366 99.99993725 81.41000366 99.99993725 0.452613816 0 1
 TXN Thioredoxin IPI00216298 13831.92969 4.82 5 406.0899963 100 113.0999985 100 0.452153751 0.1138242 6
 DCXR 26 kDa protein IPI00797249 27252.58984 8.33 6 363.5799866 100 103.5100021 100 0.451098867 0.2391219 6
 HSD17B4 Peroxisomal multifunctional enzyme 
type 2 IPI00019912 88068.99219 8.96 7 440.2000122 100 115.1399994 100 0.447403755 0.2228602 7
 CYCS Cytochrome c IPI00465315 14569.42969 9.59 4 228.3599854 100 82.93000031 100 0.446292709 0.2908261 5
 PGRMC2 Membrane-associated progesterone 
receptor component 2 IPI00005202 28072.17969 5.2 2 75.04000092 99.99972798 41.04000092 99.3167061 0.444895348 9.14E-03 2
 UGDH UDP-glucose 6-dehydrogenase IPI00031420 60869.64844 6.73 4 301.5299988 100 154.0599976 100 0.443838373 0.2453099 4
 UGT2B17 similar to UDP glycosyltransferase 2 
family, polypeptide B17 IPI00787638 68438.74219 8.79 2 91.8944397 100 60.18000031 99.99167072 0.443274951 6.83E-02 2
 - 105 kDa protein IPI00794900 115433.2422 7.3 8 472.1400146 100 131.25 100 0.442075944 0.1335476 8
 METTL7B Methyltransferase-like protein 7B 
precursor IPI00090807 30474.44922 8.71 1 60.75999832 99.99271201 60.75999832 99.99271201 0.439943059 0 1
 BLVRB Flavin reductase IPI00783862 23637.61914 7.13 2 102.4599991 100 55.20999908 99.97384181 0.437948024 0.1534966 2
 UGP2 Isoform 1 of UTP--glucose-1-phosphate 
uridylyltransferase IPI00329331 63091.28906 8.16 8 568.944458 100 147.1399994 100 0.435690072 0.4773601 9
 HSPD1 60 kDa heat shock protein, 
mitochondrial precursor IPI00784154 68931.10156 5.7 20 1502.262207 100 123.1399994 100 0.435211153 0.3046954 21
 AKR1C1 Aldo-keto reductase family 1 member 
C1 IPI00029733 41021.35156 8.02 6 241.8600006 100 53.34000015 99.95976467 0.432017835 0.2402605 7
 DPYS Dihydropyrimidinase IPI00028910 62048.10938 6.81 4 167.8000031 100 59.40999985 99.99005493 0.426515067 0.4923917 4
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 ACO1 Iron-responsive element-binding protein 
1 IPI00008485 105951.1797 6.23 3 127.9100037 100 50.13999939 99.91593646 0.421511923 0.121285 3
 NDUFAB1 Acyl carrier protein, mitochondrial 
precursor IPI00022442 18696.14063 4.82 2 99.81999969 100 69.06999969 99.99892451 0.416408516 9.25E-02 2
 PCBD1 Pterin-4-alpha-carbinolamine 
dehydratase IPI00218568 12902.16992 6.28 6 307.9400024 100 76.55000305 99.99980786 0.416223911 0.1516635 6
 BBS1 36 kDa protein IPI00163204 37530.44922 5.61 1 84.76999664 100 84.76999664 100 0.414734087 0 1
 MDH2 Malate dehydrogenase, mitochondrial 
precursor IPI00291006 39765.08984 8.92 14 1037.274414 100 150.6799927 100 0.414058784 0.317633 14
 PCK2 mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor IPI00797038 74784.85938 7.57 9 426.3299866 100 77.48000336 99.9998449 0.412111629 0.2924395 9
 DAK Dihydroxyacetone kinase IPI00551024 63392.42188 7.12 5 420.7399902 100 139.7299957 100 0.411491523 0.2505309 5
 UGT2B4 38 kDa protein IPI00790652 41813.85156 8.87 3 156.7900085 100 63.72000122 99.99631356 0.408036132 7.35E-02 3
 NUDT5 20 kDa protein IPI00644292 21952.84961 4.67 1 63.74000168 99.9963305 63.74000168 99.9963305 0.406545142 0 1
 BDH1 D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial precursor IPI00025341 41766.75 9.11 4 167.8944397 100 55.20000076 99.97378152 0.405912975 0.6647343 4
 ALDH7A1 similar to antiquitin IPI00786942 63780.78125 8.25 2 98.63000488 100 56 99.97819241 0.405701998 0.1373031 2
 GSTK1 GSTK1 protein IPI00440703 33653.75 8.85 3 200.2200012 100 111.8600006 100 0.400309423 0.123865 3
 QPRT 17 kDa protein IPI00853023 17914 7.71 2 99.80999756 100 50.66999817 99.92559402 0.399128949 8.66E-02 2
 HPD 40 kDa protein IPI00795913 44884.14063 5.93 2 96.68000031 100 51.13999939 99.93322595 0.395293092 2.09E-02 2
 GOT2 Aspartate aminotransferase, 
mitochondrial precursor IPI00018206 52087.64844 9.14 6 410.4400024 100 114.9899979 100 0.388856325 0.7726941 6
 DLD Dihydrolipoyl dehydrogenase, 
mitochondrial precursor IPI00015911 60048.35938 7.59 3 227.0699921 100 97.73999786 100 0.38787513 3.14E-02 3
 AOX1 Hypothetical protein AOX1 IPI00743616 161854.2031 6.78 7 314.460022 100 69.88999939 99.99910955 0.384738214 0.5064496 7
 PC Pyruvate carboxylase, mitochondrial 
precursor IPI00299402 138358.0469 6.37 14 833.0643921 100 124.8099976 100 0.381866588 0.3174893 15
 PGRMC1 Membrane-associated progesterone 
receptor component 1 IPI00220739 23621.98047 4.56 3 158.6699982 100 67.40000153 99.99842018 0.380648405 8.75E-02 4
 CYP2C8 45 kDa protein IPI00843846 49430.42188 8.91 3 113.8300018 100 49.99000168 99.91298233 0.377500435 0.2503743 3
 GRHPR GRHPR protein (Fragment) IPI00550682 39375.17188 5.95 5 322.0844421 100 83.84999847 100 0.373163588 7.17E-02 5
 DDT D-dopachrome decarboxylase IPI00293867 13515.79004 6.71 4 253.4144287 100 94.47000122 100 0.372595582 0.1602614 4
 SUCLG2 Succinyl-CoA ligase [GDP-forming] 
beta-chain, mitochondrial precurso IPI00096066 51941.89844 6.15 4 220.0744324 100 85.44000244 100 0.372578738 0.1055257 4
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 IDH1 Isocitrate dehydrogenase [NADP] 
cytoplasmic IPI00027223 52332.01172 6.53 20 1224.219971 100 119.0899963 100 0.371284695 0.3252229 22
 AK2 Isoform 2 of Adenylate kinase isoenzyme 
2, mitochondrial IPI00218988 28472.61914 7.71 2 114.4199982 100 74.33000183 99.99967966 0.371215308 4.60E-02 2
 NDUFA8 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 8 IPI00219034 22908.26953 7.57 2 67.58000183 99.99848432 37.61000061 98.49475368 0.371043246 0.17215 2
 AIFM1 Isoform 3 of Apoptosis-inducing factor 
1, mitochondrial precursor IPI00157908 72532.10938 9.03 3 189.1499939 100 83.56999969 100 0.365634308 0.1958388 3
 ETFA Electron transfer flavoprotein subunit 
alpha, mitochondrial precursor IPI00010810 39221.92969 8.62 6 617.0400391 100 160.8500061 100 0.365613685 0.2496209 6
 C11orf54 Isoform 1 of Ester hydrolase 
C11orf54 IPI00072044 39108.89844 6.23 3 114.8199997 100 51.54999924 99.93924141 0.365387713 0.3496618 3
 UGT2B7 similar to UDP-
glucuronosyltransferase 2B7 precursor IPI00787584 65314.41016 8.41 3 156.1900024 100 63.72000122 99.99631356 0.363973307 1.60E-02 3
 ACADM Hypothetical protein 
DKFZp686M24262 IPI00513827 55018.78906 7.94 4 198.9900208 100 78.05000305 99.99986398 0.360475383 0.2337433 4
 ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03125 8.25 7 400.5299988 100 66.34999847 99.99798809 0.358736954 0.2629936 7
 HEBP1 Heme-binding protein 1 IPI00148063 23623.80078 5.71 1 69.61000061 99.99905025 69.61000061 99.99905025 0.358457876 0 1
 HMGCL 19 kDa protein IPI00514407 21853.41016 8.9 1 84.47000122 100 84.47000122 100 0.354256427 0 1
 MMAB 19 kDa protein IPI00789857 20551.83008 8.35 1 65.26000214 99.99741413 65.26000214 99.99741413 0.353921027 0 1
 AKR1C4 Aldo-keto reductase family 1 member 
C4 IPI00289524 41137.30859 6.71 4 209.4100037 100 85.11000061 100 0.35353642 0.1544949 5
 FH Isoform Cytoplasmic of Fumarate 
hydratase, mitochondrial precursor IPI00759715 55071.17188 6.9 6 367.5100098 100 102.4300003 100 0.34768382 0.1348362 6
 NDUFA4 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 4 IPI00011770 10562.08984 9.42 2 124.0700073 100 79.23000336 99.99989634 0.346702423 0.1037811 2
 SHMT1 Isoform 2 of Serine 
hydroxymethyltransferase, cytosolic IPI00220668 53489.17969 7.59 3 156.6000061 100 61.22000122 99.99344447 0.346055904 0.2422681 3
 CYP2C19 Cytochrome P-450 II C (Fragment) IPI00657852 44746.01953 6.82 2 118.9400024 100 88.41999817 100 0.345569668 0.4025501 2
 COQ9 Isoform 1 of Ubiquinone biosynthesis 
protein COQ9, mitochondrial precu IPI00470631 37064.78125 5.61 1 67.43000031 99.99843106 67.43000031 99.99843106 0.345135936 0 1
 HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 2 120.2600021 100 64.97000122 99.99723556 0.341223093 0.3068584 2
 IDH2 Isocitrate dehydrogenase [NADP], 
mitochondrial precursor IPI00011107 56573.30859 8.88 14 762.2543945 100 96.51999664 100 0.341202068 0.2383263 14
 KHK Isoform C of Ketohexokinase IPI00216136 35220.62891 5.91 3 149.0999908 100 66.41999817 99.99802026 0.339159113 0.2756871 3
 ACADSB Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial IPI00024623 52051.67969 6.53 1 96.27999878 100 96.27999878 100 0.332672295 0 1
 REEP6 Receptor expression-enhancing 
protein 6 IPI00647161 22153.98047 8.74 2 74.77999878 99.99971119 42.90999985 99.55577024 0.330600878 4.33E-02 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 157NT
 CA2 11 kDa protein IPI00790885 13118.76953 6.21 1 62.36999893 99.99496954 62.36999893 99.99496954 0.323903626 0 1
 DCI Isoform 2 of 3,2-trans-enoyl-CoA 
isomerase, mitochondrial precursor IPI00398758 32932.46875 9.07 2 155.4400024 100 107.9400024 100 0.321668831 1.64E-03 2
 SULT1A1 Sulfotransferase 1A1 IPI00300026 47814.69922 8.61 4 259.4599915 100 90.48999786 100 0.32107992 0.0301411 4
 - 14 kDa protein IPI00788848 15907.24023 5.24 6 409.9299927 100 109.0899963 100 0.31290784 0.4417834 8
 HINT2 Histidine triad nucleotide-binding 
protein 2 IPI00000335 18349.41992 9.2 2 157.0400085 100 106.8899994 100 0.312402428 7.69E-02 2
 MPST 3-mercaptopyruvate sulfurtransferase IPI00165360 34971.80078 6.13 6 463.2999878 100 120.7699966 100 0.312284959 0.1463331 6
 MUT Methylmalonyl-CoA mutase, 
mitochondrial precursor IPI00024934 90636.34375 6.48 2 138.7799988 100 70.55999756 99.99923685 0.309162517 0.0773756 2
 CYP2E1 Cytochrome P450 2E1 IPI00007282 61500.80078 8.27 6 325.3300171 100 83.15000153 100 0.308502048 0.134847 6
 GLUD2 Glutamate dehydrogenase 2, 
mitochondrial precursor IPI00027146 66855.89844 8.63 14 868.5100098 100 91.33000183 100 0.307026697 0.2244148 16
 HGD Homogentisate 1,2-dioxygenase IPI00303174 54236.85938 6.54 4 178.1199951 100 54.11999893 99.96637922 0.299588774 0.2729922 4
 PRDX3 peroxiredoxin 3 isoform b IPI00374151 27924.48047 7.04 2 94.25999451 100 53.47999954 99.96104101 0.298945492 0.1000014 2
 SYNE1 Isoform 6 of Nesprin-1 IPI00247297 1110045.75 5.37 2 73.52999878 99.99961487 38.04000092 98.63664943 0.297039021 0.4586662 2
 PCCA Propionyl-CoA carboxylase alpha chain, 
mitochondrial precursor IPI00749503 84435.1875 6.63 1 70.95999908 99.999304 70.95999908 99.999304 0.295062418 0 1
 ACSL1 Isoform 1 of Long-chain-fatty-acid--
CoA ligase 1 IPI00012728 85201.29688 6.81 12 630.9400024 100 74.62999725 99.99970104 0.293741983 0.2570779 12
 GOT1 Aspartate aminotransferase, 
cytoplasmic IPI00219029 49570.83984 6.52 10 557.289978 100 113.0500031 100 0.2926514 0.2706112 10
 ALDH1A1 Retinal dehydrogenase 1 IPI00218914 60949.39063 6.3 12 719.000061 100 110.4499969 100 0.290227758 0.2263165 12
 CYP2C9 Cytochrome P450 2C9 IPI00007219 61374.14063 8.13 4 221.5744476 100 88.41999817 100 0.288484806 0.1349634 4
 GLYAT Isoform 1 of Glycine N-acyltransferase IPI00402759 37221.21094 8.38 5 228.9199982 100 60.38999939 99.99206389 0.287525761 0.2955587 5
 GPT Alanine aminotransferase 1 IPI00217458 57510.32813 6.77 2 94.12999725 100 50.70999908 99.9262762 0.286613913 4.94E-02 2
 CES2 carboxylesterase 2 isoform 1 IPI00332828 72247.0625 6.03 6 326.3399963 100 70.5 99.99922624 0.286079516 0.2414844 6
 ALDH1B1 Aldehyde dehydrogenase X, 
mitochondrial precursor IPI00103467 62178.58984 6.36 7 347.1100159 100 90.43000031 100 0.282611964 4.55E-02 7
 HMGCS2 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial precursor IPI00008934 61333.76953 8.4 7 376.6199951 100 68.63999939 99.99881257 0.280766378 0.3340166 7
 SOD2 manganese superoxide dismutase 
isoform A precursor IPI00847322 27176.83984 8.35 6 411.9299927 100 108.4899979 100 0.276495281 0.122785 6
Poorly Differentiated iTRAQ Individual Patients
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 ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 11 833.9199829 100 112.0500031 100 0.27629345 0.2674934 12
 HSPE1 10 kDa heat shock protein, 
mitochondrial IPI00220362 12653.11035 8.89 8 512.7800293 100 121.5500031 100 0.275587996 0.3499906 9
 ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.07813 8.72 10 597.8944092 100 104.8199997 100 0.274465854 0.3391284 10
 PBLD Phenazine biosynthesis-like domain-
containing protein IPI00024896 34011.42969 6.06 4 184.2044373 100 69.19999695 99.99895622 0.274403441 0.2858152 4
 HADH Isoform 2 of Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial precu IPI00298406 47125.23047 9.34 6 308.7999878 100 94.25 100 0.272927407 0.2151241 6
 SULT2A1 Bile salt sulfotransferase IPI00216133 37496.32813 5.71 6 313.2400208 100 77.77999878 99.99985525 0.269711938 0.1925289 6
 GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 22 1490.390015 100 102.2799988 100 0.266607767 0.2283993 26
 PEBP1 Phosphatidylethanolamine-binding 
protein 1 IPI00219446 23439.92969 7.01 9 647.960022 100 165.8999939 100 0.26364018 0.2639601 10
 AGXT Serine--pyruvate aminotransferase IPI00009367 46426.73047 8.61 7 443.6300049 100 108.9800034 100 0.259148698 0.2721108 7
 BPHL Isoform 1 of Valacyclovir hydrolase 
precursor IPI00384428 35828.30078 9.2 1 56.84999847 99.98206886 56.84999847 99.98206886 0.257112176 0 1
 ALDH4A1 Aldehyde dehydrogenase 4 family, 
member A1 IPI00647328 65056.12109 7.62 12 672.9599609 100 89.19999695 100 0.245762516 0.3755329 12
 FAH 33 kDa protein IPI00793664 34681.60938 7.12 1 66.23000336 99.99793173 66.23000336 99.99793173 0.245705652 0 1
 ATP5J ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit F6 i IPI00456008 15010.11035 9.13 2 98.88000488 100 66.26000214 99.99794597 0.244694405 3.56E-02 2
 EPHX1 Epoxide hydrolase 1 IPI00009896 57419.37891 6.77 6 416.4100037 100 115.6900024 100 0.244295105 0.2625821 6
 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial IPI00001539 46153.96875 8.32 13 806.8499756 100 112.5899963 100 0.241474675 0.3840297 15
 ASS1 Argininosuccinate synthase IPI00020632 56147.66016 8.6 7 328.0799866 100 86.38999939 100 0.237150573 0.1111469 7
 ADH1C Alcohol dehydrogenase 1C IPI00465343 45428 8.63 8 557.8399658 100 112.0500031 100 0.233706519 0.1666589 10
 ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor IPI00009532 61418.91016 8.17 8 483.8100281 100 97.55999756 100 0.232547633 0.1376939 8
 ECHS1 Enoyl-CoA hydratase, mitochondrial 
precursor IPI00024993 35335.42969 8.34 11 725.0244751 100 117.2699966 100 0.228598609 8.07E-02 11
 DECR1 2,4-dienoyl-CoA reductase, 
mitochondrial precursor IPI00003482 40019.14844 9.35 6 396.3300171 100 118.2300034 100 0.227500448 0.2551874 6
 ACAA1 3-ketoacyl-CoA thiolase, peroxisomal 
precursor IPI00012828 47604.07031 8.76 5 363.3999939 100 87.47000122 100 0.225956191 0.2714067 5
 ALDH2 Mitochondrial aldehyde 
dehydrogenase 2 variant (Fragment) IPI00792207 61065.96094 6.63 12 825.8099365 100 129.7400055 100 0.22356672 0.2002954 12
 ADH1A Alcohol dehydrogenase 1A IPI00218896 45320.80859 8.26 11 854.6399536 100 112.0500031 100 0.223111218 0.1572152 13
Poorly Differentiated iTRAQ Individual Patients
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 OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.05859 8.75 9 582.0244751 100 100.9300003 100 0.21814725 0.1763961 9
 ACSM2B Xenobiotic/medium-chain fatty 
acid:CoA ligase IPI00829974 70410.38281 8.36 3 136.0899963 100 65.75 99.99769002 0.213410661 0.1161195 3
 ACY1 Aminoacylase-1 IPI00009268 48344.23047 5.77 3 160.7599945 100 69.59999847 99.99904806 0.208000035 0.1310792 3
 BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.23828 6.58 4 231.9644318 100 77.41999817 99.99984274 0.20537631 0.1194301 4
 DBI Isoform 2 of Acyl-CoA-binding protein IPI00218836 13802.13965 5.41 4 264.3900146 100 74.29000092 99.9996767 0.202358612 4.69E-02 4
 TST Thiosulfate sulfurtransferase IPI00216293 35752.05859 6.77 9 494.0644531 100 114.8700027 100 0.191628658 0.3068047 9
 GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78125 6.61 13 925.1099243 100 124.5800018 100 0.181071629 0.2690773 14
 ACAT1 Acetyl-CoA acetyltransferase, 
mitochondrial precursor IPI00030363 49865.05859 8.98 10 774.1512451 100 142.6399994 100 0.180414216 0.1351051 10
 SOD1 Superoxide dismutase IPI00783680 17838.08984 5.7 3 179.8999939 100 103.1699982 100 0.179158867 1.74E-02 3
 CYB5A Isoform 1 of Cytochrome b5 IPI00397860 16616.71094 4.88 5 468.7200012 100 207.6499939 100 0.172427966 0.129543 6
 GSTA1 Glutathione S-transferase A1 IPI00657682 29261.05078 8.91 6 323.1300049 100 75.59999847 99.99976088 0.170434962 6.13E-02 6
 UGT1A6;UGT1A1 UDP-
glucuronosyltransferase 1-1 precursor IPI00434346 64522.89063 8.19 6 414.5 100 138.9700012 100 0.169831398 0.1352742 6
 RDH16 Microsomal NAD+-dependent retinol 
dehydrogenase 4 variant (Fragment) IPI00555683 23832.68945 7.67 2 90.88000488 100 50.58000183 99.92403607 0.163466662 2.16E-02 2
 CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 60 4232.14502 100 178.3600006 100 0.161998939 0.125535 67
 SCP2 sterol carrier protein 2 isoform 2 IPI00433347 61608.94141 6.25 5 295.2000122 100 87.93000031 100 0.150105606 0.1123207 6
 CES1 carboxylesterase 1 isoform c precursor IPI00607693 68199.60938 6.15 14 1068.299927 100 163.9700012 100 0.129009922 0.2464198 18
 FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 9 801.2800293 100 129.6499939 100 0.12365205 0.1118413 9
 FTCD Isoform C of Formimidoyltransferase-
cyclodeaminase IPI00218976 64571.53125 5.24 4 181.164444 100 56.90000153 99.98227413 0.122899469 9.49E-02 4
 ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 11 842.4343872 100 111.0599976 100 0.109515469 9.45E-02 12
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 DHRS2 dehydrogenase/reductase (SDR family) 
member 2 isoform 2 IPI00218235 32245.88 9.21 1 77.96 99.99986 77.96 99.99986 8.116348 0 1
 IFITM1 Interferon-induced transmembrane 
protein 1 IPI00300620 14931.44 7.78 2 192.54 100 112.53 100 5.683454 1.274800253 3
 S100P Protein S100-P IPI00017526 12023.44 4.75 1 102.4 100 102.4 100 5.408724 0 1
 GALK1 Galactokinase IPI00019383 43765.66 6.04 5 300.38 100 107.09 100 3.351021 1.05369088 5
 STIP1 STIP1 protein IPI00479946 77915.94 7.81 4 188.13 100 51.07 99.93214 3.203762 0.905269245 4
 ACSL4 Isoform Short of Long-chain-fatty-acid--
CoA ligase 4 IPI00219897 83902.51 8.33 2 81.3 99.99994 41.33 99.36084 2.970697 0.904314362 2
 KHSRP KH-type splicing regulatory protein IPI00479786 77908.45 6.85 2 131.3244 100 86.68 100 2.902571 4.42E-02 2
 PTGES3 19 kDa protein IPI00789101 21682.36 4.76 2 124.17 100 78.92 99.99989 2.883691 1.632853953 2
 APEX1 DNA-(apurinic or apyrimidinic site) lyase IPI00215911 40174.54 8.33 2 152.4845 100 105.41 100 2.781259 0.850952924 2
 MMAB 19 kDa protein IPI00789857 20551.83 8.35 1 65.26 99.99741 65.26 99.99741 2.728747 0 1
 QPRT 17 kDa protein IPI00853023 17914 7.71 2 99.81 100 50.67 99.92559 2.681702 0.973237627 2
 FUS Fus-like protein (Fragment) IPI00260715 55689.03 9.46 3 246.29 100 123.67 100 2.652173 2.866567511 3
 IGF2BP2 Insulin-like growth factor 2 mRNA-
binding protein 2 IPI00180983 67944.93 8.22 1 68.97 99.9989 68.97 99.9989 2.644223 0 1
 IGF2BP3 64 kDa protein IPI00746216 71308.52 9.12 1 68.97 99.9989 68.97 99.9989 2.644223 0 1
 FASN Fatty acid synthase IPI00847250 287598.8 5.99 31 1696.97 100 130.32 100 2.63146 1.461603758 33
 NPM1 Isoform 1 of Nucleophosmin IPI00549248 37589.32 4.64 6 394.85 100 102.45 100 2.608175 0.650576875 6
 TBCA Tubulin-specific chaperone A IPI00217236 15052.97 5.25 1 80.81 99.99993 80.81 99.99993 2.417026 0 1
 TPR nuclear pore complex-associated protein 
TPR IPI00742682 292969.3 4.97 1 59.56 99.99039 59.56 99.99039 2.380934 0 1
Poorly Differentiated iTRAQ Individual Patients
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 PSAT1 Isoform 1 of Phosphoserine 
aminotransferase IPI00001734 44751.16 7.56 3 186.26 100 63.97 99.99652 2.361067 0.485296108 3
 NCL Isoform 1 of Nucleolin IPI00604620 89719.57 4.6 10 590.42 100 103.39 100 2.35832 0.725253152 11
 FAM10A5 Protein FAM10A5 IPI00168839 46431.76 4.96 2 154.95 100 80.66 99.99993 2.335872 0.198524374 2
 TXNL1 37 kDa protein IPI00642032 39663.04 4.75 2 144.23 100 83.67 100 2.290523 7.27E-02 2
 DAK Dihydroxyacetone kinase IPI00551024 63392.42 7.12 5 420.74 100 139.73 100 2.277686 0.804440242 5
 PSMC3 26S protease regulatory subunit 6A IPI00018398 54730.94 5.13 3 120.4 100 56.71 99.98148 2.267275 0.496768465 3
 OTUB1 Hypothetical protein DKFZp564E242 IPI00000581 34180.75 4.9 1 95.68 100 95.68 100 2.25772 0 1
 NSFL1C Isoform 3 of NSFL1 cofactor p47 IPI00397571 43383.75 5.04 2 186.57 100 138.32 100 2.23658 0.702191788 2
 TMEM4 Isoform 1 of MIR-interacting saposin-
like protein precursor IPI00443909 22355.31 4.81 4 204.83 100 70.02 99.99914 2.231083 0.558819258 4
 SURF4 Surfeit 4 IPI00399142 22555.05 8.88 1 122.17 100 122.17 100 2.231041 0 1
 SARS Seryl-tRNA synthetase IPI00514587 68889.06 6.64 3 133.2244 100 49.54 99.90348 2.230443 0.131915472 3
 HMGB1 High mobility group protein B1 IPI00419258 31352.76 5.62 2 186.3544 100 96.87 100 2.226229 0.499710104 2
 FDPS Farnesyl diphosphate synthase IPI00101405 51970.89 5.83 4 255.56 100 89.23 100 2.224157 0.354233649 4
 - Farnesyl pyrophosphate synthetase like-4 
protein (Fragment) IPI00382869 42840.9 4.87 4 208.4 100 59.83 99.99097 2.224157 0.354233649 4
 PTBP1 polypyrimidine tract-binding protein 1 
isoform a IPI00183626 64630.35 9.21 2 118.7 100 69.21 99.99896 2.202798 2.230870686 2
 CKAP4 CKAP4 protein (Fragment) IPI00433214 72955.87 9.34 10 674.2145 100 99.14 100 2.182461 1.06568519 10
 CYB5R3 Isoform 2 of NADH-cytochrome b5 
reductase 3 IPI00446235 34240.61 7.15 4 242.4844 100 67.37 99.99841 2.170853 0.497140991 4
 HSPB1 Heat shock protein beta-1 IPI00025512 23966.67 5.98 7 399.99 100 122.59 100 2.169555 0.625755716 7
 C14orf156 SRA stem-loop-interacting RNA-
binding protein, mitochondrial prec IPI00009922 13395.59 10.25 1 58.13 99.98665 58.13 99.98665 2.165553 0 1
Poorly Differentiated iTRAQ Individual Patients
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 HNRPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 IPI00419373 42922.9 9.1 4 374.23 100 178.18 100 2.161781 2.005034332 5
 NAP1L1 43 kDa protein IPI00789029 47959.44 4.45 2 114.35 100 72.49 99.99951 2.161538 0.458023477 2
 C20orf77 Uncharacterized protein C20orf77 IPI00009659 41289.62 5.73 1 88.33 100 88.33 100 2.133475 0 1
 HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55 9.27 8 431.01 100 96.29 100 2.123985 1.316034294 8
 CLINT1 Isoform 2 of Clathrin interactor 1 IPI00397519 73929.33 6.01 1 62.57 99.9952 62.57 99.9952 2.117071 0 1
 RPS20 16 kDa protein IPI00794659 18149.66 9.4 3 153.96 100 77.06 99.99983 2.108564 0.166026648 3
 HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.06 4.97 30 1951.044 100 115.03 100 2.10582 1.133342242 33
 FBL rRNA 2'-O-methyltransferase fibrillarin IPI00025039 36735.73 10.18 1 66.78 99.99818 66.78 99.99818 2.081688 0 1
 EIF4H;LOC653994 Isoform Short of Eukaryotic 
translation initiation factor 4 IPI00220894 26958.75 7.79 1 69.79 99.99909 69.79 99.99909 2.075839 0 1
 TRIM28 Isoform 2 of Transcription intermediary 
factor 1-beta IPI00438230 85861.79 5.67 2 159.17 100 106.35 100 2.071946 0.38268805 2
 PA2G4 41 kDa protein IPI00794875 47417.53 6.82 4 233.85 100 79.52 99.9999 2.056473 0.194280156 4
 FKBP5 51 kDa protein IPI00743671 59312.21 5.79 1 71.46 99.99938 71.46 99.99938 2.052584 0 1
 ERH Enhancer of rudimentary homolog IPI00029631 13541.16 5.63 2 135.75 100 96.53 100 2.01877 2.21E-02 2
 GLUD2 Glutamate dehydrogenase 2, 
mitochondrial precursor IPI00027146 66855.9 8.63 14 868.51 100 91.33 100 2.01456 0.690186734 16
 - 12 kDa protein IPI00455557 13102.08 4.68 1 141.93 100 141.93 100 2.013059 0 1
 PPIF Peptidyl-prolyl cis-trans isomerase, 
mitochondrial precursor IPI00026519 24750.42 9.48 2 94.2 100 56.33 99.97979 2.007303 0.252235228 2
 - 14 kDa protein IPI00455040 16069.76 8.86 1 85.73 100 85.73 100 2.005748 0.37585395 2
 VDP General vesicular transport factor p115 IPI00743314 117492.7 4.85 1 117.64 100 117.64 100 1.990942 0 1
 GTPBP9 Isoform 1 of Putative GTP-binding 
protein 9 IPI00290416 51379.9 7.64 3 187.21 100 107.89 100 1.982881 1.538214011 3
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 C20orf3 47 kDa protein IPI00479431 49085.11 5.82 5 261.48 100 76.8 99.99982 1.981541 0.85135387 6
 HNRPM Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein M IPI00383296 79706.9 8.94 3 279.67 100 137.03 100 1.97323 6.85E-02 3
 RBMX Heterogeneous nuclear 
ribonucleoprotein G IPI00304692 44322.6 10.06 3 148.1644 100 70.51 99.99923 1.969061 0.635847241 3
 GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63 7.66 22 1490.39 100 102.28 100 1.96862 0.778631523 26
 MATR3 100 kDa protein IPI00789551 110688.3 5.71 2 94.50999 100 54.48 99.96905 1.965559 0.430775403 2
 G3BP2 Isoform B of Ras GTPase-activating 
protein-binding protein 2 IPI00179890 53856.43 5.27 1 59.41 99.99005 59.41 99.99005 1.960587 0 1
 CBX3;LOC653972 Chromobox protein homolog 
3 IPI00297579 24680.73 5.23 1 86.04 100 86.04 100 1.955106 0 1
 PDIA4 Protein IPI00852792 21271.92 8.33 6 305.44 100 86.51 100 1.942883 0.386784921 6
 ANXA7 Isoform 2 of Annexin A7 IPI00021771 52673.88 6.25 1 77.57 99.99985 77.57 99.99985 1.896483 0 1
 HSPA5 HSPA5 protein IPI00003362 81398.3 5.07 25 2094.601 100 141.33 100 1.893627 0.578454857 28
 SRP14 8 kDa protein IPI00789296 8752.33 10.03 1 74.84 99.99972 74.84 99.99972 1.89354 0 1
 PCNA Proliferating cell nuclear antigen IPI00021700 31474.52 4.57 2 83.99 100 42.64 99.52728 1.889842 0.295297168 2
 HSPA1A;HSPA1B Heat shock 70 kDa protein 1 IPI00304925 77583.7 5.48 16 1055.449 100 136.35 100 1.88948 0.592831967 16
 CSNK2A1 Casein kinase 2 alpha isoform IPI00741317 49134.26 7.75 2 79.91 99.99991 50.46 99.92191 1.87337 0.942411045 2
 DBI Isoform 2 of Acyl-CoA-binding protein IPI00218836 13802.14 5.41 4 264.39 100 74.29 99.99968 1.863641 0.401583004 4
 PGRMC1 Membrane-associated progesterone 
receptor component 1 IPI00220739 23621.98 4.56 3 158.67 100 67.4 99.99842 1.862146 0.759477078 4
 ENO2 6 kDa protein IPI00790892 6040.03 4.89 2 192.91 100 120.04 100 1.857822 0.059837972 2
 SYNCRIP Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q IPI00402182 72162.18 8.69 3 180.86 100 72.37 99.9995 1.856331 0.111875671 3
 HNRPD Isoform 3 of Heterogeneous nuclear 
ribonucleoprotein D0 IPI00220684 37704.56 8.23 3 179.56 100 79.04 99.99989 1.850698 0.266793997 4
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 82667.81 4.96 19 1037.396 100 115.1 100 1.848238 0.567886386 19
 HSPE1 10 kDa heat shock protein, 
mitochondrial IPI00220362 12653.11 8.89 8 512.78 100 121.55 100 1.838326 0.496969681 9
 HSP90AB4P Heat shock protein 90Bd IPI00555565 66222.18 4.65 7 425.64 100 103.38 100 1.82908 0.515599005 7
 EEF1D EEF1D protein IPI00064086 31512.7 4.81 3 248.12 100 102.39 100 1.827388 0.794367927 3
 CALR Protein IPI00794237 19298.58 4.47 4 199.6445 100 67.76 99.99855 1.826623 0.693486095 5
 NONO Non-POU domain-containing octamer-
binding protein IPI00304596 58321.69 9.01 5 213.7645 100 52.49 99.95107 1.816619 0.813877767 5
 SET Isoform 2 of Protein SET IPI00301311 35108.06 4.12 2 111.17 100 80.1 99.99992 1.811698 1.45E-02 2
 SLC9A3R1 26 kDa protein IPI00794755 27862.19 5.12 2 63.97 99.99652 34.14 96.65337 1.792776 0.808381027 2
 LOC388885 similar to 40S ribosomal protein 
S10 IPI00398673 21722.75 10.07 3 177.39 100 75.55 99.99976 1.789744 8.83E-02 4
 MARCKS Myristoylated alanine-rich C-kinase 
substrate IPI00219301 35850.28 4.47 1 96.12 100 96.12 100 1.786437 0 1
 BCAP31 21 kDa protein IPI00639976 22905.45 8.94 3 135.63 100 58.35 99.98731 1.781957 8.11E-02 3
 HINT1 Histidine triad nucleotide-binding protein 
1 IPI00239077 15325.28 6.43 3 246.15 100 98.5 100 1.780588 0.151964705 3
 SNTB1 Isoform 2 of Beta-1-syntrophin IPI00216858 44616.67 9.13 1 76.84 99.99982 76.84 99.99982 1.777718 0 1
 SSBP1 Single-stranded DNA-binding protein, 
mitochondrial precursor IPI00029744 18545.23 9.59 4 205.8 100 80.23 99.99992 1.776709 0.395526114 4
 LRPPRC Leucine-rich PPR motif-containing 
protein IPI00783271 173604.2 5.81 3 161.8344 100 90.87 100 1.772152 0.158238098 3
 RPS5 40S ribosomal protein S5 IPI00008433 25448.32 9.73 1 131.87 100 131.87 100 1.765033 0 1
 GART Isoform Long of Trifunctional purine 
biosynthetic protein adenosine-3 IPI00025273 118791.7 6.26 2 73.77 99.99964 40.43 99.21367 1.756357 1.38970177 2
 ARHGDIA 28 kDa protein IPI00794402 30709 4.94 3 278.6 100 103.19 100 1.753555 0.205291349 3
 TNS3 tensin 3 IPI00658152 166503.4 6.34 1 74.55 99.9997 74.55 99.9997 1.746249 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 SCAMP3 Isoform 2 of Secretory carrier-
associated membrane protein 3 IPI00306383 37073.83 7.53 2 113.18 100 68.44 99.99876 1.740391 0.615517983 2
 PSMC4 Isoform 2 of 26S protease regulatory 
subunit 6B IPI00216770 47172.91 5.13 2 158.72 100 82 99.99995 1.729491 0.142667124 2
 SUMO3 Small ubiquitin-related modifier 3 
precursor IPI00299147 12971.92 5.32 1 84.76 100 84.76 100 1.724582 0 1
 FUBP1 Isoform 2 of Far upstream element-
binding protein 1 IPI00644386 73175.53 7.74 3 119.72 100 45.82 99.7727 1.722625 0.762020841 3
 hCG_1983058 hypothetical protein LOC644820 IPI00414723 28320.82 4.59 3 204.67 100 102.79 100 1.719594 0.234989385 3
 DYNLL1 Dynein light chain 1, cytoplasmic IPI00019329 12081.3 6.89 2 84.43 100 45.15 99.73478 1.7156 0.532056398 2
 HNRPH3 Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein H3 IPI00216492 36558.57 6.36 3 217.61 100 79.33 99.9999 1.713307 0.307083478 3
 HSPD1 60 kDa heat shock protein, 
mitochondrial precursor IPI00784154 68931.1 5.7 20 1502.262 100 123.14 100 1.706832 0.645225253 21
 HSP90AB2P Heat shock protein 90Bb IPI00455599 57370.48 5.09 7 487.28 100 115.03 100 1.703505 1.2086136 7
 HNRPU heterogeneous nuclear 
ribonucleoprotein U isoform a IPI00644079 101350.8 5.76 5 259.68 100 70.44 99.99922 1.700977 0.485240655 5
 UNQ501 MBC3205 IPI00063130 22277.99 8.91 1 78.47 99.99988 78.47 99.99988 1.699668 0 1
 EPN1 Isoform 2 of Epsin-1 IPI00027082 63516.05 4.72 1 76.00444 99.99978 77.18 99.99983 1.693141 0 1
 HNRPH1 HNRPH1 protein IPI00479191 53875.41 6.33 6 476.8544 100 147.84 100 1.687383 0.247768208 7
 KTN1 Isoform 2 of Kinectin IPI00337736 174519.1 5.57 1 83.1 100 83.1 100 1.681124 0 1
 PAICS phosphoribosylaminoimidazole 
carboxylase, phosphoribosylaminoimidazol IPI00815732 53853.99 7.86 1 58.78 99.9885 58.78 99.9885 1.675603 0 1
 ACADSB Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial IPI00024623 52051.68 6.53 1 96.28 100 96.28 100 1.665971 0 1
 TRAP1 57 kDa protein IPI00646055 62264.06 7.21 2 107.73 100 72.46 99.99951 1.657248 0.159156973 2
 PRKCSH Glucosidase 2 beta subunit precursor IPI00792916 64937.08 4.34 7 400.6145 100 84.15 100 1.657127 0.27690097 7
 HDGF Hepatoma-derived growth factor IPI00514127 32181.3 4.77 2 149.2345 100 79.9 99.99991 1.655977 0.480126294 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 HNRPA2B1 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 IPI00414696 38478.16 8.67 11 701.1544 100 149.74 100 1.654907 0.667179288 14
 CARHSP1 Calcium-regulated heat stable 
protein 1 IPI00304409 17218.17 8.41 1 118.63 100 118.63 100 1.651572 0 1
 CS citrate synthase precursor, isoform b IPI00383539 50469.26 6.74 3 123.77 100 48.24 99.8698 1.650204 0.366873294 3
 AHCY Adenosylhomocysteinase IPI00012007 52465.54 5.92 5 320.44 100 110.51 100 1.644259 0.536537307 5
 UGDH UDP-glucose 6-dehydrogenase IPI00031420 60869.65 6.73 4 301.53 100 154.06 100 1.64181 0.385711854 4
 ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 44906.64 6.47 2 119.53 100 77.04 99.99983 1.639922 0.134287615 2
 HNRPL heterogeneous nuclear 
ribonucleoprotein L isoform b IPI00465225 54634.78 7.22 5 330.81 100 90.86 100 1.639068 0.134492532 5
 IDH1 Isocitrate dehydrogenase [NADP] 
cytoplasmic IPI00027223 52332.01 6.53 20 1224.22 100 119.09 100 1.638322 0.480172835 22
 CANX Calnexin precursor IPI00020984 75958.54 4.47 5 448.2 100 143.5 100 1.635756 0.2436979 5
 STOML2 Stomatin-like protein 2 IPI00334190 41194.49 6.88 3 128.49 100 57.02 99.98276 1.63369 0.125496948 3
 TALDO1 Transaldolase IPI00744692 42118.9 6.36 6 370.35 100 90.9 100 1.615755 0.500075798 6
 DDAH1 NG,NG-dimethylarginine 
dimethylaminohydrolase 1 IPI00220342 34258.2 5.53 2 109.41 100 57.08 99.98299 1.614278 0.3032966 2
 HNRPF Heterogeneous nuclear 
ribonucleoprotein F IPI00003881 48367.08 5.38 4 221.84 100 109.75 100 1.614241 0.263521125 4
 NEDD8 NEDD8 precursor IPI00020008 10506.17 7.98 2 117.32 100 82.3 99.99995 1.604795 0.333918402 2
 CPNE1 53 kDa protein IPI00852917 56975.76 5.52 2 119.5 100 86.37 100 1.603542 0.558504462 2
 HNRPK Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein K IPI00216049 54486.72 5.39 7 439.3044 100 100.52 100 1.603353 0.329250983 8
 HNRPH2 Heterogeneous nuclear 
ribonucleoprotein H' IPI00026230 51910.53 5.89 6 436.94 100 147.84 100 1.602494 0.202341491 7
 PRKDC Isoform 2 of DNA-dependent protein 
kinase catalytic subunit IPI00376215 508806.4 6.81 1 84.68 100 84.68 100 1.602127 0 1
 THOC4 THO complex subunit 4 IPI00328840 29269.14 11.05 1 65.82 99.99773 65.82 99.99773 1.600807 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 HYOU1 Hypoxia up-regulated protein 1 
precursor IPI00000877 122683.2 5.16 7 415.25 100 80.76 99.99993 1.596622 0.291051514 7
 PRDX5 Isoform Cytoplasmic+peroxisomal of 
Peroxiredoxin-5, mitochondrial pre IPI00759663 19174.23 6.73 7 503.33 100 102.28 100 1.594821 0.34485222 7
 ENO1 Isoform alpha-enolase of Alpha-enolase IPI00465248 53031.82 7.01 13 948.2799 100 120.04 100 1.593619 0.393030526 14
 PPA1 Inorganic pyrophosphatase IPI00015018 37183.51 5.54 4 233 100 85.52 100 1.589989 0.305972064 4
 LRRC59 Leucine-rich repeat-containing protein 
59 IPI00396321 40703.35 9.61 2 108.83 100 67.67 99.99852 1.583628 0.170878201 2
 GANAB Isoform 3 of Neutral alpha-glucosidase 
AB precursor IPI00441414 99842.16 5.43 10 542.05 100 98.09 100 1.576707 0.662601733 10
 NHP2L1 NHP2-like protein 1 IPI00026167 15932.73 8.72 2 77.66 99.99985 40.93 99.29918 1.576307 3.51E-02 2
 LMAN1 ERGIC-53 protein precursor IPI00026530 62207.39 6.3 4 274.38 100 128.45 100 1.575437 0.558641857 4
 TUFM Tu translation elongation factor, 
mitochondrial IPI00027107 54583.72 7.26 8 492.99 100 83.39 100 1.574182 0.523401455 8
 RAB1B Ras-related protein Rab-1B IPI00008964 24743.49 5.55 2 152.77 100 94.93 100 1.567831 6.51E-02 2
 EML4 Echinoderm microtubule-associated 
protein-like 4 IPI00001466 119213.9 5.88 3 137.95 100 58.02 99.9863 1.565598 0.196987592 3
 PCBD1 Pterin-4-alpha-carbinolamine 
dehydratase IPI00218568 12902.17 6.28 6 307.94 100 76.55 99.99981 1.560138 0.35801258 6
 CALR 37 kDa protein IPI00793605 41138.14 4.55 9 613.46 100 119.53 100 1.553994 0.565188592 10
 PKM2 58 kDa protein IPI00784179 63980.44 7.95 7 317.2 100 69.29 99.99898 1.552805 0.559380621 7
 BBS1 36 kDa protein IPI00163204 37530.45 5.61 1 84.77 100 84.77 100 1.548378 0 1
 HIST3H2A Histone H2A type 3 IPI00031562 16129.2 11.05 4 278.61 100 136.37 100 1.527993 1.838326044 5
 TXNDC4 Thioredoxin domain-containing protein 
4 precursor IPI00401264 50287.66 5.09 3 152.75 100 61.98 99.9945 1.525827 0.221070086 3
 LGALS3BP Galectin-3-binding protein precursor IPI00023673 68905.43 5.13 4 212.23 100 94.05 100 1.524065 0.483049366 4
 PDHB Isoform 2 of Pyruvate dehydrogenase E1 
component subunit beta, mitocho IPI00549885 40188.14 5.64 1 87.01 100 87.01 100 1.521515 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 25840.99 4.93 3 261.89 100 106.51 100 1.518155 0.195547928 3
 - 30 kDa protein IPI00472119 35896.37 9.78 2 117.09 100 62.35 99.99495 1.514896 0.448702155 3
 PSMC6 26S protease regulatory subunit S10B IPI00021926 48839.51 7.1 2 81.4 99.99994 49.15 99.89441 1.514194 0.372385952 2
 TCP1 T-complex protein 1 isoform b IPI00550591 48598.41 7.59 1 69.89 99.99911 69.89 99.99911 1.513879 0 1
 SFPQ Isoform Long of Splicing factor, proline- 
and glutamine-rich IPI00010740 81090.11 9.45 5 249.9644 100 65.47 99.99754 1.513022 0.525013457 5
 LOC650157 similar to peptidylprolyl isomerase 
A isoform 1 IPI00397191 33761.59 8.81 2 82.82 100 43.78 99.63641 1.512371 7.49E-02 2
 KHK Isoform C of Ketohexokinase IPI00216136 35220.63 5.91 3 149.1 100 66.42 99.99802 1.512131 0.302536224 3
 TPI1 Isoform 1 of Triosephosphate isomerase IPI00465028 34025.99 5.65 9 789.12 100 118.04 100 1.511496 0.337702507 9
 FKBP2 FK506-binding protein 2 precursor IPI00002535 17649.53 9.24 4 248.99 100 92.49 100 1.508774 0.203341714 4
 NUTF2 Nuclear transport factor 2 IPI00009901 15615.19 5.1 2 94.17 100 59.1 99.98932 1.50731 7.12E-02 2
 GLUL Glutamine synthetase IPI00010130 45423.51 6.43 3 119.39 100 54.91 99.97197 1.506461 0.341273291 3
 VCP Transitional endoplasmic reticulum 
ATPase IPI00022774 96730.26 5.14 11 709.2844 100 131.79 100 1.504756 0.635821248 11
 DC2 DC2 protein IPI00183603 17773.97 9.23 1 58.11 99.98658 58.11 99.98658 1.503055 0 1
 SNRP70 Isoform 3 of U1 small nuclear 
ribonucleoprotein 70 kDa IPI00219484 21454.14 7.82 1 58.11444 99.9866 59.29 99.98978 1.502094 0 1
 HSP90AA1 Isoform 1 of Heat shock protein 
HSP 90-alpha IPI00784295 96593.69 4.94 23 1505.42 100 111.49 100 1.501396 0.621281343 24
 FUBP3 similar to Far upstream element-binding 




IPI00453473 13088.62 11.36 8 485.67 100 97.44 100 1.494903 1.142172159 8
 RPLP0 60S acidic ribosomal protein P0 IPI00556485 30148.59 8.36 5 272.26 100 88.81 100 1.492038 0.137492582 5
 PDIA3 55 kDa protein IPI00657680 62595.52 6.42 19 1476.589 100 180.79 100 1.485737 0.401478807 19
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 DYNC1I2 Isoform 2B of Cytoplasmic dynein 1 
intermediate chain 2 IPI00302712 77936.73 5.1 1 66.86 99.99821 66.86 99.99821 1.477568 0 1
 ST6GAL1 CMP-N-acetylneuraminate-beta-
galactosamide-alpha-2,6-sialyltransfer IPI00013887 52461.07 9.13 1 60.91 99.99296 60.91 99.99296 1.477349 0 1
 NDUFAB1 Acyl carrier protein, mitochondrial 
precursor IPI00022442 18696.14 4.82 2 99.82 100 69.07 99.99892 1.473742 0.794458187 2
 RBP4 Retinol binding protein 4, plasma IPI00480192 24933.3 5.77 2 131.66 100 77.71 99.99985 1.46757 0.155541368 2
 GC Vitamin D-binding protein precursor IPI00555812 60697.33 5.4 4 192.0644 100 72.72 99.99954 1.467332 0.381322567 4
 RAB1A Isoform 2 of Ras-related protein Rab-1A IPI00334174 17664.9 8.31 2 127.42 100 94.93 100 1.466815 3.85E-02 2
 HSPA6 Heat shock 70 kDa protein 6 IPI00339269 77112.71 5.81 7 454.35 100 136.35 100 1.463043 0.416231736 7
 RPS12 ribosomal protein S12 IPI00847579 17275.7 6.81 4 256.74 100 75.25 99.99974 1.458107 0.363088768 4
 FKBP1A Peptidyl-prolyl cis-trans isomerase IPI00647507 12759.03 9.17 1 86.05 100 86.05 100 1.45756 0 1
 ILF3 Isoform 1 of Interleukin enhancer-binding 
factor 3 IPI00298788 105105.9 8.86 3 157.97 100 88.36 100 1.450929 0.149340225 3
 GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78 6.61 13 925.1099 100 124.58 100 1.449792 0.394704318 14
 GLO1 Lactoylglutathione lyase IPI00220766 23684.52 5.12 2 116.1 100 81.76 99.99994 1.447161 4.53E-03 2
 GANAB Isoform 2 of Neutral alpha-glucosidase 
AB precursor IPI00011454 114201.4 5.82 10 543.91 100 99.95 100 1.444169 0.67004354 10
 RBM8A Isoform 2 of RNA-binding protein 8A IPI00216659 21665.93 5.64 1 111.56 100 111.56 100 1.441316 0 1
 C4B;C4A complement component 4B 
preproprotein IPI00418163 205105.3 6.89 4 163.0944 100 49.3 99.898 1.439727 0.474018827 5
 TMEM137;RBM14 Isoform 1 of RNA-binding 
protein 14 IPI00013174 72467.21 9.68 2 99.5 100 62.55 99.99517 1.43784 0.257140254 2
 RPS19 40S ribosomal protein S19 IPI00215780 18354.82 10.31 5 286.71 100 71.07 99.99932 1.436251 0.659909237 5
 TUBB2A Tubulin beta-2A chain IPI00013475 52501.16 4.78 14 1052.6 100 144.42 100 1.435768 0.339544095 17
 APOE Apolipoprotein E precursor IPI00021842 38239.99 5.65 5 346.6 100 121.81 100 1.43088 0.382995122 5
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 DHX9 ATP-dependent RNA helicase A IPI00844578 151431.7 6.41 5 250.1689 100 62.77 99.99541 1.427903 0.430959438 6
 ALDOA Fructose-bisphosphate aldolase A IPI00465439 43651.63 8.3 10 774.1444 100 120.53 100 1.416858 0.335537113 10
 HSPA9 Stress-70 protein, mitochondrial 
precursor IPI00007765 81497.46 5.87 15 1009.074 100 120.07 100 1.415962 0.378491562 15
 EPRS glutamyl-prolyl tRNA synthetase IPI00013452 193228.7 7.02 3 163.07 100 69.7 99.99907 1.412832 0.553671278 3
 - Tubulin alpha-4 chain IPI00017454 29152.96 8.65 2 128.92 100 87.98 100 1.411732 0.287330388 3
 
HIST1H2BI;HIST1H2BG;HIST1H2BF;HIST1H2
BC;HIST1H2BE H2B histone family, membe
IPI00020101 16921.91 10.31 4 270.07 100 102.54 100 1.410981 1.132346264 11
 NUCB2 Nucleobindin-2 precursor IPI00009123 57484.05 5.03 1 71.38 99.99937 71.38 99.99937 1.410131 0 1
 PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-
trans isomerase A IPI00419585 20345.11 7.68 12 787.22 100 111.95 100 1.406229 0.18767621 13
 PKLR Pyruvate kinase L IPI00743713 67899.97 7.6 3 140.97 100 69.29 99.99898 1.403681 0.422885812 3
 TUBA1B Similar to Tubulin alpha-ubiquitous 
chain IPI00792677 49578.06 4.96 11 934.15 100 165.24 100 1.402998 0.289282015 13
 COX4I1 COX4I1 protein IPI00645361 10672.9 8.64 3 152.15 100 79.16 99.99989 1.39885 0.134378939 3
 SPTBN1 275 kDa protein IPI00794135 301224.9 5.39 9 435.7833 100 78.25 99.99987 1.397295 0.370967714 9
 RAC1 Isoform B of Ras-related C3 botulinum 
toxin substrate 1 precursor IPI00219675 26798.57 8.87 3 112.21 100 44.46 99.68911 1.395561 0.225921787 3
 EEF1G 50 kDa protein IPI00747497 55012.56 6.27 6 316.8 100 80.36 99.99992 1.39508 0.586863381 6
 - CALRETICULIN=CALCIUM binding protein 
(Fragment) IPI00383751 26354.4 4.45 5 398.02 100 119.53 100 1.3932 0.277544399 5
 LOC387934 similar to Fatty acid-binding 
protein, epidermal IPI00398985 17565.75 6.73 1 39.02 98.91205 39.02 98.91205 1.392871 0.157424435 2
 TUBB3 Tubulin beta-3 chain IPI00013683 53216.46 4.83 11 828.32 100 144.42 100 1.392038 0.330335933 12
 EIF5A Isoform 1 of Eukaryotic translation 
initiation factor 5A-1 IPI00411704 19021.62 5.08 2 152.85 100 109.25 100 1.391198 1.15E-02 2
 ACTR3 Actin-like protein 3 IPI00028091 51165.27 5.61 3 120.81 100 47.51 99.84597 0.701903 0.119161603 3
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 ACADVL Isoform 2 of Very-long-chain specific 
acyl-CoA dehydrogenase, mitoch IPI00178744 78527.98 9.06 4 235.86 100 98.33 100 0.701365 0.090502638 4
 ECGF1 46 kDa protein IPI00853163 47964.33 5.35 2 117.02 100 58.99 99.98905 0.698404 5.60E-02 2
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00472282 42025.16 5.89 6 267.5244 100 76.52 99.99981 0.697195 0.194921023 6
 DDT D-dopachrome decarboxylase IPI00293867 13515.79 6.71 4 253.4144 100 94.47 100 0.692719 0.121928998 4
 IGHA2 Hypothetical protein DKFZp686C02218 
(Fragment) IPI00642017 57449.88 6.67 9 571.69 100 134.44 100 0.691445 0.271456836 11
 ARPC2 Actin-related protein 2/3 complex 
subunit 2 IPI00005161 38147.87 6.84 5 198.3944 100 52.09 99.94635 0.688874 0.129551102 5
 UGT2B17 similar to UDP glycosyltransferase 2 
family, polypeptide B17 IPI00787638 68438.74 8.79 2 91.89444 100 60.18 99.99167 0.688679 2.71E-03 2
 MYH14 Isoform 5 of Myosin-14 IPI00029818 180709 6.27 4 274.0744 100 91.21 100 0.686569 0.178596024 4
 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial IPI00001539 46153.97 8.32 13 806.85 100 112.59 100 0.685317 0.267825128 15
 MAOB Amine oxidase [flavin-containing] B IPI00328156 63747.53 7.2 3 113.67 100 42.03 99.45599 0.682675 0.125183749 3
 TGM2 Isoform 1 of Protein-glutamine gamma-
glutamyltransferase 2 IPI00294578 82951.92 5.11 9 502.74 100 71.42 99.99937 0.682383 9.89E-02 9
 RPL15 60S ribosomal protein L15 IPI00470528 26815.37 11.62 2 70.00999 99.99913 36.48 98.04743 0.681934 7.83E-03 2
 CMPK cytidylate kinase IPI00219953 29138.62 8.14 4 270.54 100 93.48 100 0.681848 0.115295593 4
 FTH1 Ferritin heavy chain IPI00554521 23366.52 5.3 2 106.55 100 61.44 99.99377 0.681325 2.13E-02 2
 IGHG2 Hypothetical protein DKFZp686I04196 
(Fragment) IPI00399007 50615.94 7.63 7 463.82 100 116.61 100 0.680102 0.157849765 8
 IGKV1-5 IGKV1-5 protein IPI00419424 28320.14 6.3 7 651.95 100 142.8 100 0.679636 0.219329006 8
 SUCLG2 Succinyl-CoA ligase [GDP-forming] 
beta-chain, mitochondrial precurso IPI00096066 51941.9 6.15 4 220.0744 100 85.44 100 0.67762 0.228063193 4
 KRT10 57 kDa protein IPI00383111 60122.17 5.09 5 241.6945 100 88.54 100 0.676783 0.483507052 5
 BDH1 D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial precursor IPI00025341 41766.75 9.11 4 167.8944 100 55.2 99.97378 0.676488 0.250267262 4
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 PSMB8 Isoform 1 of Proteasome subunit beta 
type 8 precursor IPI00000783 32050.75 7.63 3 121.4744 100 52.95 99.95598 0.672558 8.47E-02 3
 VIL2 Ezrin IPI00843975 77526.5 5.94 10 409.8789 100 54.4 99.96848 0.671655 0.168730878 10
 AK2 Isoform 2 of Adenylate kinase isoenzyme 
2, mitochondrial IPI00218988 28472.62 7.71 2 114.42 100 74.33 99.99968 0.671124 0.329889139 2
 RPN2 Ribophorin II IPI00383680 72001.89 5.7 1 68.18 99.99868 68.18 99.99868 0.666749 0 1
 - Tryptophanyl-tRNA synthetase (Fragment) IPI00383754 12867.94 4.57 1 62.81444 99.99546 63.99 99.99654 0.666069 0 1
 SAMHD1 SAM domain and HD domain-
containing protein 1 IPI00294739 79521.29 6.69 6 352.84 100 97.97 100 0.66562 0.143595716 6
 WARS tryptophanyl-tRNA synthetase isoform b IPI00412737 53848.83 6.03 4 175.08 100 63.99 99.99654 0.663253 0.104148107 4
 REEP6 Receptor expression-enhancing protein 
6 IPI00647161 22153.98 8.74 2 74.78 99.99971 42.91 99.55577 0.657825 0.225167377 2
 PFKM CDNA FLJ44241 fis, clone 
THYMU3008436, highly similar to 6- phosphofru IPI00465179 101419 8.2 1 56.62 99.98109 56.62 99.98109 0.657176 0 1
 UGT1A6;UGT1A1 UDP-
glucuronosyltransferase 1-1 precursor IPI00434346 64522.89 8.19 6 414.5 100 138.97 100 0.654575 8.34E-02 6
 MYL6 17 kDa protein IPI00744444 18920.58 4.54 5 482.35 100 131.7 100 0.654376 9.17E-02 6
 SCP2 sterol carrier protein 2 isoform 2 IPI00433347 61608.94 6.25 5 295.2 100 87.93 100 0.652468 0.251202315 6
 ACSL1 Isoform 1 of Long-chain-fatty-acid--CoA 
ligase 1 IPI00012728 85201.3 6.81 12 630.94 100 74.63 99.9997 0.649322 0.19003652 12
 ANXA5 Annexin A5 IPI00329801 39272.76 4.94 12 753.39 100 105.29 100 0.642168 0.13563291 12
 VCL Isoform 2 of Vinculin IPI00307162 135558.8 5.5 4 257.6245 100 114.57 100 0.640453 0.192074125 4
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 58388.33 6.3 11 675.1944 100 86.13 100 0.63822 0.182095833 11
 HBA2;HBA1 Alpha 2 globin variant (Fragment) IPI00853068 17045.17 8.72 7 511.84 100 111.39 100 0.636739 0.18846872 18
 COL6A3 alpha 3 type VI collagen isoform 4 
precursor IPI00072918 345401 6.48 31 1747.335 100 110.05 100 0.635751 0.184333935 33
 SELENBP1 53 kDa protein IPI00745729 57664.27 6.03 3 122.32 100 48.38 99.87393 0.634818 0.40816821 3
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 HSPG2 Basement membrane-specific heparan 
sulfate proteoglycan core protein IPI00024284 487110.2 6.06 7 277.0344 100 54.73 99.97078 0.628273 0.103642933 7
 APCS Serum amyloid P-component precursor IPI00022391 27335.36 6.1 1 71.68 99.99941 71.68 99.99941 0.628142 0 1
 PRSS1 Trypsin-1 precursor IPI00011694 29161.24 6.08 1 72.37 99.9995 72.37 99.9995 0.625513 0 1
 DPYS Dihydropyrimidinase IPI00028910 62048.11 6.81 4 167.8 100 59.41 99.99005 0.625205 0.13935343 4
 SERPINB1 Leukocyte elastase inhibitor IPI00027444 47127.14 5.9 2 93.14 100 57.5 99.98456 0.62469 3.39E-02 2
 TPM3 Isoform 2 of Tropomyosin alpha-3 chain IPI00218319 32655.08 4.75 8 477.68 100 83.34 100 0.622066 0.210648367 8
 RPS8 Ribosomal protein S8 IPI00645201 26370.43 10.37 3 165.55 100 79.85 99.99991 0.620291 4.82E-02 3
 A1BG 41 kDa protein IPI00644018 42068.62 5.5 2 68.49001 99.99877 38.83 98.8634 0.618897 0.315866261 2
 VIM Vimentin IPI00418471 56977.44 5.06 23 1567.599 100 114.66 100 0.615189 0.101542696 26
 HIST1H1D Histone H1.3 IPI00217466 31265.18 11.02 2 105.92 100 71.89 99.99944 0.614181 0.443048711 2
 SERPINC1 SERPINC1 protein IPI00844156 32447.11 9.03 4 201.36 100 94.71 100 0.611658 0.229837544 4
 - 2,3-bisphosphoglycerate mutase variant 
(Fragment) IPI00556284 18558.81 6.59 1 74.07 99.99966 74.07 99.99966 0.611022 0 1
 HAO1 Hydroxyacid oxidase 1 IPI00006934 44682.82 8.2 3 167.63 100 63.12 99.99577 0.610558 0.181927901 3
 ACO1 Iron-responsive element-binding protein 
1 IPI00008485 105951.2 6.23 3 127.91 100 50.14 99.91594 0.608357 0.278000872 3
 CYP2C9 Cytochrome P450 2C9 IPI00007219 61374.14 8.13 4 221.5744 100 88.42 100 0.607689 0.176628552 4
 CYP4F2 Cytochrome P450 4F2 IPI00019160 63921.06 6.6 2 96.68 100 53.95 99.96504 0.605442 0.102014877 2
 SDHALP2 SDHALP2 protein IPI00479656 17968.11 6.14 2 89.31 100 49.01 99.89095 0.605028 7.06E-02 2
 FTL Ferritin light chain IPI00852596 21925.34 5.51 5 342.68 100 92.97 100 0.604866 0.285684049 5
 UGT2B4 38 kDa protein IPI00790652 41813.85 8.87 3 156.79 100 63.72 99.99631 0.601034 0.127610949 3
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 SDHA Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondri IPI00305166 77793.53 7.06 7 333.21 100 66.87 99.99822 0.597194 0.1018256 7
 COL6A1 Collagen alpha-1(VI) chain precursor IPI00291136 117302.5 5.26 7 492.52 100 110.47 100 0.596963 0.196301422 7
 HP Haptoglobin precursor IPI00641737 52573.75 6.28 12 821.32 100 109.96 100 0.595825 0.246621022 14
 CFB Isoform 2 of Complement factor B 
precursor (Fragment) IPI00218508 74644.81 6.11 2 87.4 100 46.91 99.82315 0.595396 2.05E-02 2
 PDLIM1 PDZ and LIM domain protein 1 IPI00010414 39729.32 6.56 2 80.33 99.99992 44.73 99.70785 0.590328 0.034100893 2
 TPM3 tropomyosin 3 isoform 1 IPI00183968 38592.34 4.68 6 309.06 100 59.88 99.99108 0.588914 0.212695527 6
 ANXA2 Annexin A2 IPI00455315 43516.27 7.57 14 874.8489 100 104.63 100 0.586426 0.175738381 14
 HBD;HBB Hemoglobin subunit delta IPI00473011 17865.5 7.85 10 760.98 100 137.29 100 0.586287 0.335604919 15
 JUP JUP protein IPI00789324 87025.11 5.75 1 63.87 99.99644 63.87 99.99644 0.583532 0 1
 HMOX1 33 kDa protein IPI00747450 35080.3 8.72 1 58.81 99.98858 58.81 99.98858 0.58319 0 1
 SOD2 manganese superoxide dismutase 
isoform A precursor IPI00847322 27176.84 8.35 6 411.93 100 108.49 100 0.575455 8.79E-02 6
 - 105 kDa protein IPI00794900 115433.2 7.3 8 472.14 100 131.25 100 0.574426 0.209541582 8
 MYH10 Isoform 2 of Myosin-10 IPI00479307 260063.2 5.46 9 456.8056 100 104.78 100 0.570376 0.119983918 9
 PCK2 mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor IPI00797038 74784.86 7.57 9 426.33 100 77.48 99.99984 0.568484 0.131935747 9
 ARPC3 12 kDa protein IPI00796102 13215.08 8.52 2 81.87 99.99994 48.82 99.88608 0.567455 0.220480228 2
 ARPC4 actin related protein 2/3 complex 
subunit 4 isoform b IPI00607772 10554.03 6.84 2 87.74 100 56.98 99.9826 0.565852 0.13081302 2
 SULT1A1 Sulfotransferase 1A1 IPI00300026 47814.7 8.61 4 259.46 100 90.49 100 0.565421 0.176021316 4
 ASL argininosuccinate lyase isoform 3 IPI00607563 52220 5.82 3 204.29 100 104.84 100 0.564032 0.088061989 3
 TBXAS1 TBXAS1 protein IPI00329700 56407.3 6.62 1 55.38 99.97485 55.38 99.97485 0.563432 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 HBB Hemoglobin subunit beta IPI00654755 17808.5 6.75 13 1126.75 100 137.29 100 0.55043 0.289334126 21
 ACAA1 3-ketoacyl-CoA thiolase, peroxisomal 
precursor IPI00012828 47604.07 8.76 5 363.4 100 87.47 100 0.544761 0.173943854 5
 C9 Complement component C9 precursor IPI00022395 69800.94 5.43 2 92.00999 100 59.51 99.99028 0.54388 0.140533504 2
 EPHX1 Epoxide hydrolase 1 IPI00009896 57419.38 6.77 6 416.41 100 115.69 100 0.539358 0.242105233 6
 LUM 23 kDa protein IPI00794403 25919.61 8.52 3 212.92 100 92.41 100 0.537598 0.232048266 3
 RCN3 Reticulocalbin-3 precursor IPI00101037 38766.2 4.74 2 105.19 100 56.11 99.97874 0.532264 3.48E-02 2
 DECR1 2,4-dienoyl-CoA reductase, 
mitochondrial precursor IPI00003482 40019.15 9.35 6 396.33 100 118.23 100 0.529786 0.251894093 6
 - Histone 2, H3, pseudogene 2 IPI00455457 17482.8 11.27 3 114.46 100 39.31 98.98233 0.524354 0.137984864 4
 COQ9 Isoform 1 of Ubiquinone biosynthesis 
protein COQ9, mitochondrial precu IPI00470631 37064.78 5.61 1 67.43 99.99843 67.43 99.99843 0.524271 0 1
 BGN CDNA FLJ35635 fis, clone 
SPLEN2011805, highly similar to 
BONE/CARTILAGE
IPI00385748 39528 6.31 4 198.66 100 68.31 99.99872 0.523345 4.99E-02 4
 PYGL 97 kDa protein IPI00783313 107098.9 6.71 7 371.96 100 74.46 99.99969 0.520886 0.164573999 7
 GRHPR GRHPR protein (Fragment) IPI00550682 39375.17 5.95 5 322.0844 100 83.85 100 0.515825 8.73E-02 5
 CYP2E1 Cytochrome P450 2E1 IPI00007282 61500.8 8.27 6 325.33 100 83.15 100 0.51508 0.222385191 6
 COTL1 Coactosin-like protein IPI00017704 18043.27 5.54 2 102.95 100 53.81 99.96389 0.51042 2.03E-02 2
 CPT2 Carnitine O-palmitoyltransferase 2, 
mitochondrial precursor IPI00012912 79760.86 8.38 3 159.04 100 87.1 100 0.507829 0.11397982 3
 HIST3H3 Histone H3.1t IPI00216402 17606.75 11.13 4 167.82 100 54.76 99.97099 0.507048 0.154111767 4
 HBD Hemoglobin Lepore-Baltimore (Fragment) IPI00829896 12794.05 6.17 8 558.48 100 137.29 100 0.505955 0.265737318 11
 ILK Integrin-linked protein kinase IPI00013219 55688.24 8.3 1 72.62 99.99953 72.62 99.99953 0.504729 0 1
 TPM1 Isoform 1 of Tropomyosin alpha-1 chain IPI00014581 38351.24 4.69 5 245.24 100 59.88 99.99108 0.501231 9.45E-02 5
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 EHHADH Peroxisomal bifunctional enzyme IPI00216164 86466.1 9.22 5 201.9244 100 47.53 99.84668 0.499493 0.178942445 5
 TPM4 Isoform 1 of Tropomyosin alpha-4 chain IPI00010779 32340.88 4.67 8 475.27 100 102.98 100 0.499185 0.114128738 8
 ACADM Hypothetical protein 
DKFZp686M24262 IPI00513827 55018.79 7.94 4 198.99 100 78.05 99.99986 0.497914 0.203373166 4
 COL14A1 Isoform 3 of Collagen alpha-1(XIV) 
chain precursor IPI00402215 195722 5.16 2 73.09 99.99957 37.04 98.28364 0.493378 0.10057905 2
 HRSP12 Ribonuclease UK114 IPI00005038 15826.8 8.74 2 120.26 100 64.97 99.99724 0.492397 5.39E-02 2
 KRT18 Keratin, type I cytoskeletal 18 IPI00784347 51196.9 5.34 15 897.7 100 157.17 100 0.488946 0.247254128 16
 CYP2C19 Cytochrome P-450 II C (Fragment) IPI00657852 44746.02 6.82 2 118.94 100 88.42 100 0.488141 1.88E-02 2
 ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.08 8.72 10 597.8944 100 104.82 100 0.487955 0.140569611 10
 ANXA1 Annexin A1 IPI00218918 43626.43 6.57 4 350.32 100 118.41 100 0.486535 2.52E-02 4
 UGT2B7 similar to UDP-
glucuronosyltransferase 2B7 precursor IPI00787584 65314.41 8.41 3 156.19 100 63.72 99.99631 0.483175 0.147785731 3
 EIF3S10 EIF3S10 protein (Fragment) IPI00386403 51034.98 6.24 1 62.02 99.99455 62.02 99.99455 0.483123 0 1
 ACY1 Aminoacylase-1 IPI00009268 48344.23 5.77 3 160.76 100 69.6 99.99905 0.483065 0.113414817 3
 LGALS4 Galectin-4 IPI00009750 38026.42 9.21 2 73.83 99.99964 38.64 98.81257 0.482033 1.06E-02 2
 PCCA Propionyl-CoA carboxylase alpha chain, 
mitochondrial precursor IPI00749503 84435.19 6.63 1 70.96 99.9993 70.96 99.9993 0.480116 0 1
 CA2 11 kDa protein IPI00790885 13118.77 6.21 1 62.37 99.99497 62.37 99.99497 0.479285 0 1
 CLU clusterin isoform 1 IPI00400826 62857.9 6.24 2 108.4644 100 77.81 99.99986 0.479094 0.13083983 2
 RPL28 Ribosomal protein L28 variant 
(Fragment) IPI00816097 11793.78 10.42 1 64.57 99.99697 64.57 99.99697 0.478027 0 1
 BPHL Isoform 1 of Valacyclovir hydrolase 
precursor IPI00384428 35828.3 9.2 1 56.85 99.98207 56.85 99.98207 0.466649 0 1
 CYBB Cytochrome b-245 heavy chain IPI00218646 71069.92 8.9 1 91.33 100 91.33 100 0.464571 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 AGXT Serine--pyruvate aminotransferase IPI00009367 46426.73 8.61 7 443.63 100 108.98 100 0.463747 0.132866654 7
 CALD1 Isoform 2 of Caldesmon IPI00218694 76226.47 6.37 4 247.66 100 99.24 100 0.461506 0.100982558 4
 SYNE1 Isoform 6 of Nesprin-1 IPI00247297 1110046 5.37 2 73.53 99.99961 38.04 98.63665 0.460492 0.762836942 2
 KRT8 Keratin, type II cytoskeletal 8 IPI00554648 58423.63 5.52 24 1611.229 100 113.78 100 0.456955 0.147398673 28
 LSP1 50 kDa protein IPI00554652 54843.82 5.42 1 87.08 100 87.08 100 0.45249 0 1
 NNMT Nicotinamide N-methyltransferase IPI00027681 33091.32 5.56 2 81.08 99.99993 48.76 99.88449 0.448786 0.165526567 2
 FLNA Filamin-A IPI00333541 305957.4 5.7 17 991.5889 100 112.07 100 0.444513 0.155661707 17
 S100A8 Protein S100-A8 IPI00007047 12745.89 6.51 5 246.9645 100 57.89 99.98589 0.443812 0.096007318 5
 - Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment) IPI00783024 15665.44 9.65 1 91.43 100 91.43 100 0.44369 0 1
 COL1A2 Collagen alpha-2(I) chain precursor IPI00304962 136968 9.08 2 150.8 100 86.65 100 0.438417 0.316445597 2
 TST Thiosulfate sulfurtransferase IPI00216293 35752.06 6.77 9 494.0645 100 114.87 100 0.438076 0.124298096 9
 GLYAT Isoform 1 of Glycine N-acyltransferase IPI00402759 37221.21 8.38 5 228.92 100 60.39 99.99206 0.436126 0.652411828 5
 GPT Alanine aminotransferase 1 IPI00217458 57510.33 6.77 2 94.13 100 50.71 99.92628 0.434113 0.079601726 2
 - 24 kDa protein IPI00747151 25497.47 8.59 1 70.17 99.99917 70.17 99.99917 0.428561 0 1
 ANXA4 annexin IV IPI00793199 39558.52 5.84 8 555.35 100 105.99 100 0.425466 0.112760284 8
 ANXA6 Annexin A6 IPI00221226 83734.25 5.42 21 1241.849 100 125.37 100 0.420811 0.13643287 22
 - Transforming growth factor, beta-induced, 
68kDa variant (Fragment) IPI00556324 27690.46 5.33 1 77.8 99.99986 77.8 99.99986 0.41926 0 1
 ADH1A Alcohol dehydrogenase 1A IPI00218896 45320.81 8.26 11 854.64 100 112.05 100 0.41916 0.104487349 13
 ALDH1A1 Retinal dehydrogenase 1 IPI00218914 60949.39 6.3 12 719.0001 100 110.45 100 0.41621 0.127074898 12
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 AKR7A3 Aflatoxin B1 aldehyde reductase 
member 3 IPI00293721 39376.69 6.67 4 184.2 100 59.42 99.99008 0.413547 0.126146405 4
 ANXA6 annexin VI isoform 2 IPI00002459 83137.9 5.46 21 1294.119 100 125.37 100 0.40972 0.127442597 22
 APOL2 Apolipoprotein-L2 IPI00220007 53133.3 8.51 1 63.72 99.99631 63.72 99.99631 0.409376 0 1
 LOC651249 similar to ribosomal protein L34 IPI00741167 17426.44 11.43 1 56.18 99.97908 56.18 99.97908 0.408956 0 1
 KRT77 Keratin 77 IPI00376379 65018.72 5.63 3 169.07 100 75.44 99.99975 0.404868 0.199432703 3
 ADH1C Alcohol dehydrogenase 1C IPI00465343 45428 8.63 8 557.84 100 112.05 100 0.400889 0.108360674 10
 UGP2 Isoform 1 of UTP--glucose-1-phosphate 
uridylyltransferase IPI00329331 63091.29 8.16 8 568.9445 100 147.14 100 0.399961 0.144804149 9
 CES2 carboxylesterase 2 isoform 1 IPI00332828 72247.06 6.03 6 326.34 100 70.5 99.99923 0.394389 0.156987197 6
 SULT2A1 Bile salt sulfotransferase IPI00216133 37496.33 5.71 6 313.24 100 77.78 99.99986 0.391405 0.225741218 6
 BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.24 6.58 4 231.9644 100 77.42 99.99984 0.385061 0.278986279 4
 FTCD Isoform C of Formimidoyltransferase-
cyclodeaminase IPI00218976 64571.53 5.24 4 181.1644 100 56.9 99.98227 0.377616 0.218450347 4
 S100A9 Protein S100-A9 IPI00027462 15007.73 5.71 5 473.76 100 143.73 100 0.369881 8.68E-02 8
 HGD Homogentisate 1,2-dioxygenase IPI00303174 54236.86 6.54 4 178.12 100 54.12 99.96638 0.369873 0.156767155 4
 LTF 73 kDa protein IPI00789477 80974.52 8.2 3 104.18 100 36.65 98.12238 0.364365 0.28617315 4
 CYP2C8 45 kDa protein IPI00843846 49430.42 8.91 3 113.83 100 49.99 99.91298 0.35808 0.101332587 3
 KRT79 keratin 6L IPI00241841 62350.57 6.75 4 193.81 100 53.43 99.96059 0.356146 6.87E-02 4
 ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35 8 11 842.4344 100 111.06 100 0.355333 0.145519469 12
 MGC29506 hypothetical protein LOC51237 IPI00102821 21677.3 5.37 3 150.71 100 61.25 99.99349 0.354631 0.16533242 3
 ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91 8.63 11 833.92 100 112.05 100 0.353893 0.104848203 12
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 187NT
 RDH16 Microsomal NAD+-dependent retinol 
dehydrogenase 4 variant (Fragment) IPI00555683 23832.69 7.67 2 90.88 100 50.58 99.92404 0.344116 0.151259497 2
 HPD 40 kDa protein IPI00795913 44884.14 5.93 2 96.68 100 51.14 99.93323 0.3348 0.060868391 2
 EMILIN1 EMILIN-1 precursor IPI00013079 109415.5 5.1 2 136.28 100 92.22 100 0.324485 0.253628339 2
 FMO3 Dimethylaniline monooxygenase [N-oxide-
forming] 3 IPI00329033 66260.83 7.9 2 79.89 99.99991 46.26 99.7946 0.322228 0.177796806 2
 LYZ Lysozyme C precursor IPI00019038 17902.36 9.38 2 128.17 100 92.78 100 0.317979 9.71E-03 2
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1 5.6 4 270.47 100 104.88 100 0.310772 0.278080462 4
 KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.38 5.04 7 341.17 100 83.98 100 0.310013 0.213561586 7
 FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.15 6.54 9 801.28 100 129.65 100 0.295678 0.09865427 9
 OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.06 8.75 9 582.0245 100 100.93 100 0.287102 0.160531926 9
 TAGLN Transgelin IPI00216138 25234.73 8.87 5 302.45 100 89.48 100 0.278881 0.196635935 5
 PRELP Prolargin precursor IPI00020987 46264.34 9.47 3 116.91 100 45.85 99.77426 0.263424 0.081221483 3
 KRT7 keratin 7 IPI00847342 55144.71 5.4 7 342.8644 100 71.24 99.99935 0.261428 0.130869413 7
 CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180876 6.3 60 4232.145 100 178.36 100 0.253138 0.129906658 67
 GSTP1 Glutathione S-transferase P IPI00219757 25397.22 5.43 3 164.34 100 66.2 99.99792 0.240001 8.24E-02 3
 MT1X Metallothionein-1X IPI00008753 8279.2 8.38 2 126.22 100 91.14 100 0.236027 7.92E-02 2
 ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03 8.25 7 400.53 100 66.35 99.99799 0.225796 0.110771993 7
 GSTA1 Glutathione S-transferase A1 IPI00657682 29261.05 8.91 6 323.13 100 75.6 99.99976 0.200662 0.132825039 6
 DEFA3 Neutrophil defensin 3 precursor IPI00021827 10946.22 5.71 4 150.51 100 42.83 99.54751 0.189988 7.66E-02 4
 GGTLA1 Isoform 2 of Gamma-
glutamyltransferase 5 precursor IPI00339373 61051.74 7.67 2 115.52 100 73.97 99.99965 0.12845 6.01E-02 2





























 S100P Protein S100-P IPI00017526 12023.44043 4.75 1 101.6399994 100 101.6399994 100 40.23634604 0 1
 DEFA3 Neutrophil defensin 3 precursor IPI00021827 10946.21973 5.71 2 79.36999512 99.99989493 42.93000031 99.53710435 5.655948762 2.27782103 2
 KYNU Kynureninase IPI00003818 58348.64844 6.56 2 79.53443909 99.99989883 49.52000046 99.89849602 4.692876773 1.3306637 2
 NAP1L1 43 kDa protein IPI00789029 47959.44141 4.45 1 81.54000092 99.99993625 81.54000092 99.99993625 4.640823499 0 1
 FKBP11 Peptidyl-prolyl cis-trans isomerase IPI00789642 11840.12988 4.57 1 75.73999786 99.99975763 75.73999786 99.99975763 4.017763302 0 1
 FN1 fibronectin 1 isoform 2 preproprotein IPI00845263 280315.25 5.36 12 578.178833 100 63.74000168 99.99615866 3.531886193 1.83779318 12
 S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 6 494.4100037 100 132.7700043 100 3.484993538 1.19194646 7
 PKM2 Isoform M2 of Pyruvate kinase 
isozymes M1/M2 IPI00479186 63832.46094 7.96 5 268.1099854 100 64.05000305 99.9964233 3.400636445 1.2030494 5
 S100A8 Protein S100-A8 IPI00007047 12745.88965 6.51 7 387.7444458 100 89.33999634 100 3.278518778 0.88095252 7
 OAT Ornithine aminotransferase, 
mitochondrial precursor IPI00022334 52956.57813 6.57 5 187.0099945 100 50.66999817 99.92210971 3.161515407 2.11094382 5
 ANXA2 Annexin A2 IPI00455315 43516.26953 7.57 13 743.098877 100 107.2300034 100 3.015991858 1.08767905 13
 LSP1 50 kDa protein IPI00554652 54843.82031 5.42 1 86.51000214 100 86.51000214 100 2.970087632 0 1
 RAB10 Ras-related protein Rab-10 IPI00016513 25878.90039 8.59 2 116.5700073 100 66.44000244 99.99793708 2.946380773 3.61E-02 2
 LYZ Lysozyme C precursor IPI00019038 17902.35938 9.38 1 100.2799988 100 100.2799988 100 2.828595693 0 1
 RAN 26 kDa protein IPI00792352 29358.91016 8.51 3 148.1800079 100 65.41000366 99.99738493 2.814809077 0.90425406 3
 NCL Isoform 1 of Nucleolin IPI00604620 89719.57031 4.6 7 396.3299866 100 98.73000336 100 2.739876053 0.71469586 7
 FGB Fibrinogen beta chain precursor IPI00298497 61772.66016 8.54 10 824.0500488 100 112.4199982 100 2.67215264 0.43245668 10
 EPRS glutamyl-prolyl tRNA synthetase IPI00013452 193228.6875 7.02 1 84.54000092 100 84.54000092 100 2.444217283 0 1
 - CD68 antigen variant (Fragment) IPI00555602 45637.91016 5.46 7 506.2999573 100 110.8199997 100 2.439592015 1.07046531 7
 LRPPRC Leucine-rich PPR motif-containing 
protein IPI00783271 173604.2344 5.81 3 131.5700073 100 52.22000122 99.94548914 2.417892896 0.50393709 3
 VDAC2 Isoform 2 of Voltage-dependent anion-
selective channel protein 2 IPI00216024 39125.44922 5.87 2 84.83999634 100 51.18000031 99.9307399 2.412844048 0.41265082 2
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 207NT
 ANXA1 Annexin A1 IPI00218918 43626.42969 6.57 1 108.3600006 100 108.3600006 100 2.407393515 0 1
 XRCC6 70 kDa protein IPI00465430 78696.84375 6.23 1 75.5 99.99974386 75.5 99.99974386 2.30637601 0 1
 MPO Isoform H14 of Myeloperoxidase 
precursor IPI00236554 77088.74219 9.3 5 226.0499878 100 60.97000122 99.99273086 2.273772136 0.56255613 5
 VDAC1 Voltage-dependent anion-selective 
channel protein 1 IPI00216308 34589.96094 8.62 4 193.3000031 100 67.54000092 99.99839866 2.267978913 0.34978132 4
 HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55078 9.27 6 422.5299683 100 136.6399994 100 2.251334172 0.75876352 6
 - Tubulin alpha-4 chain IPI00017454 29152.96094 8.65 2 131.2900085 100 81.88999939 99.99994119 2.2283067 1.68040825 2
 PARP1 Poly [ADP-ribose] polymerase 1 IPI00449049 131945.8906 8.99 2 112.7200012 100 61.18999863 99.99308992 2.227703364 1.51E-02 2
 HNRPU heterogeneous nuclear 
ribonucleoprotein U isoform a IPI00644079 101350.8203 5.76 2 139.6900024 100 95.94999695 100 2.213805437 1.15410684 2
 - 140 kDa protein IPI00829641 149651.875 7.92 3 160.5400085 100 83.95999908 100 2.21151654 0.92627 3
 HNRPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 IPI00419373 42922.89844 9.1 4 315.1900024 100 130.0800018 100 2.201613582 0.94041803 4
 LDHA Isoform 1 of L-lactate dehydrogenase A 
chain IPI00217966 41071.75 8.44 11 548.0044556 100 90.72000122 100 2.182228249 1.1573262 13
 SRP14 8 kDa protein IPI00789296 8752.330078 10.03 1 72.80999756 99.99952414 72.80999756 99.99952414 2.132435525 0 1
 ARHGDIB 13 kDa protein IPI00791712 14875.75977 4.69 1 115.5199966 100 115.5199966 100 2.119406881 0 1
 NPM1 Isoform 1 of Nucleophosmin IPI00549248 37589.32031 4.64 5 307.6300049 100 90.95999908 100 2.105772827 1.22049752 5
 NME1;NME2 Nucleoside diphosphate kinase IPI00604590 36163.17969 8.7 6 297.3177795 100 84.93000031 100 2.099593129 0.47884558 7
 DAZAP1 Isoform 2 of DAZ-associated protein 
1 IPI00335930 43470.07813 8.48 1 64.5 99.99677535 64.5 99.99677535 2.065011936 0 1
 SFPQ Isoform Long of Splicing factor, proline- 
and glutamine-rich IPI00010740 81090.10938 9.45 3 132.9244385 100 59.66999817 99.99019419 2.056983513 0.32448831 3
 PIR Pirin IPI00012575 35353.58984 6.42 1 74.86000061 99.99970319 74.86000061 99.99970319 2.042476028 0 1
 SERPINB1 Leukocyte elastase inhibitor IPI00027444 47127.14063 5.9 2 82.28999329 99.99994636 43.00999832 99.54555294 2.040612093 0.40635151 2
 FGG Isoform Gamma-A of Fibrinogen gamma 
chain precursor IPI00219713 55011.35938 5.7 6 289.0100098 100 83.04000092 100 1.977503577 0.46164369 6
 VDAC3 Isoform 2 of Voltage-dependent anion-
selective channel protein 3 IPI00294779 35078.69141 8.85 2 101.1999969 100 67.54000092 99.99839866 1.972251928 8.82E-02 2
 LTF 73 kDa protein IPI00789477 80974.52344 8.2 5 280.190033 100 96.54000092 100 1.953068244 0.76455 5
 GCS1 Mannosyl-oligosaccharide glucosidase IPI00328170 95022.89844 8.97 1 66.54000092 99.99798403 66.54000092 99.99798403 1.942659433 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 207NT
 ANXA5 Annexin A5 IPI00329801 39272.76172 4.94 11 673.6500244 100 106.3700027 100 1.938948157 0.80183947 12
 ATIC Bifunctional purine biosynthesis protein 
PURH IPI00289499 70461.78906 6.27 1 68.58999634 99.99874257 68.58999634 99.99874257 1.910925303 0 1
 FGA Isoform 2 of Fibrinogen alpha chain 
precursor IPI00029717 76032.28906 8.23 13 754.3845215 100 103.9300003 100 1.907973728 0.65248423 13
 TRAP1 57 kDa protein IPI00646055 62264.05859 7.21 3 134.484436 100 63.25 99.99569985 1.856870167 0.30569297 3
 EIF4A2 Isoform 2 of Eukaryotic initiation factor 
4A-II IPI00409717 49956.14063 5.33 5 368.4299927 100 110.8199997 100 1.856681192 0.90093675 5
 RBM8A Isoform 2 of RNA-binding protein 8A IPI00216659 21665.92969 5.64 1 110.5999985 100 110.5999985 100 1.841043432 0 1
 ENO1 Isoform alpha-enolase of Alpha-enolase IPI00465248 53031.82031 7.01 13 858.4200439 100 103.6800003 100 1.837945632 0.60812758 13
 CYCS Cytochrome c IPI00465315 14569.42969 9.59 3 129.1799927 100 50.18999863 99.91300721 1.835758251 0.61747588 3
 HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.0625 4.97 16 937.8744507 100 123.5299988 100 1.834798629 1.47029804 16
 HIST1H1B Histone H1.5 IPI00217468 32071.38086 10.91 1 82.69000244 100 82.69000244 100 1.827931132 0 1
 RPS3 40S ribosomal protein S3 IPI00011253 29833.74023 9.68 2 107.6399994 100 63.56999969 99.99600531 1.811035884 0.10588164 2
 YWHAZ 14-3-3 protein zeta/delta IPI00021263 30890.03906 4.73 5 383.1744385 100 145.25 100 1.804757089 0.47506278 5
 AKR1C2 Aldo-keto reductase family 1 member 
C2 IPI00005668 40922.30078 7.13 7 332.8800049 100 67.13999939 99.99824417 1.799855965 0.39685595 7
 TAGLN2 24 kDa protein IPI00647915 26448.48047 8.41 5 371.7800293 100 109.5999985 100 1.776599994 0.43976564 5
 HBD Hemoglobin Lepore-Baltimore 
(Fragment) IPI00829896 12794.0498 6.17 10 823.6199951 100 135.2899933 100 1.768347913 1.83684612 14
 ANXA4 annexin IV IPI00793199 39558.51953 5.84 10 580.6400146 100 98.5 100 1.761418999 0.36346861 10
 LOC648517 similar to Aldo-keto reductase 
family 1 member C1 (20-alpha-hydro IPI00736657 35442.78906 9.01 8 367.0599976 100 67.13999939 99.99824417 1.7561367 0.39402092 8
 ALDOA Fructose-bisphosphate aldolase A IPI00465439 43651.62891 8.3 8 464.7644348 100 91.27999878 100 1.754176549 2.77238867 10
 ANPEP Aminopeptidase N IPI00221224 116417.4531 5.31 3 121.6444397 100 47.11999893 99.82360623 1.737489174 0.20878212 3
 TUBA1B Similar to Tubulin alpha-ubiquitous 
chain IPI00792677 49578.05859 4.96 11 909.7099609 100 189.2799988 100 1.736879731 0.68109527 11
 HSPD1 60 kDa heat shock protein, 
mitochondrial precursor IPI00784154 68931.10156 5.7 20 1487.047852 100 122.9300003 100 1.726014269 0.52819537 21
 TUBA1C Tubulin alpha-1C chain IPI00218343 53295.64844 4.96 11 902.5899658 100 189.2799988 100 1.721939678 0.6665395 11
 TES Isoform 2 of Testin IPI00216425 54398.51953 7.82 1 62.75 99.99517516 62.75 99.99517516 1.716490873 0 1
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 207NT
 EEF1D EEF1D protein IPI00064086 31512.69922 4.81 1 61.41999817 99.99344635 61.41999817 99.99344635 1.704492486 0 1
 LOC651249 similar to ribosomal protein L34 IPI00741167 17426.43945 11.43 1 63.43000031 99.99587444 63.43000031 99.99587444 1.698519277 0 1
 SURF4 Surfeit 4 IPI00399142 22555.05078 8.88 1 84.88999939 100 84.88999939 100 1.698050758 0 1
 BID Isoform 2 of BH3-interacting domain death 
agonist IPI00420084 27815.5 6.6 1 63.70000076 99.99612311 63.70000076 99.99612311 1.695282857 0 1
 DHX9 ATP-dependent RNA helicase A IPI00844578 151431.7344 6.41 2 125.0699997 100 84.93000031 100 1.693805514 4.51E-02 2
 HSP90AB4P Heat shock protein 90Bd IPI00555565 66222.17969 4.65 4 185.1100006 100 65.5 99.99743857 1.693231561 0.42897494 4
 SLC25A6 ADP/ATP translocase 3 IPI00291467 36341.51953 9.76 3 130.4300079 100 45.47000122 99.7420812 1.691653624 0.96579841 3
 CAP1 Adenylyl cyclase-associated protein IPI00639931 58646.21094 8.24 3 171.0299988 100 64.97000122 99.9971061 1.689643119 6.75E-02 3
 SFRS6 Isoform SRP55-1 of Splicing factor, 
arginine/serine-rich 6 IPI00012345 43543.78906 11.42 1 62.56999969 99.99497098 62.56999969 99.99497098 1.685175714 0 1
 A2M Alpha-2-macroglobulin precursor IPI00478003 177285.7656 6 1 64.80000305 99.99699058 64.80000305 99.99699058 1.684446549 0 1
 - Elongation factor 1-alpha IPI00472724 57485.78125 9.15 11 619.9900513 100 98.19999695 100 1.684017092 0.99996512 11
 CYB5R3 Isoform 2 of NADH-cytochrome b5 
reductase 3 IPI00446235 34240.60938 7.15 2 83.68000031 100 45.75 99.75818506 1.676020818 1.07142586 2
 SCAMP3 Isoform 2 of Secretory carrier-
associated membrane protein 3 IPI00306383 37073.82813 7.53 1 74.31999969 99.99966389 74.31999969 99.99966389 1.674427209 0 1
 HNRPD Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein D0 IPI00028888 43300.76953 7.62 1 61.63000107 99.99375571 61.63000107 99.99375571 1.665540796 0 1
 CCT6A T-complex protein 1 subunit zeta IPI00027626 64980.16016 6.23 3 191.0099945 100 72.08999634 99.99943833 1.654769131 0.20476942 3
 AKR1C3 Aldo-keto reductase family 1 member 
C3 IPI00291483 41031.17969 8.05 8 375.8299866 100 75.91000366 99.99976693 1.638678638 0.27903921 8
 GGH Gamma-glutamyl hydrolase precursor IPI00023728 39719.46875 6.67 1 76.79000092 99.99980968 76.79000092 99.99980968 1.638211502 0 1
 EEF2 Elongation factor 2 IPI00186290 105563.6484 6.41 9 569.8599854 100 92.70999908 100 1.63796065 0.47411814 9
 PRPH Isoform 2 of Peripherin IPI00793184 57006.82031 5.37 3 156.3800049 100 79.87999725 99.99990657 1.635023363 0.65868075 3
 CCT5 T-complex protein 1 subunit epsilon IPI00010720 66337.35156 5.45 3 116.5 100 49.31999969 99.89371226 1.632359398 0.52687739 3
 HNRPAB Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A/B IPI00329355 41002.28906 9.04 2 128.6999969 100 76.25 99.99978448 1.627511624 0.45616132 2
 GBP2 GBP2 protein IPI00848358 76021.07813 5.54 2 149.1199951 100 78.18000031 99.99986181 1.617173448 0.49661472 2
 TPM4 Isoform 1 of Tropomyosin alpha-4 chain IPI00010779 32340.88086 4.67 6 300.9244385 100 67.69000244 99.99845303 1.610324042 0.27509382 6
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 207NT
 HSPA1A;HSPA1B heat shock 70kDa protein 
1A IPI00845339 77569.67969 5.48 8 467.5700073 100 108.4400024 100 1.610013732 0.4043797 9
 IGHM IGHM protein IPI00761159 57955.55078 7.53 7 659.9499512 100 145.9700012 100 1.607670332 0.2879175 7
 PAH Phenylalanine-4-hydroxylase IPI00017579 56707.82031 6.15 3 108.75 100 42.02999878 99.43051374 1.607557869 0.33676117 3
 LOC388720 similar to ubiquitin and ribosomal 
protein S27a precursor IPI00397808 21877.69922 9.53 5 241.3300018 100 71.72000122 99.99938838 1.598765136 0.27485976 5
 YWHAQ 14-3-3 protein theta IPI00018146 30857.03906 4.68 5 286.6499939 100 84.48000336 100 1.596827686 0.5329611 5
 IGHM Hypothetical protein DKFZp686I15212 IPI00418153 62655.28125 8.39 6 368.1600037 100 106.2600021 100 1.592659183 0.28961092 6
 PGK1 Phosphoglycerate kinase 1 IPI00169383 51100.66016 8.3 10 557.4400024 100 126.5299988 100 1.591460347 0.50224922 10
 PGD 53 kDa protein IPI00747533 59047.51953 7.12 2 91.66000366 100 56.13999939 99.97789537 1.591106481 7.22E-02 2
 ENO2 6 kDa protein IPI00790892 6040.029785 4.89 2 132.8199921 100 69.55999756 99.99899427 1.586576046 0.35880554 2
 CSTB Cystatin-B IPI00021828 12618.79004 6.96 3 174.1700134 100 80.15000153 99.9999122 1.584769495 0.35237289 3
 EEA1 Early endosome antigen 1 IPI00329536 188351.2031 5.53 1 85.29000092 100 85.29000092 100 1.57496379 0 1
 S100A6 Protein S100-A6 IPI00027463 11659.54004 5.33 2 82.44999695 99.9999483 42.25 99.45864378 1.572958585 0.08777251 2
 hCG_1983058 hypothetical protein 
LOC644820 IPI00414723 28320.82031 4.59 2 72.51000214 99.9994901 41.93000031 99.4172489 1.56746945 8.67E-03 2
 RPS15A 40S ribosomal protein S15a IPI00221091 16650.17969 10.14 4 149.6844482 100 42.88999939 99.53282113 1.565600561 0.75437269 4
 TUBB2C Tubulin beta-2C chain IPI00007752 52471.19141 4.79 11 856.9400024 100 137.6199951 100 1.553050345 0.39021271 12
 RPSA Ribosomal protein SA IPI00413108 35158.85156 4.79 3 193.9499969 100 93.75 100 1.552697286 0.3425397 3
 NNMT Nicotinamide N-methyltransferase IPI00027681 33091.32031 5.56 3 126.7999954 100 49.5 99.89802749 1.547437455 0.13483723 3
 RPS9 40S ribosomal protein S9 IPI00221088 25503.88086 10.66 3 100.0800018 100 34.77000046 96.96971774 1.545288791 0.33977197 3
 VCP 89 kDa protein IPI00843748 96637.15625 5.11 6 403.6600037 100 118.0100021 100 1.544496827 0.45154559 6
 MICA;HLA-A;HLA-A29.1;LOC730410;HLA-
B;HLA-C HLA class I histocompatibility a IPI00743359 42850.23828 6.08 4 261.714447 100 114.8199997 100 1.538966325 0.20137721 4
 IGHG1 Hypothetical protein DKFZp686K03196 IPI00423464 57631.46875 8.84 7 672.1300049 100 145.9700012 100 1.536762236 0.33813475 8
 CCT8 T-complex protein 1 subunit theta IPI00784090 66090.99219 5.42 3 201.7700043 100 77.19000244 99.99982643 1.534328958 0.31682746 3
 CLTC Isoform 2 of Clathrin heavy chain 1 IPI00455383 203165.7031 5.48 7 374.2944336 100 72.31999969 99.9994673 1.533775747 0.37413328 7
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 207NT
 LCP1 Plastin-2 IPI00010471 77185.35938 5.2 4 214.0899963 100 67.23000336 99.99828018 1.530250449 0.47229128 4
 CGN cingulin IPI00844508 149111.4844 5.44 1 105.4199982 100 105.4199982 100 1.52996065 0 1
 HNRPR HNRPR protein IPI00644055 77880.99219 8.23 1 69.23000336 99.99891487 69.23000336 99.99891487 1.521588961 0 1
 SERPINA1 Alpha-1-antitrypsin precursor IPI00553177 51885.51172 5.37 8 536.2144775 100 93.48000336 100 1.515431271 0.51969802 9
 AKR1B10 Aldo-keto reductase family 1 
member B10 IPI00105407 41078.28125 7.12 1 88.87000275 100 88.87000275 100 1.515356027 0 1
 HBB Hemoglobin subunit beta IPI00654755 17808.5 6.75 14 1269.130005 100 145.1799927 100 1.500962849 1.56622786 21
 SEC31A Isoform 4 of Protein transport protein 
Sec31A IPI00515103 138953.7344 7.03 3 202.0288849 100 108.2099991 100 1.492981784 0.23469306 3
 RPS11 40S ribosomal protein S11 IPI00025091 21725.32031 10.31 4 187.0144501 100 61.61000061 99.99372689 1.484909805 0.46446499 4
 VIM Vimentin IPI00418471 56977.44141 5.06 19 1256.898926 100 125.4199982 100 1.481563112 0.5452161 20
 FLNA Filamin-A IPI00333541 305957.375 5.7 4 183.8144531 100 78.55000305 99.99987309 1.480824959 0.12603579 4
 HNRPK Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein K IPI00216746 54394.67969 5.19 5 290.8244324 100 93.43000031 100 1.479497297 0.25413331 5
 HSPE1 10 kDa heat shock protein, 
mitochondrial IPI00220362 12653.11035 8.89 7 409.6900024 100 77.38999939 99.99983424 1.47886066 0.45362892 10
 HIST3H3 Histone H3.1t IPI00216402 17606.75 11.13 3 130.5899963 100 55.20999908 99.97261686 1.474411807 0.55639164 4
 TUBB3 Tubulin beta-3 chain IPI00013683 53216.46094 4.83 6 471.5099792 100 137.6199951 100 1.473849954 0.42758433 6
 RPLP0 60S acidic ribosomal protein P0 IPI00556485 30148.58984 8.36 3 186.7600098 100 102.8300018 100 1.466852709 0.2231332 3
 HSPA9 Stress-70 protein, mitochondrial 
precursor IPI00007765 81497.46094 5.87 15 986.6744385 100 109.8600006 100 1.464667288 0.35211581 15
 SOD2 manganese superoxide dismutase 
isoform A precursor IPI00847322 27176.83984 8.35 4 250.8299866 100 106.5299988 100 1.458499803 0.1274883 4
 HSPA8 Isoform 1 of Heat shock cognate 71 
kDa protein IPI00003865 78958.95313 5.37 19 1172.518921 100 118.0299988 100 1.457466781 0.19748925 20
 HSPA6 Heat shock 70 kDa protein 6 IPI00339269 77112.71094 5.81 4 242.6499939 100 108.4400024 100 1.456474203 0.50558929 4
 IMMT Isoform 3 of Mitochondrial inner 
membrane protein IPI00470829 88364.21094 6.31 3 203.4599915 100 118.0100021 100 1.455046869 0.4387022 3
 LONP1 Lon protease homolog IPI00334291 109879.3125 6.11 1 60.88000107 99.99257865 60.88000107 99.99257865 1.453515138 0 1
 LOC388474 similar to 60S ribosomal protein 
L7a isoform 1 IPI00397676 35921.55078 10.56 2 110.7600021 100 65.65000153 99.99752553 1.44962134 0.13118665 2
 TUBB Tubulin beta chain IPI00011654 52311.16016 4.78 11 868.8900146 100 137.6199951 100 1.448838709 0.42741624 12
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 207NT
 GAPDH 32 kDa protein IPI00795257 35122.30859 7.15 9 681.6244507 100 125.5100021 100 1.444394465 0.6921141 11
 EIF4G3 Isoform 1 of Eukaryotic translation 
initiation factor 4 gamma 3 IPI00646377 194311.3594 5.27 2 77.37999725 99.99983386 42.93999863 99.5381688 1.441493245 0.3527914 2
 EIF4G1 eukaryotic translation initiation factor 4 
gamma, 1 isoform 2 IPI00384463 180908.9531 5.15 2 77.37999725 99.99983386 42.93999863 99.5381688 1.441493245 0.3527914 2
 LRRC59 Leucine-rich repeat-containing 
protein 59 IPI00396321 40703.35156 9.61 2 92.43000031 100 53.86999893 99.96271937 1.431699177 0.22145403 2
 HNRPA2B1 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 IPI00414696 38478.16016 8.67 9 617.2045288 100 98.65000153 100 1.42512171 0.43173685 9
 TUBB2A Tubulin beta-2A chain IPI00013475 52501.16016 4.78 10 789.3699951 100 137.6199951 100 1.424005608 0.45586438 10
 PGAM1;hCG_2015138;hCG_2015269 
Phosphoglycerate mutase 1 IPI00549725 31614.14063 6.67 7 446.2199707 100 107.1299973 100 1.417457639 0.22217796 7
 CAPZB Capping protein (Actin filament) 
muscle Z-line, beta IPI00642256 32963.14844 6.45 1 66.66999817 99.99804348 66.66999817 99.99804348 1.416327825 0 1
 CS citrate synthase precursor, isoform b IPI00383539 50469.26172 6.74 3 103.6500015 100 41.40000153 99.34161038 1.413529273 0.243629 3
 HNRPH1 HNRPH1 protein IPI00479191 53875.41016 6.33 4 242.1444397 100 98.52999878 100 1.411382222 0.29803979 5
 SERPINB6 serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), me IPI00749398 46902.42188 5.18 1 68.01000214 99.99856291 68.01000214 99.99856291 1.402886894 0 1
 AKR1C4 Aldo-keto reductase family 1 member 
C4 IPI00289524 41137.30859 6.71 9 401.6599731 100 58.08000183 99.98585891 1.400143536 0.61510333 9
 CECR5 Isoform 2 of Cat eye syndrome critical 
region protein 5 precursor IPI00011511 48531.94141 8.38 1 74.34443665 99.99966577 75.51999664 99.99974503 1.399957442 0 1
 FDPS Farnesyl diphosphate synthase IPI00101405 51970.89063 5.83 4 248.4599915 100 95.16000366 100 1.399024093 0.16645783 4
 - Farnesyl pyrophosphate synthetase like-4 
protein (Fragment) IPI00382869 42840.89844 4.87 4 193.3499908 100 64.5 99.99677535 1.399024093 0.16645783 4
 ACTG1;PSPHL Actin, cytoplasmic 2 IPI00021440 44922.05859 5.31 12 1109.289917 100 201.4199982 100 1.396114576 0.43270713 16
 TUFM Tu translation elongation factor, 
mitochondrial IPI00027107 54583.71875 7.26 4 308.5100098 100 122.0599976 100 1.395068417 0.24038387 4
 HIST1H2BL Histone H2B type 1-L IPI00018534 16967.94922 10.31 3 228.8099976 100 83.56999969 100 1.390187918 0.31217616 6
 ALDH16A1 Aldehyde dehydrogenase family 16 
member A1 IPI00217920 87917.74219 6.35 1 69.54000092 99.99898962 69.54000092 99.99898962 0.704649331 0 1
 KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 3 156.2599945 100 74.25 99.99965843 0.702913876 0.27132037 3
 HINT1 Histidine triad nucleotide-binding 
protein 1 IPI00239077 15325.28027 6.43 4 271.1199951 100 93.84999847 100 0.694546912 0.31450495 4
 ANXA6 Annexin A6 IPI00221226 83734.25 5.42 19 1154.843384 100 125.3199997 100 0.689011052 0.15549822 20
 RRBP1 Isoform 1 of Ribosome-binding protein 
1 IPI00220967 178629.8125 8.73 10 699.1489258 100 153.6300049 100 0.681721589 0.29181371 10
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 ETFA 24 kDa protein IPI00792673 27117.09961 8.77 3 323.25 100 171.9499969 100 0.681023593 6.04E-02 3
 AIFM1 Isoform 3 of Apoptosis-inducing factor 
1, mitochondrial precursor IPI00157908 72532.10938 9.03 3 201.6999969 100 84.58000183 100 0.675976301 0.03010373 3
 IVD Isovaleryl-CoA dehydrogenase, 
mitochondrial precursor IPI00789848 50635.03906 8.26 1 67.91999817 99.99853282 67.91999817 99.99853282 0.67514055 0 1
 MAT1A S-adenosylmethionine synthetase 
isoform type-1 IPI00021772 47392.28906 5.86 7 343.9044495 100 85.58000183 100 0.674515954 0.20885323 7
 PRDX6 Peroxiredoxin-6 IPI00220301 27847.49023 6 7 553.1099854 100 135.1600037 100 0.670006318 0.14634367 9
 TPP1 Isoform 3 of Tripeptidyl-peptidase 1 
precursor IPI00554538 62032.14844 5.94 2 109.1300049 100 63.86000061 99.99626334 0.665062502 3.49E-02 2
 ALDOC Fructose-bisphosphate aldolase C IPI00418262 42921.51172 6.41 4 230.3299866 100 93.37999725 100 0.663793434 1.93179501 5
 COL6A3 alpha 3 type VI collagen isoform 3 
precursor IPI00072917 345457.3438 6.47 5 209.8300018 100 48.81999969 99.8807432 0.660029095 0.3098978 5
 METTL7A Methyltransferase-like protein 7A 
precursor IPI00022300 30730.71094 8.7 1 80.56999969 99.9999203 80.56999969 99.9999203 0.654776006 0 1
 C20orf3 47 kDa protein IPI00479431 49085.10938 5.82 3 150.3199921 100 73.56999969 99.99960053 0.654149855 0.36393537 3
 GOT2 Aspartate aminotransferase, 
mitochondrial precursor IPI00018206 52087.64844 9.14 5 367.2200012 100 119.5299988 100 0.651164633 0.21199404 5
 CNDP2 53 kDa protein IPI00646632 58467.37891 5.66 3 151.1600037 100 80.83999634 99.9999251 0.648711939 0.17050558 4
 ECGF1 46 kDa protein IPI00853163 47964.32813 5.35 2 130.519989 100 71.16999817 99.9993058 0.648360665 2.60E-02 2
 ANXA6 annexin VI isoform 2 IPI00002459 83137.89844 5.46 19 1164.003418 100 125.3199997 100 0.646942837 0.21120628 20
 LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 58388.32813 6.3 7 411.1499939 100 94.19999695 100 0.645682469 0.21323231 7
 DBI Isoform 2 of Acyl-CoA-binding protein IPI00218836 13802.13965 5.41 4 343.3599854 100 130.8300018 100 0.644849195 6.64E-02 4
 AK3 GTP:AMP phosphotransferase IPI00478236 20052.85938 8.73 1 71.87999725 99.9994105 71.87999725 99.9994105 0.635505382 0 1
 SORBS2 sorbin and SH3 domain containing 2 
isoform 2 IPI00477577 135030.8438 8.56 2 95.86999512 100 49.09000015 99.88793161 0.627740832 6.40E-02 2
 MPST 3-mercaptopyruvate sulfurtransferase IPI00165360 34971.80078 6.13 6 372.3500061 100 95.98999786 100 0.617491497 0.13543009 6
 FKBP2 FK506-binding protein 2 precursor IPI00002535 17649.5293 9.24 2 124.6399994 100 67.98999786 99.99855628 0.617181936 7.07E-02 2
 APOL2 Apolipoprotein-L2 IPI00220007 53133.30078 8.51 1 65.41000366 99.99738493 65.41000366 99.99738493 0.617178306 0 1
 AGL Isoform 6 of Glycogen debranching 
enzyme IPI00219066 185998.375 6.26 1 99.05999756 100 99.05999756 100 0.615164517 0 1
 ETFB Isoform 2 of Electron transfer 
flavoprotein subunit beta IPI00556451 41287.32813 6.78 2 97.86999512 100 52.68999863 99.95108036 0.614864636 0.10488794 2
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 SHMT1 Isoform 2 of Serine 




IPI00453473 13088.62012 11.36 5 283.0400085 100 77.05000305 99.99982074 0.61365226 0.28387805 5
 CRYZ 32 kDa protein IPI00647366 34670.82031 8.59 3 265.25 100 146.3999939 100 0.610146609 6.18E-02 3
 ACADVL Isoform 2 of Very-long-chain specific 
acyl-CoA dehydrogenase, mitoch IPI00178744 78527.97656 9.06 1 62.61999893 99.99502855 62.61999893 99.99502855 0.609980795 0 1
 MAOA Amine oxidase [flavin-containing] A IPI00008483 65674.00781 7.94 2 124.6600037 100 76.56999969 99.99979979 0.609599101 0.30991958 2
 GANAB Isoform 2 of Neutral alpha-
glucosidase AB precursor IPI00011454 114201.4219 5.82 3 219.8099976 100 90.94999695 100 0.605711468 0.48512432 3
 KRT6C Keratin, type II cytoskeletal 6E IPI00299145 64682.71875 8.09 5 238.7044373 100 72.30999756 99.99946607 0.603040128 0.22529676 9
 PCBD1 Pterin-4-alpha-carbinolamine 
dehydratase IPI00218568 12902.16992 6.28 2 91.15000153 100 46.02000046 99.77276089 0.602768593 7.88E-02 3
 ARG1 Isoform 2 of Arginase-1 IPI00398768 39380.19922 6.72 5 296.6099854 100 90.51999664 100 0.602516819 0.40541004 5
 CPT2 Carnitine O-palmitoyltransferase 2, 
mitochondrial precursor IPI00012912 79760.85938 8.38 2 125.5344391 100 90.81999969 100 0.600058824 0.0176979 2
 ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial precursor IPI00011416 38661.62109 8.16 3 157.1300049 100 67.40000153 99.9983462 0.599050576 0.15897946 3
 MMAB 19 kDa protein IPI00789857 20551.83008 8.35 1 79.16000366 99.99988972 79.16000366 99.99988972 0.598837173 0 1
 NNT NAD(P) transhydrogenase, mitochondrial 
precursor IPI00337541 123493.2578 8.31 4 196.3399963 100 54.20000076 99.96544722 0.592528015 0.18616118 4
 ESD 28 kDa protein IPI00641040 31266.09961 6.29 2 101.8099976 100 53.38000107 99.95826667 0.581659385 9.54E-02 2
 APOC3 13 kDa protein IPI00657670 13861.62012 7.9 1 87.90000153 100 87.90000153 100 0.579910736 0 1
 ALDH1A1 Retinal dehydrogenase 1 IPI00218914 60949.39063 6.3 12 713.7700195 100 116.6299973 100 0.578332914 0.1194347 12
 KRT2 Keratin, type II cytoskeletal 2 epidermal IPI00021304 71239.86719 8.07 4 220.1000061 100 94.55000305 100 0.572341326 0.24365179 5
 IDH2 Isocitrate dehydrogenase [NADP], 
mitochondrial precursor IPI00011107 56573.30859 8.88 9 502.694458 100 96.40000153 100 0.567220576 0.24940713 9
 C10orf125 Isoform 2 of Protein fucU homolog IPI00845372 15786.78027 5.2 1 62.58000183 99.99498255 62.58000183 99.99498255 0.563223822 0 1
 PC Pyruvate carboxylase, mitochondrial 
precursor IPI00299402 138358.0469 6.37 10 617.9589233 100 111.5699997 100 0.562111522 0.13899065 10
 BLVRB Flavin reductase IPI00783862 23637.61914 7.13 2 88.80000305 100 45.20000076 99.72553748 0.550305624 7.75E-02 2
 PGRMC2 Membrane-associated progesterone 
receptor component 2 IPI00005202 28072.17969 5.2 2 69.91999817 99.99907427 35.86999893 97.64775131 0.550024064 0.19902442 2
 CYP2E1 Cytochrome P450 2E1 IPI00007282 61500.80078 8.27 3 160.9400024 100 67.26000214 99.99829202 0.549634246 6.73E-02 3
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 KRT8 Keratin, type II cytoskeletal 8 IPI00554648 58423.62891 5.52 24 1435.693359 100 100.5199966 100 0.547577073 0.15645338 29
 UGT1A6;UGT1A1 UDP-
glucuronosyltransferase 1-1 precursor IPI00434346 64522.89063 8.19 4 242.1600037 100 71.58000183 99.99936834 0.544811534 0.35430489 4
 ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 3 147.3144379 100 74.08999634 99.99964561 0.544043307 0.12086434 3
 ACOT1 Acyl-coenzyme A thioesterase 1 IPI00333838 49306.28906 6.9 1 61.61999893 99.99374131 61.61999893 99.99374131 0.542283078 0 1
 CARHSP1 Calcium-regulated heat stable 
protein 1 IPI00304409 17218.16992 8.41 1 110.0899963 100 110.0899963 100 0.529035039 0 1
 CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 33322.12891 8.55 6 352.3799744 100 92.18000031 100 0.527179228 0.14029558 7
 KRT79 keratin 6L IPI00241841 62350.57031 6.75 4 183.3800049 100 53.36999893 99.95817045 0.524329572 0.17357955 6
 EHHADH 8 kDa protein IPI00797006 7706.140137 7.98 1 123.75 100 123.75 100 0.517959632 0 1
 KRT18 Keratin, type I cytoskeletal 18 IPI00784347 51196.89844 5.34 10 499.8800049 100 94.44000244 100 0.514990657 0.1401707 11
 - 105 kDa protein IPI00794900 115433.2422 7.3 8 417.8933411 100 89.48000336 100 0.514639671 0.27958476 8
 CA2 Carbonic anhydrase 2 IPI00218414 32874.30859 6.87 3 201.8099976 100 84.37000275 100 0.512735983 0.17527702 3
 DDAH1 NG,NG-dimethylarginine 
dimethylaminohydrolase 1 IPI00220342 34258.19922 5.53 2 108.3199997 100 58.36999893 99.98677233 0.510362221 2.45E-02 2
 LTB4DH NADP-dependent leukotriene B4 12-
hydroxydehydrogenase IPI00292657 40639.17188 8.45 3 185.1399994 100 117.6699982 100 0.505252763 5.70E-02 3
 AADAC Arylacetamide deacetylase IPI00383879 49123.19141 8.75 1 85.05444336 100 86.23000336 100 0.499872173 0 1
 GBE1 1,4-alpha-glucan-branching enzyme IPI00296635 85817.03906 5.87 2 116.2600021 100 84.94000244 100 0.49849675 0.28628799 2
 ACADSB Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial IPI00024623 52051.67969 6.53 2 138.4299927 100 98.23999786 100 0.495981717 2.66E-03 2
 COL6A1 Collagen alpha-1(VI) chain precursor IPI00291136 117302.5391 5.26 3 153.4899902 100 65.18000031 99.99724271 0.492355307 2.15E-02 3
 DECR1 2,4-dienoyl-CoA reductase, 
mitochondrial precursor IPI00003482 40019.14844 9.35 6 406.9900208 100 109.6900024 100 0.482946102 0.10661875 6
 DBT Lipoamide acyltransferase component of 
branched-chain alpha-keto acid d IPI00003944 59823.44141 8.71 2 128.5700073 100 67.80000305 99.99849172 0.47688215 0.27668581 2
 AOX1 Hypothetical protein AOX1 IPI00743616 161854.2031 6.78 6 257.3444519 100 61.47000122 99.99352137 0.471897485 0.13755349 6
 BAAT Bile acid CoA:amino acid N-
acyltransferase IPI00017819 48856.32031 6.49 2 116.8099976 100 76.13999939 99.99977895 0.466311126 0.20207701 2
 SELENBP1 53 kDa protein IPI00745729 57664.26953 6.03 3 126.8199921 100 50.59000015 99.92066166 0.466066698 0.13756307 4
 ACY1 Aminoacylase-1 IPI00009268 48344.23047 5.77 4 189.5 100 56.45000076 99.97941821 0.461514946 0.13039517 4
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 PEBP1 Phosphatidylethanolamine-binding 
protein 1 IPI00219446 23439.92969 7.01 8 666.8200684 100 204.1799927 100 0.455580886 8.44E-02 10
 AKR1A1 Alcohol dehydrogenase IPI00220271 39850.12891 6.32 7 365.5299988 100 75.26000214 99.9997293 0.446235402 0.20608501 7
 DDT D-dopachrome decarboxylase IPI00293867 13515.79004 6.71 4 227.5544586 100 85.11000061 100 0.443694155 0.16289988 5
 SOD1 Superoxide dismutase IPI00783680 17838.08984 5.7 5 344.0400085 100 116.3600006 100 0.443442842 2.62E-02 5
 AKR7A3 Aflatoxin B1 aldehyde reductase 
member 3 IPI00293721 39376.69141 6.67 2 120.7200012 100 64.08000183 99.99644792 0.441910448 0.16800398 2
 MT1X Metallothionein-1X IPI00008753 8279.200195 8.38 2 112.3200073 100 69.55000305 99.99899195 0.437214488 1.86E-02 2
 MSRA 22 kDa protein IPI00794951 23445.88086 7.12 1 63.38000107 99.99582667 63.38000107 99.99582667 0.437150277 0 1
 MAOB Amine oxidase [flavin-containing] B IPI00328156 63747.53125 7.2 2 114.8800049 100 76.56999969 99.99979979 0.435525758 3.38E-02 2
 H1F0 Histone H1.0 IPI00550239 29058.99023 10.84 1 83.52999878 100 83.52999878 100 0.434374598 0 1
 SULT1A1 Sulfotransferase 1A1 IPI00300026 47814.69922 8.61 8 371.8500061 100 58.77999878 99.98796397 0.428086325 0.1453276 8
 FMO3 Dimethylaniline monooxygenase [N-
oxide-forming] 3 IPI00329033 66260.82813 7.9 2 70.88999939 99.99925957 35.97999954 97.70658222 0.423598756 0.10390954 2
 ALDH1B1 Aldehyde dehydrogenase X, 
mitochondrial precursor IPI00103467 62178.58984 6.36 4 218.4100037 100 85.26000214 100 0.423091895 0.16238105 4
 FABP1 FABP1 protein (Fragment) IPI00010290 18729.4707 9.52 6 401.8299866 100 115.1399994 100 0.421102419 0.12676313 8
 DCXR 26 kDa protein IPI00797249 27252.58984 8.33 6 300.9799805 100 66.70999908 99.99806142 0.415402358 0.16535472 6
 KHK Isoform C of Ketohexokinase IPI00216136 35220.62891 5.91 2 70.70999908 99.99922824 38.38999939 98.68331105 0.406444734 0.59471182 2
 SLC27A5 Bile acyl-CoA synthetase IPI00016827 78658.29688 7.81 2 95.38443756 100 63.79999924 99.99621136 0.400170634 0.21630523 2
 SUCLG2 Succinyl-CoA ligase [GDP-forming] 
beta-chain, mitochondrial precurso IPI00096066 51941.89844 6.15 3 178.3399963 100 82.91999817 100 0.39865757 9.98E-02 3
 ALDH4A1 Aldehyde dehydrogenase 4 family, 
member A1 IPI00647328 65056.12109 7.62 11 583.0700073 100 90.26000214 100 0.398635216 0.12948829 11
 GPT Alanine aminotransferase 1 IPI00217458 57510.32813 6.77 3 149.25 100 55.59000015 99.97491101 0.389697007 9.07E-02 3
 CES2 carboxylesterase 2 isoform 1 IPI00332828 72247.0625 6.03 4 187.6900024 100 61.81999969 99.994023 0.384695375 0.10745092 4
 ACAT1 Acetyl-CoA acetyltransferase, 
mitochondrial precursor IPI00030363 49865.05859 8.98 12 863.3612061 100 137.1499939 100 0.383968946 0.15479506 12
 AGXT Serine--pyruvate aminotransferase IPI00009367 46426.73047 8.61 7 477.230011 100 109.4599991 100 0.382934742 0.11484164 7
 CAT Catalase IPI00465436 64367.17969 6.9 11 824.2300415 100 192.7100067 100 0.382488232 0.2462603 11
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 MUT Methylmalonyl-CoA mutase, 
mitochondrial precursor IPI00024934 90636.34375 6.48 3 233.6299896 100 92.87999725 100 0.380012262 0.1363373 3
 HADH Isoform 2 of Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial precu IPI00298406 47125.23047 9.34 5 257.5 100 93.91999817 100 0.375892732 0.19763108 5
 GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 18 1232.970093 100 136.3500061 100 0.362815548 0.13767236 18
 FAH Fumarylacetoacetase IPI00031708 49546.46094 6.46 2 102.3799973 100 60.52999878 99.99195579 0.360432164 0.14794561 2
 PGRMC1 Membrane-associated progesterone 
receptor component 1 IPI00220739 23621.98047 4.56 3 148.1399994 100 71.30999756 99.99932782 0.345808356 4.93E-02 3
 EMILIN1 EMILIN-1 precursor IPI00013079 109415.4531 5.1 1 85.91000366 100 85.91000366 100 0.339293112 0 1
 PGM1 Phosphoglucomutase 1 IPI00844159 66935.90625 6.2 3 219.4700012 100 99.80999756 100 0.335838047 0.12900664 3
 UNQ501 MBC3205 IPI00063130 22277.99023 8.91 1 76.41000366 99.99979228 76.41000366 99.99979228 0.335543292 0 1
 EHHADH Peroxisomal bifunctional enzyme IPI00216164 86466.10156 9.22 4 181.9944458 100 66.52999878 99.99797939 0.332709624 7.79E-02 4
 GRHPR Glyoxylate reductase/hydroxypyruvate 
reductase IPI00037448 38271.94141 7.01 9 660.7544556 100 124.4100037 100 0.332157018 0.18319711 9
 COMT Isoform Soluble of Catechol O-
methyltransferase IPI00375513 26915.57031 5.15 2 143.4600067 100 84.76000214 100 0.332096264 2.32E-02 2
 ACADM Hypothetical protein 
DKFZp686M24262 IPI00513827 55018.78906 7.94 4 224.1999969 100 80.98000336 99.99992748 0.331354423 0.11825541 4
 ABHD14B 22 kDa protein IPI00747859 23098.53906 5.43 2 132.9299927 100 95.76000214 100 0.33040402 1.44E-02 2
 ALDH9A1 aldehyde dehydrogenase 9A1 IPI00479877 61023.67188 6.23 1 94.34999847 100 94.34999847 100 0.329797256 0 1
 PYGL 97 kDa protein IPI00783313 107098.9297 6.71 6 311.1499939 100 92.09999847 100 0.326806301 8.33E-02 6
 DPYS Dihydropyrimidinase IPI00028910 62048.10938 6.81 5 259.3899841 100 66.80000305 99.99810118 0.32675151 0.13511939 5
 TST Thiosulfate sulfurtransferase IPI00216293 35752.05859 6.77 8 607.8144531 100 112.8000031 100 0.326622253 0.15826975 8
 PCK2 mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor IPI00797038 74784.85938 7.57 14 810.9899902 100 106.5 100 0.324551656 0.23101197 15
 HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 3 173.8899994 100 66.15000153 99.99779462 0.315552751 1.99E-02 3
 PBLD Phenazine biosynthesis-like domain-
containing protein IPI00024896 34011.42969 6.06 2 97.97444153 100 66.58000183 99.99800252 0.314278123 0.32667903 2
 HMGCS2 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial precursor IPI00008934 61333.76953 8.4 10 557.3499756 100 85.23999786 100 0.310037574 0.19317026 10
 CYP3A4 Cytochrome P450 3A4 IPI00465138 63244.41016 8.27 2 113.3099976 100 81.01999664 99.99992814 0.309043153 0.40584699 2
 IL11RA 13 kDa protein IPI00167641 14096.79004 7.79 1 71.41000366 99.99934312 71.41000366 99.99934312 0.308006069 0 1
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 ACSL1 Isoform 1 of Long-chain-fatty-acid--
CoA ligase 1 IPI00012728 85201.29688 6.81 9 591.6699829 100 121.4400024 100 0.306841859 0.12173862 9
 HAGH Hydroxyacylglutathione hydrolase IPI00745553 32141.91016 6.86 1 99.62999725 100 99.62999725 100 0.299084827 0 1
 SCP2 sterol carrier protein 2 isoform 2 IPI00433347 61608.94141 6.25 6 310.5844421 100 81.47000122 99.99993521 0.294671263 0.10145713 6
 SORD Sorbitol dehydrogenase IPI00216057 42378.10938 8.23 4 222.5700073 100 103.6699982 100 0.294242325 7.91E-02 4
 ECHS1 Enoyl-CoA hydratase, mitochondrial 
precursor IPI00024993 35335.42969 8.34 11 716.5599365 100 112.2799988 100 0.290538942 0.14422899 11
 ALDH2 Mitochondrial aldehyde 
dehydrogenase 2 variant (Fragment) IPI00792207 61065.96094 6.63 13 856.2000122 100 106.4499969 100 0.281163211 0.17237171 14
 UGP2 Isoform 1 of UTP--glucose-1-phosphate 
uridylyltransferase IPI00329331 63091.28906 8.16 11 732.9788818 100 138 100 0.264200699 0.14168397 11
 ACSM2A LOC123876 protein IPI00644771 70304.24219 8.34 4 186.1400146 100 59.06999969 99.98874143 0.260675229 0.13408905 4
 FTCD Isoform A of Formimidoyltransferase-
cyclodeaminase IPI00001441 62321.57813 5.58 7 389.1799927 100 74.90000153 99.99970591 0.25786259 0.16292638 7
 SULT2A1 Bile salt sulfotransferase IPI00216133 37496.32813 5.71 7 352.8500061 100 83.44000244 100 0.256433902 0.11572872 7
 FTL Ferritin light chain IPI00852596 21925.33984 5.51 3 199.7999878 100 75.77999878 99.99975985 0.246255634 5.16E-02 3
 OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.05859 8.75 7 420.2844543 100 104.0899963 100 0.244630453 0.12134267 7
 ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor IPI00009532 61418.91016 8.17 5 293.1699829 100 83.61000061 100 0.243131937 7.60E-02 5
 BDH1 D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial precursor IPI00025341 41766.75 9.11 3 143.5244446 100 56.22999954 99.97834874 0.228818222 0.26459057 3
 CYB5A Isoform 1 of Cytochrome b5 IPI00397860 16616.71094 4.88 6 524.5899658 100 227.2200012 100 0.227018513 4.56E-02 6
 ACAA1 3-ketoacyl-CoA thiolase, peroxisomal 
precursor IPI00012828 47604.07031 8.76 4 349.6000061 100 110.1999969 100 0.225431545 9.10E-02 4
 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial IPI00001539 46153.96875 8.32 11 707.7799683 100 138.3200073 100 0.220514994 0.14814864 11
 ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.07813 8.72 8 555.3644409 100 94.58999634 100 0.215647272 0.17281552 8
 ACSM2B Acyl-CoA synthetase medium-chain 
family member 2 IPI00329444 70450.35938 8.5 4 169.4700012 100 55.27000046 99.97299258 0.205965148 9.91E-02 4
 COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 1 95.41999817 100 95.41999817 100 0.205684898 0 1
 CYP2C8 45 kDa protein IPI00843846 49430.42188 8.91 4 229.0500031 100 64.80999756 99.9969975 0.204592735 0.10040232 4
 CYP2C9 Cytochrome P450 2C9 IPI00007219 61374.14063 8.13 3 186.4799957 100 79.30999756 99.99989347 0.194452276 6.02E-02 3
 CYP3A5 Cytochrome P450 3A5 IPI00025831 63206.64063 8.86 2 116.9899979 100 81.08999634 99.99992929 0.193498805 0.08675896 2
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 FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 9 692.1900024 100 123.7600021 100 0.190802158 0.22849112 9
 BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.23828 6.58 14 768.6488647 100 125.2300034 100 0.180062713 0.10995276 16
 ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03125 8.25 9 690.5800171 100 116.8899994 100 0.178223351 0.13288805 9
 UGT2B7 similar to UDP-
glucuronosyltransferase 2B7 precursor IPI00787584 65314.41016 8.41 4 214.0400085 100 74.30999756 99.99966311 0.177838805 8.30E-02 4
 LOC554235 29 kDa protein IPI00419903 29217.00977 6.5 1 109.6800003 100 109.6800003 100 0.176564177 0 1
 CYP2C19 Cytochrome P-450 II C (Fragment) IPI00657852 44746.01953 6.82 2 118.1800003 100 61.59000015 99.99369793 0.176431233 4.66E-02 2
 EPHX1 Epoxide hydrolase 1 IPI00009896 57419.37891 6.77 6 468 100 112.0899963 100 0.176255207 0.14702675 7
 GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78125 6.61 16 1090.650024 100 136.7899933 100 0.175484401 0.17455749 18
 GGTLA1 Isoform 2 of Gamma-
glutamyltransferase 5 precursor IPI00339373 61051.73828 7.67 1 74.33999634 99.99966543 74.33999634 99.99966543 0.16565382 0 1
 CYP1A2 Isoform 1 of Cytochrome P450 1A2 IPI00719591 62467.67188 9.18 1 76.54000092 99.9997984 76.54000092 99.9997984 0.158577674 0 1
 DAK Dihydroxyacetone kinase IPI00551024 63392.42188 7.12 5 521.5 100 156.3899994 100 0.150961653 9.81E-02 6
 GLYAT Isoform 1 of Glycine N-acyltransferase IPI00402759 37221.21094 8.38 3 135.8099976 100 57.43000031 99.98357584 0.150897903 0.33367253 3
 ADH1A Alcohol dehydrogenase 1A IPI00218896 45320.80859 8.26 11 859.1099854 100 121.3399963 100 0.13377832 0.1133497 12
 UGT2B17 UDP-glucuronosyltransferase 2B17 
precursor IPI00026932 67707.59375 8.76 1 66.90000153 99.99814441 66.90000153 99.99814441 0.129522258 0 1
 CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 60 4328.580078 100 149.0200043 100 0.12154383 0.14185499 70
 CYP2A6 Cytochrome P450 2A6 IPI00299568 61083.51172 9.24 3 171.6900024 100 90.04000092 100 0.112595776 7.90E-02 3
 ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 11 826.0499268 100 121.3399963 100 0.109795835 5.04E-02 12
 ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 12 865.0800171 100 112.6500015 100 0.109708808 0.10960813 16
 GSTA2 Glutathione S-transferase A2 IPI00745233 29104 8.51 8 439.5299683 100 84.43000031 100 0.105112377 0.13296491 9
 ADH1C Alcohol dehydrogenase 1C IPI00465343 45428 8.63 7 533.5999756 100 121.3399963 100 9.83E-02 4.07E-02 8
 RDH16 Retinol dehydrogenase 16 IPI00289551 38852.73828 8.83 4 219.2744446 100 69.81999969 99.99905271 9.14E-02 6.35E-02 4
 CES1 carboxylesterase 1 isoform c precursor IPI00607693 68199.60938 6.15 20 1418.180054 100 199.9900055 100 8.93E-02 0.10970959 21
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NAP1L1 43 kDa protein IPI00789029 47959.44141 4.45 1 81.54000092 99.99993625 81.54000092 99.99993625 5.354643197 0 1
S100P Protein S100-P IPI00017526 12023.44043 4.75 1 101.6399994 100 101.6399994 100 5.317678828 0 1
DEFA3 Neutrophil defensin 3 precursor IPI00021827 10946.21973 5.71 2 79.36999512 99.99989493 42.93000031 99.53710435 4.761464395 0.359685876 2
AKR1B10 Aldo-keto reductase family 1 
member B10 IPI00105407 41078.28125 7.12 1 88.87000275 100 88.87000275 100 4.072898589 0 1
SCAMP3 Isoform 2 of Secretory carrier-
associated membrane protein 3 IPI00306383 37073.82813 7.53 1 74.31999969 99.99966389 74.31999969 99.99966389 3.61504749 0 1
FKBP11 Peptidyl-prolyl cis-trans isomerase IPI00789642 11840.12988 4.57 1 75.73999786 99.99975763 75.73999786 99.99975763 3.544819338 0 1
RAN 26 kDa protein IPI00792352 29358.91016 8.51 3 148.1800079 100 65.41000366 99.99738493 3.003883752 1.305086144 3
S100A9 Protein S100-A9 IPI00027462 15007.73047 5.71 6 494.4100037 100 132.7700043 100 2.998110678 0.532129617 7
HNRPA1 Isoform A1-A of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00465365 37003.55078 9.27 6 422.5299683 100 136.6399994 100 2.986286635 1.354563121 6
EEA1 Early endosome antigen 1 IPI00329536 188351.2031 5.53 1 85.29000092 100 85.29000092 100 2.966948037 0 1
CKAP4 CKAP4 protein (Fragment) IPI00433214 72955.86719 9.34 7 489.9144287 100 113.2300034 100 2.901862073 0.896562266 7
ANXA5 Annexin A5 IPI00329801 39272.76172 4.94 11 673.6500244 100 106.3700027 100 2.824878454 0.84201029 12
ARHGDIA 9 kDa protein IPI00791180 10974.86035 6.73 1 67.66999817 99.99844588 67.66999817 99.99844588 2.771813654 0 1
RBM8A Isoform 2 of RNA-binding protein 8A IPI00216659 21665.92969 5.64 1 110.5999985 100 110.5999985 100 2.642653515 0 1
SFPQ Isoform Long of Splicing factor, proline- 
and glutamine-rich IPI00010740 81090.10938 9.45 3 132.9244385 100 59.66999817 99.99019419 2.592366193 0.689945158 3
SEC22B Vesicle-trafficking protein SEC22b IPI00006865 27022.99023 8.67 1 80.02999878 99.99990974 80.02999878 99.99990974 2.520517846 0 1
MPO Isoform H14 of Myeloperoxidase 
precursor IPI00236554 77088.74219 9.3 5 226.0499878 100 60.97000122 99.99273086 2.510180608 0.326251497 5
S100A8 Protein S100-A8 IPI00007047 12745.88965 6.51 7 387.7444458 100 89.33999634 100 2.475471766 0.325446586 7
PARP1 Poly [ADP-ribose] polymerase 1 IPI00449049 131945.8906 8.99 2 112.7200012 100 61.18999863 99.99308992 2.46580716 0.182159232 2
TAGLN2 24 kDa protein IPI00647915 26448.48047 8.41 5 371.7800293 100 109.5999985 100 2.4064876 0.873876626 5
HNRPU heterogeneous nuclear 
ribonucleoprotein U isoform a IPI00644079 101350.8203 5.76 2 139.6900024 100 95.94999695 100 2.40615783 0.378173495 2
RBP4 Retinol binding protein 4, plasma IPI00480192 24933.30078 5.77 1 74.86000061 99.99970319 74.86000061 99.99970319 2.284951446 0 1
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HNRPR HNRPR protein IPI00644055 77880.99219 8.23 1 69.23000336 99.99891487 69.23000336 99.99891487 2.279460467 0 1
LTF 73 kDa protein IPI00789477 80974.52344 8.2 5 280.190033 100 96.54000092 100 2.25547026 0.954917033 5
HNRPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 IPI00419373 42922.89844 9.1 4 315.1900024 100 130.0800018 100 2.242980749 0.877849304 4
XRCC6 70 kDa protein IPI00465430 78696.84375 6.23 1 75.5 99.99974386 75.5 99.99974386 2.205478373 0 1
NME1;NME2 Nucleoside diphosphate kinase IPI00604590 36163.17969 8.7 6 297.3177795 100 84.93000031 100 2.189905327 0.118405016 7
LRPPRC Leucine-rich PPR motif-containing 
protein IPI00783271 173604.2344 5.81 3 131.5700073 100 52.22000122 99.94548914 2.187649552 0.290160215 3
NUMA1 Isoform 1 of Nuclear mitotic apparatus 
protein 1 IPI00292771 260878.9688 5.63 1 62.68999863 99.99510804 62.68999863 99.99510804 2.182246513 0 1
DAZAP1 Isoform 2 of DAZ-associated protein 1 IPI00335930 43470.07813 8.48 1 64.5 99.99677535 64.5 99.99677535 2.158285207 0 1
CYCS Cytochrome c IPI00465315 14569.42969 9.59 3 129.1799927 100 50.18999863 99.91300721 2.123067506 0.26490132 3
- CD68 antigen variant (Fragment) IPI00555602 45637.91016 5.46 7 506.2999573 100 110.8199997 100 2.120582746 0.61767021 7
HNRPM Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein M IPI00383296 79706.89844 8.94 3 202.4100037 100 80.76000214 99.99992371 2.119396315 0.3389737 3
TES Isoform 2 of Testin IPI00216425 54398.51953 7.82 1 62.75 99.99517516 62.75 99.99517516 2.115683377 0 1
CLTC Isoform 2 of Clathrin heavy chain 1 IPI00455383 203165.7031 5.48 7 374.2944336 100 72.31999969 99.9994673 2.106781071 0.573316338 7
TUBA1B Similar to Tubulin alpha-ubiquitous 
chain IPI00792677 49578.05859 4.96 11 909.7099609 100 189.2799988 100 2.092644192 0.829464211 11
HNRPD Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein D0 IPI00028888 43300.76953 7.62 1 61.63000107 99.99375571 61.63000107 99.99375571 2.091512352 0 1
EIF4A2 Isoform 2 of Eukaryotic initiation factor 
4A-II IPI00409717 49956.14063 5.33 5 368.4299927 100 110.8199997 100 2.079646316 0.510422696 5
hCG_1983058 hypothetical protein LOC644820 IPI00414723 28320.82031 4.59 2 72.51000214 99.9994901 41.93000031 99.4172489 2.076934051 1.55E-02 2
EIF4G3 Isoform 1 of Eukaryotic translation 
initiation factor 4 gamma 3 IPI00646377 194311.3594 5.27 2 77.37999725 99.99983386 42.93999863 99.5381688 2.072207842 0.875534986 2
EIF4G1 eukaryotic translation initiation factor 4 
gamma, 1 isoform 2 IPI00384463 180908.9531 5.15 2 77.37999725 99.99983386 42.93999863 99.5381688 2.072207842 0.875534986 2
COPB1 Coatomer subunit beta IPI00295851 118074.4609 5.72 2 144.9900055 100 111.3700027 100 2.054938643 0.548451994 2
DDAH1 NG,NG-dimethylarginine 
dimethylaminohydrolase 1 IPI00220342 34258.19922 5.53 2 108.3199997 100 58.36999893 99.98677233 2.036326279 0.469373286 2
SARS Seryl-tRNA synthetase IPI00514587 68889.0625 6.64 2 76.16000366 99.99977997 43.29000092 99.57392796 2.035821991 2.80E-03 2
TUBA1C Tubulin alpha-1C chain IPI00218343 53295.64844 4.96 11 902.5899658 100 189.2799988 100 2.030883346 0.770038495 11
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DHX9 ATP-dependent RNA helicase A IPI00844578 151431.7344 6.41 2 125.0699997 100 84.93000031 100 2.022986036 1.30E-02 2
LDHA Isoform 1 of L-lactate dehydrogenase A 
chain IPI00217966 41071.75 8.44 11 548.0044556 100 90.72000122 100 1.99727102 0.602474115 13
HNRPA2B1 Isoform A2 of Heterogeneous 
nuclear ribonucleoproteins A2/B1 IPI00414696 38478.16016 8.67 9 617.2045288 100 98.65000153 100 1.994613346 0.633092389 9
ILF3 Isoform 1 of Interleukin enhancer-binding 
factor 3 IPI00298788 105105.8906 8.86 1 60.95999908 99.9927141 60.95999908 99.9927141 1.993276852 0 1
HSPA5 HSPA5 protein IPI00003362 81398.29688 5.07 25 1999.231445 100 163.1699982 100 1.966795338 0.62805506 26
PSAT1 Isoform 2 of Phosphoserine 
aminotransferase IPI00219478 38754.37109 6.23 2 113.6800003 100 70.63999939 99.9992157 1.960626787 6.97E-02 2
EPRS glutamyl-prolyl tRNA synthetase IPI00013452 193228.6875 7.02 1 84.54000092 100 84.54000092 100 1.959573623 0 1
ITGB1 integrin beta 1 isoform 1A precursor IPI00645194 99377.10938 5.27 2 127.6600037 100 72.98000336 99.9995424 1.958134986 9.89E-02 2
P4HB Protein disulfide-isomerase precursor IPI00010796 64315.26953 4.76 25 1679.800049 100 108.0100021 100 1.946705062 0.319952397 29
SFRS6 Isoform SRP55-1 of Splicing factor, 
arginine/serine-rich 6 IPI00012345 43543.78906 11.42 1 62.56999969 99.99497098 62.56999969 99.99497098 1.943484679 0 1
ENO2 6 kDa protein IPI00790892 6040.029785 4.89 2 132.8199921 100 69.55999756 99.99899427 1.935503011 5.15E-02 2
PPIA;PPIAL3;LOC654188 Peptidyl-prolyl cis-
trans isomerase A IPI00419585 20345.10938 7.68 8 570.9000244 100 112.1900024 100 1.925110441 0.367401906 10
- Tubulin alpha-4 chain IPI00017454 29152.96094 8.65 2 131.2900085 100 81.88999939 99.99994119 1.916505669 1.443911136 2
ENO1 Isoform alpha-enolase of Alpha-enolase IPI00465248 53031.82031 7.01 13 858.4200439 100 103.6800003 100 1.9000646 0.473431618 13
SRP14 8 kDa protein IPI00789296 8752.330078 10.03 1 72.80999756 99.99952414 72.80999756 99.99952414 1.899110243 0 1
CS citrate synthase precursor, isoform b IPI00383539 50469.26172 6.74 3 103.6500015 100 41.40000153 99.34161038 1.893221318 0.124340257 3
LSM8 U6 snRNA-associated Sm-like protein 
LSm8 IPI00219871 10684.41016 4.34 1 110.9000015 100 110.9000015 100 1.890253636 0 1
LOC388720 similar to ubiquitin and ribosomal 
protein S27a precursor IPI00397808 21877.69922 9.53 5 241.3300018 100 71.72000122 99.99938838 1.87694711 0.213333592 5
TUBB Tubulin beta chain IPI00011654 52311.16016 4.78 11 868.8900146 100 137.6199951 100 1.87335447 0.571129605 12
C20orf77 Uncharacterized protein C20orf77 IPI00009659 41289.62109 5.73 1 105 100 105 100 1.855604572 0 1
HSP90AB4P Heat shock protein 90Bd IPI00555565 66222.17969 4.65 4 185.1100006 100 65.5 99.99743857 1.854476561 0.294067525 4
HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 94433.0625 4.97 16 937.8744507 100 123.5299988 100 1.839153005 1.318642652 16
CSTB Cystatin-B IPI00021828 12618.79004 6.96 3 174.1700134 100 80.15000153 99.9999122 1.837122264 7.02E-02 3
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LOC388474 similar to 60S ribosomal protein 
L7a isoform 1 IPI00397676 35921.55078 10.56 2 110.7600021 100 65.65000153 99.99752553 1.817207124 0.212218164 2
TUBB2A Tubulin beta-2A chain IPI00013475 52501.16016 4.78 10 789.3699951 100 137.6199951 100 1.814744718 0.524667615 10
RPS5 40S ribosomal protein S5 IPI00008433 25448.32031 9.73 1 131.6699982 100 131.6699982 100 1.813192824 0 1
RAD23B UV excision repair protein RAD23 
homolog B IPI00008223 46214.96094 4.79 2 83.91999817 100 43.49000168 99.59310443 1.808907296 1.21E-02 2
LONP1 Lon protease homolog IPI00334291 109879.3125 6.11 1 60.88000107 99.99257865 60.88000107 99.99257865 1.786388827 0 1
MARCKS Myristoylated alanine-rich C-kinase 
substrate IPI00219301 35850.28125 4.47 1 55.40000153 99.97378904 55.40000153 99.97378904 1.780808675 0.100002788 2
C20orf3 47 kDa protein IPI00479431 49085.10938 5.82 3 150.3199921 100 73.56999969 99.99960053 1.777626703 0.446750574 3
SND1 Staphylococcal nuclease domain-
containing protein 1 IPI00140420 110982.1797 6.74 2 177.9400024 100 99.43000031 100 1.71628826 2.76E-02 2
APOE Apolipoprotein E precursor IPI00021842 38239.98828 5.65 6 311.9599915 100 94.48999786 100 1.711130757 0.434253868 6
PDIA4 Protein IPI00852792 21271.91992 8.33 7 387.1300049 100 96.79000092 100 1.709198577 0.377748314 8
HYOU1 Hypoxia up-regulated protein 1 
precursor IPI00000877 122683.2188 5.16 5 346.3800049 100 110.9400024 100 1.708469378 0.815761529 6
HNRPH1 HNRPH1 protein IPI00479191 53875.41016 6.33 4 242.1444397 100 98.52999878 100 1.695461744 0.630332634 5
- Elongation factor 1-alpha IPI00472724 57485.78125 9.15 11 619.9900513 100 98.19999695 100 1.688901052 0.84945531 11
LYZ Lysozyme C precursor IPI00019038 17902.35938 9.38 1 100.2799988 100 100.2799988 100 1.669624579 0 1
RAB10 Ras-related protein Rab-10 IPI00016513 25878.90039 8.59 2 116.5700073 100 66.44000244 99.99793708 1.659837945 0.126950874 2
PFKL Liver phosphofructokinase isoform a 
variant (Fragment) IPI00742657 47091.33984 9.06 1 60.79000092 99.99242325 60.79000092 99.99242325 1.659551898 0 1
HIST1H1B Histone H1.5 IPI00217468 32071.38086 10.91 1 82.69000244 100 82.69000244 100 1.64856673 0 1
RPS9 40S ribosomal protein S9 IPI00221088 25503.88086 10.66 3 100.0800018 100 34.77000046 96.96971774 1.643004363 0.183503678 3
GPI Glucose-6-phosphate isomerase IPI00027497 68475.72656 8.43 5 259.0899963 100 81.62999725 99.99993756 1.641240897 0.153891773 5
FASN Fatty acid synthase IPI00847250 287598.7813 5.99 14 714.7844238 100 77.76999664 99.99984813 1.63888755 0.304767695 14
TUBB2C Tubulin beta-2C chain IPI00007752 52471.19141 4.79 11 856.9400024 100 137.6199951 100 1.632882526 0.651222757 12
CCT6A T-complex protein 1 subunit zeta IPI00027626 64980.16016 6.23 3 191.0099945 100 72.08999634 99.99943833 1.628877859 0.255626833 3
GC Vitamin D-binding protein precursor IPI00555812 60697.32813 5.4 4 176.934433 100 54.16999817 99.96520769 1.627865453 0.308354931 4
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RPS15A 40S ribosomal protein S15a IPI00221091 16650.17969 10.14 4 149.6844482 100 42.88999939 99.53282113 1.61580032 0.272314813 4
RPL3 60S ribosomal protein L3 IPI00550021 54518.5 10.19 2 99.88444519 100 50.97999954 99.92747576 1.612407395 0.191695111 2
CAP1 Adenylyl cyclase-associated protein IPI00639931 58646.21094 8.24 3 171.0299988 100 64.97000122 99.9971061 1.598967726 0.239726056 3
CALR 37 kDa protein IPI00793605 41138.14063 4.55 7 513.4699707 100 99.38999939 100 1.597592202 0.137498178 8
TUBB3 Tubulin beta-3 chain IPI00013683 53216.46094 4.83 6 471.5099792 100 137.6199951 100 1.596939579 0.225825373 6
NCL Isoform 1 of Nucleolin IPI00604620 89719.57031 4.6 7 396.3299866 100 98.73000336 100 1.59185754 0.424921781 7
HNRPK Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein K IPI00216746 54394.67969 5.19 5 290.8244324 100 93.43000031 100 1.588317145 0.162778656 5
TXNDC5;MUTED thioredoxin domain 
containing 5 isoform 2 IPI00395646 48461.78125 5.77 6 240.6944427 100 57.52999878 99.9839497 1.583554625 0.323926433 7
PFN1 Profilin-1 IPI00216691 16766.75 8.44 4 269.7099915 100 117.1699982 100 1.580040166 0.26219137 5
PSMC2 26S protease regulatory subunit 7 IPI00021435 53677.53125 5.71 2 97.81999969 100 51.79000092 99.93981572 1.570870957 0.231666377 2
STAT3 Isoform Del-701 of Signal transducer 
and activator of transcription 3 IPI00306436 95480.85938 5.94 1 64.27999878 99.99660779 64.27999878 99.99660779 1.569566327 0 1
CTSD Protein IPI00853455 44335.46875 5.38 9 580.4544678 100 108.7099991 100 1.569380693 0.200497204 9
YWHAQ 14-3-3 protein theta IPI00018146 30857.03906 4.68 5 286.6499939 100 84.48000336 100 1.561350857 0.608100336 5
PRKCSH Glucosidase 2 beta subunit precursor IPI00792916 64937.07813 4.34 9 435.9844055 100 72.43000031 99.99948062 1.560139601 0.320582418 10
EIF3S7 Eukaryotic translation initiation factor 3 
subunit 7 IPI00006181 70198.88281 5.79 1 62.22999954 99.99456145 62.22999954 99.99456145 1.555932008 0 1
GANAB Isoform 3 of Neutral alpha-glucosidase 
AB precursor IPI00441414 99842.15625 5.43 3 265.9700012 100 108.1100006 100 1.550318632 0.522184336 4
SEC31A Isoform 4 of Protein transport protein 
Sec31A IPI00515103 138953.7344 7.03 3 202.0288849 100 108.2099991 100 1.545340341 0.252672722 3
GDI2 GDP dissociation inhibitor 2 IPI00640006 50710.62109 5.91 3 175.6344452 100 97.18000031 100 1.5424086 0.235571788 3
HSPA8 Isoform 1 of Heat shock cognate 71 
kDa protein IPI00003865 78958.95313 5.37 19 1172.518921 100 118.0299988 100 1.541065312 0.21576387 20
SURF4 Surfeit 4 IPI00399142 22555.05078 8.88 1 84.88999939 100 84.88999939 100 1.540865597 0 1
GAPDH 32 kDa protein IPI00795257 35122.30859 7.15 9 681.6244507 100 125.5100021 100 1.53930271 0.595740077 11
SET Isoform 2 of Protein SET IPI00301311 35108.05859 4.12 2 114.6800003 100 73.90000153 99.99962976 1.524080431 4.14E-02 2
PGD 53 kDa protein IPI00747533 59047.51953 7.12 2 91.66000366 100 56.13999939 99.97789537 1.52325366 9.13E-02 2
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YWHAB Isoform Short of 14-3-3 protein 
beta/alpha IPI00759832 30949.07031 4.76 5 287.6699829 100 85.5 100 1.510829485 0.537411494 5
- 140 kDa protein IPI00829641 149651.875 7.92 3 160.5400085 100 83.95999908 100 1.510815775 0.14537548 3
RPLP0 60S acidic ribosomal protein P0 IPI00556485 30148.58984 8.36 3 186.7600098 100 102.8300018 100 1.509692828 0.124209406 3
LOC440055 similar to ribosomal protein S12 IPI00456898 17312.76953 6.43 3 182.2700043 100 68.05000305 99.99857609 1.509452355 0.18685234 3
RPS3 40S ribosomal protein S3 IPI00011253 29833.74023 9.68 2 107.6399994 100 63.56999969 99.99600531 1.507156687 0.174513325 2
ORM1 Alpha-1-acid glycoprotein 1 precursor IPI00022429 25840.99023 4.93 3 165.4900055 100 74.91000366 99.99970658 1.501298763 0.264231189 3
FN1 fibronectin 1 isoform 2 preproprotein IPI00845263 280315.25 5.36 12 578.178833 100 63.74000168 99.99615866 1.499239492 0.383193625 12
CALR Protein IPI00794237 19298.58008 4.47 2 151.3444366 100 97.84999847 100 1.498239066 5.39E-02 3
EEF1G 50 kDa protein IPI00747497 55012.55859 6.27 7 327.4299927 100 93.30000305 100 1.495115515 0.547996924 7
BID Isoform 2 of BH3-interacting domain death 
agonist IPI00420084 27815.5 6.6 1 63.70000076 99.99612311 63.70000076 99.99612311 1.492463399 0 1
SERPINA1 Alpha-1-antitrypsin precursor IPI00553177 51885.51172 5.37 8 536.2144775 100 93.48000336 100 1.492236018 0.207381492 9
HSP90B1 Endoplasmin precursor IPI00027230 104018.3516 4.76 23 1253.778809 100 113.8899994 100 1.492211687 0.430570974 24
HDGF Hepatoma-derived growth factor IPI00020956 30896.2793 4.7 2 76.26443481 99.9997852 41.29999924 99.32627416 1.489978144 0.235668789 2
PDIA6 Isoform 1 of Protein disulfide-isomerase 
A6 precursor IPI00644989 52733.64063 4.95 6 340.7799683 100 97.93000031 100 1.487506845 0.22211049 6
MIF 12 kDa protein IPI00790382 12661.19043 9.3 2 86.61999512 100 43.47999954 99.59216624 1.483382004 0.238005632 2
PRKDC Isoform 2 of DNA-dependent protein 
kinase catalytic subunit IPI00376215 508806.4375 6.81 1 89.05999756 100 89.05999756 100 1.479186639 0 1
CFL1 24 kDa protein IPI00784459 28091.64063 8.13 3 175.7799988 100 79.68000031 99.99990217 1.47892307 0.269690981 4
EIF5 Eukaryotic translation initiation factor 5 IPI00022648 56760.42188 5.41 1 75.93000031 99.999768 75.93000031 99.999768 1.475069702 0 1
KPNB1 Importin subunit beta-1 IPI00001639 104502.3672 4.68 2 109.4100037 100 73.15000153 99.99955997 1.474064583 0.180898279 2
HSP90AA1 Isoform 1 of Heat shock protein 
HSP 90-alpha IPI00784295 96593.6875 4.94 17 962.3700562 100 115.0800018 100 1.469523391 0.734101106 17
FDPS Farnesyl diphosphate synthase IPI00101405 51970.89063 5.83 4 248.4599915 100 95.16000366 100 1.46149936 7.53E-02 4
- Farnesyl pyrophosphate synthetase like-4 
protein (Fragment) IPI00382869 42840.89844 4.87 4 193.3499908 100 64.5 99.99677535 1.46149936 7.53E-02 4
FAM10A5 Protein FAM10A5 IPI00168839 46431.76172 4.96 2 129.6300049 100 75.08000183 99.99971785 1.461395612 6.15E-02 2
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- RET tyrosine kinase/cAMP protein kinase A 
subunit RI (Fragment) IPI00783751 72900.52344 5.87 2 90.06999969 100 56.72000122 99.98065882 1.459964263 0.256432855 2
ATIC Bifunctional purine biosynthesis protein 
PURH IPI00289499 70461.78906 6.27 1 68.58999634 99.99874257 68.58999634 99.99874257 1.438550707 0 1
LRP1 Low-density lipoprotein receptor-related 
protein 1 precursor IPI00020557 544525 5.16 1 71.43000031 99.99934614 71.43000031 99.99934614 1.438001461 0 1
- CALRETICULIN=CALCIUM binding protein 
(Fragment) IPI00383751 26354.40039 4.45 5 336.7299805 100 99.38999939 100 1.43744184 0.19821875 7
PDIA4 Protein disulfide-isomerase A4 
precursor IPI00009904 82667.8125 4.96 13 713.0912476 100 96.79000092 100 1.436581845 0.643184275 15
VDAC2 Isoform 2 of Voltage-dependent anion-
selective channel protein 2 IPI00216024 39125.44922 5.87 2 84.83999634 100 51.18000031 99.9307399 1.432002983 0.612792332 2
M6PRBP1 Isoform B of Mannose-6-phosphate 
receptor-binding protein 1 IPI00303882 50756.28125 5.3 2 118.1600037 100 75.11000061 99.99971979 1.425627801 0.213560741 2
CAPZB Capping protein (Actin filament) muscle 
Z-line, beta IPI00642256 32963.14844 6.45 1 66.66999817 99.99804348 66.66999817 99.99804348 1.423427359 0 1
TMED9 transmembrane emp24 protein 
transport domain containing 9 IPI00023542 29224.41992 7.82 3 109.7099915 100 41.50999832 99.35807647 1.422583049 4.87E-03 3
CCT8 T-complex protein 1 subunit theta IPI00784090 66090.99219 5.42 3 201.7700043 100 77.19000244 99.99982643 1.422271188 0.225009563 3
RPLP2 60S acidic ribosomal protein P2 IPI00008529 13242.07031 4.42 1 112.5800018 100 112.5800018 100 1.422132858 0 1
EEF2 Elongation factor 2 IPI00186290 105563.6484 6.41 9 569.8599854 100 92.70999908 100 1.4102872 0.26325213 9
DBI Isoform 2 of Acyl-CoA-binding protein IPI00218836 13802.13965 5.41 4 343.3599854 100 130.8300018 100 1.405868777 0.160507474 4
RPN1 Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 67 kDa IPI00025874 78729.54688 5.87 8 400.3912354 100 73.27999878 99.99957295 1.405252219 0.385162086 8
FLNA Filamin-A IPI00333541 305957.375 5.7 4 183.8144531 100 78.55000305 99.99987309 0.699398995 0.158874634 4
DDT D-dopachrome decarboxylase IPI00293867 13515.79004 6.71 4 227.5544586 100 85.11000061 100 0.696049978 0.115019818 5
ASL 50 kDa protein IPI00514772 52806.57031 5.99 4 213.9500122 100 100.5699997 100 0.69178872 0.473434891 4
MCCC2 Isoform 2 of Methylcrotonoyl-CoA 
carboxylase beta chain, mitochondria IPI00789428 61882.76172 7.59 2 93.05999756 100 57.93000031 99.98536195 0.689434694 0.392611367 2
TXNL5 11 kDa protein IPI00789285 12574.73047 5.18 1 93.70999908 100 93.70999908 100 0.685448616 0 1
AIFM1 Isoform 3 of Apoptosis-inducing factor 1, 
mitochondrial precursor IPI00157908 72532.10938 9.03 3 201.6999969 100 84.58000183 100 0.684649078 0.174312807 3
ALDH4A1 Aldehyde dehydrogenase 4 family, 
member A1 IPI00647328 65056.12109 7.62 11 583.0700073 100 90.26000214 100 0.680127339 9.97E-02 11
HP Haptoglobin precursor IPI00641737 52573.75 6.28 9 624.9700317 100 123.5400009 100 0.67203124 0.178701202 9
AKR1A1 Alcohol dehydrogenase IPI00220271 39850.12891 6.32 7 365.5299988 100 75.26000214 99.9997293 0.671375591 0.240575306 7
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SORBS2 sorbin and SH3 domain containing 2 
isoform 2 IPI00477577 135030.8438 8.56 2 95.86999512 100 49.09000015 99.88793161 0.64739897 0.102807777 2
PAH Phenylalanine-4-hydroxylase IPI00017579 56707.82031 6.15 3 108.75 100 42.02999878 99.43051374 0.642642069 2.24E-02 3
ARHGDIB 13 kDa protein IPI00791712 14875.75977 4.69 1 115.5199966 100 115.5199966 100 0.642058364 0 1
VIM Vimentin IPI00418471 56977.44141 5.06 19 1256.898926 100 125.4199982 100 0.641902248 0.206891731 20
KRT2 Keratin, type II cytoskeletal 2 epidermal IPI00021304 71239.86719 8.07 4 220.1000061 100 94.55000305 100 0.635602963 0.563268236 5
MAOA Amine oxidase [flavin-containing] A IPI00008483 65674.00781 7.94 2 124.6600037 100 76.56999969 99.99979979 0.633912676 2.32E-02 2
ALDH1B1 Aldehyde dehydrogenase X, 
mitochondrial precursor IPI00103467 62178.58984 6.36 4 218.4100037 100 85.26000214 100 0.631783746 0.296810081 4
MMAB 19 kDa protein IPI00789857 20551.83008 8.35 1 79.16000366 99.99988972 79.16000366 99.99988972 0.63010828 0 1
GLUD1 Glutamate dehydrogenase 1, 
mitochondrial precursor IPI00016801 66531.63281 7.66 18 1232.970093 100 136.3500061 100 0.627133187 0.104454304 18
ACADVL Isoform 2 of Very-long-chain specific 
acyl-CoA dehydrogenase, mitoch IPI00178744 78527.97656 9.06 1 62.61999893 99.99502855 62.61999893 99.99502855 0.619817358 0 1
GBE1 1,4-alpha-glucan-branching enzyme IPI00296635 85817.03906 5.87 2 116.2600021 100 84.94000244 100 0.618293376 0.10896935 2
ARG1 Isoform 2 of Arginase-1 IPI00398768 39380.19922 6.72 5 296.6099854 100 90.51999664 100 0.617329262 0.192660305 5
AKR1C3 Aldo-keto reductase family 1 member 
C3 IPI00291483 41031.17969 8.05 8 375.8299866 100 75.91000366 99.99976693 0.616212367 0.17179649 8
ANXA6 Annexin A6 IPI00221226 83734.25 5.42 19 1154.843384 100 125.3199997 100 0.612825679 0.152475461 20
SDHA Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondri IPI00305166 77793.53125 7.06 5 286.25 100 84.20999908 100 0.61243749 7.93E-02 5
NAPRT1 Nicotinate phosphoribosyltransferase 
domain-containing protein 1 IPI00465085 61989.39063 5.59 2 118.5999908 100 65.83999634 99.99763144 0.610857743 0.136315684 2
DCI Isoform 2 of 3,2-trans-enoyl-CoA 
isomerase, mitochondrial precursor IPI00398758 32932.46875 9.07 2 150.519989 100 102.9199982 100 0.607878019 1.15E-02 2
HADHA Trifunctional enzyme subunit alpha, 
mitochondrial precursor IPI00031522 93913.70313 9.16 13 831.9099731 100 136.2899933 100 0.604611258 0.261755907 13
ACAT1 Acetyl-CoA acetyltransferase, 
mitochondrial precursor IPI00030363 49865.05859 8.98 12 863.3612061 100 137.1499939 100 0.60265697 0.143350807 12
COX4I1 COX4I1 protein IPI00645361 10672.90039 8.64 1 86.23999786 100 86.23999786 100 0.602129338 0 1
METTL7A Methyltransferase-like protein 7A 
precursor IPI00022300 30730.71094 8.7 1 80.56999969 99.9999203 80.56999969 99.9999203 0.597430611 0 1
ALDOC Fructose-bisphosphate aldolase C IPI00418262 42921.51172 6.41 4 230.3299866 100 93.37999725 100 0.591407925 1.070476818 5
UGP2 Isoform 1 of UTP--glucose-1-phosphate 
uridylyltransferase IPI00329331 63091.28906 8.16 11 732.9788818 100 138 100 0.589549727 0.104834218 11
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IDH2 Isocitrate dehydrogenase [NADP], 
mitochondrial precursor IPI00011107 56573.30859 8.88 9 502.694458 100 96.40000153 100 0.589263617 0.175067944 9
PGM1 Phosphoglucomutase 1 IPI00844159 66935.90625 6.2 3 219.4700012 100 99.80999756 100 0.583059496 0.222870736 3
ANXA6 annexin VI isoform 2 IPI00002459 83137.89844 5.46 19 1164.003418 100 125.3199997 100 0.582043817 0.229554722 20
CNDP2 53 kDa protein IPI00646632 58467.37891 5.66 3 151.1600037 100 80.83999634 99.9999251 0.579371507 0.161196563 4
CGN cingulin IPI00844508 149111.4844 5.44 1 105.4199982 100 105.4199982 100 0.57828691 0 1
PGLS 6-phosphogluconolactonase IPI00029997 29055.68945 5.7 2 74.86999512 99.99970387 43.54999924 99.59868702 0.576151804 0.179124685 2
ALDH2 Mitochondrial aldehyde dehydrogenase 
2 variant (Fragment) IPI00792207 61065.96094 6.63 13 856.2000122 100 106.4499969 100 0.574772081 0.230323784 14
SUCLG1 succinate-CoA ligase, GDP-forming, 
alpha subunit IPI00759493 39717.12109 9.01 2 201.1100006 100 123.6500015 100 0.573125393 0.29745233 2
CRYZ 32 kDa protein IPI00647366 34670.82031 8.59 3 265.25 100 146.3999939 100 0.571814032 6.74E-02 3
HADHB Trifunctional enzyme beta subunit, 
mitochondrial precursor IPI00022793 56777.03906 9.45 6 315.1699829 100 81.19999695 99.99993106 0.56968467 0.166928956 6
ESD 28 kDa protein IPI00641040 31266.09961 6.29 2 101.8099976 100 53.38000107 99.95826667 0.566424147 0.142422804 2
ACSL1 Isoform 1 of Long-chain-fatty-acid--CoA 
ligase 1 IPI00012728 85201.29688 6.81 9 591.6699829 100 121.4400024 100 0.564200237 0.141639832 9
- 105 kDa protein IPI00794900 115433.2422 7.3 8 417.8933411 100 89.48000336 100 0.56145444 0.204001489 8
NDUFAB1 Acyl carrier protein, mitochondrial 
precursor IPI00022442 18696.14063 4.82 2 76.83999634 99.99981186 42.20999908 99.45363456 0.554531494 9.98E-03 2
COMT Isoform Soluble of Catechol O-
methyltransferase IPI00375513 26915.57031 5.15 2 143.4600067 100 84.76000214 100 0.553326228 0.104972487 2
SELENBP1 53 kDa protein IPI00745729 57664.26953 6.03 3 126.8199921 100 50.59000015 99.92066166 0.54588442 0.289257114 4
LAP3 Isoform 2 of Cytosol aminopeptidase IPI00789806 58388.32813 6.3 7 411.1499939 100 94.19999695 100 0.544348643 0.336521206 7
LTB4DH NADP-dependent leukotriene B4 12-
hydroxydehydrogenase IPI00292657 40639.17188 8.45 3 185.1399994 100 117.6699982 100 0.535863243 5.67E-02 3
ALDH9A1 aldehyde dehydrogenase 9A1 IPI00479877 61023.67188 6.23 1 94.34999847 100 94.34999847 100 0.53357937 0 1
AKR1C2 Aldo-keto reductase family 1 member 
C2 IPI00005668 40922.30078 7.13 7 332.8800049 100 67.13999939 99.99824417 0.530903107 0.134311606 7
LOC648517 similar to Aldo-keto reductase 
family 1 member C1 (20-alpha-hydro IPI00736657 35442.78906 9.01 8 367.0599976 100 67.13999939 99.99824417 0.528947893 0.130105789 8
ETFA 24 kDa protein IPI00792673 27117.09961 8.77 3 323.25 100 171.9499969 100 0.528755589 0.114205111 3
SNTB1 Isoform 2 of Beta-1-syntrophin IPI00216858 44616.67188 9.13 1 75.76000214 99.99975874 75.76000214 99.99975874 0.522803241 0 1
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AKR1C4 Aldo-keto reductase family 1 member 
C4 IPI00289524 41137.30859 6.71 9 401.6599731 100 58.08000183 99.98585891 0.515276088 0.15069302 9
PC Pyruvate carboxylase, mitochondrial 
precursor IPI00299402 138358.0469 6.37 10 617.9589233 100 111.5699997 100 0.510588816 0.155875148 10
KRT6C Keratin, type II cytoskeletal 6E IPI00299145 64682.71875 8.09 5 238.7044373 100 72.30999756 99.99946607 0.505240398 0.202748378 9
CTSB Cathepsin B precursor IPI00295741 40882.91016 5.88 3 216.3999939 100 106.6100006 100 0.505002674 8.41E-02 3
IL11RA 13 kDa protein IPI00167641 14096.79004 7.79 1 71.41000366 99.99934312 71.41000366 99.99934312 0.501627318 0 1
SCP2 sterol carrier protein 2 isoform 2 IPI00433347 61608.94141 6.25 6 310.5844421 100 81.47000122 99.99993521 0.500933381 3.89E-02 6
GOT1 Aspartate aminotransferase, cytoplasmic IPI00219029 49570.83984 6.52 7 378.1199951 100 119.7099991 100 0.498134227 0.171622573 7
UNQ501 MBC3205 IPI00063130 22277.99023 8.91 1 76.41000366 99.99979228 76.41000366 99.99979228 0.49727244 0 1
ABCD3 ABCD3 protein IPI00185503 68716.28906 9.31 1 88.08000183 100 88.08000183 100 0.493585779 0 1
KHK Isoform C of Ketohexokinase IPI00216136 35220.62891 5.91 2 70.70999908 99.99922824 38.38999939 98.68331105 0.491911487 0.61627863 2
ALDH1A1 Retinal dehydrogenase 1 IPI00218914 60949.39063 6.3 12 713.7700195 100 116.6299973 100 0.487870292 9.44E-02 12
BAAT Bile acid CoA:amino acid N-
acyltransferase IPI00017819 48856.32031 6.49 2 116.8099976 100 76.13999939 99.99977895 0.487615183 0.170457772 2
BLVRB Flavin reductase IPI00783862 23637.61914 7.13 2 88.80000305 100 45.20000076 99.72553748 0.485188997 7.15E-02 2
CPT2 Carnitine O-palmitoyltransferase 2, 
mitochondrial precursor IPI00012912 79760.85938 8.38 2 125.5344391 100 90.81999969 100 0.484234609 2.61E-02 2
APOC3 13 kDa protein IPI00657670 13861.62012 7.9 1 87.90000153 100 87.90000153 100 0.481672593 0 1
H1F0 Histone H1.0 IPI00550239 29058.99023 10.84 1 83.52999878 100 83.52999878 100 0.477712143 0 1
GATM Isoform Cytoplasmic of Glycine 
amidinotransferase, mitochondrial precu IPI00216279 48966.78125 6.61 16 1090.650024 100 136.7899933 100 0.468700407 0.149332596 18
HADH Isoform 2 of Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial precu IPI00298406 47125.23047 9.34 5 257.5 100 93.91999817 100 0.464903885 0.175090438 5
NNMT Nicotinamide N-methyltransferase IPI00027681 33091.32031 5.56 3 126.7999954 100 49.5 99.89802749 0.462527163 8.75E-02 3
PYGL 97 kDa protein IPI00783313 107098.9297 6.71 6 311.1499939 100 92.09999847 100 0.451907244 0.107860938 6
DBT Lipoamide acyltransferase component of 
branched-chain alpha-keto acid d IPI00003944 59823.44141 8.71 2 128.5700073 100 67.80000305 99.99849172 0.449552631 0.286746756 2
C10orf125 Isoform 2 of Protein fucU homolog IPI00845372 15786.78027 5.2 1 62.58000183 99.99498255 62.58000183 99.99498255 0.448066906 0 1
HSD17B4 Peroxisomal multifunctional enzyme 
type 2 IPI00019912 88068.99219 8.96 4 248.4700012 100 111.9300003 100 0.447745596 0.110540327 4
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KRT8 Keratin, type II cytoskeletal 8 IPI00554648 58423.62891 5.52 24 1435.693359 100 100.5199966 100 0.445827867 0.133097741 29
CA2 Carbonic anhydrase 2 IPI00218414 32874.30859 6.87 3 201.8099976 100 84.37000275 100 0.445680397 0.270205552 3
AGL Isoform 6 of Glycogen debranching 
enzyme IPI00219066 185998.375 6.26 1 99.05999756 100 99.05999756 100 0.444440641 0 1
MAT1A S-adenosylmethionine synthetase 
isoform type-1 IPI00021772 47392.28906 5.86 7 343.9044495 100 85.58000183 100 0.439050199 0.195045363 7
GPT Alanine aminotransferase 1 IPI00217458 57510.32813 6.77 3 149.25 100 55.59000015 99.97491101 0.435943075 0.103582451 3
PEBP1 Phosphatidylethanolamine-binding 
protein 1 IPI00219446 23439.92969 7.01 8 666.8200684 100 204.1799927 100 0.434367991 8.84E-02 10
SUCLG2 Succinyl-CoA ligase [GDP-forming] 
beta-chain, mitochondrial precurso IPI00096066 51941.89844 6.15 3 178.3399963 100 82.91999817 100 0.432801275 0.121889446 3
KRT18 Keratin, type I cytoskeletal 18 IPI00784347 51196.89844 5.34 10 499.8800049 100 94.44000244 100 0.431715906 0.133893635 11
ALDH1L1 Formyltetrahydrofolate 
dehydrogenase isoform a variant IPI00793673 109020.6328 5.63 3 147.3144379 100 74.08999634 99.99964561 0.412926523 0.094784117 3
KRT79 keratin 6L IPI00241841 62350.57031 6.75 4 183.3800049 100 53.36999893 99.95817045 0.40933095 9.15E-02 6
COL6A3 alpha 3 type VI collagen isoform 3 
precursor IPI00072917 345457.3438 6.47 5 209.8300018 100 48.81999969 99.8807432 0.406413844 0.384537067 5
DPYS Dihydropyrimidinase IPI00028910 62048.10938 6.81 5 259.3899841 100 66.80000305 99.99810118 0.402646254 0.129384633 5
SLC27A5 Bile acyl-CoA synthetase IPI00016827 78658.29688 7.81 2 95.38443756 100 63.79999924 99.99621136 0.399810417 0.388472136 2
AKR7A3 Aflatoxin B1 aldehyde reductase 
member 3 IPI00293721 39376.69141 6.67 2 120.7200012 100 64.08000183 99.99644792 0.39811272 0.119935505 2
SHMT1 Isoform 2 of Serine 
hydroxymethyltransferase, cytosolic IPI00220668 53489.17969 7.59 5 269.2744446 100 91.13999939 100 0.390866489 0.116648651 5
HMGCS2 Hydroxymethylglutaryl-CoA synthase, 
mitochondrial precursor IPI00008934 61333.76953 8.4 10 557.3499756 100 85.23999786 100 0.387349251 0.231648823 10
SOD1 Superoxide dismutase IPI00783680 17838.08984 5.7 5 344.0400085 100 116.3600006 100 0.3833138 0.045341039 5
ECHS1 Enoyl-CoA hydratase, mitochondrial 
precursor IPI00024993 35335.42969 8.34 11 716.5599365 100 112.2799988 100 0.376487099 0.140857369 11
ASS1 Argininosuccinate synthase IPI00020632 56147.66016 8.6 14 891.2999878 100 145.4400024 100 0.375343896 0.123097012 14
AOX1 Hypothetical protein AOX1 IPI00743616 161854.2031 6.78 6 257.3444519 100 61.47000122 99.99352137 0.371782628 0.120071905 6
ETFB Isoform 2 of Electron transfer 
flavoprotein subunit beta IPI00556451 41287.32813 6.78 2 97.86999512 100 52.68999863 99.95108036 0.368501417 1.99E-02 2
FMO3 Dimethylaniline monooxygenase [N-
oxide-forming] 3 IPI00329033 66260.82813 7.9 2 70.88999939 99.99925957 35.97999954 97.70658222 0.367085506 6.41E-02 2
MUT Methylmalonyl-CoA mutase, 
mitochondrial precursor IPI00024934 90636.34375 6.48 3 233.6299896 100 92.87999725 100 0.365205416 7.44E-02 3
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CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 33322.12891 8.55 6 352.3799744 100 92.18000031 100 0.36038392 7.41E-02 7
TST Thiosulfate sulfurtransferase IPI00216293 35752.05859 6.77 8 607.8144531 100 112.8000031 100 0.35902541 0.15092372 8
SULT1A1 Sulfotransferase 1A1 IPI00300026 47814.69922 8.61 8 371.8500061 100 58.77999878 99.98796397 0.357107125 0.242652162 8
ACADS Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor IPI00027701 47857.05859 8.13 2 93.52999878 100 52.16999817 99.9448579 0.346054799 0.476820127 2
SORD Sorbitol dehydrogenase IPI00216057 42378.10938 8.23 4 222.5700073 100 103.6699982 100 0.345159078 7.53E-02 4
ALDH6A1 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondria IPI00024990 63211.07813 8.72 8 555.3644409 100 94.58999634 100 0.339850925 0.190832537 8
EHHADH Peroxisomal bifunctional enzyme IPI00216164 86466.10156 9.22 4 181.9944458 100 66.52999878 99.99797939 0.337618926 0.186726206 4
AGXT Serine--pyruvate aminotransferase IPI00009367 46426.73047 8.61 7 477.230011 100 109.4599991 100 0.337345167 8.14E-02 7
DECR1 2,4-dienoyl-CoA reductase, 
mitochondrial precursor IPI00003482 40019.14844 9.35 6 406.9900208 100 109.6900024 100 0.336664878 0.207259032 6
FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 41289.14844 6.54 9 692.1900024 100 123.7600021 100 0.335755355 0.213770552 9
DCXR 26 kDa protein IPI00797249 27252.58984 8.33 6 300.9799805 100 66.70999908 99.99806142 0.334975455 0.15976316 6
CES2 carboxylesterase 2 isoform 1 IPI00332828 72247.0625 6.03 4 187.6900024 100 61.81999969 99.994023 0.319850996 8.44E-02 4
FAH Fumarylacetoacetase IPI00031708 49546.46094 6.46 2 102.3799973 100 60.52999878 99.99195579 0.318129831 0.271060947 2
EHHADH 8 kDa protein IPI00797006 7706.140137 7.98 1 123.75 100 123.75 100 0.316339162 0 1
GRHPR Glyoxylate reductase/hydroxypyruvate 
reductase IPI00037448 38271.94141 7.01 9 660.7544556 100 124.4100037 100 0.303983164 0.167879777 9
CES1 carboxylesterase 1 isoform c precursor IPI00607693 68199.60938 6.15 20 1418.180054 100 199.9900055 100 0.301104655 7.78E-02 21
ABHD14B 22 kDa protein IPI00747859 23098.53906 5.43 2 132.9299927 100 95.76000214 100 0.297778796 2.11E-02 2
ACADSB Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial IPI00024623 52051.67969 6.53 2 138.4299927 100 98.23999786 100 0.295092282 0.122843934 2
HRSP12 Ribonuclease UK114 IPI00005038 15826.7998 8.74 3 173.8899994 100 66.15000153 99.99779462 0.292460237 8.73E-02 3
CAT Catalase IPI00465436 64367.17969 6.9 11 824.2300415 100 192.7100067 100 0.28859813 0.226602972 11
HGD Homogentisate 1,2-dioxygenase IPI00303174 54236.85938 6.54 3 136.5500031 100 52.99000168 99.95434557 0.282075849 6.31E-02 3
ACSM2B Acyl-CoA synthetase medium-chain 
family member 2 IPI00329444 70450.35938 8.5 4 169.4700012 100 55.27000046 99.97299258 0.281032751 0.116167675 4
ACADM Hypothetical protein 
DKFZp686M24262 IPI00513827 55018.78906 7.94 4 224.1999969 100 80.98000336 99.99992748 0.280258224 0.131217851 4
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 215NT
CYP3A4 Cytochrome P450 3A4 IPI00465138 63244.41016 8.27 2 113.3099976 100 81.01999664 99.99992814 0.280087256 9.93E-02 2
HPD 40 kDa protein IPI00795913 44884.14063 5.93 4 243.9700012 100 99.56999969 100 0.27703497 0.110086831 4
LOC554235 29 kDa protein IPI00419903 29217.00977 6.5 1 109.6800003 100 109.6800003 100 0.275776873 0 1
PBLD Phenazine biosynthesis-like domain-
containing protein IPI00024896 34011.42969 6.06 2 97.97444153 100 66.58000183 99.99800252 0.272116828 0.254207618 2
EPHX1 Epoxide hydrolase 1 IPI00009896 57419.37891 6.77 6 468 100 112.0899963 100 0.27133733 0.18652572 7
PCK2 mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor IPI00797038 74784.85938 7.57 14 810.9899902 100 106.5 100 0.267152864 0.237991846 15
GOT2 Aspartate aminotransferase, 
mitochondrial precursor IPI00018206 52087.64844 9.14 5 367.2200012 100 119.5299988 100 0.265611313 7.02E-02 5
ABAT 4-aminobutyrate aminotransferase, 
mitochondrial precursor IPI00009532 61418.91016 8.17 5 293.1699829 100 83.61000061 100 0.265041348 7.77E-02 5
ACSM2A LOC123876 protein IPI00644771 70304.24219 8.34 4 186.1400146 100 59.06999969 99.98874143 0.262839856 8.48E-02 4
ACY1 Aminoacylase-1 IPI00009268 48344.23047 5.77 4 189.5 100 56.45000076 99.97941821 0.257161298 0.115417865 4
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial IPI00001539 46153.96875 8.32 11 707.7799683 100 138.3200073 100 0.249699095 0.133874861 11
CYP3A5 Cytochrome P450 3A5 IPI00025831 63206.64063 8.86 2 116.9899979 100 81.08999634 99.99992929 0.249680553 5.18E-02 2
UGT1A6;UGT1A1 UDP-
glucuronosyltransferase 1-1 precursor IPI00434346 64522.89063 8.19 4 242.1600037 100 71.58000183 99.99936834 0.243836956 0.147123014 4
KRT19 Keratin, type I cytoskeletal 19 IPI00479145 46225.37891 5.04 3 156.2599945 100 74.25 99.99965843 0.243770925 0.228261471 3
COL6A1 Collagen alpha-1(VI) chain precursor IPI00291136 117302.5391 5.26 3 153.4899902 100 65.18000031 99.99724271 0.230245 0.113140106 3
FMO5 Dimethylaniline monooxygenase [N-
oxide-forming] 5 IPI00215760 66454.40625 8.41 1 92.36000061 100 92.36000061 100 0.223316497 0 1
HAGH Hydroxyacylglutathione hydrolase IPI00745553 32141.91016 6.86 1 99.62999725 100 99.62999725 100 0.212380115 0 1
CPS1 Isoform 1 of Carbamoyl-phosphate 
synthase [ammonia], mitochondrial pre IPI00011062 180875.9531 6.3 60 4328.580078 100 149.0200043 100 0.209942627 0.128045938 70
MT1X Metallothionein-1X IPI00008753 8279.200195 8.38 2 112.3200073 100 69.55000305 99.99899195 0.209333742 7.96E-02 2
BDH1 D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial precursor IPI00025341 41766.75 9.11 3 143.5244446 100 56.22999954 99.97834874 0.207026356 0.191009232 3
ADH1A Alcohol dehydrogenase 1A IPI00218896 45320.80859 8.26 11 859.1099854 100 121.3399963 100 0.206379645 0.112566428 12
OTC Ornithine carbamoyltransferase, 
mitochondrial precursor IPI00295363 43936.05859 8.75 7 420.2844543 100 104.0899963 100 0.204474915 0.146839251 7
FTCD Isoform A of Formimidoyltransferase-
cyclodeaminase IPI00001441 62321.57813 5.58 7 389.1799927 100 74.90000153 99.99970591 0.204108108 0.221065709 7
Poorly Differentiated iTRAQ Individual Patients
Poor Diff 215NT
CYP2C8 45 kDa protein IPI00843846 49430.42188 8.91 4 229.0500031 100 64.80999756 99.9969975 0.198464796 9.45E-02 4
ADH1B Alcohol dehydrogenase 1B IPI00473031 45270.91016 8.63 11 826.0499268 100 121.3399963 100 0.191141542 7.27E-02 12
UGT2B7 similar to UDP-
glucuronosyltransferase 2B7 precursor IPI00787584 65314.41016 8.41 4 214.0400085 100 74.30999756 99.99966311 0.188711773 0.094843293 4
CYP2C19 Cytochrome P-450 II C (Fragment) IPI00657852 44746.01953 6.82 2 118.1800003 100 61.59000015 99.99369793 0.184918014 7.57E-02 2
CYP2C9 Cytochrome P450 2C9 IPI00007219 61374.14063 8.13 3 186.4799957 100 79.30999756 99.99989347 0.18187408 5.34E-02 3
SULT2A1 Bile salt sulfotransferase IPI00216133 37496.32813 5.71 7 352.8500061 100 83.44000244 100 0.17553379 6.35E-02 7
UGT2B17 UDP-glucuronosyltransferase 2B17 
precursor IPI00026932 67707.59375 8.76 1 66.90000153 99.99814441 66.90000153 99.99814441 0.175422632 0 1
FABP1 FABP1 protein (Fragment) IPI00010290 18729.4707 9.52 6 401.8299866 100 115.1399994 100 0.168469766 7.66E-02 8
ADH1C Alcohol dehydrogenase 1C IPI00465343 45428 8.63 7 533.5999756 100 121.3399963 100 0.159375773 3.57E-02 8
CYB5A Isoform 1 of Cytochrome b5 IPI00397860 16616.71094 4.88 6 524.5899658 100 227.2200012 100 0.158753224 8.68E-02 6
BHMT Betaine--homocysteine S-
methyltransferase 1 IPI00004101 49946.23828 6.58 14 768.6488647 100 125.2300034 100 0.152224165 0.100297875 16
ACAA1 3-ketoacyl-CoA thiolase, peroxisomal 
precursor IPI00012828 47604.07031 8.76 4 349.6000061 100 110.1999969 100 0.151389736 5.50E-02 4
GLYAT Isoform 1 of Glycine N-acyltransferase IPI00402759 37221.21094 8.38 3 135.8099976 100 57.43000031 99.98357584 0.149251882 0.417065012 3
GSTA2 Glutathione S-transferase A2 IPI00745233 29104 8.51 8 439.5299683 100 84.43000031 100 0.147881253 0.100485918 9
ADH4 Alcohol dehydrogenase 4 IPI00218899 45828.03125 8.25 9 690.5800171 100 116.8899994 100 0.142183921 0.12914088 9
RDH16 Retinol dehydrogenase 16 IPI00289551 38852.73828 8.83 4 219.2744446 100 69.81999969 99.99905271 0.138199711 0.12760772 4
CYP2A6 Cytochrome P450 2A6 IPI00299568 61083.51172 9.24 3 171.6900024 100 90.04000092 100 0.127664078 5.91E-02 3
DAK Dihydroxyacetone kinase IPI00551024 63392.42188 7.12 5 521.5 100 156.3899994 100 0.122755941 0.130857111 6
ALDOB Fructose-bisphosphate aldolase B IPI00218407 43462.35156 8 12 865.0800171 100 112.6500015 100 0.121983706 0.13276425 16
CYP1A2 Isoform 1 of Cytochrome P450 1A2 IPI00719591 62467.67188 9.18 1 76.54000092 99.9997984 76.54000092 99.9997984 0.121336795 0 1
EMILIN1 EMILIN-1 precursor IPI00013079 109415.4531 5.1 1 85.91000366 100 85.91000366 100 0.111415738 0 1
GGTLA1 Isoform 2 of Gamma-
glutamyltransferase 5 precursor IPI00339373 61051.73828 7.67 1 74.33999634 99.99966543 74.33999634 99.99966543 0.108954915 0 1
COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 148007.1406 5.6 1 95.41999817 100 95.41999817 100 7.49E-02 0 1
